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Abstract 
 
Mitochondria are dynamic organelles that produce energy for the cell.  In skeletal muscle, 
mitochondria adapt as a result of regular exercise by increasing their content and improving their 
function, resulting in better muscle energy production. p53 is a protein that maintains basal 
mitochondria function in muscle. However, it is unknown whether it is required for skeletal 
muscle adaptations with exercise. We thus subjected normal, wild-type mice, as well as those 
with a specific p53 deletion within muscle, to a 6-week endurance training program. Our results 
confirm that p53 is required for mitochondrial maintenance in muscle under basal conditions, but 
that it is not required for the adaptive responses in mitochondrial content and function observed 
with training. This suggests that exercise can activate viable alternative compensatory pathways 
to maintain muscle health in the absence of p53.  
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1.0. Skeletal Muscle Function and Maintenance  
1.1. Introduction: Importance of Muscle Health 
Skeletal muscle is a dynamic tissue that coordinates movement, posture, and homeostasis 
through multiple signaling pathways including metabolism, thermogenesis, and mitochondrial 
biogenesis (67, 127). Though it is one of three major muscle types, the others being cardiac and 
smooth muscle, it comprises 40-50% of the total body mass of a healthy individual (64).  Its 
dominant presence throughout the body allows it to serve as an energy reservoir and metabolic 
regulator of interorgan crosstalk (9).  
Energy metabolism is a critical function of skeletal muscle. Its role in glucose uptake and 
storage for the conversion of chemical energy to mechanical energy is required both for 
movement and optimal organ function. Energy derived for work is primarily through ATP 
production which requires rapid re-synthesis for continued availability. The second source of 
readily available energy is creatine phosphate which is a reservoir of high energy phosphate 
bonds vital to rebuild ATP (110). Carbohydrates (CHO) are the only macronutrient that can 
generate ATP aerobically and anaerobically. Anaerobically, glucose/glycogen utilization in the 
cytosol generates low levels of ATP and builds lactic acid which can impede muscle contractions 
over time (110, 177). The aerobic pathway on the other hand provides 18 times more ATP due to 
pyruvate entry into the Krebs’ cycle within the mitochondria. ATP can additionally be provided 
by metabolizing fats and proteins. Triglycerides can be hydrolized to generate fatty acids which 
undergo β-oxidation in the mitochondria producing high energy yields per each acetyl-coA unit. 
However, this process requires greater oxygen levels than CHO oxidation (110). The 
requirement for amino acid substrate utilization for fuel is increased when other substrates are 
unavailable. During prolonged exercise with normal substrate availability, protein oxidation 
3 
 
accounts for only 5% of the energy requirements (108, 110). Therefore, the major requirements 
are CHO oxidation, which increases with exercise intensity, and fat oxidation, which increases 
from low to moderate exercise duration, but decreases from moderate to high exercise intensities.   
Numerous conditions and diseases lead to an imbalance in the metabolic demands placed 
on muscle. This can outweigh the protein synthesis occurring with dietary intake and eventually 
can lead to muscle atrophy and a loss of appropriate metabolic functioning. The specific 
conditions that lower dietary intake, such as malnutrition and starvation, and those that alter the 
metabolic load on muscle, such as cancer, immune disorders and muscular dystrophies, can have 
serious consequences (9, 169). Most of these conditions are associated with variable degrees of 
inflammation which activate proinflammatory cytokines to accelerate muscle catabolism (111). 
Ultimately, the loss of muscle mass, function, and strength can lead to longer recovery times, 
selective fiber type transitions, slower wound healing, physical disability, and greater health care 
costs (3, 60, 109, 136). To combat these adverse outcomes, controlled nutrition and exercise 
programs can be implemented for muscle recovery to promote overall health (5, 9, 82, 175).  
1.2. Physiology of Skeletal Muscle 
1.2.1. Structural Physiology 
Skeletal muscle consists of bundles of single large cells, termed myocytes, which develop 
from myoblast fusion in a process known as myogenesis (35). Its architecture originates through 
several distinct phases: 1) embryonic phase, wherein mesoderm-derived structures generate 
template muscle fibers, 2) perinatal phase, whereby myogenic progenitors proliferate and 
myofibrillar protein synthesis peaks and plateaus, 3) mature phase, wherein progenitors enter 
into quiescence and reside in muscle as satellite cells, and 4) regenerative phase, whereby 
satellite cells in the fiber sarcolemma expand mitotically and differentiate into new fibers when 
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damaged (7, 14). Each muscle fiber contains multiple myofibrils, composed of cylindrical 
bundles of thick myosin and thin actin filaments, each of which are organized to form repeating 
sarcomere units.  
Muscle fibers are delineated based on their myosin profiles. Myosin is a hexameric 
protein consisting of four light chains which modulate interactions between myosin and actin, 
and two heavy chains (fast and slow) which are differentiated into nine isoforms to dictate 
appropriate fiber composition (128). With an influx of calcium into the sarcoplasmic reticulum, 
rapid repetition of myosin, working in conjunction with actin to form a cross-bridge, initiates a 
power stroke that allows for contraction (35). Differences in muscle types are a result of 
metabolic properties, histochemical features, and most importantly, structural protein 
composition based primarily on the myosin heavy chain (MHC) protein, which dictates the 
velocity of contraction (9, 128). There are three pure fiber types containing a single MHC 
isoform. Slow twitch red type I fibers with the MHCIβ isoform function as oxidative and fatigue 
resistant fibers. Fast twitch red type IIa fibers with the MHCIIa isoform contain intermediate 
metabolic properties for fast oxidative capacity. Lastly, fast twitch white type IIx fibers with the 
MHCIIx isoform for high glycolytic energy production, result in high force output but 
consequentially have a high fatigue rate (126, 138, 148). Fast twitch white type IIb fibers with 
the MHCIIb isoform are analogous to the type IIx fibers, but are found in humans and not 
mammals. Hybrid fibers types are further created through the mix of major isoforms and include 
type I/IIA (IC), IIA/I (IIC), IIAD, IIDA, and IIBD (126). The dynamic property of muscle is a 
result of fiber type transitions. This is associated with gradual changes in energy costs as a result 
of different muscle usage patterns that dictate sequential and reversible transitions of slow-to-fast 
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and fast-to-slow transformations following the paradigm MHCIβ ↔ MHCIIa ↔ MHCIIx ↔ 
MHCIIb (126). 
1.2.2. Cellular Structure 
To interpret how muscle adapts to incoming stimuli in order to provide energy for 
cellular and mechanical functions, a thorough understanding of the components and properties of 
the myocyte is required. Myocytes are similar in organelle structure to other eukaryotic cells, 
however the addition of myofibrils allows for its contractile ability. Under apt conditions, the cell 
functions to meet energy and signaling demands, however under conditions such as starvation or 
organelle dysfunction, other pathways are induced to maintain cellular integrity. Though all 
organelles are essential, skeletal muscle plasticity is attributed to mitochondria.  
1.2.2.1. Mitochondrial Structure and Function 
The endosymbiotic theory postulates that the rise of mitochondria within cells, 
approximately 1.45 billion years ago, occurred through eukaryotic engulfment to provide its 
anaerobic host with aerobic capacity (105). As the symbiosis matured, the mitochondrial 
organelle transferred a portion of its bacterial plasmid to the nucleus, thereby losing its ability to 
survive as a free-living organism. The current 16.5 kb mitochondrial plasmid now possesses 37 
genes coding for two ribosomal RNAs (12S and 16S rRNA), 22 tRNAs, and 13 electron 
transport chain genes for energy generation (64, 170, 176). The remaining gene products from 
the original mitochondrial genome (~1200) are now encoded within chromosomal DNA. These 
proteins are imported into the mitochondria via protein import machinery (PIM) (170). 
Mitochondria are elliptically shaped double phospholipid membraned organelles with 
multiple folds in the inner membrane called cristae (64, 76). The matrix of the mitochondria 
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contains the mtDNA. Outside of the inner membrane is the intermembrane space which is 
enclosed by the outer membrane. The inner membrane contains the subunits of the electron 
transport chain (ETC) which is made up of five complexes (Figure 1). Ubiquinone and 
cytochrome c proteins shuttle electrons between complexes I ÆIII and II Æ III, and complexes 
IIIÆIV respectively. As the electrons are shuttled across the complexes, proton pumping is 
facilitated out of complexes I, III, and IV and into the intermembrane space (27, 99). This creates 
an electrochemical potential gradient that facilitates proton re-entry into the matrix through 
complex V (ATP synthase), thus generating ATP energy for cellular utilization (27, 99). This is 
known as the chemiosmotic theory for energy generation (113). It is important to note that 
reactive oxygen species (ROS) and heat are by-products of energy metabolism that likely 
activate/regulate downstream signaling mechanisms (115). The production of superoxides and 
radical formation at the NADH dehydrogenase complex I and cytochrome bc1 complex III, as a 
result of substrate unavailability and/or electron slippage through the buildup of the 
electrochemical gradient, can lead to detrimental outcomes such as peroxidized lipids, oxidized 
proteins and damaged DNA, if not removed (66, 112, 116, 135). On the other hand, 
mitochondrial-derived ROS can exert beneficial effects, when maintained at a certain threshold, 
by acting as signaling mechanism for mitochondrial biogenesis (22, 66, 72). Therefore, it seems 
that there is a specific threshold tolerance of the cell to ROS production levels. 
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Figure 1. Substrate utilization and schematic representation of the electron transport 
chain. Large carbohydrates are broken down into glucose molecules that can enter into 
glycolysis within the cytosol, which is then further broken down into two pyruvate molecules in 
a process that yields 4 ATP. Pyruvate diffuses into the intermembrane space where it is 
converted to acetyl-CoA through a transition reaction yielding NADH. Acetyl-CoA, two per 
glucose molecule, can then enter into the Krebs’ cycle. Lipids are broken down to acetyl-coA 
units through beta-oxidation, yielding large amounts of ATP depending on the size of the fatty 
acid molecule. Proteins are the last energy source to be catabolized, and are broken down to 
amino acids through deamination to then enter into the Krebs’ cycle. Once substrates diffuse into 
the mitochondrial matrix, acetyl-coA enters the aerobic Krebs’ cycle yielding 3 NADH, 1 
FADH2 and 1 ATP per acetyl-coA, or a total of 6 NADH, 2 1 FADH2, and 2 ATP per glucose 
molecule. The NADH and FADH2 substrates, generated from both anaerobic and aerobic 
processes, can then be utilized by the electron transport chain (ETC) to generate ATP energy. 
NADH and FADH2 are oxidized by complexes I (NADH dehydrogenase) and II (succinate 
dehydrogenase) respectively. The electrons donated from these processes are passed through 
subsequent complexes including complex III (cytochrome bc1) through reduction of the mobile 
electron carrier ubiquinone (UQ), and complex IV (cytochrome c oxidase) by cytochrome c 
reduction to generate energy required to pump protons into the intermembrane space. This 
transfer process through the ETC can result in the escape of electrons through complexes I and 
III prematurely which reduces oxygen and generates H2O2, also known as reactive oxygen 
species (ROS). The final electron acceptor is oxygen to produce H2O. This electron transfer 
throughout the ETC contributes to the buildup of H+ ions in the intermembrane space, creating a 
proton gradient which is utilized by complex V (ATP synthase) to convert ADP to ATP in a 
process known as chemiosmosis.  This entire process produces an ATP yield of approximately 
36 ATP. 
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Mitochondria function to regulate cellular signaling processes. The dynamic property of 
mitochondria are a result of its existence as a functional reticulum, maintained through fission 
and fusion events (28, 70). This interconnected network ultimately facilitates oxygen diffusion 
and allows for mitochondrial quality control (28, 115). Interestingly, the presence of a reticulum 
conflicts with the well-known existence of mitochondrial sub-populations which form within 
their own networks in discrete subcellular locations. The rise of separate populations with 
distinct biochemical differences is presumed to be a result of the different energy requirements of 
specific locations within the myofiber. The subsarcolemmal (SS) mitochondria are located 
beneath the sarcolemmal membrane in close proximity to myonuclei, therefore permitting greater 
adaptations to stimuli (5, 34, 85). These mitochondrial provide ATP energy for nuclear and 
membrane functions, exhibit higher membrane potentials, and produce greater amounts of ROS 
(34, 123). The intermyofibrillar (IMF) mitochondria coalesce within the myofibrils and comprise 
80-85% of the total mitochondrial volume (5, 34). They have a greater rate of oxygen 
consumption, ~2.5-fold greater than SS populations, and consequentially generate higher ATP 
levels to supply myosin and actin with energy for muscular contractions (4, 5). Furthermore, this 
population has higher rates of protein import and synthesis, and a greater capacity for fatty acid 
oxidation (115, 159). As these populations differ in their structure and function, and possibly in 
the signaling pathways that may exist to facilitate these differences, they do share similar 
mechanisms to regulate metabolic demands. 
1.2.2.1a. Signaling Pathways Regulating Mitochondrial Health 
 There are many important signaling mechanisms that are employed by the cell to 
maintain optimal skeletal muscle function. The primary mechanism of mitochondrial biogenesis 
ensures regulation of energy sensitive pathways including calcium homeostasis, ROS production 
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and signaling, and apoptosis. As a result, a healthy mitochondrial pool is required, with its 
dynamics tightly regulated by opposing fission and fusion processes. Fusion, through Opa1 and 
Mfn-2 proteins, coincides with signals that induce mitochondrial biogenesis, such as endurance 
training, leading to the intermixing of mitochondrial material and expansion of the reticulum  
(70, 83). Fission on the other hand, facilitated by Fis-1 and Drp-1 proteins, promotes the division 
of organelles leading to a reduction of the reticulum. 
 Additional signals that regulate the health of the mitochondrial pool includes the 
antioxidant production pathway whereby primary enzyme antioxidants, non-enzymatic 
antioxidants, and dietary antioxidants function to maintain redox balance (112, 132). In response 
to changes in the cellular environment, optimal mitochondrial functioning may be disrupted 
through increased ROS/RNS leading to DNA, protein, and lipid damage. This induces either the 
cell death or mitophagy pathways. Mitophagy, a component of autophagy, utilizes numerous 
mechanisms to signal the binding of damaged mitochondria to the phagophore causing the 
organelle to be engulfed within the autophagosome and directed to the lysosome for degradation 
(140). With greater genotoxic stress levels due to DNA damage, hypoxia, and oxidative stress, 
the mitochondria can a source of cellular death through permeabilization of the outer 
mitochondrial membrane (MOMP) (87). Ultimately, maintenance of a healthy mitochondrial 
reticulum is required for optimal skeletal muscle function, which can be regulated by the tight 
coordination of numerous signaling mechanisms.  
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2.0. Skeletal Muscle Adaptations to Exercise 
 
2.1. Exercise: Its Pleiotropic Benefits 
 
Exercise is a beneficial signal, not only for skeletal muscle cellular health and 
maintenance, but for whole body health and fitness as well. The exercise regimen, based on type 
of exercise as well as its parameters including duration, frequency, intensity and length, can 
induce a variety of molecular and phenotypic adaptations. Furthermore, the application of a 
recovery period following exercise allows for a sufficient interval in which transient changes in 
gene expression can induce adaptations. Therefore, depending on the type of exercise regimen 
and its parameters, one can optimize and maximize the desired results.  
 Skeletal muscle is a major recipient for the advantageous effects of exercise. Increased 
fiber contractility with aerobic exercise can lead to elevated myoglobin, increased capillarization, 
and enhanced mitochondrial content to ultimately improve the oxidative capacity of muscle (65, 
77, 117). Interestingly, growth of the capillary network, through a process known as 
angiogenesis, is thought to precede adaptations in skeletal muscle. Aerobic exercise 
preferentially utilizes lipid energy metabolism which reduces the formation of lactic acid and the 
use of high energy phosphate, and attenuates the loss of glycogen to reduce the rate at which 
muscle fatigues (64). With other types of exercise, such as with resistance exercise, hypertrophy 
is a consequence due to fiber enlargement according to the myonuclear domain theory (125, 
152). Whole body health can further be improved with prolonged exercise regimens as observed 
through cardiovascular benefits, greater endurance and work capacity, enhanced nutrient delivery 
and uptake, and even enriched mood and cognition (6, 64, 68, 78, 164). As a result of its 
pleiotropic effects in skeletal muscle and throughout the body, exercise can be utilized as an 
intervention to promote a healthier phenotype, and reduce and even reverse symptoms associated 
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with aging, muscle atrophy, and mitochondrial disease (66). However, due to the immense 
variety of signals that regulate adaptations to exercise including fiber type composition, 
intercellular crosstalk, nutrient requirements and mitochondrial content and function, the 
different exercise parameters will result in unique effects in muscle (119). 
2.1.1. Acute versus Chronic Training: Teasing out the Differences 
Exercise can be grouped into two major categories: Resistance and Aerobic exercise. 
Aerobic exercise in particular is further subcategorized into acute exercise and prolonged 
exercise, for which each category results in an umbrella of distinct molecular and morphological 
effects. 
Aerobic exercise provides numerous beneficial results to skeletal muscle, as a result of its 
ability to induce mitochondrial biogenesis to a greater extent than with resistance exercise. 
Depending on the level of training prior to undergoing a single bout of exhaustive exercise, it can 
produce significant adaptations. An acute bout is sufficient enough to increase signaling kinases 
such as p38 MAPK (0.5-fold), AMPK (2.5-fold), and CaMKII (2.5-fold) which further remain 
elevated after 3 hours of recovery (143, 166). These kinases activate numerous transcription 
factors such as the mitochondrial transcription factors NRF-1 and 2, antioxidant transcription 
factor Nrf2, and the guardian of the genome p53, facilitating enhanced nuclear localization and 
activation. Additionally, the major mitochondrial coactivator PGC-1-α, can also be 
phosphorylated by these signaling kinases, allowing for its subcellular localization. Once in the 
nucleus, PGC-1α can assist in the transcription of NUclear Genes Encoding Mitochondrial 
Proteins (NUGEMPs) such as COX IV (60%), Tfam (50%) and NRF-1 (200%), which can be 
further increased during a recovery period (143, 166). The antioxidant pathway is notably 
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activated with acute exercise leading to Nrf2-mediated transcription of GSH and MnSOD 
antioxidants at a threshold of above 90 minutes of acute exercise (171). Furthermore, autophagy 
has also been shown to increase following an acute bout of endurance exercise. Increased LC3-II 
and reduced p62 levels are indicative markers of autophagy activation (166). DNA 
fragmentation, a marker of cell death caused by an increase in the Bax/Bcl-2 ratio and caspase 3 
activation, has been noted following eccentric resistance exercise and acute strenuous treadmill 
exercise programs; chronic aerobic exercise training can relieve these effects (84, 156, 157). 
Further mechanisms induced with acute exercise include increased muscle protein turnover, 
activation of the UPR, and transient changes in myogenic and metabolic genes (20, 81, 88, 178). 
With endurance training on the other hand, mitochondrial content can increase from 30-
100% within a time frame of 4 to 6 weeks (66). As such, greater adaptations will be apparent in 
the low oxidative fibers, where the greatest percentage of mitochondrial content is found. 
Improvements associated with endurance capacity are a result of mitochondrial biogenesis and 
its improved reticular formation. Increased  NUGEMP transcription factors such as p53, and the 
coactivator PGC-1α, enhance mitochondrial content and facilitates a reduction in glycolytic 
activation (lowered lactic acid  production, attenuated glycogen utilization, reduced 
phosphocreatine usage) to prevent an acidotic state, and increases fatty acid fuel oxidation (62, 
64). Other adaptive signals include accelerated mRNA turnover for rapid phenotypic plasticity, 
reduced ROS activation, attenuated apoptotic signaling, and increased autophagy to maintain a 
healthy organelle pool (42, 61, 66, 89, 165). These improvements over time assist in the 
transition to a greater oxidative fiber phenotype and improve capillary density to enhance 
respiratory capacity and increase contractile capability (45, 46). Various models of exercise 
training exist, including constant and progressive treadmill training, electrical stimulation, and 
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voluntary wheel running. Manipulations in these parameters can alter signaling mechanisms to 
lead to the aforementioned effects to enhance muscular endurance.  
2.2 Aerobic Exercise-Mediating Signaling Pathway Regulation 
2.2.1. Kinase Activation and Downstream Pathways 
With cross bridge cycling during contractile activity, there is an increase in specific 
signaling pathways that collectively activate transcription factors within the nucleus and 
mitochondria to alter gene expression. These signals include a) a reduced ATP/free ADP ratio, b) 
changes in intracellular calcium levels following release from the sarcoplasmic reticulum, and c) 
an increase in oxygen consumption and consequentially its by-product reactive oxygen species, 
which cooperatively leads to the activation of intracellular protein kinases such as AMPK, 
CaMKII, Akt, and MAPKs to trigger post-translational protein modifications (63, 66, 77).  
Phosphorylation of transcription factor p53 and transcriptional coactivator PGC-1α, the master 
regulators of cellular homeostasis and mitochondrial biogenesis respectively, allows for their 
nuclear localization and activation of NUGEMPs such as NRF-1/2 and Tfam  (119). Once these 
genes are transcribed, they proceed through the central dogma of protein formation, forming 
their respective mRNAs which then exit the nucleus and are translated to functional proteins in 
the cytosol. Tfam, once folded, can be imported into the mitochondria through the TIM and 
TOM complexes to regulate mtDNA transcription and replication (68, 147). Other proteins 
imported into the mitochondria, such as those regulated by p53, including cytochrome c oxidase 
assembly (SCO2) and apoptosis inducing factor (AIF) proteins, as well as other metabolic 
enzymes, function to assist in the formation of the multi-subunit ETC complexes to increase 
muscle aerobic capacity (68). Furthermore, enahnced transcription of mitochondrial DNA by 
Polγ increases COX I and II gene expression to improve mitochondrial respiration with aerobic 
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exercise. Ultimately these signals lead to the activation of mitochondrial biogenesis and 
expansion of the reticulum with exercise which can feedback to other signaling mechanisms such 
as the antioxidant and mitophagy pathways to maintain optimal cellular homeostasis.  
2.2.2. Intracellular Communication and Crosstalk 
Intercellular and intracellular crosstalk is the process of exchanging molecular messages 
and material between and within cells respectively, to maintain optimal physiological activity 
and coordinate homeostasis, adaptation, and survival (130). This ability for cell-cell 
communication is mediated by numerous mechanisms including ligand-receptor signaling, 
secretion/uptake of the exosome transmitting system, intercellular structures (synapses, gap 
junctions), organelles, and trafficking signaling molecules (130, 183). Thus, in order to maintain 
optimal cellular homeostasis for ideal tissue health, communication is required between signaling 
mechanisms regulating cellular proliferation, maintenance, and degradation.  
With varying stress loads, dependent on the type, duration and intensity, cellular 
degradation pathways may be activated to prevent aberrant proliferation and signaling. Prior to 
this however, certain signaling mechanisms are employed under to maintain cellular integrity. 
Antioxidant enzyme defenses are regulated by the major transcription factor Nrf2 to produce 
enzymes such as SOD2, catalase,  glutathione peroxidase, and reductase to neutralize ROS/RNS 
(129). Furthermore cell cycle arrest and autophagy pathways can be activated to allow for 
genomic repair and dysfunctional organelle removal, respectively. However, when ROS 
production exceeds the antioxidant capacity, apoptosis can be triggered (66). Thus cellular 
maintenance, whilst under the influence of exercise, is required through signaling cross-talk to 
maintain optimal mitochondrial biogenesis to suffice workload requirements, without generating 
above threshold ROS levels that induce cell death pathways.  
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3.0. p53 Transcription Factor 
 
3.1. Introduction to the Tumor Suppressor p53 
 
 The tumor suppressor protein p53 is a rapid-response transcriptional regulator of diverse 
signaling pathways involved in maintaining cellular homeostasis. Thus, it is affectionately 
termed the “Guardian of the Genome” for its master regulatory role. Immense progress has since 
been made from its initial and monumental discovery in 1979 by David Lane and Lionel 
Crawford. The p53 protein was an unexpected finding during an immunoprecipitation 
experiment for the T tumour antigen of the Simian Virus 40, whereby a protein with a molecular 
weight of 53 kDa accompanied the antigen (90). Due to the presence of p53 in numerous cancer 
cell lines and the SV40 cell line, it became persistently characterized as an oncogene. It took a 
decade of elaborate investigations before its true role as a tumor suppressor was revealed. This 
spurred research into the role of p53 in cancer biology for the reason that approximately 50% of 
malignancies carry a p53 mutation/inactivation (24, 56, 69). Within the last fourty years, and 
~78,000 publications later, research on p53 has exploded to define its numerous applications in 
cancer and other diseases. 
New discoveries on the pleiotropic effects of p53 on signaling mechanisms that maintain 
cellular and genomic integrity are continuously being made. With varying levels of stress, 
specific modifications to the p53 protein, activate or impair downstream signaling pathways that 
regulate cell cycle arrest and senescence, pro- and anti-oxidant function, apoptosis, DNA repair, 
metabolism, differentiation, and angiogenesis (93). Though its many roles in the cell are known, 
research on the communication that occurs between these pathways to maintain cellular 
homeostasis are still being pursued, with the goal to elucidate how p53 leads to cooperative 
interactions depending on the level of cellular stress. 
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3.1.1. Cellular Localization Dictates Function 
The p53 gene, also termed TP53 in humans or TRP53 in rodents, contains a large core-
DNA binding domain (DBD) that is preceded by two N-terminal transactivation regions with a 
proline rich domain for protein-protein interactions, and is additionally followed by a 
tetramerisation (TET)/oligomerization motif and C-terminal regulatory region (101, 122). 
Interestingly, the DBD is the region that undergoes heavy mutagenesis during tumour formation, 
with >90% of the mutations occurring within this section (122). Following post-transcriptional 
modifications, the p53 gene codes for eleven exons with two translational start sites in exons 2 
and 4, that when translated, create the 393 amino acid that homodimerizes to form the functional 
p53 protein structure (122). Post-translational modifications can occur in all of these domains 
leading to high variability in the stability and function of p53 (Figure 2). The p53 pathway is 
divided into distinct sections: 1) input signals that trigger cellular biochemical changes, 2) 
detection of signals by upstream mediators that initiate alterations to the p53 protein, 3) 
activation/inhibition of p53 and its subcellular localization, 4) p53 downstream signaling 
activation by transcriptional regulation or sequence specific protein-protein interactions, and 5) 
cellular outputs of these signaling pathways (93). Intrinsic and extrinsic stress signals induce 
post-translational modifications to the p53 protein through mediators such as kinases (ATM, 
ATR, Chk1 and 2, JNK, p38, AMPK), phosphatases (PP2A), sumoylases (PIAS-1, Ubc9, 
Topors, SUMO1), deacetylases (HDAC, SIRT-1), neddylases (NEDD8), methylases (Set9), 
acetyltransferases (p300, CBP, PCAF), and ubiquitin enzymes (UbcH5B/C, Mdm2, Pirh2) (92, 
93). Phosphorylation is the dominant covalent modification as it occurs on ten different residues 
within the 100 amino acid N-terminal region and within the C-terminus, and as such can be 
targeted by numerous kinases (92). This modification can destabilize the interaction between 
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Figure 2. p53 protein domain structure and post-translational modifications. Schematic 
representation of the 393 amino acid domain structure of the p53 protein indicating the important 
sites where numerous post-translational modifications occur such as phosphorylation, 
acetylation, methylation, sumoylation, ubiquitination, and neddylation. There are numerous 
phosphorylation sites within TAD1 (Serine 6, 9, 15, 20, 33, 37 and Threonine 18), TAD2 (Serine 
46 and Threonine 55, 81), DBD (Serine 149, 215 and Threonine 150, 155), before the TET 
(Serine 313-315), and within the REG (Serine 366, 371, 376, 378, 392 and Threonine 377, 387). 
Acetylation sites are present within the DBD (Lysine 120), before the TET (Lysine 305, 320), 
and within the REG (Lysine 370, 372, 373, 381, 382). Methylation sites are found within the 
TET (Arginine 333, 335, 337) and within the REG (Lysine 370, 372, 382). Ubiquitination for 
targeted degradation specifically occurs before the TET (Arginine 320) and within the REG 
(Arginine 370, 372, 37, 381, 382, 386). Neddylation and sumoylation are less frequent, occurring 
within the REG at Arginine 370, 372, 373 and Arginine 386 respectively. Abbreviations: N-
terminal transactivation domain (TAD), proline-rich domain (PRD), tetramerisation domain 
(TET), C-terminal regulatory domain (REG), nuclear export signal (NES), amino acids (aa). 
Figure adapted from (101). 
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p53 and its negative regulators (Mdm2, Pirh2, Cop1) to prevent ubiquitination and proteasomal 
degradation in the cytosol (92). 
In response to stress, phosphorylated p53, most commonly found on Ser15, Thr18 and 
Ser20, is stabilized and accumulates in the cytosol (30, 144). It can then localize to varying 
subcellular compartments, such as the nucleus or mitochondria, to regulate genomic integrity. 
Upon exposure of its nuclear localization motif in the C-terminal region, p53 enters the nucleus 
to bind to p53-response elements identified by RRRCWWGYYY (R=purine, W=A or T, 
Y=pyramidine) consensus sequences (93). A p53 response element comprises two of these 10 
base-paired sequences, often located in the first or second intron or within the 5’ region, 
interspersed by 0-13 base pairs (93). Approximately 13,774 genes have p53 response elements 
within their promoters and can therefore be transcriptionally regulated by p53 (161). Hence, due 
to the high volume of p53- consensus sequences, p53 can transcribe and regulate genes in 
numerous pathways including those within apoptosis, autophagy, metabolism, cell cycle 
arrest/senescence, and mitochondrial biogenesis. 
Though nuclear localization can occur with a host of intrinsic and extrinsic signals that 
expose the nuclear localization motif on p53, p53 does not contain a mitochondrial targeting 
sequence and therefore mitochondrial localization has been shown to occur with specific signals 
including high cellular stress (signals that induce apoptosis), and more recently exercise. The 
localization of p53 either to the mitochondrial membrane or to the matrix dictates the signaling 
response. With apoptotic stress signals, p53 localizes to the mitochondrial membrane to interact 
with multi-domain members of the anti- and pro-apoptotic Bcl-2 family to inhibit/activate 
respectively, leading to robust MOMP induction (168). This process is facilitated by Bax/Bak 
oligomerization on the outer membrane to initiate pore formation as well as opening of the 
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mitochondrial permeability transition pore (mtPTP) that simultaneously releases lethal proteins 
to activate enzymatic caspase machinery for chromatin degradation, and increases mitochondrial 
swelling through cytosolic influx (168). On the other hand, with exercise stimuli, p53 can 
localize to the mitochondrial matrix to regulate mtDNA integrity for maintenance and 
proliferation of the mitochondrial pool.  
3.2. p53 Signaling Pathways  
Within the last decade, the mechanisms by which p53 regulates homeostasis are 
becoming apparent and may be distinguished based on the intensity of oxidative stress. Exquisite 
sensitivity of the p53 pathway is essential, as highlighted by studies assessing cellular function 
when p53 is overexpressed, reduced, or completely removed (69). Though the well-known 
molecular functions of p53 have been determined through knockout models, overexpression 
models cause an imbalance in normal p53 isoform ratios leading to a premature aging phenotype 
(69, 103, 163). Though numerous studies have attempted to fully understand p53 regulation of 
signaling pathways, the debate still ensues on how cellular stress signals induce its activation. 
3.2.1. Organelle Turnover and Destruction: Autophagy/Apoptosis 
To maintain a healthy organelle pool and optimal cellular function, selective signaling 
processes, such as autophagy, are induced in response to stress to catabolize accumulated 
misfolded/aggregated proteins, dysfunctional organelles, and intracellular pathogens (49). When 
cellular dysfunction reaches a critical level, apoptosis is induced. Autophagy and apoptosis are 
processes that involve overlapping kinase and transcriptional regulators, but they differ in their 
activation depending on the level of genotoxic intensity. p53 is an upstream transcriptional 
regulator of both pathways (Figure 3).   
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p53 
p53 AMPK 
TSC1 
TSC2 
mTORC1 
ATG 
ULK1 
Beclin  
Complex ATGs 
LC3-II 
LC3-I 
Phagophore 
p62 
Ub 
Ub 
p62 
BNIP3 
Ub 
Ub 
Nix 
PINK1 
Parkin 
p 
ROS 
Lysosome 
AA 
Cargo  
Selection 
Autophagosome 
Degradation  
& Efflux 
LC3-II 
LC3-II 
LC3-II 
LC3-II 
Fusion 
Bcl-2 
Bax, PUMA, NOXA 
NOXA 
PUMA 
Cytchrome C 
AIF 
Endo G 
APAF-1 
Caspase 9 
Caspase  
Cascade 
Bcl-2 
p53 
p53 
ULK1 
APOPTOSIS 
AUTOPHAGY 
sestrins 
X 
Bcl-2 
ROS 
ROS 
Pro-Apoptotic 
Anti-Apoptotic 
Nucleus 
21 
22 
 
Figure 3. p53 maintenance of cellular homeostasis and survival through regulation of the 
autophagy/mitophagy and apoptosis pathways. Autophagy and apoptosis are similar 
processes that involve overlapping kinase and transcriptional regulators to maintain cellular 
homeostasis through degradation of dysfunctional organelles and cells, respectively. However, 
they differ in their activation depending on the level of genotoxic intensity imposed on the cell. 
p53 is interestingly an upstream transcriptional regulator of both pathways. p53 can upregulate 
the autophagy pathway through the transcriptional activation of AMPK, TSC1 and 2 (Tuberous 
Sclerosis Complex 1 and 2), and sestrins 1 and 2 to ultimately inhibit mTORC1 (mammalian 
target of rapamycin complex 1), a transcription factor that dephosphorylates the serine threonine 
kinase ULK1 (Unc-51 Like Autophagy Activating Kinase 1), a central regulator of autophagy 
induction. Cytoplasmic p53 levels inhibit autophagy by blocking the activation of ULK1. With 
mTORC1 inhibition, ULK1 can form a complex with ATG13 (autophagy related gene 13) and 
FIP200 (FAK family kinase-interacting protein) allowing for Beclin-1 complex activation with 
PI3K (phosphoinositide 3-kinase) and AMBRA1 (activating molecule in Beclin-1-regulated 
autophagy) for subsequent initiation of phagophore formation. Additionally, ATGs (ATG3, ATG 
4, ATG5, ATG7, ATG10, ATG12, ATG16) allow for LC3-I to LC3-II (Microtubule-associated 
protein 1A/1B-light chain 3) lipidation which can then surround the phagophore and direct it to 
tagged mitochondrial membrane proteins (ubiquitinated VDAC (Voltage-dependent anion-
selective channel 1) and associated adaptor protein p62). This process is initiated through 
increased mitochondrial ROS levels and decreased membrane potential leading to PINK1 
(PTEN-induced putative kinase 1) phosphorylation of  Parkin. Additional membrane proteins 
like Nix and BNIP3 assist in phagophore binding and surrounding of the dysfunctional organelle. 
The damaged mitochondria is then engulfed in the autophagosome and directed to the lysosome 
where it can then fuse with the assistance of LAMP 1 and 2 (Lysosome-associated membrane 
proteins 1 and 2) and be degraded into functional amino acid (AA) components. p53 has been 
shown to additionally transcriptionally regulate LAMP 2 and cathepsin D lysosomal proteins, 
and therefore plays a role in autophagic substrate clearance. With exercise, there may be a shift 
favouring autophagy to regulate cellular homeostasis, whereby degraded amino acid components 
may inhibit activation of apoptosis. In the nucleus, p53 can further transcribe proteins to 
maintain cellular homeostasis such as through p21, a cellular senescent protein, and Bcl-2, a 
protein preventing Bax/Bak membrane integration and oligomerization and subsequent MOMP 
(mitochondrial outer-membrane permeabilization) (indicated by the black line in apoptosis). 
MOMP is a process of intrinsic apoptosis in which p53-transcribed apoptotic markers localize to 
the mitochondria and BH3-only proteins (BID or BIM) can induce the oligomerization of Bax 
leading to cytochrome c release, among other proteins, which can then bind APAF-1 to caspase 9 
to initiate the caspase cascade and subsequent apoptosome formation for completion of the 
apoptotic process (indicated by blue line in apoptosis). 
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p53 can act as either an endogenous repressor or activator of autophagy depending on its 
localization with stress intensities. Under basal non-stressful conditions, cytosolic p53 represses 
autophagy by interacting with the FIP200 protein of the upstream ULK1-ATG13-ATG101-
FIP200 complex thus blocking the formation of autophagosomes and inhibiting autophagy (104, 
160, 182). However, upon cellular stress, p53 localizes to the nucleus to transcriptionally 
regulate activators of the pathway like AMPK and TSC 1 and 2, core-machinery components 
including numerous ATG’s, autophagy initiator ULK1, and lysosomal protein-encoding genes 
such as cathepsin D and LAMP 2 (80). Nuclear p53 therefore upregulates autophagy through the 
activation of AMPK, TSC1 and 2, and sestrin1 and 2 which inhibit MTORC1, thus leading to the 
activation of ULK1. ULK1 complex initiation can then activate the Beclin-1 complex 
concomitant with PI3K and AMBRA1 for phagophore formation, which is assisted by ATGs that 
lipidate LC3-I to LC3-II to surround the phagophore and direct targeted organelles/dysfunctional 
proteins to the autophagosome (114). Autophagosomes travel along microtubules to fuse with 
the lysosome for degradation into functional amino acids. Interestingly, p53 can also localize to 
the mitochondria to interact with cyclophilin D which promotes an association with ANT-I in the 
inner mitochondrial membrane to open the mitochondrial transition pore (31, 104). This process 
stimulates autophagic removal of dysfunctional mitochondria detected by the dissipated proton 
gradient (104). However, the opening of this pore beyond a critical threshold can lead to MOMP 
and cell death. Thus a fine line in the crosstalk between these two pathways is required.  
There are numerous ways in which cell death can be induced: extrinsic apoptosis, 
intrinsic apoptosis, regulated necrosis, autophagic cell death, and mitotic catastrophe (104). p53 
is primarily involved in regulating the intrinsic apoptosis pathway. Upon high levels of genotoxic 
stress, p53 nuclear localization allows for its transcriptional regulation of numerous pro-
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apoptotic genes such as Bax, Puma, and Bid (34). Furthermore, p53 has an extra-nuclear function 
where it can bind and inactivate Bcl-2 while activating multi-domain Bcl-2 family proteins (Bak 
and Bax), or it can itself localize to the mitochondria to interact with cyclophilin D; both 
processes induce MOMP (34). MOMP is a process of intrinsic apoptosis in which p53-
transcribed proteins localize to the mitochondria, and with the assistance of BH3-only proteins 
(BID, BIM, PUMA, NOXA), to induce the oligomerization of the Bax/Bak heterodimer on the 
outer mitochondrial membrane (104). This leads to an opening in the mitochondrial transition 
pore (mtPTP). This pore structure is composed of a hexokinase on the cytosolic surface, VDAC 
on the outer mitochondrial membrane, creatine kinase and nucleoside diphosphate kinase within 
the intermembrane space, and ANC on the inner mitochondrial membrane (15). Thus, the 
increased release of cytochrome c, among other proteins like AIF and EndoG, initiates APAF-1 
association with caspase 9 to induce the caspase cascade and subsequent apoptosome formation 
for completion of the apoptotic process (104). 
3.2.2. Cellular Maintenance of Stress: Cell Cycle Arrest/Senescence/Antioxidants 
Upon exposure of low to moderate levels of cellular stress, the cell manages these 
perturbations through regulatory pathways including antioxidant enzyme production and cell 
cycle arrest and senescence, as a safeguard mechanism against cell death or mutation. Redox 
signaling, through the generation of ROS and its by-products hydrogen peroxide, 
alkoxyl/peroxyl radicals and peroxynitrite, can either lead to detrimental cellular oxidative stress 
when produced in large quantities, or they can act as a second messenger system under low to 
moderate stress levels (97). Upstream kinases regulated by ROS include p38 MAPK, ATM, and 
ERK which can phosphorylate p53 on cysteine residues 124, 135, 141, 182 and 277, as these 
contain redox-sensitive thiol groups (97). Under non-toxic ROS conditions, p53 sustains 
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antioxidant gene expression by regulating the levels of MnSOD, catalase, SCO2, and GPX1 (97). 
MnSOD converts oxygen radicals to H2O2, and GPX and catalase converts H2O2 to H2O. 
Furthermore, an interesting cross-talk exists between p53-mediated antioxidant transcription and 
the major antioxidant Nrf2-KEAP1-ARE signaling pathway. Nrf2 levels are maintained by its 
negative regulator KEAP1, which directs Nrf2 to the CUL3 E3 ubiquitin ligase for proteasomal 
degradation (37). Interestingly, the p53-target gene p21 can stabilize Nrf2 by binding KEAP1 
and preventing its degradation (32, 137). The Nrf2 pathway reciprocates by transcribing NQO1 
which interacts with p53, thus blocking its degradation by the 20S proteasome (10, 137). Though 
the existence of this beneficial cross-talk yields new roles for p53 in mediating oxidative stress, 
there are discrepancies wherein the Nrf2 pathway can increase p53 degradation by Mdm2, and 
p53 can reduce Nrf2 binding to the ARE through competitive inhibition (43, 137, 181). With 
greater ROS levels, p53 can switch to trans-activate pro-oxidant ROS-generating enzymes like 
NQO1, PIG3/6 and FDXR, and apoptotic genes including Bax, Puma, and p66Shc to uncouple 
mitochondrial electron transport, leading to MOMP (97, 121). Hence, a fine balance between 
antioxidant production and incoming oxidants is required; if the balance tips, oxidative stress 
ensues and cell cycle arrest/senescence, autophagy, and apoptosis pathways become activated.  
Cell cycle arrest is the initial step of cellular senescence, whereby cells sustaining limited 
DNA damage can initiate arrest at the G1 and G2 phase during checkpoints G1/S and G2/M, 
respectively to afford the opportunity to repair DNA damage (80). G1 arrest prevents replication 
of damaged/mutated DNA, while G2 arrest prevents improper chromosomal segregation (185). It 
is important to note that skeletal muscle cells cannot undergo cell cycle arrest and senescence as 
they are post-mitotic; mitotic stem cells, or satellite cells, can undergo this process. p53 is an 
upstream transcriptional regulator of numerous cell cycle arrest genes, the most prominent being 
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p21, a cyclin/cyclin-dependent kinase inhibitor (1, 134). p21 functions to induce G1 arrest 
following DNA damage by inhibiting kinase phosphorylation and activation of pRb, or by 
binding to E2F and PCNA (1, 134). The p21-PCNA complex blocks PCNA’s role as a 
polymerase processivity factor in DNA replication, but not its DNA repair function (94). The Rb 
protein induces senescence rather than cell cycle arrest by repressing gene transcription and 
progression into the S phase (48). The G2/M checkpoint is additionally proposed to be regulated 
by p53 to prevent premature entry into the S phase (94).  Gadd45a and 14-3-3-σ are genes 
transcriptionally regulated by p53 to stimulate G2 arrest. .  
In response to cumulative increases in stress levels causing DNA damage, such as by IR 
or oxidative stress, the p53 pathway is activated resulting in cellular senescence (134). Senescent 
cells lack proliferative markers, have an enlarged flattened morphology, and express the 
lysosomal enzyme β-galactosidase (26). p53 is activated by upstream signals including ATR-
ATM (phosphorylates p53 at Ser15), Chk2 (phosphorylates p53 at Ser20), PCAF (acetylates p53 
at K320), and PML-IV (acetylates p53 at Lys382 and phosphorylates at Ser15 and Ser46), 
allowing for its dissociation from Mdm2 and its nuclear localization and transcription of 
senescent genes (134). p53 transcribes senescent genes  p21, DEC1, and  PAI-1 which inhibits a 
protease that promotes the G1/S transition (134). Conserved sequence identity in the DBD 
regions of p53-regulated genes allows for p53 family members p63 and p73 to activate p21 and 
DEC1, thus allowing for redundancy (134).  
3.2.3. Improvements to Cellular Health: Mitochondrial Biogenesis, Metabolism 
p53 promotes cell viability by enhancing the activation of catabolic pathways to maintain 
energy production during periods of low nutrient availability (102). These metabolic signaling 
pathways include fatty acid oxidation (FAO), mitochondrial respiration, and glucose metabolism. 
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Within the glucose energy pathway, p53 limits glycolytic flux directly at the transcriptional level 
through repression of glucose transporter genes GLUT1 and GLUT4, or indirectly through 
inhibition of NF-kB (79, 102, 150). p53 can additionally suppress the insulin receptor promoter, 
thereby further reducing cellular glucose uptake (102, 173). p53 also binds PGM to inhibit 
enzyme catalysis of 1,3-biphosphoglycerate to 1,2-bisphosphoglycerate, suppresses ChREBP to 
stimulate lipid and nucleotide biogenesis, and regulates G6PD to catalyze the rate limiting step in 
the pentose phosphate pathway (PPP) (102, 160). p53 further transcriptionally upregulates 
TIGAR which inhibits fructose-2,6-biphosphate, thus impairing glycolysis progression and 
diverting glycolytic intermediates into the PPP (13). Though overwhelming evidence indicates 
that p53 negatively regulates glycolysis, depending on the energy requirements of the cell, p53 
can switch to facilitate glycolysis by transcriptionally regulating hexokinase II levels which 
catalyzes the first step in glycolysis (106). A fine balance in glycolytic energy production is 
therefore required. The Warburg effect, a shift towards a high glycolytic rate for rapid ATP 
synthesis caused by mutated p53, can lead to increased cellular proliferation (121). FAO is 
another energy pathway regulated by p53. Nutrient deprivation is one mechanism which 
mediates AMPK-dependent activation of β-oxidation to initiate p53 activation of fatty acid 
uptake and mitochondrial oxidation proteins (86). Inhibition of p53 on the other hand reduces 
mitochondrial biogenesis and decreases oxygen consumption, facilitating a more anaerobic 
environment and thus changing the ATP production ratio of glycolysis versus oxidative 
phosphorylation from 3:1 rather than the normal 1:3 ratio (121). Mitochondrial respiration is 
regulated by p53 through its promotion of oxidative phosphorylation genes such as the SCO2 
regulator of complex IV composition of the ETC,  AIF which is an essential subunit of complex I 
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of the ETC, PGC-1α-mediated activation of NUGEMPs such as COX-IV, and post-
transcriptional regulation of COX-II by p53R2 on mtDNA (19, 102, 107, 153).  
Proper mitochondrial function, indicated by appropriate respiration and ROS output, 
allows for these organelles to exist as part of a dynamic network regulated by fusion and fission 
events. Knockout (KO) studies on p53 have revealed reduced fission events due to the ability of 
p53 to transcriptional regulate Drp1, an adaptor protein that serves as a mitochondrial targeting 
sequence, and Fis1 a recruiter of mediator fission proteins (18, 95, 145). p53 also regulates 
fusion by transcriptionally activating Mfn2, a GTPase that signals for accelerated mitochondrial 
fusion events (118, 172). No evidence has yet concluded the vital necessity for p53 maintenance 
of the mitochondrial network due to the presence of redundant signaling. However, 
mitochondrial morphological detriments have been observed using p53 KO models. A deficit in 
the volume of SS (61%) and IMF (70%) mitochondrial subfractions was observed in the absence 
of p53, with further structural deficits in IMF mitochondria evidence by reduced reticular 
network and in the SS mitochondria which displayed cristae deformities (141). These resulting 
morphological differences are a result of a lack in p53 expression in the nuclear and 
mitochondrial compartments. In the nucleus, p53 transcribes its own NUGEMPS such as COX 
IV, SCO2, AIF and Tfam, or it can transcribe PGC-1α which co-transcriptionally regulates NRF-
1 and 2 to enhance the expression of Tfam, cytochrome c, ETC proteins, and import machinery 
proteins (64, 75, 141).  Within the mitochondria, p53 displays an intrinsic 3’Æ 5’ exonuclease 
activity for base excision repair, interacts with Polγ and mtDNA to increase replication, 
facilitates Tfam binding to mtDNA to regulate copy number and transcriptional activity, and 
transcribes vital COX subunits such as COX I and II (Figure 4) (2, 141). As such COX activity, a  
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Figure 4. p53 regulation of mitochondrial biogenesis with exercise. Muscular contractions 
induce the activation of numerous signals, such as kinase phosphorylation, increased ROS 
production, enhanced calcium production through action potential generation, and an increased 
AMP: ATP ratio, which collectively leads to p53 phosphorylation of its Serine15 residue to 
enhance its stability and activation. Once activated, p53 cellular localization to the mitochondria 
through PIM (protein import machinery), rather than to the nucleus, is increased and assisted by 
CHCHD4 (coiled-coil-helix-coiled-coil-helix domain containing 4) import machinery by 
cysteine-135 residue modification of p53. As shown in previous studies, once in the 
mitochondria, p53 has numerous roles including assisting Tfam, a nuclear p53-regulated gene, in 
binding to the D loop region (regulatory sequences that contain the only three promoters of 
mtDNA) where it can regulate mitochondrial replication and transcription. Additionally, p53 can 
bind polymerase gamma to the mtDNA, the only polymerase to regulate the mitochondrial 
plasmid, and can also increase 16S rRNA production to facilitate improved translation. 
Ultimately, once in the mitochondria, p53 can increase mitochondrial biogenesis through 
enhanced production of ATP by improving the efficiency of the electron transport chain. Though 
there may be greater mitochondrial relative to nuclear p53 localization, nuclear p53 levels are 
still required to bind to the regulatory sequence regions of NUGEMP promoters. This is 
accomplished both through p53’s direct transcription of mitochondrial biogenesis proteins such 
as Tfam, COX IV (Cytochrome c oxidase subunit 4), SCO2 (Cytochrome C Oxidase Assembly 
Protein), and AIF (Apoptosis Inducing Factor) as well as its regulation of PGC-1α at multiple E-
Boxes to enhance NUGEMP transcription. p53 additionally regulates glycolysis through the 
regulation of enzymes, such as TIGAR (TP53-inducible glycolysis and apoptosis regulator), 
which impairs fructose-2,6-bisphosphate in the glycolytic pathway (4). Through glycolysis 
inhibition, there is a greater reliance on the pentose phosphate pathway (PPP) and fatty acid 
oxidation (FAO) to increase oxidative phosphorylation and energy production. It is predicted that 
with training, there will be an increased drive for p53 cellular localization, rather than remaining 
in the cytoplasm where is can be degraded by the Mdm2 – MdmX (Mouse double minute 2 
homolog) complex which functions as an E3 ubiquitin ligase to direct p53 to the 26S proteasome 
for degradation to maintain a low pool of this protein. Interestingly, Mdm2 can signal for p53 
mono-ubiquitination within the nucleus, thus exposing its nuclear export signal to allow for 
cytoplasmic accumulation and poly-ubiquitination to increase degradation. Abbreviations: Ψ = 
membrane potential. 
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marker of mitochondrial biogenesis, was reduced by 26% in p53 whole body KO mice (141). 
This complex, essential for its role in aerobic respiration, is made up of 13 subunits, both nuclear 
and mtDNA-encoded, and primarily catalyzes electron transfer from reduced cytochrome c to 
molecular oxygen. p53 KO models indicate impaired respiration, evident by a 40% reduction in 
state 3 IMF respiration, and increased ROS production observed by 1.5-3 fold increases in state 4 
and state 3 levels in IMF mitochondria (141). The greater deficits observed in the IMF 
subfraction pose significant repercussions as this population comprises 80-85% of the total 
mitochondrial volume (67). These results allude to the vital requirement of p53 in the regulation 
of proper mitochondrial morphology and adaptability towards incoming stimuli.  
3.2.4. Does a Crosstalk Exist Between Pathways?  
p53 has been dubbed the “molecular policeman” for its role in lowering ROS levels and 
repairing DNA to promote survival (good cop); with high stress intensity it initiates cellular 
senescence and cell death (bad cop) (50). Therefore, coordinated communication is required, i.e. 
“cross-talk”, between the signaling mechanisms regulated by p53.  
In pre-mitotic satellite stem cells, temporary cell cycle arrest is initiated in response to 
exogenous or endogenous sources of oxidative stress. When stress accumulates and the repair 
mechanisms are overwhelmed, p53 downregulates the proliferative potential by inducing cellular 
senescence (16). The p53 target p21 is the major rheostat of this pathway. This is confirmed by 
one study whereby at day 1 cell cycle arrest is induced, and when p21 is switched off they can 
revert back to their proliferative state, but by day 3 cells acquire a senescent morphology (17, 
29).  
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On the other hand, in post-mitotic differentiated skeletal muscle cells, two major 
pathways are employed to limit the damage induced by oxidative stress, in order to enhance cell 
survival. The antioxidant enzyme production system is evolutionarily conserved to protect and 
preserve cellular components, and is thus is the first responder to cellular oxidative stress. Redox 
imbalance plays a pivotal role in driving cellular deterioration. p53-dependent processes that 
enhance antioxidant production can be accomplished by either p21-mediated activation of Nrf2 
transcription at the ARE region, or p53 specific binding to the ARE (32). Additionally, p53 can 
transcriptionally activate upstream autophagy regulators such as AMPK and sestrins, as well as 
additional regulatory proteins including Ulk1 and Atg’s (36, 41, 80, 174). Prolonged stress 
induces mitochondrial depolarization and fragmentation to further assist in mitophagic removal 
(44). Failure to restore homeostasis through the aforementioned signaling pathways, can lead to 
the transcription of cell death proteins towards apoptosis, rather than autophagy (120, 160).  
Essential crosstalk is required for mechanisms facilitating antioxidant enzyme 
production, metabolism, and mitochondrial biogenesis. p53 promotes a shift away from 
glycolysis under exercise stimuli, navigating away from the well-known cancerous Warburg 
pathway (184). Mitochondrial integrity and oxidative capacity is maintained by antioxidant 
systems through both p53-dependent and independent mechanisms, with a fine coordination 
occurring between the upstream regulators Nrf2, p53, and PGC-1α. With mitochondrial 
biogenesis, increased respiration and ROS by-products are released, requiring a larger volume 
response by antioxidants regulators. If ROS production increases to a substantial level, inhibition 
of mitochondrial biogenesis may occur to allow antioxidant removal of ROS before continuing 
the mitochondrial proliferation processes (16).  
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The literature available on the regulation of numerous signaling mechanisms by p53 is 
astounding. However, researchers are at the point of amalgamating primary research to create 
mechanistic models of p53 to determine how these different pathways exhibit a fine crosstalk 
with various oxidative stressors, such as exercise, to maintain cellular homeostasis.  
3.3. p53- Mediated Skeletal Muscle Adaptations with Exercise 
3.3.1. Systematic Review of Literature: p53 and Acute vs Chronic Exercise 
Acute and chronic contractile activity triggers a plethora of signals that induce beneficial 
metabolic and biochemical adaptations to enhance muscle health and performance. For example, 
the moderate increases in ROS produced by exercise are able to repair and strengthen the 
oxidative capacity of the cell by increasing mitochondrial content and fuel oxidation (96, 133, 
154). To date, a total of seven exercise studies in animal models have assessed the role of p53 
regulatory pathways with exercise (Table 1). 
One bout of acute exercise is sufficient to initiate transcriptional signaling towards 
mitochondrial biogenesis (33, 142). A host of upstream signals, such as ROS production and 
calcium signaling, enhances AMPK and p38 MAPK kinase expression leading to Ser15 
phosphorylation of p53 to facilitate both nuclear and mitochondrial localization (66, 142–144). 
In the nucleus, p53 binds to response elements within the PGC-1α promoter, specifically at site -
2317 in mouse or -1237 in humans, to enhance the expression of NUGEMPs such as Tfam, COX 
IV, SCO2, and AIF (38, 98, 107, 124, 143). With an acute exercise bout, a recovery period of ~3 
hours further improves signaling events (i.e. nuclear p53 localization and transcriptional 
regulation) to further enhance mitochondrial biogenesis proteins in both rodent and human 
models (52, 144, 158). p53 localizes to mitochondria where it acts as an exonuclease on mtDNA,  
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Table 1: Literature compiled on p53 and exercise regimens. Literature (7 studies) was 
grouped by acute (2 studies) or chronic (5 studies) exercise. Arrows indicate whether markers 
regulated by this form of stress increased (↑) or decreased (↓) in expression and/or activation. If a 
WT vs KO model is employed, only the results from the WT group are indicated. A caveat to 
this is the study published by Safdar et al., Skelet Muscle, 2016 which examines exercise in 
Polg1 MSKO models only. Various time measurements are indicated for the length of imposed 
stress. This table has been adapted from Beyfuss & Hood (2018). Abbreviations: WT 
(wildtype), KO (knockout), HT (heterozygous), MSKO (muscle specific KO), mito 
(mitochondria), SS (sub-sarcolemmal), IMF (intermyofibrillar), PAT (patagialis), ADL (anterior 
latissimus dorsi).  
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and increases the expression and binding of Tfam and Polg1 to mtDNA to maintain genomic 
integrity, and enhance SS and IMF mitochondrial biogenesis (2, 11, 144, 180).   
In contrast to acute bout of exercise, training is classified as repeated bouts of endurance 
exercise interspersed with recovery sessions over a period of time. The result of chronic exercise 
is a heightened adaptive state in which signaling responses to each exercise bout is attenuated, 
including ROS production (98). This adaptation is modulated by p53 signaling which is one of 
the major upstream regulators that confers increased mitochondrial content and improved 
mtDNA integrity, decreased cellular senescent and apoptotic signaling, less emphasis on 
glycolytic energy utilization and more on oxidative phosphorylation, reduced lactate production, 
and ultimately improved VO2 max and skeletal muscle performance (124, 139, 141). Though it is 
true that a 5-fold reduction in the exercise ability of p53 whole body KO mice is observed during 
an 8-week voluntary wheel running program, and that the subcellular localization of p53 seems 
indispensable for exercise-mediated mtDNA repair (initiator of Tfam-Polg1 complexes) and 
mitochondrial biogenesis and respiration (transcription of NUGEMPs, TIGAR, SCO2, p53R2), 
the absence of p53 does not seem to necessarily hinder the ability to adapt with exercise (124, 
139, 141). One study showed a similar increase in mitochondrial content compared to wildtype 
(WT) mice in response to exercise, indicating that exercise provokes the overlap of redundant 
signals to induce normal adaptations in mitochondria (141). An interesting divergence in the 
signaling patterns in humans arises in response to exercise, whereby short interval training, more 
than continuous exercise in humans, increases p53 Ser15 phosphorylation and PGC-1α nuclear 
localization for enhanced mitochondrial biogenesis and respiration (51, 52). However, another 
study reported no differences in signaling or gene expression when high and lower intensity 
exercise regimens were performed, when matched for workload (12). Therefore, further 
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examination into the variable parameters associated with exercise, including sex, age, exercise 
protocol and muscle type, is required.  
3.3.2. Regulatory Signaling Pathways with Endurance Exercise 
Though mitochondrial biogenesis is the well-known adaptation that enhances muscle 
plasticity with exercise, as described above, there are numerous additional signaling mechanisms 
regulated by p53 under the influence of aerobic exercise to improve skeletal muscle health (16).  
Antioxidant production is one of the first signaling pathways activated in response to 
increased oxidative stress, i.e. ROS generation, with acute and chronic exercise. In skeletal 
muscle, antioxidants are produced in an intensity-dependent manner and commonly include 
MnSOD, GPX, CAT, and NQO1 (39, 59, 91, 131). Nrf2, the major upstream regulator of these 
antioxidant enzymes, is increased by 1.5-fold in response to exercise training (37). p53 also 
transcriptionally regulates many of these enzymes including MnSOD, GPX1, and GLS2 to 
maintain cellular integrity (23). The metabolic shift in energy substrate utilization is another 
early response mechanism to improve mitochondrial handling of exercise. p53 directly 
transcribes glycolysis regulators (i.e. TIGAR) to switch substrate utilization towards oxidative 
phosphorylation and away from glycolytic energy usage, thereby reducing lactate production.  
Exercise, though a beneficial form of induced “oxidative stress” due to signaling ROS-
mediated cascades, is still an oxidative stressor that can activate various pathways. In response to 
exercise, satellite cells play a pivotal role in regeneration and are activated, proliferate, undergo 
self-renewal, and differentiate into mature muscle cells (86, 179). The cell cycle arrest pathway 
is activated with moderate endurance exercise and is transcriptionally regulated by p53. This is 
confirmed by Yu et al. (2016), whereby mice trained for 10 weeks expressed elevated levels of 
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p21 (29%), PTEN (12%), and IGFBP-3 (25%) compared to sedentary controls. Greater 
intensities of oxidative stress, such as telomere erosion, DNA lesions and high ROS levels, 
induces cellular senescence and can be a precipitating cause for sarcopenia, the degenerative loss 
in skeletal muscle mass with age (21, 53). This pathway is not commonly activated with exercise 
as exercise is often used a treatment to reverse sarcopenia or pathological muscle degeneration.  
Autophagy is known to be activated with acute endurance exercise, however  whether it 
is mediated by p53 is ambiguous (54, 57, 58, 164). One study by He et al. (2012) showed 
increased lipidated LC3II and degraded p62 with acute exercise, while Saleem et al. (2014) 
found no differences in these proteins in WT mice following an exhaustive exercise bout. 
However, an increase in ubiquitination (Ub), a tag for the removal of cellular debris, was found 
in p53 KO mice indicating p53-independent targeting of dysfunctional organelles for degradation 
(143). This discrepancy may be due to a lack of intensity or duration of the exercise protocol. 
Perhaps a greater intensity is required, as indicated by one study whereby an upregulation of 
autophagy proteins was found after an ultraendurance bout of exercise lasting 24 hours in 
humans (74). Mitophagy, on the other hand, is upregulated with acute exercise as indicated by 
increased mitochondrial LC3II, p62 and Ub expression, which can also function independently 
of p53 (143). Maintenance of the mitochondrial reticulum is further maintained through fission 
and fusion events whereby chronic contractile activity increases the reticulum through increased  
(53%) Mfn2 protein, known to have a p53-response element within its promoter, and Opa1 (71). 
Should the mitochondria become dysfunctional in response to exercise, p53-regulated fission 
proteins such as Drp1 can be activated to shuttle damaged mitochondria towards mitophagy. 
Further research is warranted to determine the p53-regulated maintenance of the mitochondrial 
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reticulum through fusion and fission events with exercise, and once fission is underway, the 
process by which both mitophagy and autophagy are induced in skeletal muscle. 
With strenuous bouts of exercise, high ROS levels can destabilize the mitochondrial 
membrane to induce apoptosis, as evidenced by increased DNA fragmentation and reduced Bcl-2 
levels (146, 151). However, it has been shown that an 8 week exercise training protocol, reduced 
apoptosis by increasing Bcl-2 and reducing APAF-1 and Bax transcript levels; signals all 
dependent on p53 activation  (151). Furthermore, another study revealed with chronic contractile 
activity an increase in mitochondrial biogenesis and a simultaneous decrease in apoptotic 
susceptibility indicated by reduced IMF ROS production and diminished cytochrome c and AIF 
protein release (4). As apoptosis is the last resort to maintaining cellular integrity, earlier 
signaling pathways in response to exercise are activated in an intensity-dependent manner. 
3.3.3. Applicable Models to Study p53 Function 
Live animal work (i.e. in vivo experimentation), is the typical stage following in vitro cell 
work, and before detailed human analysis. The benefits of utilizing rodent models, which share a 
99% genomic similarity to humans, allows for further genetic engineering to determine the 
morphological and molecular regulation by specific genes (167). Various models have been 
utilized including transgenic, tissue specific deletions/knockdowns, and whole body gene 
deletions/knockdowns.  
Whole body genetic deletions of the p53 gene have been utilized for decades in cancer 
research and are now expanding their use to understand other p53-mediated pathways. To create 
this model, a neomycin cassette is used to replace approximately 40% of the coding sequences in 
the TRP53 locus extending from exons 2 to 6, which contains the translation start codon, of the 
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total 11 exon structure (73). The average age for spontaneous tumour development in these mice 
is approximately 6 months of age, after which they die by 10 months of age (40). Though 
phenotypically there are no observed differences, deficits in exercise capacity have been noted to 
be a result of reduced gait synchronization (25, 141). Campana et al. (2003), demonstrated 
differences in fiber type distribution  whereby in the EDL, p53 KO mice displayed significantly 
fewer fast fibers (Type IIA) and more hybrid fibers (IC) than their WT counterparts, while in the 
oxidative soleus muscle p53 KO muscle contained a greater percentage of IIA than IA fibers. As 
it is unknown whether the discrepancies in skeletal muscle function are a result of p53 deletion in 
the muscle, or p53 deletion in neural networks, further investigations are necessary. Work 
previously described on understanding the phenotypic characteristics, morphological differences, 
skeletal muscle function, and signaling pathways mediated by p53 has been widely published 
using this whole body knockout model (107, 124, 141, 143–145). 
Though a wealth of evidence is present confirming the essential role that p53 plays in 
regulating whole body metabolism and skeletal muscle mitochondrial function, the importance of 
p53 in regulating skeletal muscle health cannot be established from whole body p53 deletion. 
Thus, a muscle specific p53 knockout model, one that has been recently developed, allows for 
greater analysis into p53 regulatory signaling pathways solely in skeletal muscle (47). This 
model is created by breeding two mouse strains. The first strain is a transgenic mouse expressing 
the Cre recombinase gene driven by the muscle creatine kinase (MCK) promoter found in 
skeletal muscle (47). The second strain is a homozygous mouse with a floxed p53 allele, 
whereby LoxP restriction sites are located at exons 2 and 10 (47). Once these two strains breed, 
their progeny will have the functional part of the p53 gene, flanked at exons 2 and 10, excised by 
Cre recombinase to create a muscle specific knockout (Figure 5). Efficiency of the knockout 
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Figure 5. Rodent Genetic Models. (A) Wildtype (WT) mice contained regular gene expression 
and optimal ability for transcription and translation; (B) Whole Body (WB) knockout (KO) mice 
were created using a neomycin (NEO) cassette to replace 40% of the p53 coding region by 
homodimerizing with exons 2 and 6 thus replacing this region so that it cannot be translated; (C) 
Muscle Specific KO (mKO) mice were created using a Cre-lox recombinase system. In one 
mouse, exons 2 and 10 are flanked by loxP sites. These mice are bred with mice that contain a 
cre recombinase gene under the control of a promoter of interest, i.e. the MCK promoter for 
skeletal muscle. The progeny will have the loxP sites cleaved leading to removal of the p53 
allele and ablation of its expression solely in skeletal muscle. 
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was confirmed by measuring p53 mRNA and protein expression which revealed a 70% and 60% 
reduction respectively, indicating that this the Cre-lox recombination system does not completely 
remove functional p53 protein from skeletal muscle, as it does in the whole body KO mice (155). 
One theory is that the observed p53 protein reflects the expression of protein from non-muscle 
fibre cells within skeletal muscle tissue, however further analysis is required to determine 
whether the present protein is functional (155). According to observations following these mice 
across 15 months of age, no overt differences in total body weight, skeletal muscle mass, muscle 
histology, grip strength, or organ/tissue (heart, liver, kidney, fat pad) masses were observed (47). 
Further analysis into signaling mechanisms was performed indicating no difference in 
mitochondrial content, evidenced by similar electron transport chain protein expression and 
citrate synthase enzyme activity (155). Furthermore, mitochondrial biogenesis proteins were 
comparable between genotypes, while mitochondrial dynamics was analogous with comparable 
fission and fusion protein expression (155). Lastly, fatty acid transport and carbohydrate 
metabolism were similar between groups (155).  Therefore, p53 in fully-differentiated skeletal 
muscle may not be required for maintenance into adulthood, as its absence does not induce any 
overt phenotype nor does it affect any significant signaling pathways (47, 155).  
To elucidate whether the alterations in exercise capacity observed with training are the result 
of p53 loss in skeletal muscle and not the result of the systemic deletion of p53, both mouse 
models are useful to employ. One theory on the observed differences that may exist between the 
neomycin cassette insertion (WB) and Cre-lox recombination-mediated p53 deletion (mKO), 
may indeed be a result of the timing of p53 deletion. In mKO mice, p53 would be deleted at 
approximately 13 days into embryonic development, whereas in the germline WB mice, p53 is 
absent throughout the entirety of embryonic development (100, 149). As p53 plays a significant 
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role in the differentiation phase of myogenesis, greater mitochondrial deficits may be observed in 
the WB mice as a result of its loss during this developmental period (155). Furthermore, it is 
posited that the impairments observed in mitochondrial content and function in WB KO mice is a 
secondary consequence of the loss of p53 in alternative tissues, rather than loss of p53 in skeletal 
muscle fibres. Previously, these WB mice have been observed to experience lower spontaneous 
activity, which could be a result of p53 KO loss in skeletal muscle, however it could also be a 
result of the loss of p53 in neural networks. Therefore, further research is warranted to determine 
the role p53 plays neurologically.   
3.3.4. Systemic Benefits: Neurological Maintenance 
Consistent endurance aerobic exercise provides many systemic benefits that extend life 
expectancy and reduce morbidity by improving cardiovascular function, shifting substrate 
requirement towards lipid utilization, and ameliorating contractile and metabolic dysfunction due 
to disease states and aging (66). The role of p53 in skeletal muscle with exercise is more well-
known compared to its systemic effects, especially in neurological functioning with exercise.  
Regular engagement in aerobic exercise is associated with superior brain structure and 
integrity, neural connectivity, and greater circulation of cerebral blood flow and neurotrophin 
release to ultimately improve strategic executive functions (working memory, volitional 
inhibition, selective/sustained attention) (55). When neural networks are dysfunctional as a result 
of p53 deletion and inhibition of its apoptotic function, exacerbation of neural deficits in 
response to adverse stimuli, like exercise, can reduce the activation of motor synchronization 
structures and networks (8, 25). Motor synchronization is primarily controlled by the olivo-
cerebellar system connected by axons of the olivary cells to Purkinje cells in the cerebellum (25). 
During coordinated movements such as running, groups of Purkinje cells fire synchronously in 
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response to olivary input allowing for movement. Though no differences were found in exercise 
capacity under an acute bout of exercise, when a rotarod test was performed, the WB p53 KO 
mice displayed significantly reduced walking times (10%), which was more pronounced at 
higher rotation speeds (30%) (25). Interestingly, all other neurological responses and reflexes 
(clasping movement of paws, horizontal/vertical rearing, evidence of ataxia, anxiety dispositions, 
and gait) were similar between the KO and WT mice (25). Another study by Amson et al. 
(2000), observed that during the an open field test and Morris water maze test, p53 KO mice 
displayed reduced thigmotaxis (wall-seeking tendency), and reduced central activity, spatial 
learning, and memory capacity. Therefore, advanced analysis into the role of p53 in the 
maintenance of neural structure and connectivity for optimal exercise performance is required 
through further analysis of neurological function between WB p53 KO and WT models.  
3.4. Directions for Future Research 
Regular exercise, either through acute bouts of exercise or endurance training programs, 
can induce a plethora of adaptive outcomes leading to numerous physical and mental health 
benefits. Though p53 is a relatively new player in this field, it is established as a major 
transcriptional regulator of signaling mechanisms facilitating these beneficial adaptations. 
However, further understanding of the p53-mediated coordination of signaling pathways with 
varying intensities, durations, and types of exercise/oxidative stress is still required. This can be 
accomplished by determining an optimal exercise protocol to elicit the specific activation of 
beneficial downstream signaling pathways like antioxidant and metabolic events. Fine tuning of 
this protocol will depend on the intensity (low versus high; progressive versus consistent), the 
duration (2, 4, 6, 8 weeks; every day verus certain days/week), and the type of exercise (aerobic 
versus anaerobic versus resistance). Greater analysis into the subcellular compartmentalization of 
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p53 can assist in determining the activation of specific signaling pathways, concomitant with 
microarrays or co-immunoprecipitation assays to determine the upregulation of specific markers 
by p53 within each signaling pathway. Then exposing the model to some form of stress will 
allow for an understanding in the coordinated upregulation of pathways that maintain cellular 
homeostasis. Furthermore, understanding model differences that occur between whole body 
deletion and muscle specific deletion will yield new findings on the essential requirement of p53 
in skeletal muscle. The integration of p53 in the regulatory networks governing specific 
adaptations is astounding and further work in this field will contribute to fitting the pieces of the 
signaling puzzle together to provide a picture of the cellular cooperation that occurs in response 
to exercise. 
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Research Objectives 
 
To understand the role of p53 in directly regulating skeletal muscle mitochondrial 
signaling basally and under the influence of exercise training, we must first assess p53 regulation 
in WT mice. p53 transcriptional regulation will be determined through mRNA analysis and by 
understanding p53 subcellular localization. p53 translational regulation will be determined 
through protein and post-translational modification analysis. Once an understanding of p53 in 
skeletal muscle at the transcriptional and translational level is understood, both basally and under 
the influence of exercise, the next objective will be to understand whether the 6-week 
progressive training program has been piloted correctly, i.e. is of sufficient intensity and duration 
to increase mitochondrial biogenesis adaptations in skeletal muscle. Once it is understood that 
the training program induces the appropriate adaptations, we will observe the signaling pathways 
of mitochondrial biogenesis, antioxidant production, cell cycle arrest, autophagy and apoptosis, 
in both WT and p53 KO mice, basally and under the influence of exercise. This will be required 
to understand whether these signaling pathways are regulated by p53 basally and whether 
exercise induced adaptation are dependent on p53. Furthermore, if these pathways are regulated 
by p53 basally, we will investigate whether exercise-training is sufficient to attenuate the deficit 
induced by the basal absence of p53. Lastly, we are interested in investigating the neurological 
role of p53 in regulating exercise ability, and will thus employ a whole body p53 deletion model 
in addition to a skeletal muscle p53 deletion model. This will delineate whether p53 deletion in 
alternative tissues impacts skeletal muscle signaling.  
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Hypotheses 
 
 
We hypothesize that: 
 
1. The 6-week training protocol will lead to sufficient increases in mitochondrial biogenesis 
in skeletal muscle, with a notable reduction in the training adaptation of the KO mice; 
2. Training will activate p53 through post-translational serine phosphorylation, increase its 
mRNA and protein content, and lead to enhanced nuclear and mitochondrial localization; 
3. In response to an endurance training program, p53 will be required to upregulate cell 
cycle arrest, autophagy, mitochondrial biogenesis and antioxidant enzyme production 
signaling pathways, and will downregulate cellular senescent and apoptosis; 
4. p53 whole body KO will have greater deficits in exercise capacity and mitochondrial 
biogenesis rather than the muscle specific mKO model, as a result of the influence of 
possible neurological lesions on walking synchronization. 
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Abstract  
p53 plays an important role in regulating mitochondrial homeostasis. However, it is unknown 
whether p53 is required for the physiological and mitochondrial adaptations with exercise 
training. Furthermore, it is also unknown whether impairments in the absence of p53 are a result 
of its loss in skeletal muscle, or a secondary effect due to its deletion in alternative tissues. Thus, 
we investigated the role of p53 in regulating mitochondria both basally, and under the influence 
of exercise, by subjecting C57Bl/6J whole-body (WB) and muscle-specific p53 knockout (mKO) 
mice to a 6-week training program. Our results confirm that p53 is important for regulating 
mitochondrial content and function, as well as proteins within the autophagy and apoptosis 
pathways. Despite an increased proportion of phosphorylated p53 (Ser15) in the mitochondria, 
p53 is not required for training-induced adaptations in exercise capacity or mitochondrial content 
and function. In comparing mouse models, similar directional alterations were observed in basal 
and exercise-induced signaling modifications in WB and mKO mice, however the magnitude of 
change was less pronounced in the mKO mice. Our data suggest that p53 is required for basal 
mitochondrial maintenance in skeletal muscle, but is not required for the adaptive responses to 
exercise training.  
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Introduction 
The tumor suppressor protein p53 is a rapid-response transcriptional regulator of numerous 
pathways involved in maintaining cellular homeostasis. Though extensively researched in the 
context of cancer and its role in the Warburg effect, few studies have examined the role of p53 in 
skeletal muscle, an organ that comprises 40% of total body mass (19, 23). Skeletal muscle is an 
exceptionally malleable tissue that can adapt to multiple physiological stimuli (2, 19), and 
mitochondria are the organelles that display plasticity within muscle. 
 Recently, the role of p53 has been examined in mitochondrial biogenesis within skeletal 
muscle. Exercise enhances p53 activation through kinase activation (AMPK, p38 MAPK) 
leading to the phosphorylation of specific p53 residues to increase its mitochondrial and nuclear 
localization (35, 37, 38). Once in mitochondria, p53 functions to enhance biogenesis through its 
interaction with Tfam, and its requirement for the expression of mtDNA gene products in 
response to exercise (1, 36, 48). Acute exercise has specifically been shown to increase p53 
serine15 phosphorylation and subsequent localization to subsarcolemmal (SS) and 
intermyofibrillar (IMF) mitochondria, with concomitant increases in  mtDNA copy number and 
elevated COX-I protein (37, 38). p53 additionally localizes to the nucleus where it can bind to 
the promoters of PGC-1α and nuclear genes encoding mitochondrial proteins (NuGEMPs) such 
as Tfam, COX IV, and SCO2, to upregulate transcription (26, 33, 38). p53 mitochondrial 
localization with acute exercise seems to be preferred over nuclear accumulation (38), however it 
has yet to be established whether exercise training modifies this distribution and further, and 
whether p53 is required within the mitochondria for adaptation purposes.  
 p53 is also known to play a role in regulating additional mitochondrial-dependent 
signaling pathways, including autophagy/mitophagy and apoptosis. Within the cytosol, p53 acts 
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as an upstream endogenous repressor of autophagy, through its interaction with the ULK1 
complex (31, 45). When nuclear localized, p53 can regulate autophagy through transcription of 
upstream activators AMPK and TSC2 (14), as well as lysosomal genes (13, 21, 37). 
Furthermore, p53 monitors ubiquitination and regulates autophagy flux through LC3 and p62 
modulation (21, 37, 40). Although autophagic flux and lysosomal activation in response to acute 
exercise does not depend on p53, it is required for the regulation of ubiquitination (37). 
However, it has not been established how the autophagy pathway is regulated by p53 with 
exercise training. p53 is also well-known for its role in regulating apoptosis, since it can 
transcriptionally regulate numerous pro-apoptotic genes including Bax and Bid to induce DNA 
fragmentation (16, 35, 47). Furthermore p53 itself can localize to the mitochondrial surface 
where it can regulate permeability transition pore kinetics (30, 47). Chronic exercise has been 
previously shown to reduce the Bax:Bcl-2 ratio (42, 46) concomitant with reductions in 
cytochrome c and AIF protein release  (3), indicative of anti-apoptotic adaptations in 
mitochondria. However, the role of p53 in mediating these exercise training effects on the 
apoptotic pathway is still unknown. Furthermore, literature published on the role of p53 in 
regulating autophagy, apoptosis, mitochondrial biogenesis and metabolism, have been 
established largely through the use of a whole body p53 knockout model. Though this research 
has elucidated novel roles for p53, recently published work utilizing a muscle-specific p53 
knockout model did not observe any reductions in mitochondrial content or the expression of 
nuclear genes encoding mitochondrial proteins (15, 43). Thus, the purpose of this study was to 
elucidate the role of p53 in regulating skeletal muscle adaptations to endurance training, 
particularly related to the mitochondrial biogenesis, autophagy, and apoptosis pathways. To 
accomplish this, we utilized a muscle-specific p53 deficient mouse and when relevant, compared 
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this model to traditionally employed p53 whole body knockout animals under identical 
endurance training stimuli.  
Methods 
Animal Breeding. The C57Bl/6J whole body (WB) p53 wildtype (WT) and knockout (KO) 
mouse groups originated from two companies, one from Taconic labs (New York, USA) and one 
from the Jackson Laboratory (California, USA). The C57Bl/6J muscle specific (MS) p53 WT 
and KO mice were generously provided by Dr. Christopher M. Adams (Iowa, USA). Mice were 
bred and treated experimentally in accordance with principles of the York University Animal 
Care Committee in accordance with the Canadian Council on Animal Care. Progeny of breeding 
pairs were genotyped using ear clippings obtained from each mouse for crude DNA extraction. 
Extracts were then added to a polymerase chain reaction (PCR) tube containing DNA Taq 
polymerase (Sigma Jumpstart REDtaq Ready Mix PCR Reaction Mix). Forward and reverse 
primers for the WT and KO p53 gene were added to test the genotype of the whole body mice, 
whereas for the muscle-specific mice, a forward and reverse primer for the Cre gene was added. 
Genomic differences were detected using PCR amplification and the reaction products were 
separated on 2% agarose gels at 120 V for ~one hour and visualized with the ethidium bromide. 
Experimental Design. At approximately12-14 weeks of age, male C57Bl/6J WT and KO mice in 
the WB and MS mouse models were matched for sex and body weight. All mice were 
acclimatized to the treadmill for two days prior to the first graded exercise performance test. 
Animals commenced at 5m/min for 5 min, followed by 10 m/min for 10 min, then increasing 
from 15 m/min to 20 to 25 m/min for 5 min each before beginning the exhaustive portion of 
increased the speed by 1 m/min every 3 min until exhaustion. Exhaustion was defined as the 
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point whereby mice remained on an electric shock pad for 10 seconds despite prodding with air 
currents. Lactate measurements were obtained following removal from the treadmill to ensure 
that exhaustion was reached. Mice in both models were then randomized to a sedentary or 
training group. The sedentary group involved no treadmill exercise for 6 weeks, while the 
training group participated in a 6-week training protocol exercising 5 days/week and beginning 
at 5 m/min for 20 min and progressing to 26 m/min for 90 min. Following the 6 weeks, both the 
sedentary and training groups underwent a second exercise performance test following the same 
parameters as the first.  Approximately 48 hours later, all mice underwent an acute bout of 
treadmill exercise at 15 m/min for 90 min. Full details are in Figure 1. All mice were sacrificed 
by cervical dislocation immediately following the acute bout for instantaneous tissue removal.  
Tissue Extraction and Experimental Organization. All mice underwent the same tissue 
extraction protocol. One gastrocnemius (~ 170 mg) and one tibialis anterior (TA) (~50 mg) were 
extracted and immediately snap frozen and stored at -80◦C for mRNA analysis, whole muscle 
western blotting, and COX enzyme activity. Part of one TA (~ 30 mg) was placed in buffer and 
utilized for nuclear/cytosolic fractionation. The rest of the skeletal muscle (one gastrocnemius, 
two quadriceps femoris, two triceps) (~ 1000 mg) was utilized for mitochondrial fractionation 
and subsequent functional testing. The heart and epididymal fat were removed, weighed, and 
frozen in liquid nitrogen for later use. Frozen skeletal muscle samples were pulverized into a 
powder with a stainless steel mortar cooled to the temperature of liquid nitrogen and stored in 
liquid nitrogen for subsequent analysis.  
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Figure 1. Exercise training protocol. Muscle specific (MS) WT and p53 mKO mice and whole 
body (WB) WT and p53 KO mice underwent a two-day acclimatization program to the treadmill 
followed by an exhaustive performance test to measure baseline differences between mouse 
model and genotype. Mice were randomized to a training and sedentary arm. Mice in the training 
group underwent a 6-week progressive training program. Speed was expressed in m/min and 
(time) was measured in minutes. Once individual programs were completed, all mice underwent 
a second exhaustive performance test to measure training adaptations. Following 48 hours, 
animals were subjected to an acute bout of exercise to upregulate transcriptional signaling, 
followed by immediate extraction of the skeletal muscles, heart, and epdididymal fat. 
 
 
6-week Chronic Endurance Exercise Program 
Acute Exercise Bout to induce gene expression 
Immediate Tissue Extraction 
Post-Training Period: Exercise Performance  Stress Test 
Pre-Training  Exhaustive  Stress Test 
6-week  Sedentary 
Fig. 1  
48 hrs 
Two-day Treadmill Acclimatization 
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Protein Extraction. Tissue powders were diluted 5X with an extraction buffer containing 
protease and phosphatase inhibitors. Diluted samples were rotated end-over-end at 4°C for one 
hour, followed by sonication at 3x3 at 30% of maximum power. Samples were then centrifuged 
at 4°C for 10 minutes at 16,000g and the supernate was stored at -80°C until required.  
Protein Concentration. The Bradford protein assay was used to determine the protein 
concentration of samples, as previously described (6). Briefly, to standardize for concentration, 
bovine serum albumin (2mg/ml) was combined with double distilled water and Sakamoto 
extraction buffer in eppendorf tubes. Protein extracts were mixed with double- distilled water 
and analyzed in comparison with the standard curve using a Bio-Tek Synergy HT micro plate 
reader. 
Mitochondrial Fractionation. Briefly, approximately 1000 mg of fresh skeletal muscle was 
minced, homogenized, and subjected to differential centrifugation to yield the SS and IMF 
subfractions (11). The mitochondria were re-suspended in a small volume of resuspension buffer 
(100 mM KCl, 10 mM MOPS, and 0.2% BSA at pH=7.4). All centrifugation steps were carried 
out at 4°C. Mitochondrial homogenates were analyzed for protein content using the Bradford 
assay, and used immediately for mitochondrial respiration, ROS analysis, and the protein release 
assay before being frozen at -80°C for later biochemical analysis by immunoblotting.  
Mitochondrial Respiration. Isolated SS and IMF mitochondria (50 μl) were incubated with 250 
μl of V̇O2 buffer (in mM: 250 sucrose, 50 KCl, 25 Tris·HCl, 10 K2HPO4, pH=7.4), at 30°C in a 
water-jacketed respiratory chamber with continuous stirring. Respiration rates (nanoatoms 
O2·min−1·mg−1) were evaluated in the presence of 10 mM glutamate (state 4 or passive 
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respiration) and 0.44 mM ADP (state 3 or active respiration) with the use of a Clark oxygen 
electrode. 
Mitochondrial Reactive Oxygen Species (ROS) Production. SS and IMF mitochondria (50 μg) 
were incubated with 50 μM dichlorodihydro-fluorescein diacetate (H2DCF-DA) and V̇O2 buffer 
at 37°C for 30 min in a polystyrene 96-well plate. The fluorescence emission (between 485 and 
528 nm) is directly proportional to ROS production and was measured with a Synergy HT 
microplate reader. ROS production was assessed during state 4 and state 3 respiration by the 
addition of 10 mM glutamate and 0.44 mM ADP respectively, to isolated mitochondria 
immediately before the addition of H2DCF-DA. 
Nuclear and Cytosolic Fractionation. Nuclear and cytosolic fractions were prepared from 
freshly isolated skeletal muscle using a commercially available nuclear extraction kit (Pierce NE-
PER, Rockford, IL, USA). Approximately 50 mg of skeletal muscle was minced and 
homogenized in CER-I buffer containing protease inhibitor cocktail Complete, EDTA free 
(Roche Applied Sciences, Manheim, Germany). After a series of wash steps, nuclear proteins 
were extracted in high salt NER buffer supplemented with protease-inhibitors. The cytosolic 
fraction was spun at 100,000 x g at 4°C for 60 min to obtain pure cytosolic fraction.  
Cytochrome c Oxidase (COX) Enzyme Activity. Mitochondrial extracts from skeletal muscle 
were added to a test solution containing fully reduced cytochrome c. Enzyme activity was 
determined as the maximal rate of oxidation of fully reduced cytochrome c measured by the 
change in absorbance at 550 nm in a Synergy HT microplate reader at 30°C. Full protocol is 
previously described elsewhere (12). 
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Protein Release Assay. Isolated SS and IMF mitochondrial fractions (150 μg) were incubated in 
resuspension medium for 60 min at 30°C as described previously (3). Reaction mixtures were 
subsequently centrifuged at 14,000 g (4°C) to pellet mitochondria, and the supernate was 
analyzed for cytochrome c and AIF release from the mitochondria by Western blot analysis. 
Immunoblotting. Whole muscle and isolated subfractions including mitochondrial, nuclear, and 
cytosolic protein extracts were separated on a 10% - 15% sodium dodecyl sulfate polyacrylamide 
gel through electrophoresis (SDS-PAGE) at 120V for ~90 minutes. Proteins were then 
transferred onto a nitrocellulose membrane. The membrane was stained with Ponceau Red, cut at 
the appropriate molecular weights, and blocked in 5% skim milk for one hour to prevent non-
specific binding. The membrane strips were immunoblotted overnight at 4°C with a primary 
antibody, as detailed in Table 1. Membranes were washed three times (5 min each) with tris-
buffered-saline-tween-20 (TBST) solution containing 25 mM Tris-HCL (pH=7.5), 1 mM NaCl 
and 0.1% Tween 20. Membranes were incubated with the appropriate secondary antibody 
coupled to horseradish peroxidase at room temperature for one hour. Loading controls were 
utilized for specific extracts. GAPDH was utilized for whole muscle extracts, VDAC for 
mitochondrial subfractions, and histone 2B and α-tubulin were utilized for nuclear and cytosolic 
fractions, respectively. Following incubation, membranes were washed three times again in 
TBST, developed using an enhanced chemiluminescence (ECL) kit and Imager technology, and 
quantified via densitometric analysis based on signal intensity using the Sigma Scan Pro Version 
5 software (Jandel Scientific, San Rafael, CA).  
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Table 1. List of primary and secondary antibodies for immunoblotting.  
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RNA Isolation. Total RNA was isolated from approximately 70 - 80mg of frozen powdered 
muscle tissue according to the manufacturer’s instructions. Briefly, tissue was added to TRIzol ® 
reagent, homogenized, and mixed with choloroform. Samples were centrifuged at 4°C at 16,000g 
for 15 min and the aqueous supernate was transferred to a new tube with the addition of 
isopropanol and left overnight at -20°C to precipitate. Samples were again centrifuged at 16,000 
g for 10 min and the resultant supernate was discarded. The pellet was resuspended in 10-20 µl 
of sterile H2O. RNA concentration and quality were measured using the Nanodrop 2000 (Thermo 
Scientific, Wilmington, DE, USA). SuperScript ® III reverse transcriptase (Invitrogen, Carlsbad, 
CA, USA) was used to reverse transcribe 1.5 µg of total RNA into cDNA.  
mRNA Expression Analyses. The mRNA expression of SCO2, TIGAR, Mdm2, p62, LC3, p52, 
p21, Bax, PGC-1α, and Tfam were quantified using the 7500 Real-Time PCR system (Applied 
Biosystems Inc., Foster City, CA, USA) and SYBR® Green chemistry (PerfeCTa SYBR® Green 
Supermix, ROX, Quanta BioSciences, Gaithersburg, MD, USA). First-strand cDNA synthesis 
from 2µg of total RNA was performed with primers using Superscript III transcriptase 
(Invitrogen) according to the manufacturer’s directions. Forward and reverse primers (Table 2) 
for the aforementioned genes were designed based on sequences available in GenBank 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) using the MIT Primer 3 designer software 
(http://wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), and were confirmed for specificity using 
the basic local alignment search tool (www.ncbi.nlm.nih.gov/BLAST/). B2M and GAPDH were 
used as housekeeping genes, the expression of which did not change between conditions, 
genotype and rodent model. Each well within a 96-well plate contained: SYBR ® Green 
SuperMix, forward and reverse primers (20 µM), sterile H2O and 10 ng of cDNA, for a final 
reaction volume of 25 µl. All samples were run in duplicate simultaneously with negative 
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controls that contained no cDNA. The PCR program consisted of an initial holding stage (95°C 
for 10 min), an amplification phase (40 cycles at 60°C for 1 min, 95°C for 15 sec), and melting 
stage (95°C for 15 sec, 60°C for 1 min, 95°C for 25 sec). Melting point dissociation curves 
generated by the instrument were used to confirm the specificity of the amplified product. Primer 
efficiency curves were generated for each set to ensure 100 ± 2% efficiency. For quantification, 
the threshold cycle (CT) number of endogenous references genes was subtracted from the CT 
number of the target gene [ΔCT = CT(target) – CT(reference)] . The ΔCT value of the control 
tissue was subtracted from the ΔCT value of the experimental tissue [ΔΔCT = ΔCT 
(experimental) - ΔCT(control}]. Results were reported as fold-changes using the ΔΔCT, 
calculated as 2-ΔΔCT.  
Statistical Analysis. Data were analyzed using the Graph Pad Prism 7.0 software and values are 
reported as means ± SEM. All data was analyzed using a two-way ANOVA and Bonferroni post-
tests unless otherwise indicated. Significance levels were set at p ≤ 0.05. 
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Table 2. List of primer oligonucleotide sequences used in real-time qPCR analysis for 
Mus Musculus. 
PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1 α; Tfam, mitochondrial 
transcription factor; Mdm2, Mouse double minute 2 homolog; SCO2, synthesis of cytochrome-
c oxidase 2;TIGAR, TP53-inducible glycolysis and apoptosis regulator; LC3, light chain 3; 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; b2 microglobulin, beta-2 microglobulin.
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Results 
Exercise-induced p53 localization to the nucleus is reduced with training and increases to the 
mitochondria. p53 protein expression in whole muscle, nuclear and cytosolic fractions, as well 
as mitochondrial subfractions was examined following the final acute exercise test in both 
trained and untrained WT mice. Total p53 protein was reduced by 2.6-fold with exercise training 
(Fig. 2A, B). However, the proportion of activated p53, measured by p53-Ser15 phosphorylation, 
was increased by 2.5-fold following exercise in the trained state (Fig. 2A, C).  
p53 was largely localized to the cytosolic fraction in both trained and untrained muscle 
(Fig. 2D, E). However, the distribution of phosphorylated p53 (Ser15) differed. In untrained 
muscle p-p53 was largely (70%) nuclear-localized, whereas trained muscle exhibited only 40% 
of p-p53 in the nucleus (Fig. 2D, F). Exercise training also reduced total p53 levels within SS 
and IMF mitochondria by 2.1-2.6-fold. However, activated p53 localization increased in both 
IMF and SS mitochondrial subfractions by ~2.3-fold following acute exercise in trained muscle 
(Fig. 2, G-K).  
Confirmation of muscle specific mouse model. The muscle-specific genotype was confirmed 
through the Cre recombinase transcript (Fig. 3A). When the Cre recombinase gene is expressed, 
it targets the LoxP restriction sites at exons 2 and 10 of the p53 transcript, allowing for targeted 
excision and deletion of p53 solely within skeletal muscle to create the mKO model. In 
agreement with previous literature (15, 43), this abolished p53 protein expression (Fig. 3B).   
Exercise training induces a leaner phenotype and increases cardiac hypertrophy regardless of 
genotype. The phenotypic characteristics of the p53 WT and mKO mice are described in Table 3. 
No difference in baseline parameters including body mass or exercise capacity were observed 
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Figure 2. p53 subcellular localization with training.  A) Whole muscle B) total p53 protein 
and C) phosphorylated p53-Ser15 protein was measured in WT mice. GAPDH was utilized as the 
loading control for all immunoblotting in whole muscle (n=6-7/group); *p<0.05, **p<0.01, UT 
vs. T, Student’s t-test. D) p53 protein was measured in nuclear and cytosolic fractions in WT 
mice. H2B was used as a nuclear loading control and α-tubulin was used as a cytosolic loading 
control. Basally and with training, nuclear and cytosolic E) total p53 protein, and F) percent total 
of phosphorylated p53-Ser15 protein was measured (n=4-5/group); *p<0.05, UT vs. T; #p<0.05, 
Nuclear vs. Cytosolic (n=4-5/group), Student’s t-test, 2-way ANOVA. A main effect of training 
was observed. G) Mitochondrial p53 protein was examined in SS and IMF mitochondrial 
subfractions. VDAC was utilized as a mitochondrial loading control. Total p53 protein in H) 
IMF, and I) SS mitochondria was measured (n=4-5/group); *p<0.05, **p<0.01, UT vs. T, 
Student’s t-test. Activated p53, corrected for total, was additionally measured in J) IMF, and K) 
SS mitochondria (n=4-5/group); *p<0.05, UT vs. T, Student’s t-test. Data are presented as mean 
± SEM.  
 
 
 
 
 
 
78 
 
between genotypes (Table 3A). Training induced a leaner phenotype in both WT and mKO mice 
compared to their untrained counterparts, exemplified by 28% and 56% reduction in epididymal 
fat mass in WT and mKO mice, respectively (Table 3B). No effect of training was observed on 
quadriceps or gastrocnemius skeletal muscle mass (Table 3B). Cardiac hypertrophy (7-21%), a 
typical consequence of training, was also evident (Table 3B). 
p53 is not required for exercise capacity adaptations to a long term training program. A post-
training exercise performance test was employed to examine whether p53 is required for whole 
body performance improvements with training. Both WT and mKO trained mice significantly 
improved their exercise capacity by ~2.3-fold relative to untrained mice (Fig. 3C). Blood lactate 
levels were markedly elevated (>10 mM) in all WT and mKO animals following the exercise 
test, with a 12-27% reduction observed in the trained animals, an expected adaptation to training 
(Fig. 3D). There was no difference in final lactate production levels between genotypes under 
basal conditions. 
p53 is required to maintain basal mitochondrial content and function, but not for exercise 
training-induced adaptations. Untrained mKO mice exhibited a 17% reduction in mitochondrial 
content, as measured by COX activity, compared to the untrained WT mice (Fig. 3E). In 
addition, PGC-1α protein was reduced by 36%, accompanied by a 28% reduction in Tfam levels 
(Fig. 3, F-H). In response to training, both WT and mKO mice increased their mitochondrial 
content by 1.3- and 1.7-fold respectively, relative to untrained counterparts (Fig. 3E). SS and 
IMF mitochondrial yield increased with training by ~31% and ~22% respectively, with no 
reduction observed in the mKO mice under basal conditions (Table 3C). The respiratory control 
ratio measured in mitochondrial subfractions was not significantly affected by training (Table 
3C). Training increased PGC-1α protein levels by 1.8-2.6-fold, regardless of genotype (p<0.05; 
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Fig. 3F, G). Tfam protein levels also increased in the mKO mice with training by 2.1-fold, while 
only a modest increase was observed in the WT mice (Fig. 3F, H). Therefore mitochondrial 
biogenesis markers increase with exercise training, even in the absence of p53.   
Mitochondrial function was assessed by measuring respiration and reactive oxygen 
species production (ROS) in both SS and IMF subfractions. No baseline differences in SS or 
IMF state 4 mitochondrial respiration were observed in the absence of p53 (Fig. 4A, B). 
However, state 3 respiration in SS mitochondria was 2-fold higher in the mKO mice, but was 
22% lower in the IMF subfraction, indicating a differential dependency on p53 (Fig. 4C, D). 
With exercise training, state 4 respiration increased similarly in both genotypes, by ~2.2-fold in 
SS mitochondria and by 1.4-1.7-fold in IMF mitochondria (p<0.05; Fig. 4A, B). State 3 
respiration in SS mitochondria improved by 4.8-fold in the WT mice with training, but only 
increased by 1.7-fold in the mKO mice (Fig. 4C). IMF state 3 respiration did not improve in the 
WT mice with training, but training did attenuate the deficit observed in the mKO mice, such 
that state 3 respiration was similar to control values (Fig. 4D). Therefore, SS mitochondria 
appear to adapt more readily to training stimuli compared to the IMF mitochondria, with only a 
minor dependency on p53.  
In the absence of p53, state 3 and 4 ROS levels were elevated under basal conditions in 
both the SS and IMF subfractions (Fig. 5A, B, D). Exercise training attenuated state 3 and 4 SS 
ROS levels by 23-58% in WT mice and normalized ROS production in both SS and IMF 
subfractions under state 3 and state 4 conditions in mKO mice (p<0.05; Fig. 5, A-D).  Thus, 
although the absence of p53 led to increase ROS levels under basal conditions, p53 is not 
required for the adaptive decreases in mitochondrial ROS production with training.  
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Figure 3. Mitochondrial content, exercise capacity, and lactate handling improves with exercise 
training. The deletion of p53 in skeletal muscle of MS mKO mice was examined through A) 
genotype against the Cre transcript, and B) total p53 protein in whole muscle. Following the 6-week 
training/sedentary protocol, mice were subjected to an exhaustive bout of exercise to determine 
training-induced adaptations by measuring C) distance to exhaustion (n=6-8/group); **p<0.01, UT 
vs. T, 2-way ANOVA, and D) final lactate production levels (n=6-17/group), **p<0.01, UT vs. T, 
Student’s t-test. Mitochondrial biogenesis with training was measured through assessment of E) 
COX enzyme activity, a marker of mitochondrial content (n=6-8/group); **p<0.01, UT vs. T, 2-way 
ANOVA; ††p<0.01, UT WT vs. mKO, Student’s  t-test, and F) mitochondrial biogenesis markers G) 
PGC-1α protein (n=5-8/group); **p<0.01 , UT vs. T, 2-way ANOVA; ††p<0.01, UT WT vs. mKO, 
Student’s  t-test, and H) Tfam protein (n=6-7/group); **p<0.01 , UT vs. T, 2-way ANOVA; †p<0.05, 
UT WT vs. mKO, Student’s  t-test. Data are presented as mean ± SEM. 
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Table 1. Phenotypic alterations and exercise capacity under basal and exercise training 
conditions.  
 
A. Pre-Training WT  mKO 
Initial Body wt, g 30.4 ± 0.4 31.4 ± 1.0 
Distance to Exhaustion (m) 1,286 ± 51 1,156 ± 85 
 
B. Post-Training WT mKO UT T UT T 
Final Body wt, g 33.2 ± 1.1  30.1 ± 0.3 * 34.8 ± 1.7  27.8 ± 0.4* 
TA wt/ body wt (mg/g) 2.0 ± 0.08 1.6 ± 0.07 * 2.1 ± 0.08 1.8 ± 0.04* 
Gastrocnemius wt/ body wt, 
(mg/g) 
6.3 ± 0.3 5.8 ± 0.2 6.3 ± 0.3 6.2 ± 0.1 
Quadriceps wt/ body wt (mg/g) 6.2 ± 0.1 6.2 ± 0.1 6.6 ± 0.2 6.6 ± 0.08 
Heart wt/body wt, (mg/g) 5.4 ± 0.4 5.8 ± 0.2 4.8 ± 0.2 5.8 ± 0.1* 
Epididymal Fat wt/ body wt 
(mg/g) 
43.6 ± 3.3 31.5 ± 3.5 * 54.6 ± 3.4 † 23.9 ± 1.8 * 
   C. Mitochondrial Parameters 
SS Mitochondrial Yield 0.5 ± 0.07 0.8 ± 0.05 * 0.6 ± 0.09 0.8 ± 0.05 * 
IMF Mitochondrial Yield 1.1  ±  0.02 1.3  ±  0.1 1.0  ±  0.1 1.4  ±  0.08* 
SS RCR 3.8 ± 0.8 12.9 ± 5.3 4.6 ± 0.6 7.2 ± 1.8 
IMF RCR 6.1 ± 0.2 10.1 ± 2.9 7.0 ± 1.1 12.1 ± 4.5 
 
A) Pre-training variables (initial body mass and distance to exhaustion) were compared between 
genotype in the muscle specific (n=13-23/group). B) Phenotypic variables were measured 
following the training or sedentary program (n=6-10/group); *p≤0.05, UT vs. T; †p≤0.05, WT vs. 
mKO, 2-way ANOVA and Student’s t-test. C) Mitochondrial parameters measured in SS and 
IMF mitochondrial subfractions (n=5-10/group); *p≤0.05, UT vs. T, 2-way ANOVA and 
Student’s t-test. Data are presented as mean ± SEM. Abbreviations: RCR, respiratory control 
ratio; TA; tibialis anterior; SS, subsarcolemmal; IMF, intermyofibrillar. 
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Figure 4. Mitochondrial respiration improves with exercise training. State 4 respiration was 
measured in A) SS (n=6-7/group); *p<0.05, **p<0.01, UT vs. T, Student’s t-test and 2-way 
ANOVA, and B) IMF mitochondria (n=6-7/group); *p<0.05, main effect of genotype and 
training, 2-way ANOVA. State 3 respiration was further measured in C) SS 
(n=6/group);*p<0.05, **p<0.01, UT vs. T, Student’s t-test and 2-way ANOVA; †p<0.05, UT 
WT vs. mKO, Student’s  t-test, and D) IMF mitochondria (n=6-7/group); *p<0.05, UT vs. T, 
Student’s t-test; †p<0.05, UT WT vs. mKO, Student’s  t-test. Data are presented as mean ± SEM. 
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Figure 5. Mitochondrial reactive oxygen species (ROS) is reduced with exercise training.  
State 4 ROS levels were measured in A) SS, and B) IMF mitochondria (n=6-8/group); *p<0.05, 
UT vs. T, 2-way ANOVA. State 3 ROS levels were measured in C) SS, and D) IMF 
mitochondria (n=6-8/group); *p<0.05, **p<0.01, UT vs. T, Student’s t-test and 2-way ANOVA; 
†p<0.05, UT WT vs. mKO, 2-way ANOVA. Data are presented as mean ± SEM. 
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Transcripts of genes related to downstream p53 signaling targets alter with exercise training. 
The mRNA transcripts of numerous signaling pathways regulated by p53 were examined. 
Training downregulated p53 (1.4-fold), p21 (~1.4-fold), and Bax (1.2-fold) transcripts (p<0.05; 
Fig. 6A). TIGAR, Mdm2, Tfam, LC3, p62, SCO2, and PGC-1α mRNA transcripts were not 
significantly altered with training in WT mice. In the absence of p53 under basal conditions, 
there was a 1.2-1.6-fold reduction in the transcripts of genes involved in mitochondrial 
biogenesis (Tfam), autophagy (LC3, p62), and cell cycle arrest/cell death (p21, Bax) signaling 
pathways (p<0.05; Fig. 6B). In contrast, TIGAR and SCO2 mRNA levels increased in the 
absence of p53. The effect of training was evaluated to determine if exercise could reverse the 
gene expression pattern defined by the absence of p53. With training, the decrease in PGC-1α 
mRNA was reversed, exhibiting a ~1.3-fold increase above WT untrained levels. The decrease in 
Bax mRNA and the increase in SCO2 were further amplified with training (p<0.05) while the 
reductions in p21, Tfam, and LC3 transcripts were normalized. Thus, these training-induced 
alterations are not dependent on the presence of p53. Changes in the transcripts of TIGAR and 
p62, brought about by p53 deficiency, did not respond to training, indicating a strong 
dependence on p53 for basal expression. Mdm2 expression was not significantly affected by 
either training, or the absence of p53, at the transcript level.  
Targeted regulation of p53 protein. The effect of training was examined on proteins that 
determine p53 steady state levels (Mdm2) and mitochondrial localization (CHCHD4). Mdm2 
levels were unaffected by the absence of p53, and were increased by 1.7-2.1-fold with training  
(Fig. 7A). CHCHD4 protein was reduced by 52% in the absence of p53 under basal conditions 
(p<0.05; Fig. 7B). Training induced modest (1.5-fold) and large (4.6-fold) increases in CHCHD4 
expression in the WT and mKO mice, respectively.  
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Figure 6. mRNA expression of downstream p53-regulated targets and the effect of training. 
A) The effect of training on mRNA transcripts of signaling pathways including cellular 
senescence (p21), apoptosis (Bax), metabolism (TIGAR), autophagy (p62, LC3), oxidative 
phosphorylation (SCO2), mitochondrial biogenesis (PGC-1α, Tfam) and p53 and its negative 
regulator Mdm2, in WT mice. Data are presented as fold change over WT control levels (n=8-
10/group); *p<0.05, UT vs. T, Student’s t-test. B) Effect of the absence of p53, and training on 
mRNA transcripts of signaling pathways. Data presented as fold change of mKO over WT 
untrained levels and as mKO trained over untrained levels (n=7-11/group); *p<0.05, mKO UT 
vs. T, Student’s t-test; †p<0.05, UT WT vs. mKO, Student’s t-test. Data are presented as mean ± 
SEM. 
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Differential apoptotic release occurs in mitochondrial subfractions however, training reduces 
intrinsic mitochondrial apoptosis. To assess mitochondrial apoptotic susceptibility, we 
measured cytochrome c protein release from isolated organelles in the presence (H2O2) and 
absence (basal) of apoptotic stimuli. Under basal conditions, cytochrome c release from SS 
mitochondria was increased by 45% in the absence of p53, but was reduced by 44% in the IMF 
subfraction compared to WT counterparts (Fig. 8A, B). Training attenuated the elevated 
cytochrome c release rate in the SS subfraction of mKO mice to reach WT levels (p<0.05; Fig. 
8A).  An attenuation of cytochrome c release from SS mitochondria by 42-60% in the WT and 
mKO mice was also observed in the presence of H2O2 (Fig. 8C). There was no effect of training 
or genotype on H2O2–induced cytochrome c release in the IMF subfraction (Fig. 8D). Therefore, 
p53 and exercise training result in differential apoptotic adaptations, dependent on the 
mitochondrial subfraction. 
To relate patterns of cytochrome c release to upstream activators, we measured p21, Bax, 
and Bcl-2 protein in whole muscle lysates. In the absence of p53, Bax protein levels increased by 
2.3-fold, whereas Bcl-2 and p21 protein expression was reduced by 49% and 32%, respectively 
(Fig. 8, E-H). Training reduced Bax protein by 43% in the mKO mice, to values reaching WT 
control levels (Fig. 8F). Bcl-2 protein was reduced in both WT and mKO genotypes by ~34% 
with training (Fig. 8G). Though p21 expression was unaffected by training in WT mice, training 
induced a significant augmentation in p21 levels in the mKO mice by 2.1-fold (Fig. 8H). 
Therefore, p53 plays a role in regulating apoptotic protein signaling under basal conditions, but it 
does not appear to be required for the anti-apoptotic adaptations induced by exercise training.   
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Figure 7. Regulators of p53 expression (Mdm2) and its mitochondrial localization 
(CHCHD4). Whole muscle protein expression of A) Mdm2 (n=5-6/group); *p<0.05, **p<0.01, 
UT vs. T, 2-way ANOVA, and B) CHCHD4 (n=5-6/group); **p<0.01, UT vs. T, Student’s t-test 
and 2-way ANOVA; ††p<0.01, UT WT vs. mKO, Student’s t-test, was measured. Data are 
presented as mean ± SEM. 
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Exercise training increases autophagy signaling. We evaluated the potential role of p53 in 
mediating autophagy signaling through the examination of LC3, p62, Parkin and Beclin-1 
proteins. In the absence of p53 under basal conditions, the autophagy protein markers p62, 
Parkin, and Beclin-1 were upregulated by 2.4-3-fold (Fig. 9, B-D). LC3-I and LC3-II levels were 
unaffected (Fig. 9A). Training induced relatively similar 1.7-2.2-fold increases in all of these 
autophagy proteins in WT mice. This increase was attenuated for LC3-II, and reversed for p62, 
Parkin, and Beclin-1 in the absence of p53, suggesting that training can normalize the aberrant 
expression of these proteins in p53 null mice, through a potential substrate clearance mechanism. 
Signaling pathways and mitochondrial properties in muscle-specific and whole body p53 
deletion models. Since a large number of studies have utilized whole-body (WB) p53 KO 
animals to examine mitochondrial content and function in (32, 33, 35, 37–39) muscle, we 
conducted a limited comparison of mitochondrial parameters between WB and mKO p53 
knockout models under basal conditions. Mitochondrial content in the mKO and WB p53 KO 
mice was reduced by 17% and 27% respectively, with no difference in levels between models 
(Fig. 10A). PGC-1α mRNA was not altered in the mKO mice, however it was reduced by 47% in 
WB KO mice compared to WT counterparts (p<0.05; Fig. 10B). Furthermore, PGC-1α mRNA 
and protein in WB WT mice was higher when compared to their muscle-specific counterparts. 
PGC-1α protein was reduced in the absence of p53 by 36% and 40% in the mKO and WB mice, 
respectively (Fig. 10C). Differences in state 3 respiration were observed in the absence of p53 in 
SS mitochondria whereby mKO mice had 2-fold higher respiration, while WB KO mice had a 
1.4-fold lower state 3 respiration compared to their WT counterparts (Fig. 10D). State 3 ROS in 
SS mitochondria was not elevated in the absence of p53 in either model, however the WB mice 
displayed greater (2.5-4.1-fold) ROS levels overall (Fig. 10E). Basal cytochrome c release 
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Figure 8. Effect of training and p53 on mitochondrially-mediated apoptosis. In the absence 
of p53 basally, A) greater cytochrome c release is observed in SS mitochondria with training 
reducing release (n=5-8/group); *p<0.05, UT vs. T, One-way ANOVA; †p<0.05, UT WT vs. 
mKO, Student’s t-test, and B) reduced basal release is observed in IMF mitochondria (n=7-
14/group); †p<0.05, UT WT vs. mKO, Student’s t-test. Under apoptotic stimuli (H2O2), 
cytochrome c release was reduced with training in C) SS mitochondria (n=6-10/group); *p<0.05, 
UT vs. T, One-way ANOVA, and D) did not change in IMF mitochondria (n=6-12/group). E) 
Apoptosis, anti-apoptosis, and cellular senescent proteins were measured in whole muscle; F) 
Bax protein (n=4-6/group); *p<0.05; UT vs. T, 2-way ANOVA; ††p<0.01, UT WT vs. mKO, 2-
way ANOVA; G) Bcl-2 protein (n=5-8/group); *p<0.05, UT vs. T, Student’s t-test; ††p<0.01, 
UT WT vs. mKO, 2-way ANOVA; H) p21 cellular senescent protein (n=5-6/group); **p<0.01, 
UT vs. T, 2-way ANOVA; †p<0.05, UT WT vs. mKO, Student’s t-test. Data are presented as 
mean ± SEM. 
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Figure 9. Autophagic protein responses in the absence of p53 and with training. A) LC3-
II/LC3-I ratio (n=6-8/group);*p<0.05, **p<0.01, UT vs. T, 2-way ANOVA, B) p62 (n=5-
8/group), *p<0.05, UT vs. T, 2-way ANOVA; ††p<0.01, UT WT vs. mKO, 2-way ANOVA, C) 
Parkin (n=5-7/group); *p<0.05, UT vs. T, Student’s t-test and 2-way ANOVA; ††p<0.01, UT 
WT vs. mKO, 2-way ANOVA, and D) Beclin-1 (n=5-7/group); *p<0.05, UT vs. T, Student’s t-
test; ††p<0.01, UT WT vs. mKO, 2-way ANOVA. Data are presented as mean ± SEM. 
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in SS mitochondria was elevated by ~45% in the absence of p53 in both models compared to WT 
mice (Fig. 10F).Therefore, some differences in gene expression, respiration, and ROS production 
exist between mouse models in the absence of p53. 
 The autophagy signaling pathway was measured through the examination of LC3, p62, 
and Beclin-1 proteins. Though LC3-I remained relatively constant between genotypes, activated 
LC3-II protein was increased in the WB KO mice, leading to an elevation in the LC3 II/I ratio 
(p<0.05; Fig. 11A, B). p62 protein was elevated by 2.4- and 1.6-fold in the mKO and WB KO 
mice (Fig. 11A, C). Beclin-1 protein was increased in the mKO mice by 2.6-fold, but the higher 
level evident in the WB WT control mice precluded a significant increase in the WB KO animals 
(Fig. 11A, D).  
Understanding the combined effect of genotype, training, and mouse model on exercise 
capacity adaptations and mitochondrial biogenesis. We sought to understand whether the 
adaptive response to training would be similar in WB p53 KO and mKO mice. Exercise capacity 
was significantly improved (~2.5-fold) following the training program in all mice regardless of 
genotype or model (Fig. 12A). Training increased mitochondrial content by 27-43% in the KO 
and WT mice, attaining similar levels post-training (Fig. 12B). In the WB mice, training 
increased mitochondrial content by 43% in the WT mice, and by 36% in the KO mice. In the 
absence of p53, training elevated PGC-1α protein levels to a similar extent in both WB p53 KO 
and mKO mice, thus attenuating the deficit induced by p53. Thus, the absence of p53 does not 
impact the improvements in performance, mitochondrial content, or expression of PGC-1α in 
response to training.    
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Figure 10. Basal mitochondrial biogenesis and apoptotic signaling comparisons in mouse 
models. Muscle specific (mKO) and whole body (WB) WT and p53 deletion models were 
compared under basal conditions. Mitochondrial biogenesis was measured through A) COX 
enzyme activity (n=6-8/group); †p<0.05, ††p<0.01, UT WT vs. KO, Student’s t-test and 2-way 
ANOVA, and whole muscle B) PGC-1α mRNA (n=5-10/group); ††p<0.01, UT WT vs. KO, 2-
way ANOVA; ¶p<0.05, WT MS vs. WB, 2-way ANOVA, and C) PGC-1α protein (n=5-
7/group); †p<0.05, ††p<0.01, UT WT vs. KO, Student’s t-test and 2-way ANOVA; ¶p<0.05, 
WT MS vs. WB, Student’s t-test. Immunoblots were retrieved from the same blot but were 
spliced for direct comparison of untrained animals. SS mitochondrial state 3 D) respiration 
(n=6/group); †p<0.05, UT WT vs. KO, Student’s t-test; ¶¶p<0.01, KO MS vs. WB, 2-way 
ANOVA, and E) ROS emission (n=6-7/group); ¶p<0.05, MS vs. WB, Student’s t-test and 2-way 
ANOVA. F) Basal cytochrome c release in SS mitochondria (n=5-9/group); †p<0.05, UT WT vs. 
KO, Student’s t-test and 2-way ANOVA. Data are presented as mean ± SEM. 
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Figure 11. Autophagic signaling occurs similarly between mouse models in the absence of 
p53. The alterations in the autophagy signaling pathway in the absence of p53 was compared 
between MS and WB mouse models. A) Immunoblots of whole muscle autophagic proteins 
including B) LC3-II/LC3-I ratio (n=6-8/group); †p<0.05, UT WT vs. KO, Student’s t-test, C) 
p62 (n=5-8/group); †p<0.05, ††p<0.01, UT WT vs. KO, 2-way ANOVA, and D) Beclin-1 were 
measured (n=5-7/group); ††p<0.01, UT WT vs. KO, 2-way ANOVA; ¶¶p<0.01, WT MS vs. 
WB, Student’s t-test.  Data are presented as mean ± SEM. 
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Figure 12. Adaptive mitochondrial responses with training in two mouse models. Following 
the 6-week training/sedentary protocol, MS and WB mice were subjected to an exhaustive 
exercise test. A) Distance to exhaustion in both mouse models (n=6-9/group); **p<0.01, UT vs. 
T, 2-way ANOVA. B) COX activity (n=6-8/group); *p<0.05, **p<0.01, UT vs. T, Student’s t-
test and 2-way ANOVA; †p<0.05, UT WT vs. KO, Student’s t-test. C) PGC-1α protein (n=5-
10/group); *p<0.05, **p<0.01, UT vs. T, Student’s t-test and 2-way ANOVA; †p<0.05, UT WT 
vs. KO, Student’s t-test; ¶p<0.05, WT MS vs. WB, Student’s t-test. Data are presented as mean ± 
SEM. 
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Discussion  
The function of p53 in the transcriptional regulation of numerous signaling pathways is 
well established. However, its role in maintaining mitochondrial content and function, as well as 
the adaptive responses to endurance training remains unresolved. Thus, we sought to 
comprehensively evaluate this function of p53 by using muscle-specific p53 knockout animals. 
Our results reveal that 1) training reduces p53 at the mRNA and protein levels, but increases the 
proportion of activated p53, particularly within mitochondria, 2) p53 is important for regulating 
basal mitochondrial biogenesis, respiration, ROS emission and apoptosis, but is not essential for 
training-induced adaptations in mitochondrial content, exercise capacity, and lactate handling, 3) 
p53 is not required for autophagy signaling but may be necessary for substrate clearance (21, 
37), a process improved with training, 4) p53 is important for maintaining the expression of 
specific transcripts regulating mitochondrial biogenesis, metabolism, autophagy, apoptosis and 
cellular senescence, both basally and with training, and 5) training can improve mitochondrial 
content and function, as well as attenuate the deficits in mitochondrial function induced by the 
absence of p53.  
It is well-established that acute exercise results in p53 re-localization. We and others have 
shown that p53 can be redirected to the mitochondria (34, 38) and nucleus (17, 44, 50) with acute 
exercise, concomitant with the activation of both AMPK and p38 MAPK kinases (5, 25, 38) and 
the phosphorylation of p53 on Ser15 (4, 38). This is important for the transcriptional activation of 
nuclear and mitochondrial gene products, as well as for the dissociation of p53 from its negative 
regulator Mdm2 (20, 24, 36, 38, 41). The results presented in our study extend these findings to 
show that endurance training modifies this subcellular redistribution during acute exercise. 
Though nuclear accumulation of p53 does occur with acute exercise (17, 27, 29, 38, 44, 50), 
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training resulted in the re-localization of activated p53 out of the nucleus, leading to its cytosolic 
accumulation (Fig. 1F) where it can then localize to mitochondria (Fig. 1J, K). p53 
mitochondrial accumulation was likely facilitated by enhanced CHCHD4 levels (Fig. 5H), a 
component of the mitochondrial import machinery, which specifically targets p53 to increase 
trafficking into the organelle (50). Once inside, p53 can maintain mitochondrial genome integrity 
by interacting with Tfam, increasing mtDNA transcription, and enhancing polymerase-γ activity 
(1, 18, 38, 39, 48).  
We sought to identify the mitochondrial impairments in muscle consequent to the 
absence of p53, and the potential corrective effects of a chronic endurance training program.  
Under basal conditions, the presence of a genome-wide p53 deletion has been shown to result in 
morphological disruptions of SS and IMF mitochondria, reduced mitochondrial content and 
mtDNA copy number, and decreases in numerous transcriptional targets including PGC-1α and 
Tfam (28, 33, 35, 38, 39). Functional deficits include impaired state 3 respiration and elevated 
ROS levels in IMF mitochondria, altered DNA fragmentation and enhanced apoptotic potential, 
evidenced through increased cytochrome c release from SS mitochondria (10, 32, 35).  Our data 
reveal that the muscle-specific absence of p53 results in a modest, but significant reduction in 
mitochondrial content, along with decreases in both Tfam and PGC-1α mRNA and protein. 
Functional mitochondrial deficits were also observed, including impaired state 3 respiration, 
elevated ROS levels and increased pro-apoptotic signaling, accompanied by an increase in the 
Bax:Bcl-2 protein ratio. Interestingly, a recent study employing 8-week old muscle-specific p53 
mKO mice (43) observed no deficits in mitochondrial proteins or mRNA. This difference in 
results may be developmentally-related, as our study was conducted using ~3 month old mice for 
comparison. This would suggest that the influence of p53 on mitochondrial function is dependent 
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on age. Although cage activity, based on voluntary running wheel data, differs markedly between 
whole body p53 knockout and WT animals (35), we found no differences in voluntary wheel 
running activity over a 2-week period between mKO and WT mice (n=3-4). Thus, differences in 
activity level do not appear to be the cause of the reduced mitochondrial content in mKO mice.  
We additionally probed the autophagy pathway, known to be altered in the absence of 
p53 (9, 21, 31, 35, 37, 45, 49). Elevations in p62, Parkin, and Beclin-1 autophagy proteins were 
observed in the absence of p53, with a trend for an increase in the LC3 II/I ratio. These data 
suggest that autophagic signaling is enhanced in the absence of p53, but that clearance of 
autophagosomes, and substrates such as p62, is impaired. Similar results have previously been 
shown (37), whereby the absence of p53 led to elevated p62 protein and reduced ubiquitination. 
This impaired clearance could contribute to the accumulation of dysfunctional mitochondria that 
we observed in the mKO mice (Fig. 3D, H). 
We also examined the consequences of muscle-specific p53 deletion on muscle mass and 
physiological performance. Analogous to previous work (15), our mKO mice revealed no 
baseline differences in body or hindlimb mass, indicating that p53 is not required for the 
maintenance of skeletal muscle mass. While one study identified significant reductions in whole 
body exercise performance and aerobic capacity, evidenced by 3-fold higher lactate levels and 
impaired aerobic swimming performance as a result of p53 deletion (33, 35), another  
investigation revealed  no effect on performance during an acute bout of exhaustive exercise 
(38). We confirmed these findings, whereby our mKO mice displayed similar pre-training 
exercise performance as the WT mice. However, the lower oxidative capacity of these mice 
resulted in higher blood lactate following their exercise test, suggesting a greater reliance on 
glycolysis to achieve this same performance.  
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We sought to determine whether p53 is necessary for adaptations to exercise training. In 
contrast to a previous study using a whole body p53 knockout model in which a reduced adaptive 
capacity was noted (33), we observed that WT and mKO mice respond with similar phenotypic 
and physiological adaptations to training, as shown by >2-fold improvement in exercise capacity 
and an attenuation in final lactate levels. Mitochondrial content was increased in the mKO mice 
by 42%, to attain similar levels as the WT trained mice, which increased their COX activity by 
27%. In the absence of p53, we observed similar elevations in PGC-1α and Tfam proteins. 
Furthermore, mitochondrial respiration was increased while ROS emission was reduced in the 
mKO mice, indicating that training improved the mitochondrial deficits induced basally by the 
absence of p53. Apoptosis was down-regulated with exercise training, as evidenced by reduced 
cytochrome c release from SS mitochondria and attenuated Bax protein levels in the mKO mice. 
Proteins of the autophagy pathway, including Parkin, Beclin-1, and LC3-II were significantly 
upregulated in the WT mice with training, as shown in other models of chronic exercise (7, 8, 
22). In contrast, training reduced the already elevated levels of these proteins in mKO mice 
toward levels observed in the WT trained mice. Of particular relevance is the training-induced 
reduction in p62 protein, in the absence of a change in p62 mRNA, signifying enhanced p62 
degradation via autophagic flux. Thus, training induces the activation of redundant signals to 
increase mitochondrial biogenesis and autophagy, and reduce apoptosis, to compensate for the 
loss of p53, resulting in similar final adaptations between groups.  
As most literature on the role of p53 in skeletal muscle has been performed using a whole 
body (WB) p53 deletion model, we inquired as to whether deficits observed in the WB model are 
a result of the loss of p53 in muscle, or a consequence of its absence in alternative tissues. 
Though we observed similar directional alterations in mitochondrial content, autophagy proteins, 
102 
 
PGC-1α mRNA and protein, state 3 respiration and ROS emission in SS mitochondria of both 
WB p53 KO and mKO models basally, the magnitude of change was less pronounced in the 
mKO mice (33, 35, 37, 38). This may be a result of the lingering, yet vanishingly low, p53 
protein in the mKO mice, or a consequence of blood-borne metabolic, endocrine, or 
immunological influences on muscle as a result of a genome-wide p53 deletion. Whatever the 
cause, it is evident that chronic exercise is able to combat these defects to produce similar 
adaptations in performance, mitochondrial function, and PGC-1α protein between these two 
experimental models. 
 This study has sought to provide a greater understanding of the role of p53 in mediating 
exercise-induced adaptations in muscle. Though p53 is required for mitochondrial maintenance 
and function, autophagy and apoptotic regulation, its absence in muscle does not cause an 
impairment in endurance exercise performance. Thus, redundant signaling exists to compensate 
for its loss, allowing for beneficial exercise-induced mitochondrial adaptations to occur, thereby 
improving muscle health. Our data also indicate that exercise, in the form of a progressive and 
regulated endurance training program, can be a viable therapeutic option for individuals with 
mutated or non-functional p53. 
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Future Work 
Based on the present findings and on previous research performed in the field of p53 and 
mitochondrial signaling with exercise, future research could focus on: 
Short-Term Goals 
x Examining glycolytic proteins through immunoblotting to determine metabolic reliance 
on glycolysis rather than oxidative phosphorylation in the mKO mice, basally; 
x Measuring mitophagy flux and lysosomal biogenesis to understand mitochondrial 
turnover with exercise training, and its dependency on p53; 
x Understanding the role of p53 on additional mechanisms that regulate cellular 
homeostasis through protein analysis via immunoblotting for the antioxidant and ROS 
pathways; 
x Evaluating whether additional post-translational modifications are facilitating the 
subcellular re-localization of p53 by immunoblotting for residue modifications. 
x Elucidating transcription factors that may compensate for the loss of p53, allowing for 
training-induced adaptations in mitochondrial biogenesis and gene transcription; 
 
Long-Term 
x Determining the transcription factors that may compensate for the loss of p53 with 
exercise training by performing a microarray; 
x Ascertaining the mechanisms that assist in the re-localization of p53 to alternate cellular 
compartments with exercise, accomplished through in vitro inhibition of channels and 
additional fluorescent tagging to determine transport proteins; 
x Discovering an ideal exercise program by creating a time course with altered exercise 
parameters (length of program, intensity, frequency, duration), to determine the point for 
optimal skeletal muscle mitochondrial adaptations, and the whether there is a dependency 
on p53 within the variable exercise regimens. 
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Appendix A: Manuscript Data and Statistical Analysis 
 
Table 3A: Pre-training body mass and performance test, distance to exhaustion 
Initial Body Mass (g) – Muscle 
Specific Mice 
  Pre-Training Distance to Exhaustion 
(m) – Muscle Specific Mice 
N WT mKO   N WT mKO 
1 30.8 38.4   1 1144.22 1381.40 
2 30.4 28.5   2 1322.50 1012.56 
3 29.6 29.5   3 1597.00 1546.42 
4 26.8 27.2   4 1150.00 1322.50 
5 31.0 29.4   5 970.00 1387.88 
6 31.4 44.4   6 1559.00 477.00 
7 31.5 34.6   7 1578.00 523.25 
8 30.1 27.0   8 962.00 855.23 
9 31.2 36.7   9 1287.50 1466.50 
10 31.3 32.0   10 1189.44 1616.00 
11 30.4 32.8   11 1012.56 1635.00 
12 29.2 29.2   12 1201.00 804.80 
13 31.7 27.8   13 1509.42 922.50 
14  28.8   14 1394.00 876.00 
15  27.8   15 1192.50 970.00 
16  28.2   16 1301.50 1313.75 
17  27.7   17 1485.00 1503.50 
18  36.9   18  1201.00 
19  31.1   X 1285.626 1156.405 
20  31.4   SEM 50.830 85.428 
21  29.5      
X 30.415 31.376      
SEM 0.367 0.985      
 
Unpaired T-test – WT versus KO 
P value 0.4621 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
 
 
 
Unpaired T-test – WT versus KO 
P value 0.2091 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3B: Post-training body mass measurement 
 
 Final Body Mass (g) - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 31.52 29.02 42.40 27.10 
2 31.23 30.52 30.60 27.72 
3 34.03 30.35 33.40 25.61 
4 30.07 30.74 30.40 28.42 
5 36.13 30.07 30.40 28.92 
6 36.15 29.75 43.00 27.06 
7   38.40 26.82 
8   29.10 29.41 
9   38.40 30.10 
10   32.30 27.00 
X 33.188 30.075 34.840 27.816 
SEM 1.072 0.254 1.660 0.434 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1138 ns No 
Mouse Model 0.8017 ns No 
Genotype/Training 0.0002 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 3.113 1.644 >0.05 ns 
WT:UT vs. KO:UT -1.652 0.9750 > 0.05 ns 
WT:UT vs. KO:T 5.372 3.171 ≤ 0.05 * 
WT:T vs. KO:UT -4.765 2.813 > 0.05 ns 
WT:T vs. KO:T 2.259 1.333 > 0.05 ns 
KO:UT vs. KO:T 7.024 4.788 <0.005 *** 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0180 
P value summary * 
Significantly different? (P<0.05) Yes 
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Table 3B: Post-training tibialis anterior (TA) mass measurement, corrected for body mass 
 
 Tibialis Anterior (TA) Skeletal Muscle Mass/Body  
Mass (mg/g) – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 2.00 1.51 2.57 1.93 
2 2.20 1.62 1.98 1.64 
3 2.20 1.69 1.91 1.82 
4 1.95 1.49 2.06 1.85 
5 1.86 1.83 1.91 1.62 
6 1.68 1.30 2.05 1.72 
7   2.01 1.78 
8   2.21 1.94 
X 1.982 1.573 2.088 1.788 
SEM 0.0822 0.0747 0.0768 0.0429 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4457 ns No 
Mouse Model 0.0311 * Yes 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.4083 3.866 ≤ 0.01 ** 
WT:UT vs. KO:UT -0.1058 1.071 > 0.05 ns 
WT:UT vs. KO:T 0.1942 1.965 > 0.05 ns 
WT:T vs. KO:UT -0.5142 5.204 ≤ 0.005 *** 
WT:T vs. KO:T -0.2142 2.168 > 0.05 ns 
KO:UT vs. KO:T 0.3000 3.280 ≤ 0.05 * 
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Table 3B: Post-training gastrocnemius mass measurement, corrected for body mass 
 
 Gastrocnemius Skeletal Muscle Mass/Body Mass (mg/g) – 
Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 7.42 6.32 8.13 6.24 
2 6.73 6.28 5.88 6.32 
3 5.89 5.56 6.18 6.52 
4 6.10 5.74 6.15 6.14 
5 5.90 5.81 6.16 6.36 
6 6.00 5.34 5.88 5.19 
7   6.25 6.45 
8   5.83 6.19 
X 6.340 5.842 6.308 6.176 
SEM 0.251 0.160 0.267 0.148 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4092 ns No 
Mouse Model 0.4961 ns No 
Genotype/Training 0.1626 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.4983 1.508 > 0.05 ns 
WT:UT vs. KO:UT 0.03250 0.1052 > 0.05 ns 
WT:UT vs. KO:T 0.1638 0.5299 > 0.05 ns 
WT:T vs. KO:UT -0.4658 1.507 > 0.05 ns 
WT:T vs. KO:T -0.3346 1.083 > 0.05 ns 
KO:UT vs. KO:T 0.1313 0.4588 > 0.05 ns 
 
Unpaired T-test – WT UT versus WT T 
P value 0.1246 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3B: Post-training quadriceps mass measurement, corrected for body mass 
 
 Quadriceps Skeletal Muscle Mass/Body Mass (mg/g) – Muscle 
Specific Mice 
 WT mKO 
N UT T UT T 
1 6.56 5.65 7.28 6.56 
2 6.51 5.95 6.96 6.50 
3 5.87 6.58 6.64 6.56 
4 6.15 6.08 6.52 6.45 
5 6.18 6.57 6.05 6.52 
6 6.15 6.22 6.05 6.60 
7   7.61 7.15 
8   5.93 6.73 
X 6.237 6.175 6.630 6.634 
SEM 0.105 0.148 0.218 0.0793 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.8358 ns No 
Mouse Model 0.0117 * Yes 
Genotype/Training 0.8544 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.06167 0.2614 > 0.05 ns 
WT:UT vs. KO:UT -0.3933 1.782 > 0.05 ns 
WT:UT vs. KO:T -0.3971 1.799 > 0.05 ns 
WT:T vs. KO:UT -0.4550 2.062 > 0.05 ns 
WT:T vs. KO:T -0.4588 2.078 > 0.05 ns 
KO:UT vs. KO:T -0.003750 0.01835 > 0.05 ns 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.1708 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3B: Post-training heart mass measurement, corrected for body mass 
 
 Heart Mass/Body Mass (mg/g) – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 6.14 6.04 3.69 5.42 
2 5.71 6.26 4.29 5.69 
3 4.89 5.69 5.07 6.01 
4 3.99 5.13 4.76 5.51 
5 6.59 5.76 5.06 6.13 
6 4.94 5.66 5.14 5.64 
7   5.04 6.10 
8   5.11 6.00 
X 5.377 5.757 4.770 5.813 
SEM 0.388 0.157 0.184 0.0989 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1388 ns No 
Mouse Model 0.2151 ns No 
Genotype/Training 0.0031 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.3800 1.162 > 0.05 ns 
WT:UT vs. KO:UT 0.6067 1.983 > 0.05 ns 
WT:UT vs. KO:T -0.4358 1.425 > 0.05 ns 
WT:T vs. KO:UT 0.9867 3.225 ≤ 0.05 * 
WT:T vs. KO:T -0.05583 0.1825 > 0.05 ns 
KO:UT vs. KO:T -1.043 3.681 ≤ 0.01 ** 
 
Unpaired T-test – WT UT versus WT T 
P value 0.3853 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3B: Post-training epididymal fat mass measurement, corrected for body mass 
 
 Epididymal Fat Mass /Body Mass (mg/g) – Muscle Specific 
Mice 
 WT mKO 
N UT T UT T 
1 33.60 22.25 67.17 26.68 
2 43.06 24.78 59.87 27.04 
3 51.42 29.34 41.71 30.32 
4 38.65 39.98 53.59 24.04 
5 39.77 44.16 39.43 19.37 
6 54.89 28.43 58.87 27.07 
7   59.64 14.52 
8   56.22 22.32 
X 43.565 31.490 54.563 23.920 
SEM 3.307 3.545 3.352 1.792 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0054 ** Yes 
Mouse Model 0.5773 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 12.08 2.633 > 0.05 ns 
WT:UT vs. KO:UT -11.00 2.564 > 0.05 ns 
WT:UT vs. KO:T 19.65 4.579 ≤ 0.005 *** 
WT:T vs. KO:UT -23.07 5.378 ≤ 0.001 **** 
WT:T vs. KO:T 7.570 1.765 > 0.05 ns 
KO:UT vs. KO:T 30.64 7.715 ≤ 0.001 **** 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0319 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.0417 
P value summary * 
Significantly different? (P<0.05) Yes 
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Table 3C: Post-training SS mitochondrial yield  
 
 SS Mitochondrial Yield (µg/mg) - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.47 0.95 0.58 0.80 
2 0.62 0.83 0.44 1.03 
3 0.71 0.89 0.83 0.90 
4 0.22 0.79 0.69 0.76 
5 0.56 0.87 0.036 0.85 
6 0.67 0.61 0.6 0.69 
7   0.59 0.64 
8   0.72  
X 0.542 0.823 0.561 0.81 
SEM 0.0730 0.0481 0.0853 0.0498 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.8178 ns No 
Mouse Model 0.9674 ns No 
Genotype/Training 0.0009 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2817 2.719 > 0.05 ns 
WT:UT vs. KO:UT -0.01908 0.1969 > 0.05 ns 
WT:UT vs. KO:T -0.2683 2.688 > 0.05 ns 
WT:T vs. KO:UT 0.2626 2.710 > 0.05 ns 
WT:T vs. KO:T 0.01333 0.1336 > 0.05 ns 
KO:UT vs. KO:T -0.2493 2.684 > 0.05 ns 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0091 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
 
 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0304 
P value summary * 
Significantly different? (P<0.05) Yes 
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Table 3C: Post-training IMF mitochondrial yield  
 
 IMF Mitochondrial Yield (µg/mg) - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 1.11 1.05 0.98 1.10 
2 1.00 1.06 1.18 1.17 
3 1.09 1.56 1.15 1.35 
4 1.08 1.58 1.06 1.21 
5 1.04 1.14 1.15 1.61 
6  1.38 0.12 1.54 
7   0.96 1.76 
8   0.99 1.44 
X 1.064 1.295 0.949 1.398 
SEM 0.0196 0.0999 0.122 0.0820 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.2909 ns No 
Mouse Model 0.9521 ns No 
Genotype/Training 0.0027 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2305 1.481 > 0.05 ns 
WT:UT vs. KO:UT 0.1153 0.7864 > 0.05 ns 
WT:UT vs. KO:T -0.3335 2.276 > 0.05 ns 
WT:T vs. KO:UT 0.3458 2.490 > 0.05 ns 
WT:T vs. KO:T -0.1030 0.7419 > 0.05 ns 
KO:UT vs. KO:T -0.4488 3.491 ≤ 0.05 * 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0694 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3C: Post-training Respiratory Control Ratio (RCR) (state 3/4) in SS Mitochondria  
 
 SS Respiratory Control Ratio (RCR)- Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 2.09 4.56 3.19 5.00 
2 0.70 3.62 2.52 4.22 
3 5.82 10.30 4.33 5.55 
4 3.56 37.00 7.35 5.64 
5 7.20 17.00 5.44 9.32 
6 3.15 4.71 4.90 4.39 
7 3.93  6.45 4.31 
8   2.75 19.00 
X 3.779 12.865 4.616 7.179 
SEM 0.826 5.251 0.621 1.787 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1917 ns No 
Mouse Model 0.3282 ns No 
Genotype/Training 0.0244 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -9.086 2.513 > 0.05 ns 
WT:UT vs. KO:UT -0.8377 0.2490 > 0.05 ns 
WT:UT vs. KO:T -3.400 1.011 > 0.05 ns 
WT:T vs. KO:UT 8.249 2.350 > 0.05 ns 
WT:T vs. KO:T 5.686 1.620 > 0.05 ns 
KO:UT vs. KO:T -2.563 0.7885 > 0.05 ns 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0911 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test – KO UT versus KO T 
P value 0.1971 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3C: Post-training Respiratory Control Ratio (RCR) (state 3/4) in IMF Mitochondria  
 
 IMF Respiratory Control Ratio (RCR)- Muscle Specific Mice 
 WT KO 
N UT T UT T 
1 6.59 2.82 8.62 7.89 
2 5.43 18.47 5.22 7.97 
3 6.89 4.74 5.77 8.17 
4 5.86 19.06 12.36 1.80 
5 5.64 7.49 7.80 6.27 
6 5.89 8.04 6.66 4.97 
7   2.85 18.36 
8    41.50 
X 6.0500 10.103 7.0400 12.116 
SEM 0.232 2.847 1.134 4.521 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.8692 ns No 
Mouse Model 0.6296 ns No 
Genotype/Training 0.1508 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -4.053 0.8862 > 0.05 ns 
WT:UT vs. KO:UT -0.9900 0.2246 > 0.05 ns 
WT:UT vs. KO:T -6.066 1.418 > 0.05 ns 
WT:T vs. KO:UT 3.063 0.6950 > 0.05 ns 
WT:T vs. KO:T -2.013 0.4705 > 0.05 ns 
KO:UT vs. KO:T -5.076 1.238 > 0.05 ns 
 
Unpaired T-test –WT UT versus WT T 
P value 0.1863 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test –  KO UT versus KO T 
P value 0.3257 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 2B: Whole muscle total p53 protein – WT Muscle-Specific Mice 
 Total-p53 Protein Expression – Whole 
Muscle Extracts - Muscle Specific Mice 
 WT 
N UT T 
1 0.74 0.29 
2 0.35 0.41 
3 1.29 0.28 
4 0.63 0.13 
5 0.47 0.050 
6 0.75 0.44 
7  0.28 
X 0.704 0.269 
SEM 0.133 0.0528 
 
Unpaired T-test-  WT UT versus T 
P value 0.0080 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
 
Figure 2C: Whole muscle phosphorylated-p53 (Ser15) protein – WT Muscle-Specific Mice 
 Phospho-p53/ Total p53 Protein Expression – 
Whole Muscle Extracts - Muscle Specific Mice 
 WT 
N UT T 
1 0.60 0.67 
2 0.11 0.66 
3 0.48 0.58 
4 0.24 0.65 
5 0.60 1.55 
6 0.42 2.039 
X 0.407 1.0254 
SEM 0.0809 0.251 
 
Unpaired T-test-  WT UT versus T 
P value 0.0413 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 2E: Total p53 protein in nuclear and cytosolic cellular compartments - WT Muscle-
Specific Mice 
 Nuclear/Cytosolic – Total p53 Protein - Muscle Specific Mice 
 Nuclear Cytosolic 
N UT T UT T 
1 1.012 0.32 1.25 0.65 
2 0.74 0.50 0.96 1.22 
3 0.43 0.22 1.29 0.83 
4 0.47 0.13 1.54 0.41 
5    0.98 
X 0.661 0.295 1.257 0.816 
SEM 0.136 0.0793 0.119 0.139 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9730 ns No 
Mouse Model 0.0025 ** Yes 
Genotype/Training 0.0086 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Nuc:UT vs. Nuc:T 0.3659 2.018 > 0.05 ns 
Nuc:UT vs. Cyto:UT -0.5968 3.291 ≤ 0.05 # 
Nuc:UT vs. Cyto:T -0.1554 0.9033 > 0.05 ns 
Nuc:T vs. Cyto:UT -0.9627 5.309 ≤ 0.005 *** 
Nuc:T vs. Cyto:T -0.5213 3.030 > 0.05 ns 
Cyto:UT vs. Cyto:T 0.4414 2.566 > 0.05 ns 
 
Unpaired T-test- Nuc UT versus Nuc T 
P value 0.0552 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  Cyto UT versus Cyto T 
P value 0.0525 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  Nuc T versus Cyto T 
P value 0.0194 
P value summary # 
Significantly different? (P<0.05) Yes 
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Figure 2E: Phosphorylated p53 (Ser15) protein in nuclear and cytosolic cellular 
compartments, percentage of total - WT Muscle-Specific Mice 
 
 Phospho-p53 (% Total) Nuc/Cyto - Muscle Specific Mice 
 UT T 
N NUC CYTO NUC CYTO 
1 0.73 – 73.0% 0.27 – 27.0% 0.31 – 31.0% 0.69 – 69.0% 
2 0.62 – 62.0% 0.38 – 38.0% 0.43 – 43.0% 0.57 – 57.0% 
3 0.71 – 71.0% 0.29 – 29.0% 0.33 – 33.0% 0.67 – 67.0% 
4 0.82 – 82.0% 0.18 – 18.0% 0.44 – 44.0% 0.56 – 56.0% 
X 0.722 – 72.2% 0.278 – 27.8% 0.378 – 37.8% 0.623 – 62.3% 
SEM 0.0418 0.0418 0.0345 0.0345 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction < 0.0001 **** Yes 
Mouse Model > 0.9999 ns No 
Genotype/Training 0.0222 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
UT:Nuc vs. UT:Cyto 0.4443 3.428 ≤ 0.001 #### 
UT:Nuc vs. T:Nuc 0.3436 3.006 ≤ 0.005 *** 
UT:Nuc vs. T:Cyto 0.1006 2.049 > 0.05 ns 
UT:Cyto vs. T:Nuc -0.1006 0.2590 > 0.05 ns 
UT:Cyto vs. T:Cyto -0.3436 1.267 ≤ 0.005 *** 
T:Nuc vs. T:Cyto -0.2430 0.9566 ≤ 0.01 ## 
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Figure 2H: Total p53 protein in IMF mitochondria - WT Muscle-Specific Mice 
 
 IMF Mitochondria –Total p53 Protein - 
Muscle Specific Mice 
 WT 
N UT T 
1 0.81 0.31 
2 1.09 0.42 
3 0.93 0.36 
4 1.50 0.48 
5 0.73  
X 1.0124 0.393 
SEM 0.136 0.0368 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0056 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
 
Figure 2I: Total p53 protein in SS mitochondria - WT Muscle-Specific Mice 
 
 SS Mitochondria –Total p53 Protein - Muscle 
Specific Mice 
 WT 
N UT T 
1 0.95 0.78 
2 0.56 0.20 
3 0.69 0.38 
4 1.36 0.30 
5 0.75  
X 0.863 0.416 
SEM 0.139 0.128 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.0544 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 2J: Phosphorylated p53 (Ser15) protein in IMF mitochondria - WT Muscle-Specific 
Mice 
 IMF Mitochondria – Phospho-p53/ Total p53 
Protein - Muscle Specific Mice 
 WT 
N UT T 
1 0.34 1.85 
2 0.41 1.62 
3 0.56 0.78 
4 0.68 0.71 
5 0.41 0.91 
X 0.479 1.173 
SEM 0.0418 0.0345 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0209 
P value summary * 
Significantly different? (P<0.05) Yes 
 
 
 
Figure 2K: Phosphorylated p53 (Ser15) protein in SS mitochondria - WT Muscle-Specific 
Mice 
 SS Mitochondria – Phospho-p53/ Total p53 
Protein - Muscle Specific Mice 
 WT 
N UT T 
1 0.63 1.29 
2 0.66 1.79 
3 0.34 0.73 
4 0.50 0.82 
5 0.53  
X 0.530 1.160 
SEM 0.0560 0.244 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.0257 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 3C: Post-training performance test, distance to exhaustion  
 
 Post-Training Performance Stress Test – Distance to 
Exhaustion (m)- Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 891.50 1623.60 726.00 1731.50 
2 1349.00 2990.30 1067.00 2555.00 
3 922.50 1376.00 1059.00 2117.00 
4 852.80 1578.00 1084.00 2465.00 
5 1252.50 2834.00 1150.00 2487.50 
6 830.00 2992.70 926.00 1946.90 
7   400.00 2112.80 
8   557.00 1533.10 
X 1016.383 2232.433 871.125 2118.600 
SEM 91.705 318.679 98.330 131.523 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9275 ns No 
Mouse Model 0.4559 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -1216 4.705 ≤ 0.005 *** 
WT:UT vs. KO:UT 145.3 0.6009 > 0.05 ns 
WT:UT vs. KO:T -1102 4.559 ≤ 0.005 *** 
WT:T vs. KO:UT 1361 5.631 ≤ 0.001 **** 
WT:T vs. KO:T 113.8 0.4709 > 0.05 ns 
KO:UT vs. KO:T -1247 5.574 ≤ 0.001 **** 
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Figure 3D: Post-training performance test, final lactate levels  
 Post-Training Performance Stress Test - Post-Exercise 
Lactate Levels (mM)- Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 12.3 10.9 11.9 7.9 
2 11.4 7.8 11.5 8 
3 12.2 10.7 12.2 7.4 
4 9.5 8.8 10.8 11.3 
5 11.1 11.7 17.8 9.5 
6 11.5 11.8 13.9 9.3 
7 10.6  10.9 12.6 
8 10.5  12.7 9.4 
9 8.8  13.4  
10 10  12  
11 11.8  10.9  
12 12.8  18.6  
13 9  13.2  
14   14.2  
15   12.2  
16   13.8  
17   13.3  
X 10.885 10.283 13.135 9.425 
SEM 0.356 0.664 0.531 0.628 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 1.122 1.375 > 0.05 ns 
WT:UT vs. KO:UT -2.251 3.364 ≤ 0.01 ** 
WT:UT vs. KO:T 1.46 1.789 > 0.05 ns 
WT:T vs. KO:UT -3.373 4.332 ≤ 0.005 *** 
WT:T vs. KO:T 0.3375 0.3717 > 0.05 ns 
KO:UT vs. KO:T 3.71 4.765 ≤ 0.005 *** 
 
Unpaired T-test – WT UT versus WT T 
P value 0.1002 
P value summary ns 
Significantly different? (P<0.05) No 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0268 * Yes 
Mouse Model 0.0972 ns No 
Genotype/Training 0.0001 *** Yes 
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Figure 3E: Post-Training COX Enzyme Activity, marker of mitochondrial content 
 
 COX Enzyme Activity (µmol/min/g tissue)– 
Mitochondrial Content - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 19.21 19.63 14.84 22.22 
2 16.66 21.86 11.04 22.61 
3 13.76 21.52 12.21 24.46 
4 16.87 20.65 14.41 22.49 
5 15.90 24.89 13.29 25.42 
6 16.80 20.09 14.65 22.34 
7  22.98 14.66 21.18 
8  26.86 14.50 25.49 
X 16.533 22.310 13.700 23.276 
SEM 0.718 0.881 0.495 0.572 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0105 * Yes 
Mouse Model 0.1868 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -5.777 5.716 ≤ 0.001 **** 
WT:UT vs. KO:UT 2.833 2.804 > 0.05 ns 
WT:UT vs. KO:T -6.743 6.672 ≤ 0.001 **** 
WT:T vs. KO:UT 8.610 9.203 ≤ 0.001 **** 
WT:T vs. KO:T -0.9662 1.033 > 0.05 ns 
KO:UT vs. KO:T -9.576 10.24 ≤ 0.001 **** 
 
Unpaired T-test –WT UT versus KO UT 
P value 0.0056 
P value summary †† 
Significantly different? (P<0.05) Yes 
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Figure 3G: Post-training whole muscle PGC-1α protein 
 
 Whole Muscle PGC-1α Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.35 0.93 0.39 0.69 
2 0.40 0.74 0.27 0.89 
3 0.43 0.71 0.21 0.41 
4 0.58 1.17 0.42 0.93 
5 0.52 0.73 0.30 0.93 
6  0.88 0.24 0.69 
7  0.71 0.21 0.61 
8    0.91 
X 0.456 0.840 0.291 0.759 
SEM 0.0410 0.0641 0.0321 0.0675 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4746 ns No 
Mouse Model 0.0452 * Yes 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.3841 4.429 ≤ 0.01 ** 
WT:UT vs. KO:UT 0.1646 1.898 > 0.05 ns 
WT:UT vs. KO:T -0.3036 3.596 ≤ 0.01 ** 
WT:T vs. KO:UT 0.5487 6.931 ≤ 0.001 **** 
WT:T vs. KO:T 0.08049 1.050 > 0.05 ns 
KO:UT vs. KO:T -0.4682 6.108 ≤ 0.001 **** 
 
Unpaired T-test-  WT UT versus KO UT 
P value 0.0094 
P value summary †† 
Significantly different? (P<0.05) Yes 
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Figure 3H: Post-training whole muscle Tfam protein 
 
 Whole Muscle Tfam Protein Expression - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.56 0.55 0.47 0.72 
2 0.52 0.65 0.31 0.80 
3 0.74 0.75 0.59 0.92 
4 0.71 0.53 0.30 0.91 
5 0.43 0.78 0.49 0.95 
6 0.47 0.88 0.33 0.89 
7    0.81 
X 0.573 0.691 0.414 0.855 
SEM 0.0512 0.0559 0.0479 0.0314 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0023 ** Yes 
Mouse Model 0.9634 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.1180 1.762 > 0.05 ns 
WT:UT vs. KO:UT 0.1594 2.381 > 0.05 ns 
WT:UT vs. KO:T -0.2818 4.366 ≤ 0.01 ** 
WT:T vs. KO:UT 0.2774 4.143 ≤ 0.01 ** 
WT:T vs. KO:T -0.1637 2.537 > 0.05 ns 
KO:UT vs. KO:T -0.4412 6.837 ≤0.001 **** 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.1505 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test-  WT UT versus KO UT 
P value 0.0462 
P value summary † 
Significantly different? (P<0.05) Yes 
 
 
131 
 
Figure 4A: Post-training state 4 (basal) respiration in SS mitochondria  
 
 State 4 Respiration (natoms O2/mg protein/min) – SS 
Mitochondria- Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 4.08 2.63 3.05 7.75 
2 3.26 3.54 7.49 8.48 
3 4.87 8.87 2.82 7.80 
4 1.28 3.96 2.43 11.15 
5 3.06 11.01 3.23 8.39 
6 1.67 10.68 6.32 11.07 
7 3.26   8.18 
X 3.069 6.782 4.223 8.974 
SEM 0.476 1.561 0.868 0.561 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.5755 ns No 
Mouse Model 0.0803 ns No 
Genotype/Training 0.0001 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -3.713 2.876 > 0.05 ns 
WT:UT vs. KO:UT -1.155 0.8944 > 0.05 ns 
WT:UT vs. KO:T -5.906 4.761 ≤ 0.005 *** 
WT:T vs. KO:UT 2.558 1.909 > 0.05 ns 
WT:T vs. KO:T -2.193 1.698 > 0.05 ns 
KO:UT vs. KO:T -4.751 3.680 ≤ 0.01 ** 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0331 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.2499 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 4B: Post-training state 4 (basal) respiration in IMF mitochondria  
 
 State 4 Respiration (natoms O2/mg protein/min) – IMF 
Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 16.12 23.62 12.68 27.73 
2 6.77 19.64 16.96 19.67 
3 4.12 6.04 15.10 13.61 
4 5.61 19.13 10.36 13.05 
5 10.39 14.11 10.19 12.55 
6 12.46 9.24 11.77 27.66 
7   16.20 14.64 
X 9.245 15.297 13.323 18.416 
SEM 1.867 2.748 1.047 2.556 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.8249 ns No 
Mouse Model 0.1069 ns No 
Genotype/Training 0.0162 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -6.052 1.926 > 0.05 ns 
WT:UT vs. KO:UT -4.078 1.347 > 0.05 ns 
WT:UT vs. KO:T -9.171 3.029 ≤ 0.05 * 
WT:T vs. KO:UT 1.974 0.6519 > 0.05 ns 
WT:T vs. KO:T -3.119 1.030 > 0.05 ns 
KO:UT vs. KO:T -5.093 1.751 > 0.05 ns 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0985 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.0732 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0900 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 4C: Post-training state 3 (active) respiration in SS mitochondria  
 
 State 3 Respiration (natoms O2/mg protein/min) – SS 
Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 8.53 84.37 31.93 42.97 
2 10.89 91.41 34.80 47.79 
3 17.80 55.31 13.20 48.98 
4 12.01 67.38 25.16 26.79 
5 16.16 30.21 11.91 47.67 
6 12.82 50.28 40.79 47.03 
X 13.035 63.160 26.298 43.538 
SEM 1.396 9.271 4.809 3.453 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0076 ** Yes 
Mouse Model 0.5728 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -50.13 6.392 ≤ 0.001 **** 
WT:UT vs. KO:UT -13.26 1.691 > 0.05 ns 
WT:UT vs. KO:T -30.50 3.890 ≤ 0.01 ** 
WT:T vs. KO:UT 36.86 4.701 ≤ 0.005 *** 
WT:T vs. KO:T 19.62 2.502 > 0.05 ns 
KO:UT vs. KO:T -17.24 2.199 > 0.05 ns 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0155 
P value summary † 
Significantly different? (P<0.05) Yes 
 
 
 
 
 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0244 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 4D: Post-training state 3 (active) respiration in IMF mitochondria  
 State 3 Respiration (natoms O2/mg protein/min) – IMF 
Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 106.21 66.68 88.48 67.67 
2 122.63 111.53 87.14 107.29 
3 94.36 90.78 79.44 103.95 
4 110.43 90.34 86.33 102.55 
5 120.03 105.65 78.36 130.77 
6 71.54 74.30 46.20 91.83 
7 73.03   157.57 
X 99.747 89.880 77.658 108.804 
SEM 7.912 7.070 6.520 10.808 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0249 * Yes 
Mouse Model 0.8543 ns No 
Genotype/Training 0.2247 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 9.867 0.8193 > 0.05 ns 
WT:UT vs. KO:UT 22.09 1.834 > 0.05 ns 
WT:UT vs. KO:T -9.057 0.7827 > 0.05 ns 
WT:T vs. KO:UT 12.22 0.9779 > 0.05 ns 
WT:T vs. KO:T -18.92 1.571 > 0.05 ns 
KO:UT vs. KO:T -31.15 2.586 > 0.05 ns 
 
 
 
 
 
 
 
 
 
 
Unpaired T-test –WT UT versus WT T 
P value 0.3796 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – KO UT versus KO T 
P value 0.0377 
P value summary * 
Significantly different? (P<0.05) Yes 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0549 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 5A: Post-training state 4 (basal) reactive oxygen species (ROS) in SS mitochondria  
 State 4 ROS (natoms O2/mg protein/min) –  
SS Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 56.33 19.14 32.69 30.67 
2 8.58 32.07 36.12 25.32 
3 50.22 9.38 36.87 30.52 
4 20.80 28.67 43.90 22.53 
5 47.18 22.45 62.50 16.15 
6 58.54 22.18 187.55 30.91 
7   148.74 16.64 
8    30.95 
X 40.275 22.315 78.339 25.461 
SEM 8.410 3.230 23.858 2.259 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1987 ns No 
Mouse Model 0.1319 ns No 
Genotype/Training 0.0132 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 17.96 0.9143 > 0.05 ns 
WT:UT vs. KO:UT -38.06 2.011 > 0.05 ns 
WT:UT vs. KO:T 14.81 0.8062 > 0.05 ns 
WT:T vs. KO:UT -56.02 2.960 > 0.05 * 
WT:T vs. KO:T -3.146 0.1712 > 0.05 ns 
KO:UT vs. KO:T 52.88 3.003 > 0.05 * 
 
Unpaired T-test – WT UT versus WT T 
P value 0.0742 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.1872 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 5B: Post-training state 4 (basal) reactive oxygen species (ROS) in IMF mitochondria  
 State 4 ROS (natoms O2/mg protein/min) –  
IMF Mitochondria- Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 5.83 1.51 10.27 3.09 
2 6.24 5.46 5.31 2.50 
3 10.07 6.74 5.67 6.52 
4 11.93 3.49 8.29 5.68 
5 7.06 4.78 10.75 4.95 
6 2.59 11.82 17.61 9.05 
7   16.26 2.92 
8   25.46 2.70 
X 7.287 5.633 12.453 4.676 
SEM 1.350 1.436 2.436 0.822 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0877 ns No 
Mouse Model 0.2329 ns No 
Genotype/Training 0.0114 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 1.653 0.6359 > 0.05 ns 
WT:UT vs. KO:UT -5.166 2.124 > 0.05 ns 
WT:UT vs. KO:T 2.610 1.073 > 0.05 ns 
WT:T vs. KO:UT -6.819 2.804 > 0.05 ns 
WT:T vs. KO:T 0.9571 0.3936 > 0.05 ns 
KO:UT vs. KO:T 7.776 3.454 ≤ 0.05 * 
 
Unpaired T-test – WT UT versus WT T 
P value 0.4211 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.1179 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 5C: Post-training state 3 (active) reactive oxygen species (ROS) in SS mitochondria  
 
 State 3 ROS (natoms O2/mg protein/min)  –  
SS Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 1.91 7.07 6.56 3.41 
2 11.94 7.32 5.36 2.85 
3 3.91 1.91 5.81 2.49 
4 16.04 1.33 9.40 3.01 
5 10.95 1.35 5.70 4.23 
6 12.26 1.19 8.99 5.00 
7  7.72 8.66 5.81 
8  4.22  2.89 
X 9.502 4.014 7.211 3.711 
SEM 2.216 1.042 0.657 0.419 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3953 ns No 
Mouse Model 0.2700 ns No 
Genotype/Training 0.0006 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 5.488 3.307 ≤ 0.05 * 
WT:UT vs. KO:UT 2.290 1.340 > 0.05 ns 
WT:UT vs. KO:T 5.790 3.489 ≤ 0.05 * 
WT:T vs. KO:UT -3.198 2.011 > 0.05 ns 
WT:T vs. KO:T 0.3025 0.1969 > 0.05 ns 
KO:UT vs. KO:T 3.500 2.201 > 0.05 ns 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0005 
P value summary *** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WT UT versus KO UT 
P value 0.3112 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 5D: Post-training state 3 (active) reactive oxygen species (ROS) in IMF 
mitochondria  
 
 State 3 ROS (natoms O2/mg protein/min) –  
IMF Mitochondria - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.78 0.68 1.19 0.63 
2 0.60 0.69 1.05 0.60 
3 0.85 0.90 1.09 0.65 
4 0.66 0.48 1.38 0.53 
5 0.40 0.39 1.58 0.66 
6 1.38 1.31 1.35 1.03 
7 0.94  3.80 0.39 
8 0.35  1.15 0.51 
X 0.745 0.742 1.574 0.625 
SEM 0.116 0.135 0.324 0.0660 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0237 * Yes 
Mouse Model 0.0818 ns No 
Genotype/Training 0.0228 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.003333 0.01155 > 0.05 ns 
WT:UT vs. KO:UT -0.8288 3.101 ≤ 0.05 † 
WT:UT vs. KO:T 0.1200 0.4491 > 0.05 ns 
WT:T vs. KO:UT -0.8321 2.883 ≤ 0.05 * 
WT:T vs. KO:T 0.1167 0.4042 > 0.05 ns 
KO:UT vs. KO:T 0.9488 3.550 ≤ 0.01 ** 
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Figure 6: mRNA expression (ΔCt) of genes examined basally in the absence of p53, under 
the influence of training, and training reversal of basal p53-induced deficits  
 
 p53 mRNA – Muscle Specific Mice 
 WT 
N UT T 
1 4.32 2.74 
2 3.99 3.47 
3 3.96 1.74 
4 3.81 3.62 
5 3.53 1.43 
6 3.85 1.25 
7  2.90 
8  3.67 
9  1.033 
10  1.43 
X 3.910 2.327 
SEM 0.106 0.334 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unpaired T-test – p53 WT UT versus WT T 
P value 0.0031 
P value summary ** 
Significantly different? (P<0.05) Yes 
 p21 mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 6.53 3.50 3.50 6.04 
2 6.66 2.99 4.71 5.41 
3 4.61 4.40 4.69 3.65 
4 5.38 3.74 4.20 3.81 
5 4.90 3.69 4.76 5.79 
6  2.92 3.73 7.08 
7  4.35 4.41 5.09 
8  2.70 1.93 6.65 
9   4.68  
X 5.614 3.536 4.068 5.441 
SEM 0.419 0.226 0.307 0.436 
Unpaired T-test – p21 WT UT versus WT T 
P value 0.0006 
P value summary *** 
Significantly different? (P<0.05) Yes 
Unpaired T-test – p21 KO UT versus KO T 
P value 0.0193 
P value summary * 
Significantly different? (P<0.05) Yes 
Unpaired T-test – p21 WT UT versus KO UT 
P value 0.0112 
P value summary † 
Significantly different? (P<0.05) Yes 
140 
 
 Bax mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 8.81 5.18 4.78 4.93 
2 7.48 6.48 5.33 4.54 
3 8.00 7.21 4.11 4.21 
4 9.00 7.20 5.30 4.93 
5 8.00 6.64 6.09 2.08 
6  7.16 4.79 2.28 
7  6.90 6.02 2.34 
8  6.93 4.86 2.34 
9   4.38 2.59 
10   4.97  
X 8.260 6.712 5.065 3.361 
SEM 0.282 0.239 0.202 0.417 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unpaired T-test – Bax WT UT versus WT T 
P value 0.0017 
P value summary ** 
Significantly different? (P<0.05) Yes 
Unpaired T-test – Bax WT UT versus KO UT 
P value < 0.0001 
P value summary †††† 
Significantly different? (P<0.05) Yes 
Unpaired T-test – Bax KO UT versus KO T 
P value 0.0014 
P value summary ** 
Significantly different? (P<0.05) Yes 
 TIGAR mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 3.70 3.22 6.72 5.49 
2 4.90 4.19 5.25 5.84 
3 4.40 3.62 5.59 5.38 
4 3.84 4.14 5.98 5.84 
5 3.93 4.50 6.36 5.70 
6 3.75 3.85 6.91 2.99 
7  3.64 5.90 3.22 
8  2.00 5.17  
9  2.62 5.17  
10   3.18  
11   3.16  
X 4.089 3.533 5.398 4.922 
SEM 0.193 0.267 0.377 0.475 
Unpaired T-test – TIGAR WT UT versus WT T 
P value 0.1524 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – TIGAR WT UT versus KO UT 
P value 0.0276 
P value summary † 
Significantly different? (P<0.05) Yes 
Unpaired T-test – TIGAR KO UT versus KO T 
P value 0.4428 
P value summary ns 
Significantly different? (P<0.05) No 
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 Mdm2 mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 3.41 2.28 2.84 2.84 
2 3.72 2.50 2.78 2.63 
3 3.37 3.02 2.58 2.46 
4 3.01 3.99 3.21 2.56 
5 2.86 3.50 2.47 3.53 
6 2.21 3.06 2.92 3.23 
7  3.21 3.03 3.25 
8  1.36  1.52 
9  1.85  1.80 
X 3.098 2.752 2.834 2.648 
SEM 0.217 0.277 0.0953 0.221 
 
 
 
 
 
 
 
 
 
 
Unpaired T-test – Tfam WT UT versus KO UT 
P value < 0.0001 
P value summary †††† 
Significantly different? (P<0.05) Yes 
 
 
 
 
 
 
Unpaired T-test – Mdm2 WT UT versus WT T 
P value 0.3842 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – Mdm2 WT UT versus KO UT 
P value 0.2649 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – Mdm2 KO UT versus KO T 
P value 0.4957 
P value summary ns 
Significantly different? (P<0.05) No 
 Tfam mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 6.38 5.19 3.84 3.93 
2 6.52 5.67 3.71 3.69 
3 6.93 5.42 3.55 3.76 
4 6.86 6.76 4.07 4.72 
5 6.32 6.88 3.85 3.72 
6 5.53 5.57 3.71 4.06 
7  5.04 3.33 4.90 
8   3.56 5.95 
9   2.10 3.12 
10   2.61 4.52 
11   1.05  
X 6.425 5.790 3.216 4.237 
SEM 0.206 0.278 0.279 0.256 
Unpaired T-test – Tfam WT UT versus WT T 
P value 0.1023 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – Tfam KO UT versus KO T 
P value 0.0148 
P value summary * 
Significantly different? (P<0.05) Yes 
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Unpaired T-test – SCO2 WT UT versus KO UT 
P value < 0.0001 
P value summary †††† 
Significantly different? (P<0.05) Yes 
 
 
 
 
 
 
 
 
 
 
Unpaired T-test – p62 WT UT versus KO UT 
P value 0.0093 
P value summary †† 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – SCO2 WT UT versus WT T 
P value 0.9306 
P value summary ns 
Significantly different? (P<0.05) No 
 SCO2 mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 1.76 1.22 5.11 6.53 
2 1.83 1.49 5.84 5.70 
3 1.61 1.90 5.85 6.42 
4 1.40 1.86 4.85 7.64 
5 1.62 1.88 6.70 7.23 
6  1.86 6.95 6.34 
7  2.17 4.46 6.53 
8  1.27 4.76 6.46 
9  1.32 6.00 5.92 
10  1.34   
X 1.645 1.631 5.614 6.531 
SEM 0.0747 0.107 0.292 0.199 
Unpaired T-test – SCO2 KO UT versus KO T 
P value 0.0194 
P value summary * 
Significantly different? (P<0.05) Yes 
 p62 mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 5.68 5.21 5.34 4.75 
2 5.38 5.51 4.85 3.78 
3 5.64 5.47 4.31 5.34 
4 6.05 5.95 5.10 4.17 
5 5.51 5.91 4.59 4.89 
6  5.04 4.57 5.36 
7  5.76 4.29 5.92 
8   3.43 5.61 
9   3.26 4.75 
10   5.73 4.76 
X 5.655 5.550 4.548 4.934 
SEM 0.113 0.131 0.246 0.205 
Unpaired T-test – p62 WT UT versus WT T 
P value 0.5791 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – p62 KO UT versus KO T 
P value 0.2440 
P value summary ns 
Significantly different? (P<0.05) No 
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 LC3 mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 4.93 4.37 3.30 2.92 
2 6.66 4.39 1.86 3.17 
3 4.70 4.77 2.67 3.85 
4 3.51 4.50 2.91 3.89 
5 4.51 6.69 3.05 3.69 
6  5.81 2.85 3.70 
7  4.19 3.01 3.58 
8  4.69 2.84 3.85 
9   2.86 3.02 
10   2.50 3.21 
11   1.83  
X 4.863 4.927 2.699 3.487 
SEM 0.510 0.307 0.141 0.117 
 
Unpaired T-test – LC3 WT UT versus KO UT 
P value < 0.0001 
P value summary †††† 
Significantly different? (P<0.05) Yes 
 
 
 PGC-1α mRNA – Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 5.76 6.29 4.64 7.27 
2 5.56 4.43 3.92 5.70 
3 4.46 4.70 5.44 6.99 
4 5.08 5.53 5.42 6.59 
5 5.20 5.81 4.74 5.55 
6  6.31 5.45 5.36 
7  4.66 4.58 8.31 
8   2.83 7.88 
9   5.11  
10   1.28  
X 5.212 5.391 4.342 6.706 
SEM 0.225 0.299 0.426 0.390 
 
Unpaired T-test – PGC-1α WT UT versus KO UT 
P value 0.1921 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
Unpaired T-test – LC3 WT UT versus WT T 
P value 0.9116 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – LC3 KO UT versus KO T 
P value 0.0004 
P value summary *** 
Significantly different? (P<0.05) Yes 
Unpaired T-test – PGC-1α  WT UT versus WT T 
P value 0.6668 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – PGC-1α KO UT versus KO T 
P value 0.0010 
P value summary ** 
Significantly different? (P<0.05) Yes 
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Figure 6A: mRNA expression of genes in response to exercise training in WT mice, 
expressed as fold change 
 
mRNA WT T/ mRNA WT UT (Fold Change) - Muscle Specific Mice 
N p53 p21 Bax TIGAR Mdm2 Tfam p62 SCO2 LC3 PGC-1α 
1 0.70 0.62 0.63 0.79 0.73 0.81 0.92 0.74 0.90 1.21 
2 0.89 0.53 0.78 1.026 0.81 0.88 0.97 0.91 0.90 0.85 
3 0.45 0.78 0.87 0.88 0.98 0.84 0.97 1.15 0.98 0.90 
4 0.92 0.67 0.87 1.014 1.29 1.052 1.053 1.13 0.93 1.060 
5 0.37 0.66 0.80 1.099 1.13 1.071 1.044 1.14 1.38 1.12 
6 0.32 0.52 0.87 0.94 0.99 0.87 0.89 1.13 1.19 1.21 
7 0.74 0.77 0.84 0.89 1.04 0.78 1.019 1.32 0.86 0.89 
8 0.94 0.48 0.84 0.49 0.44   0.77 0.96  
9 0.26   0.64 0.60   0.80   
10 0.36       0.82   
X 0.595 0.630 0.813 0.864 0.890 0.901 0.981 0.991 1.0130 1.0344 
SEM 0.0854 0.0403 0.0289 0.0653 0.0892 0.0432 0.0231 0.0650 0.0631 0.0575 
∆ ↓1.405 
 
↓1.370 
 
↓1.187 
 
↓1.136 
 
↓1.110 
 
↓ 1.099 
 
↓ 1.019 
 
↓ 1.009 
 
↑ 1.013 
 
↑ 1.034 
 
 
 
Figure 6B: mRNA expression of genes in the absence of p53 basally, and the response of 
training on restoring deficits induced by the absence of p53 basally; expressed as fold 
change 
 
mRNA KO UT/ mRNA WT UT and mRNA KO T/mRNA WT T – Muscle Specific Mice 
 p21 Bax TIGAR Mdm2 Tfam p62 SCO2 LC3 PGC-1α 
N KO UT KO T KO UT KO T KO UT KO T KO UT KO UT KO UT KO T KO UT KO T KO UT KO T KO UT KO T KO UT KO T 
1 0.62 1.077 0.58 0.60 1.64 1.34 0.92 0.92 0.60 0.61 0.94 0.84 3.11 3.97 0.68 0.60 0.89 1.39 
2 0.84 0.96 0.65 0.55 1.29 1.43 0.90 0.85 0.58 0.57 0.86 0.67 3.55 3.46 0.38 0.65 0.75 1.09 
3 0.84 0.65 0.50 0.51 1.37 1.32 0.83 0.79 0.55 0.59 0.76 0.95 3.55 3.90 0.55 0.79 1.04 1.34 
4 0.75 0.68 0.64 0.60 1.46 1.43 1.04 0.83 0.63 0.74 0.90 0.74 2.95 4.65 0.60 0.80 1.04 1.27 
5 0.85 1.031 0.74 0.25 1.56 1.39 0.80 1.14 0.60 0.58 0.81 0.87 4.07 4.40 0.63 0.76 0.91 1.07 
6 0.66 1.26 0.58 0.28 1.69 0.73 0.94 1.04 0.58 0.63 0.81 0.95 4.23 3.86 0.59 0.76 1.05 1.03 
7 0.79 0.91 0.73 0.28 1.44 0.79 0.98 1.05 0.52 0.76 0.76 1.05 2.71 3.97 0.62 0.74 0.88 1.60 
8 0.34 1.19 0.59 0.28 1.27   0.49 0.55 0.93 0.61 0.99 2.89 3.93 0.58 0.79 0.54 1.51 
9 0.83  0.53 0.31 1.26   0.58 0.33 0.49 0.58 0.84 3.65 3.60 0.60 0.62 0.98  
10   0.60  0.78    0.41 0.70 1.01 0.84   0.51 0.66 0.25  
11     0.77    0.16      0.38    
X 0.725 0.969 0.613 0.407 1.321 1.204 0.915 0.855 0.501 0.659 0.804 0.873 3.412 3.970 0.555 0.717 0.833 1.287 
SEM 0.055 0.078 0.025 0.051 0.092 0.116 0.031 0.072 0.043 0.040 0.044 0.036 0.177 0.121 0.029 0.024 0.082 0.075 
∆ ↓1.28  ↓1.03  ↓1.39  ↓1.59  ↑1.32  ↑1.20  ↓ 1.09  ↓ 1.15  ↓ 1.50  ↓ 1.34  ↓ 1.20  ↓ 1.13  ↑3.41  ↑ 3.97  ↓ 1.45  ↓ 1.28  ↓ 1.17  ↑1.29  
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Figure 7A: Post-training whole muscle Mdm2 protein  
 
 Whole Muscle - Mdm2 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.32 0.69 0.34 0.65 
2 0.48 0.48 0.46 0.94 
3 0.40 0.44 0.40 0.63 
4 0.19 0.47 0.34 0.74 
5 0.44 0.55 0.22 0.73 
6 0.18 0.74   
X 0.336 0.561 0.352 0.738 
SEM 0.0519 0.0510 0.0395 0.0542 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1267 ns No 
Mouse Model 0.0712 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2253 3.320 ≤ 0.05 * 
WT:UT vs. KO:UT -0.01588 0.2232 > 0.05 ns 
WT:UT vs. KO:T -0.4024 5.654 ≤ 0.005 *** 
WT:T vs. KO:UT 0.2094 2.943 > 0.05 ns 
WT:T vs. KO:T -0.1771 2.488 > 0.05 ns 
KO:UT vs. KO:T -0.3865 5.199 ≤ 0.005 *** 
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Figure 7B: Post-training whole muscle CHCHD4 protein  
 
 Whole Muscle - CHCHD4 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.44 0.84 0.22 0.99 
2 0.33 0.67 0.38 0.73 
3 0.45 0.65 0.19 0.98 
4 0.54 0.67 0.16 1.84 
5 0.58 0.71 0.18 0.70 
6  0.60   
X 0.469 0.688 0.226 1.0492 
SEM 0.0431 0.0336 0.0386 0.206 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0096 ** Yes 
Mouse Model 0.5762 ns No 
Genotype/Training 0.0001 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2190 1.530 > 0.05 ns 
WT:UT vs. KO:UT 0.2430 1.625 > 0.05 ns 
WT:UT vs. KO:T -0.5799 3.879 ≤ 0.01 ** 
WT:T vs. KO:UT 0.4620 3.227 ≤ 0.05 * 
WT:T vs. KO:T -0.3609 2.521 > 0.05 ns 
KO:UT vs. KO:T -0.8229 5.504 ≤ 0.005 *** 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.0028 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  WT UT versus KO UT 
P value 0.0030 
P value summary †† 
Significantly different? (P<0.05) Yes 
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Figure 8A: Post-training cytochrome c protein release from SS mitochondria under basal 
conditions 
 
 Cytochrome C Protein Release – Basal – SS Mitochondrial - 
Muscle Specific Mice  
 
N 
WT mKO 
UT T UT T 
1 639.36 635.94 2459.55 887.55 
2 1087.31 1021.79 1042.72 1048.89 
3 1000.00 1674.26 1129.84 739.48 
4 1044.012 1020.21 1340.31 1110.96 
5 1024.033 1475.38 1719.96 704.21 
6 757.033  2238.96 1065.89 
7 
  
1519.79 836.50 
8 
  
1911.43 2252.13 
X 925.290 1165.513 1670.319 1080.701 
SEM 74.329 183.991 180.495 175.740 
 
One-Way ANOVA 
P value 0.0195 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT versus WT T -240.2 0.9074 > 0.05 ns 
WT UT versus KO UT -745 3.155 ≤ 0.05 † 
WT UT versus KO T -155.4 0.6582 > 0.05 ns 
WT T versus KO UT -504.8 2.025 > 0.05 ns 
WT T versus KO T 84.81 0.3403 > 0.05 ns 
KO UT versus KO T 589.6 2.697 > 0.05 ns 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0346 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 8B: Post-training cytochrome c protein release from IMF mitochondria under basal 
conditions 
 Cytochrome C Protein Release - Basal - IMF Mitochondria – 
Muscle Specific Mice  
 WT mKO  
N UT T UT T 
1 14777.075 4417.15 11805.23 8125.28 
2 10879.30 13339.98 876.77 8153.28 
3 5276.39 8788.91 8269.96 8690.47 
4 10847.033 13100.61 7693.74 11403.33 
5 12690.50 10239.98 15333.42 9175.10 
6 16205.13 15551.18 840.96 18378.42 
7 13608.81 2707.55 10962.15 15938.78 
8 
 
1727.67 10698.42 13659.49 
9  2861.15 958.89 
10   790.69 1353.72 
11   9118.45  
12   3422.40  
13   1381.96  
14   11137.79  
X 12040.605 8734.129 6799.506 9583.675 
SEM 1347.328 1856.789 1327.0812 1779.248 
 
One-Way ANOVA 
P value 0.1636 
P value summary ns 
Significantly different? (P<0.05) No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT versus WT T 3306 1.278 > 0.05 ns 
WT UT versus KO UT 5241 2.265 > 0.05 ns 
WT UT versus KO T 2457 0.9973 > 0.05 ns 
WT T versus KO UT 1935 0.8731 > 0.05 ns 
WT T versus KO T -849.5 0.3583 > 0.05 ns 
KO UT versus KO T -2784 1.345 > 0.05 ns 
 
Unpaired T-test - WT UT versus KO UT 
P value 0.0228 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 8C: Post-training cytochrome c protein release from SS mitochondria treated with 
apoptotic stimulus (H2O2), presented as fold change 
 Cytochrome C Protein Release - Treated/Control - SS 
Mitochondria – Muscle Specific Mice 
 WT mKO  
N UT T UT T 
1 11.063 3.22 2.14 1.12 
2 5.13 2.63 5.73 1.70 
3 2.29 2.33 1.58 3.27 
4 10.80 9.39 8.15 1.75 
5 11.60 4.42 7.98 1.022 
6 6.45 5.75 1.79 4.32 
7 
  
1.73 
 8 
  
8.076 
 9 10.66 
10   7.41  
X 7.888 4.624 5.524 2.197 
SEM 1.564 1.0830 1.0783 0.536 
 
One-Way ANOVA 
P value 0.0276 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT versus WT T 3.263 1.859 > 0.05 ns 
WT UT versus KO UT 2.364 1.506 > 0.05 ns 
WT UT versus KO T 5.69 3.242 ≤ 0.05 * 
WT T versus KO UT -0.8998 0.5732 > 0.05 ns 
WT T versus KO T 2.427 1.383 > 0.05 ns 
KO UT versus KO T 3.327 2.119 > 0.05 ns 
 
Unpaired T-test – KO UT versus KO T 
P value 0.0399 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test –WT UT versus WT T 
P value 0.1170 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 8D: Post-training cytochrome c protein release from IMF mitochondria treated 
with apoptotic stimulus (H2O2), presented as fold change 
 Cytochrome C Protein Release - Treated/Control - IMF 
Mitochondria - Muscle Specific Mice  
 WT mKO 
N UT T UT T 
1 1.19 4.20 1.24 2.56 
2 1.61 1.31 2.21 1.54 
3 1.75 2.26 1.95 2.97 
4 1.69 1.22 1.27 1.16 
5 1.19 2.13 6.50 1.53 
6 1.23 1.32 1.49 16.74 
7 
  
1.52 
 8 
  
4.90 
 9 8.00 
10   1.38  
11   8.076  
12   1.84  
X 1.443 2.0717 3.362 4.417 
SEM 0.110 0.464 0.785 2.481 
 
One-Way ANOVA 
P value 0.3852 
P value summary ns 
Significantly different? (P<0.05) No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT versus WT T -0.6284 0.3361 > 0.05 ns 
WT UT versus KO UT -1.919 1.185 > 0.05 ns 
WT UT versus KO T -2.974 1.59 > 0.05 ns 
WT T versus KO UT -1.291 0.797 > 0.05 ns 
WT T versus KO T -2.345 1.254 > 0.05 ns 
KO UT versus KO T -1.055 0.6514 > 0.05 ns 
 
Unpaired T-test –WT UT versus KO UT 
P value 0.1087 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test –WT UT versus WT T 
P value 0.2165 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 8F: Post-training whole muscle Bax protein  
 
 Whole Muscle - Bax Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.31 0.5 0.59 0.57 
2 0.2 0.29 0.64 0.31 
3 0.38 0.24 0.65 0.32 
4 0.11 0.41 0.49 0.38 
5  0.27 0.64 0.11 
6  0.59 0.5 0.32 
X 0.25 0.383 0.585 0.335 
SEM 0.0596 0.0575 0.0297 0.0603 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0022 ** Yes 
Mouse Model 0.0157 * Yes 
Genotype/Training 0.2920 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.1333 1.664 > 0.05 ns 
WT:UT vs. KO:UT -0.3350 4.182 ≤ 0.01 †† 
WT:UT vs. KO:T -0.08500 1.061 > 0.05 ns 
WT:T vs. KO:UT -0.2017 2.815 > 0.05 ns 
WT:T vs. KO:T 0.04833 0.6746 > 0.05 ns 
KO:UT vs. KO:T 0.2500 3.489 ≤ 0.05 * 
 
Unpaired T-test – WT UT versus WT T 
P value 0.1593 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 8G: Post-training whole muscle Bcl-2 protein  
 
 Whole Muscle - Bcl-2 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.59 0.21 0.22 0.16 
2 0.84 0.71 0.16 0.27 
3 0.86 0.73 0.52 0.24 
4 0.54 0.29 0.46 0.14 
5 0.70 0.55 0.41 0.24 
6  0.23 0.30 0.38 
7  0.58 0.48 0.34 
8  0.44 0.35 0.11 
X 0.705 0.468 0.363 0.237 
SEM 0.0640 0.0738 0.0457 0.0333 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3394 ns No 
Mouse Model < 0.0001 **** Yes 
Genotype/Training 0.0039 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.2369 2.761 > 0.05 ns 
WT:UT vs. KO:UT 0.3422 3.989 ≤ 0.01 †† 
WT:UT vs. KO:T 0.4679 5.455 ≤ 0.001 **** 
WT:T vs. KO:UT 0.1053 1.400 > 0.05 ns 
WT:T vs. KO:T 0.2310 3.071 ≤ 0.05 * 
KO:UT vs. KO:T 0.1257 1.671 > 0.05 ns 
 
Unpaired T-test- WT UT versus WT T 
P value 0.0488 
P value summary * 
Significantly different? (P<0.05) Yes 
 
 
 
 
Unpaired T-test-  KO UT versus KO T 
P value 0.0431 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 8H: Post-training whole muscle p21 protein  
 
 Whole Muscle - p21 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.35 0.24 0.28 0.53 
2 0.23 0.24 0.29 0.53 
3 0.56 0.33 0.34 0.54 
4 0.46 0.42 0.28 0.88 
5 0.42 0.46 0.30 0.48 
6 0.51  0.24  
X 0.420 0.339 0.288 0.592 
SEM 0.0491 0.0447 0.0134 0.0724 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0008 *** Yes 
Mouse Model 0.2182 ns No 
Genotype/Training 0.0308 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.08095 1.202 > 0.05 ns 
WT:UT vs. KO:UT 0.1317 2.052 > 0.05 ns 
WT:UT vs. KO:T -0.1723 2.559 > 0.05 ns 
WT:T vs. KO:UT 0.05079 0.7544 > 0.05 ns 
WT:T vs. KO:T -0.2532 3.601 ≤ 0.05 * 
KO:UT vs. KO:T -0.3040 4.515 ≤ 0.01 ** 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.2621 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test-  WT UT versus KO UT 
P value 0.0271 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 9A: Post-training whole muscle LC3 II/ LC3 I protein  
 
 Whole Muscle - LC3 II/LC3 I Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.37 0.57 0.62 0.66 
2 0.60 1.087 0.32 0.60 
3 0.34 0.57 0.35 0.62 
4 0.16 0.80 0.37 0.77 
5 0.22 0.59 0.46 0.69 
6 0.36 0.79 0.45 0.51 
7  0.93 0.56 0.41 
8  0.52   
X 0.343 0.732 0.447 0.609 
SEM 0.0613 0.0718 0.0419 0.0446 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0618 ns No 
Mouse Model 0.8749 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.3896 4.728 ≤ 0.005 *** 
WT:UT vs. KO:UT -0.1044 1.229 > 0.05 ns 
WT:UT vs. KO:T -0.2668 3.143 ≤ 0.05 * 
WT:T vs. KO:UT 0.2853 3.612 ≤ 0.01 ** 
WT:T vs. KO:T 0.1228 1.555 > 0.05 ns 
KO:UT vs. KO:T -0.1625 1.992 > 0.05 ns 
 
Unpaired T-test-  WT UT versus KO UT 
P value 0.1777 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test-  KO UT versus KO T 
P value 0.0222 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 9B: Post-training whole muscle p62 protein  
 
 Whole Muscle - p62 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.24 0.87 0.93 0.63 
2 0.47 0.76 1.17 0.76 
3 0.53 0.74 0.76 0.54 
4 0.47 0.51 0.88 0.59 
5 0.41 0.47 0.85 0.74 
6  1.10 1.27 0.73 
7  0.78 1.13 1.024 
8   1.079  
X 0.425 0.747 1.00699 0.715 
SEM 0.0505 0.0809 0.0633 0.0605 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0002 *** Yes 
Mouse Model 0.0005 *** Yes 
Genotype/Training 0.8279 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.3225 3.149 ≤ 0.05 * 
WT:UT vs. KO:UT -0.5824 5.840 ≤ 0.005 †††† 
WT:UT vs. KO:T -0.2900 2.831 > 0.05 ns 
WT:T vs. KO:UT -0.2599 2.871 > 0.05 ns 
WT:T vs. KO:T 0.03257 0.3483 > 0.05 ns 
KO:UT vs. KO:T 0.2925 3.230 ≤ 0.05 * 
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Figure 9A: Post-training whole muscle Parkin protein  
 
 Whole Muscle - Parkin Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.19 0.49 0.77 0.46 
2 0.30 0.49 0.72 0.47 
3 0.25 0.55 0.69 0.31 
4 0.31 0.54 0.63 0.84 
5 0.12 0.47 0.62 0.48 
6   0.56 0.55 
7   0.95  
X 0.234 0.509 0.705 0.518 
SEM 0.0360 0.0153 0.0489 0.0717 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0003 *** Yes 
Mouse Model 0.0002 *** Yes 
Genotype/Training 0.4081 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2745 3.543 ≤ 0.05 * 
WT:UT vs. KO:UT -0.4710 6.566 ≤ 0.001 †††† 
WT:UT vs. KO:T -0.2837 3.825 ≤ 0.01 ** 
WT:T vs. KO:UT -0.1964 2.738 > 0.05 ns 
WT:T vs. KO:T -0.009180 0.1238 > 0.05 ns 
KO:UT vs. KO:T 0.1872 2.747 > 0.05 ns 
 
Unpaired T-test-  KO UT versus KO T 
P value 0.0490 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 9A: Post-training whole muscle Beclin-1 protein  
 
 Whole Muscle - Beclin-1 Protein - Muscle Specific Mice 
 WT mKO 
N UT T UT T 
1 0.24 0.76 0.69 0.31 
2 0.18 0.50 0.69 0.48 
3 0.32 0.55 1.028 0.56 
4 0.40 0.73 0.65 0.60 
5 0.41 0.41 0.99 0.75 
6  0.40 0.85 0.54 
7  0.36 0.67 0.72 
X 0.308 0.531 0.796 0.567 
SEM 0.0453 0.0612 0.0608 0.0563 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0009 *** Yes 
Mouse Model 0.0002 *** Yes 
Genotype/Training 0.9582 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.2227 2.558 > 0.05 ns 
WT:UT vs. KO:UT -0.4880 5.605 ≤ 0.001 †††† 
WT:UT vs. KO:T -0.2590 2.975 ≤ 0.05 * 
WT:T vs. KO:UT -0.2653 3.338 ≤ 0.05 * 
WT:T vs. KO:T -0.03636 0.4574 > 0.05 ns 
KO:UT vs. KO:T 0.2289 2.880 > 0.05 ns 
 
 
 
Unpaired T-test-  KO UT versus KO T 
P value 0.0171 
P value summary * 
Significantly different? (P<0.05) Yes 
 
 
Unpaired T-test-  WT UT versus WT T 
P value 0.0223 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 10A: COX Enzyme Activity, marker of mitochondrial content, in untrained Muscle 
Specific (MS) versus Whole Body (WB) mice  
 
 COX Enzyme Activity (µmol/min/g tissue)  – Untrained MS 
versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 19.21 14.84 22.49 11.59 
2 16.66 11.04 19.12 12.30 
3 13.76 12.21 12.88 13.00 
4 16.87 14.41 22.31 14.93 
5 15.90 13.29 16.76 17.58 
6 16.80 14.65 13.56 8.88 
7  14.66   
8  14.50   
X 16.533 13.700 17.853 13.047 
SEM 0.718 0.495 1.706 1.213 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3657 ns No 
Mouse Model 0.7579 ns No 
Genotype/Training 0.0017 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO 2.833 1.941 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -1.320 0.8461 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO 3.487 2.235 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:WT -4.153 2.846 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO 0.6533 0.4477 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO 4.807 3.081 ≤ 0.05 † 
 
Unpaired T-test-  MS WT UT versus mKO UT 
P value 0.0056 
P value summary †† 
Significantly different? (P<0.05) Yes 
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Figure 10B: PGC-1α mRNA in untrained Muscle Specific (MS) versus Whole Body (WB) 
mice 
 
 PGC-1α mRNA – Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 5.76 4.64 6.89 2.61 
2 5.56 3.92 7.21 4.43 
3 4.46 5.44 5.31 3.47 
4 5.08 5.42 6.64 1.23 
5 5.20 4.74 7.94 3.66 
6  5.45 7.19 4.48 
7  4.58 5.51 4.75 
8  2.83 7.10 3.61 
9  5.11  4.10 
10    3.19 
X 5.212 4.342 6.722 3.553 
SEM 0.225 0.426 0.316 0.330 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0004 *** Yes 
Mouse Model 0.5619 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO 0.5309 1.066 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -1.512 2.971 ≤ 0.05 ¶ 
Muscle Specific:WT vs. Whole Body:KO 1.659 3.394 ≤ 0.05 * 
Muscle Specific:KO vs. Whole Body:WT -2.043 4.710 ≤ 0.005 *** 
Muscle Specific:KO vs. Whole Body:KO 1.128 2.751 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO 3.171 7.490 ≤ 0.001 †††† 
 
Unpaired T-test-  MS WT UT versus mKO UT 
P value 0.2340 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 10C: PGC-1α protein in untrained Muscle Specific (MS) versus Whole Body (WB) 
mice 
 
 PGC-1α Protein – Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.35 0.39 0.43 0.50 
2 0.40 0.27 0.37 0.33 
3 0.43 0.21 0.70 0.50 
4 0.58 0.42 0.66 0.077 
5 0.52 0.30 0.70 0.52 
6  0.24 0.83 0.40 
7  0.21 0.75 0.35 
X 0.456 0.291 0.633 0.382 
SEM 0.0410 0.0321 0.0650 0.059 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4194 ns No 
Mouse Model 0.0183 * Yes 
Genotype/Training 0.0007 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO 0.1646 2.102 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -0.1787 2.282 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO 0.07319 0.9348 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:WT -0.3433 4.803 ≤ 0.005 *** 
Muscle Specific:KO vs. Whole Body:KO -0.09143 1.279 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO 0.2519 3.524 ≤ 0.05 † 
 
Unpaired T-test-  MS WT UT versus mKO UT 
P value 0.0094 
P value summary †† 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.0133 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
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Figure 10D: State 3 respiration in the SS mitochondria of untrained Muscle Specific (MS) 
versus Whole Body (WB) mice 
 State 3 Respiration – SS Mitochondria – Untrained MS versus 
WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 8.53 31.93 5.50 6.47 
2 10.89 34.80 6.51 15.24 
3 17.80 13.20 27.50 9.51 
4 12.01 25.16 21.37 2.34 
5 16.16 11.91 14.40 12.89 
6 12.82 40.79 11.46 5.80 
X 13.035 26.298 14.457 8.708 
SEM 1.396 4.809 3.513 1.956 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0077 ** Yes 
Mouse Model 0.0205 * Yes 
Genotype/Training 0.2557 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -13.26 2.921 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -1.422 0.3130 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO 4.327 0.9527 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:WT 11.84 2.608 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO 17.59 3.873 ≤ 0.01 ¶¶ 
Whole Body:WT vs. Whole Body:KO 5.748 1.266 > 0.05 ns 
 
Unpaired T-test-  MS WT UT versus mKO UT 
P value 0.0244 
P value summary † 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.7147 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test-  WB WT UT versus KO UT 
P value 0.1833 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 10E: State 3 reactive oxygen species (ROS) in the SS mitochondria of untrained 
Muscle Specific (MS) versus Whole Body (WB) mice 
 
 State 3 ROS - SS Mitochondria - Untrained MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 1.91 6.56 18.25 26.02 
2 11.94 5.36 15.58 18.63 
3 3.91 5.81 47.29 62.22 
4 16.04 9.40 17.70 7.39 
5 10.95 5.70 12.46 8.34 
6 12.26 8.99 31.39 55.22 
7  8.66   
X 9.502 7.211 23.778 29.637 
SEM 2.216 0.657 5.396 9.659 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4605 ns No 
Mouse Model 0.0028 ** Yes 
Genotype/Training 0.7453 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO 2.290 0.3045 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -14.28 1.829 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO -20.14 2.580 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:WT -16.57 2.203 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO -22.43 2.982 ≤ 0.05 ¶ 
Whole Body:WT vs. Whole Body:KO -5.858 0.7506 > 0.05 ns 
 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.0344 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
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Figure 10F: Basal cytochrome c protein release in the SS mitochondria of untrained 
Muscle Specific (MS) versus Whole Body (WB) mice  
 
 Cytochrome C Protein Release – Basal - SS Mitochondria –- 
Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 639.36 2459.55 877.48 1246.67 
2 1087.31 1042.72 571.96 1907.21 
3 1000.00 1129.84 554.55 1279.26 
4 1044.012 1340.31 1399.13 972.77 
5 1024.033 1719.96 688.26 2038.98 
6 757.033 2238.96   
7  1519.79   
8  1911.43   
X 925.290 1670.319 818.275 1488.976 
SEM 74.329 180.495 156.210 205.741 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.8287 ns No 
Mouse Model 0.4052 ns No 
Genotype/Training 0.0005 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -745.0 3.383 ≤ 0.05 † 
Muscle Specific:WT vs. Whole Body:WT 107.0 0.4335 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO -563.7 2.283 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:WT 852.0 3.666 ≤ 0.01 ** 
Muscle Specific:KO vs. Whole Body:KO 181.3 0.7802 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO -670.7 2.601 > 0.05 ns 
 
Unpaired T-test-  WB WT UT versus KO UT 
P value 0.0318 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 11B: Whole muscle LC3 II/ LC3 I protein in untrained Muscle Specific (MS) versus 
Whole Body (WB) mice  
 
 LC3 II/ LC3 I Protein- Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.37 0.62 0.30 0.41 
2 0.60 0.32 0.45 0.96 
3 0.34 0.35 0.56 0.60 
4 0.16 0.37 0.48 0.53 
5 0.22 0.46 0.47 0.66 
6 0.36 0.45 0.54 0.55 
7  0.56 0.21  
8   0.27  
X 0.343 0.447 0.411 0.619 
SEM 0.0613 0.0419 0.0465 0.0770 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3641 ns No 
Mouse Model 0.0443 * Yes 
Genotype/Training 0.0105 * Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -0.1044 1.295 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT -0.06748 0.8627 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO -0.2758 3.298 ≤ 0.05 * 
Muscle Specific:KO vs. Whole Body:WT 0.03687 0.4919 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO -0.1715 2.128 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO -0.2083 2.663 > 0.05 ns 
 
Unpaired T-test-  MS mKO UT versus WB KO UT 
P value 0.0649 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test-  WB WT UT versus KO UT 
P value 0.0302 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 11C: Whole muscle p62 protein in untrained Muscle Specific (MS) versus Whole 
Body (WB) mice 
 
 p62 Protein- Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.24 0.93 0.64 1.033 
2 0.47 1.17 0.75 1.021 
3 0.53 0.76 0.81 1.29 
4 0.47 0.88 0.44 0.84 
5 0.41 0.85 0.21 0.90 
6  1.27 0.76 0.75 
7  1.13   
8  1.08   
X 0.425 1.007 0.601 0.971 
SEM 0.0505 0.0633 0.0949 0.0771 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1750 ns No 
Mouse Model 0.3558 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -0.5824 5.495 ≤ 0.005 ††† 
Muscle Specific:WT vs. Whole Body:WT -0.1771 1.573 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO -0.5478 4.865 ≤ 0.005 *** 
Muscle Specific:KO vs. Whole Body:WT 0.4053 4.036 ≤ 0.01 ** 
Muscle Specific:KO vs. Whole Body:KO 0.03465 0.3451 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO -0.3707 3.453 ≤ 0.05 † 
 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.1567 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 11D: Whole muscle Beclin-1 protein in untrained Muscle Specific (MS) versus 
Whole Body (WB) mice 
 
 Beclin-1 Protein- Untrained MS versus WB Mice  
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.24 0.69 0.40 0.73 
2 0.18 0.69 0.73 1.59 
3 0.32 1.03 0.56 0.75 
4 0.40 0.65 0.58 0.80 
5 0.41 0.99 0.79 0.67 
6  0.85 0.62 0.99 
7  0.67 1.018 0.49 
X 0.308 0.796 0.671 0.859 
SEM 0.0453 0.0608 0.0751 0.134 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1185 ns No 
Mouse Model 0.0302 * Yes 
Genotype/Training 0.0013 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -0.4880 3.589 ≤ 0.01 †† 
Muscle Specific:WT vs. Whole Body:WT -0.3629 2.669 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:KO -0.5517 4.058 ≤ 0.01 ** 
Muscle Specific:KO vs. Whole Body:WT 0.1251 1.008 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO -0.06377 0.5138 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO -0.1889 1.522 > 0.05 ns 
 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.0039 
P value summary ¶¶ 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  WB WT UT versus KO UT 
P value 0.2423 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 12A: Post-training performance test, exercise capacity comparison between Muscle 
Specific (MS) versus Whole Body (WB) mice 
 Post-Training Performance Stress Test – Distance to Exhaustion (m) 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 891.5 1623.6 726.0 1731.5 1258.1 2382.6 661.0 2317.04 
2 1349.0 2990.3 1067.0 2555.0 477.0 3002.5 1111.0 1715.9 
3 922.5 1376.0 1059.0 2117.0 980.6 2202.0 755.0 2033.0 
4 852.8 1578.0 1084.0 2465.0 662.4 1836.0 332.0 2345.2 
5 1252.5 2834.0 1150.0 2487.5 982.8 1830.0 970.0 2127.5 
6 830.0 2992.7 926.0 1946.9 944.4 2064.5 733.0 2210.6 
7   400.0 2112.8 726.0 3027.0 1117.0 2810.5 
8   557.0 1533.1 1043.9 1946.9 1084.0 2519.0 
9     1245.5 2270.8 915.0 2568.8 
X 1016.383 2232.433 871.125 2118.600 924.522 2284.700 853.111 2294.171 
SEM 91.705 318.679 98.330 131.523 86.913 151.545 86.559 107.565 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.7933 ns No 
Mouse Model 0.7646 ns No 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -1216 5.445 ≤ 0.001 **** 
Muscle Specific:WT UTvs.Muscle Specific:KO UT 145.4 0.696 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 91.86 0.4506 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T 113.8 0.5449 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -52.28 0.2564 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -1248 6.451 ≤ 0.001 **** 
Muscle Specific:KO UT vs. Whole Body:KO UT 17.99 0.0957 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T -175.6 0.9342 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -1360 7.46 ≤ 0.001 **** 
Whole Body:WT UT vs. Whole Body:KO UT 71.53 0.3923 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T -9.471 0.0519 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -1441 7.904 ≤ 0.001 **** 
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Figure 12B: Post-training COX Enzyme Activity, a marker of mitochondrial content, and 
the comparison between Muscle Specific (MS) versus Whole Body (WB) mice 
 COX Enzyme Activity – Muscle Specific Mice versus Whole Body Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 19.21 19.63 14.84 22.22 22.49 37.96 11.59 19.80 
2 16.66 21.86 11.04 22.61 19.12 39.13 12.30 26.16 
3 13.76 21.52 12.21 24.46 12.88 37.71 13.00 19.82 
4 16.87 20.65 14.41 22.49 22.31 31.72 14.93 18.66 
5 15.90 24.89 13.29 25.42 16.76 28.80 17.58 24.33 
6 16.80 20.09 14.65 22.34 13.56 22.79 8.88 17.83 
7  22.98 14.66 21.18  30.12  19.34 
8  26.86 14.50 25.49  21.53  18.03 
X 16.533 22.310 13.700 23.276 17.853 31.220 13.047 20.496 
SEM 0.718 0.881 0.495 0.572 1.706 2.399 1.213 1.082 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0001 *** Yes 
Mouse Model 0.0604 ns No 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -6.111 3.233 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT 2.499 1.322 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -1.656 0.8193 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.9663 0.5522 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -8.909 5.091 ≤ 0.005 *** 
Muscle Specific:KO UT vs. Muscle Specific:KO T -9.576 5.472 ≤ 0.001 **** 
Muscle Specific:KO UT vs. Whole Body:KO UT 0.6516 0.3448 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 2.779 1.588 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -13.36 7.071 ≤ 0.001 **** 
Whole Body:WT UT vs. Whole Body:KO UT 4.806 2.379 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 10.72 6.127 ≤ 0.001 **** 
Whole Body:KO UT vs. Whole Body:KO T -7.448 3.941 ≤ 0.01 ** 
 
Unpaired T-test – MS WT UT versus MS WT T 
P value 0.0003 
P value summary *** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WB WT UT versus WB KO UT 
P value 0.0446 
P value summary † 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS WT UT versus MS KO UT 
P value 0.0140 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 12C: Post-training whole muscle PGC-1α protein comparison between Muscle 
Specific (MS) versus Whole Body (WB) mice 
 Whole Muscle PGC-1α Protein Expression 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 0.35 0.93 0.39 0.69 0.43 0.38 0.50 0.66 
2 0.40 0.74 0.27 0.89 0.37 0.38 0.33 0.51 
3 0.43 0.71 0.21 0.41 0.70 0.47 0.50 0.93 
4 0.58 1.17 0.42 0.93 0.66 0.85 0.077 0.73 
5 0.52 0.73 0.30 0.93 0.70 0.66 0.52 0.93 
6  0.88 0.24 0.69 0.83 1.24 0.40 0.66 
7  0.71 0.21 0.61 0.75 1.31 0.35 0.80 
8    0.91  0.78  0.40 
9      0.43  0.53 
10      1.05   
X 0.456 0.840 0.291 0.759 0.633 0.755 0.382 0.683 
SEM 0.041 0.064 0.0321 0.068 0.0650 0.112 0.0585 0.0611 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.2697 ns No 
Mouse Model 0.6093 ns No 
Genotype/Training < 0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -0.3841 3.182 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT 0.1646 1.364 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.1787 1.480 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T 0.08049 0.7543 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T 0.08471 0.8337 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -0.4682 4.388 ≤ 0.01 ** 
Muscle Specific:KO UT vs. Whole Body:KO UT -0.09143 0.8296 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 0.07589 0.7575 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -0.1207 1.188 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.2519 2.285 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.07167 0.7565 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -0.3009 2.896 > 0.05 ns 
 
Unpaired T-test-  MS WT UT versus T 
P value 0.0011 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  WB KO UT versus T 
P value 0.0038 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test-  WB WT UT versus T 
P value 0.4166 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test-  MS WT UT versus KO UT 
P value 0.0095 
P value summary †† 
Significantly different? (P<0.05) Yes 
Unpaired T-test-  WB WT UT versus KO UT 
P value 0.0133 
P value summary † 
Significantly different? (P<0.05) Yes 
Unpaired T-test-  MS WT UT versus WB WT UT 
P value 0.0604 
P value summary ns 
Significantly different? (P<0.05) No 
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Appendix B: Supplementary and Additional Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Antibody concentrations for western blot analyses.  
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Table 2. Phenotypic alterations and exercise capacity under basal and exercise training 
conditions in MS and WB mice.  
  
A) Pre-training variables (initial body mass and distance to exhaustion) were compared in the 
absence of p53 between mouse models (n=13-23/group); ¶p≤0.05, ¶¶p≤0.01, MS vs. WB; 
††p≤0.01, WT vs. KO, 2-way ANOVA. B) Phenotypic variables were measured following the 
training or sedentary program (n=6-10/group); *p≤0.05, **p≤0.01, UT vs. T; ¶p≤0.05, 
¶¶p≤0.01, MS vs. WB; †p≤0.05, MS WT vs. KO, Student’s t-test and 2-way ANOVA. C) 
Mitochondrial parameters including yield and RCR values in both SS and IMF mitochondrial 
subfractions were measured (n=6-11/group); *p≤0.05, **p≤0.01, UT vs. T; ¶p≤0.05, MS vs. 
WB, Student’s t-test. Data are presented as mean± SEM. Abbreviations: RCR, respiratory 
control ratio; TA; tibialis anterior; SS, subsarcolemmal; IMF, intermyofibrillar. 
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Increased expression is measured through fold change and reduced expression is 
measured as a percent difference. Patterns in mRNA and protein regulation are 
similar for p53, p21, Tfam, PGC-1α, LC3, but are different for Bax and Mdm2 
(n=4-11/group); *p≤0.05, **p≤0.01, UT vs. T, Student’s t-test and 2-way ANOVA; 
†p≤0.05, ††p≤0.01, Student’s t-test and 2-way ANOVA. NS= non-significant.  
Table 3. mRNA and protein fold-change comparison to examine the effect of genotype 
and training in muscle-specific mice. 
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To examine  the transcription factors that may compensate for the lack of p53 with exercise, 
structural similarities were compared from similar proteins to p53 (393 aa, chr 17p13.1, 53 kDA, 
28 exons). Using the Dali Server and PSI-BLAST search against the p53 2GEQA region, which 
contains the DNA binding region in mus musculus, and examined  the structural similarities of 
proteins. This server utilizes a sum of pairs method which analyzes intramolecular distances; a 
high z score indicates similar distances between structures. This analysis concluded six  
noteworthy transcription factors. Additional transcriptional regulators, determined through 
review of literature, include 16 proteins (12, 20, 35, 49). Further analysis is required to provide a 
complete inquiry into viable compensatory mechanisms. Details on the aforementioned proteins 
are listed in the order of amino acid (aa) length, kilo dalton size, number of exons, chromosome 
(chr) location, and number of isomers. Abbreviations: Bcl-2A1, BCL2 related protein 1; 
NFATC1, Nuclear factor of activated T-cells 1; p65/NF-kB1, Nuclear factor kappa B subunit 1; 
Table 4. Structural protein analysis to determine analogous features to the p53 transcription 
factor. 
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RELB, RELB proto-oncogene, NF-kB subunit; SIRT1, Sirtuin 1; FOXO1, Forkhead Box O1; 
IGF-1, Insulin like growth factor 1; NR4A1, Nuclear receptor subfamily 4 group 1 member 1; 
JUNB, JunB proto-oncogene; Myc, Myc proto-oncogene; FOS, Fos proto-oncogene, ATF3, 
Activating transcription factor 3; ID1-3, Inhibitor of DNA binding 3, HLH protein; CTGF, 
Connective tissue growth factor; HIF1-a, Hypoxia inducible factor 1 alpha subunit; MEF2A, 
Myocyte enhancer factor 2A; HDAC1, histone de-acetylase 1;  NRF1, nuclear respiratory factor 
1; CREB1, CAMP responsive element binding protein 1. 
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 Whole Body p53 (WB) Muscle Specific p53 (MS) 
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RANDOMIZATION 
Fig 1.  
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Figure 1. Detailed exercise protocol for sedentary and exercise grouped mice. Muscle 
specific and whole body WT and KO mice underwent a two-day acclimatization program to the 
treadmill. 24 hours following the second day of acclimatization, all mice underwent a pre-
training exhaustive stress test. A 48 hour time delay occurred between the first exhaustive stress 
test and the initiation of the 6-week exercise training or sedentary program. 48 hours following 
the exercise/sedentary intervention, a second exhaustive exercise stress test was performed to 
measure the adaptations with training. After a 48 hour wait period, all mice were subjected to an 
acute bout of exercise prior to euthanization and tissue extraction immediately following the 90 
min bout. Acute exercise was employed prior to tissue extraction to upregulate signaling 
transcription for mRNA analysis.  
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Figure 2. Differences in baseline exercise performance. MS and WB mice were subjected to a 
pre-training exhaustive bout of exercise. Exercise performance was measured by recording A) 
distance to exhaustion (n=17-18/group); N.S. p>0.05, 2-way ANOVA, and B) lactate production 
before and after exercise (n=7-20/group); †p≤0.05, ††p≤0.01, WT vs. KO, 2-way ANOVA; 
****p≤0.001, Pre-lactate vs. Post-lactate (effect of exercise), 2-way ANOVA. Red line indicates 
an exhaustive lactate threshold (>8mM). Data are presented as mean ± SEM.  
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Figure 3. The absence of p53 does not impact skeletal muscle strength. Skeletal muscle 
strength in whole body mice was measured through a cage hanging test. Strength was measured 
by A) length of time spent hanging (n=14/group). N.S., p>0.05, WT vs KO, student’s T-test, and 
by the B) holding impulse (n=14/group). N.S., p>0.05, WT vs KO, student’s T-test. Data are 
presented as mean ± SEM. This model for resistance exercise indicated that WB KO mice, 
though not significantly different from the WT mice, did display an increased trend for improved 
strength capacity. N.S.= non-significant. 
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Figure 4. Neurological testing to assess cerebral function in the absence of p53. To examine 
walking synchronization in the WB mice, a balance beam test was employed to measure the A) 
time to cross (n=14/group); †p≤0.05, WT vs. KO, Student’s t-test, and the B) number of paw 
slips (n=14/group); N.S., p>0.05, Student’s t-test. A pole test was employed to examine motor 
coordination and synchronization for correct paw placement during vertical navigation down a 
pole by measuring C) the time to traverse down the pole (n=14/group);N.S., p>0.05, Student’s t-
test. To establish central neural activity for voluntary movement identified through spatial 
learning, memory, and behavioural parameters, a cylinder escape test was employed. D) The 
time to escape the cylinder was measured (n=14/group); N.S., p>0.05. Data are presented as 
mean ± SEM. N.S. = non-significant 
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Figure 5. Reduced DNA fragmentation and apoptosis with training. DNA fragmentation was 
measured following training in both mouse models. Though no significant differences are 
detected with training and genotype, the WB mice do experience greater apoptosis than the MS 
mice (n=6-8/group); ¶ p≤0.05, WB vs. MS, Student’s t-test. Furthermore, a trend for reduced 
DNA fragmentation with training in the WB WT and KO mice was observed. Data are presented 
as mean ± SEM.  
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Figure 6. AIF mitochondrial protein release. Mitochondrial AIF protein release was measured 
from SS and IMF subfractions under basal conditions in A) MS mice (n=7-14/group); ##p≤0.01, 
main effect of SS mitochondria, 2-way ANOVA, and B) WB mice (n=10-13/group); #p≤0.05, 
main effect of IMF mitochondria, 2-way ANOVA. AIF protein release was further measured in 
SS and IMF mitochondria when activated through apoptotic stimuli (H2O2)  in C) MS mice 
(n=6-11/group); ##p≤0.01, main effect of IMF mitochondria, 2-way ANOVA, and D) WB mice 
(n=8-12/group); #p≤0.05, main effect of SS mitochondria, 2-way ANOVA. Data are presented as 
mean ± SEM.  
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Figure 7. Respiration analysis of permeabilized fibres in WB mice.  A) Mitochondrial 
respiration for Complex I (state 4 and state 3) Complex I & II (state 3), and Complex II (state 3) 
was performed on a subset of whole body mice (n=2-5/group); *p≤0.05, UT vs. T; †p≤0.05, WT 
vs. KO, Student’s t-test and 2-way ANOVA. B) The fold change on the effect of training on 
respiration was calculated between WT and KO mice (n=2-5/group); ††p≤0.01, main effect of 
genotype, 2-way ANOVA. C) Mitochondrial respiration corrected for total mitochondrial 
volume was measured (n=2-5/group); N.S., p>0.05, 2-way ANOVA. D) Fold change on the 
effect of training on corrected respiration was measured (n=2-5/group); ††p≤0.01, main effect of 
genotype, 2-way ANOVA. Data are presented as mean ± SEM. N.S. = non-significant. 
Abbreviations: P/M, pyruvate/malate; ADP, adenosine diphosphate; Succ, succinate; CI, 
Complex I; CII, Complex 2.  
WT UT 
WT T 
KO UT 
KO T 
WT (T/UT) 
KO (T/UT) 
+P/M +ADP +Succ +Succ +ADP 
0 
50 
100 
150 
200 
250 
  
  
O 2
 C
on
su
mp
tio
n  
(p
mo
l/s
/m
g t
iss
ue
) 
CI CII 
+P/M +AD +Succ +Succ +ADP 
0 
0.5 
1.0 
1.5 
2.0 
2.5 
Fo
ld 
Ch
an
ge
 O
2 C
on
su
mp
tio
n  
(p
mo
l/s
/m
g t
iss
ue
) 
CII CI 
+P/M +ADP +Succ +Succ +ADP 
0 
5 
10 
15 
20 
  
  
  
O 2
 C
on
su
mp
tio
n  
(p
mo
l/s
/m
g t
iss
ue
/C
OX
 A
cti
vit
y)
 
CII CI 
+P/M +ADP +Succ +Succ +ADP 
0 
0.5 
1.0 
1.5 
Fo
ld 
Ch
an
ge
 O
2 C
on
su
mp
tio
n  
(p
mo
l/s
/m
g t
iss
ue
/ C
OX
 A
cti
vit
y) 
CII CI 
A B 
C D 
* 
* 
† 
†† 
† 
Fig 7.  
183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Reactive Oxygen Species (ROS) analysis in permeabilized fibers in WB mice. A) 
Mitochondrial ROS in Complex I (state 4 and state 3), Complex I & II (state 3), and Complex II 
(state 3) was measured using the Oroboros instrument on a subset of whole body mice (n=2-
5/group); N.S., p>0.05, 2-way ANOVA. B) The fold change on the effect of training on ROS 
was calculated between WT and KO mice (n=2-5/group); N.S., p>0.05, 2-way ANOVA. C) 
Mitochondrial ROS corrected for total mitochondrial volume was measured (n=2-5/group); 
*p≤0.05, UT vs. T, Student’s t-test. D) Fold change on the effect of training on corrected ROS 
was measured (n=2-5/group); †p≤0.05, WT vs. KO, Student’s t-test. Data are presented as mean 
± SEM. N.S.= non-significant. Abbreviations: P/M, pyruvate/malate; ADP, adenosine 
diphosphate; Succ, succinate; CI, Complex I; CII, Complex 2.  
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Figure 9. Antioxidant regulation with exercise training.  A) The major antioxidant 
transcriptional regulator Nrf2, and its B) negative regulator KEAP1 were examined in the 
context of exercise training (n=4-5/group); *p≤0.05, **p≤0.05, UT vs. T,  2-way ANOVA . Data 
are presented as mean ± SEM.  
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Figure 10. Signaling regulation in untrained and trained MS and WB mice. A) p53 mRNA 
was reduced with training in MS mice (n=6-10/group); **p≤0.01, UT vs. T, Student’s t-test. B) 
Mitochondrial biogenesis was measured through COX IV protein in whole muscle lysates of MS 
mice (n=5-7/group); **p≤0.01, UT vs. T, 2-way ANOVA; †† p≤0.01, UT WT vs. KO, 2-way 
ANOVA. C) The effects of the absence of p53 on apoptotic signaling in untrained MS and WB 
mice was measured through protein analysis of D) Bax (n=4-6/group); †p≤0.05; ††p≤0.01, UT 
WT vs. KO; ¶¶p≤0.01, MS vs. WB, 2-way ANOVA, E) Bcl-2 (n=5-8/group); †p≤0.05, UT WT 
vs. KO, 2-way ANOVA; ¶p≤0.05, MS vs. WB, Student’s t-test, and F) p21 (n=6-8/group); 
†p≤0.05, ††p≤0.01, UT WT vs. KO, Student’s t-test and 2-way ANOVA; ¶¶p≤0.01, MS vs. WB, 
2-way ANOVA. Data are presented as mean  ±  SEM.  
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Figure 11. IMF mitochondrial functional (respiration and ROS) and apoptosis signaling 
comparison between MS and WB mice in the absence of p53. IMF mitochondrial function 
was measured through state 3 A) respiration (n=6-8/group); †p≤0.05, UT WT vs, KO; ¶p≤0.05, 
MS vs. WB, Student’s t-test, and B) ROS (n=7-8/group); †p≤0.05, UT WT vs, KO, Student’s t-
test. C) Apoptosis was basally measured through cytochrome c release from IMF mitochondria 
(n=6-14/group); †p≤0.05, UT WT vs, KO, Student’s t-test. Data are presented as mean ±  SEM.  
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Appendix C: Data and Statistical Analysis for Supplementary 
Table 2A: Pre-training initial body mass measurement, comparison between Muscle-
Specific (MS) and Whole-Body (WB) Mice 
 Pre-Training Initial Body Mass – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 30.8 38.4 28.4 34.1 
2 30.4 28.5 17.7 25.5 
3 29.6 29.5 19.5 33.5 
4 26.8 27.2 23.4 39.5 
5 31.0 29.4 27.6 30.3 
6 31.4 44.4 26.2 29.3 
7 31.5 34.6 23.9 25.6 
8 30.1 27.0 25.4 28.8 
9 31.2 36.7 28.8 24.8 
10 31.3 32.0 25.6 25.1 
11 30.4 32.8 26.3 26.9 
12 29.2 29.2 20.3 27.6 
13 31.7 27.8 20.2 25.9 
14  28.8 25.6 29.4 
15  27.8 19.5 30.7 
16  28.2 19.8 29.4 
17  27.7 24.8 29.1 
18  36.9 24.2 28.2 
19  31.1 26.4 27.7 
20  31.4 26.5 29.5 
21  29.5 26.0  
22   27.2  
23   25.0  
X 30.415 31.376 24.274 29.045 
SEM 0.367 0.984 0.667 0.789 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0329 * Yes 
Mouse Model <0.0001 **** Yes 
Genotype/Training 0.0010 *** Yes 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO -0.9608 0.8352 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT 6.141 5.429 ≤ 0.001 ¶¶¶¶ 
Muscle Specific:KO vs. Whole Body:KO 2.831 2.78 ≤ 0.05 ¶ 
Whole Body:WT vs. Whole Body:KO -4.271 4.285 ≤ 0.005 ††† 
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Table 2A: Pre-training initial body mass measurement, comparison between Muscle-
Specific (MS) and Whole-Body (WB) Mice 
 
 Pre-Training Performance Test – Distance to Exhaustion (m)  - MS 
versus WB Mice 
 Muscle-Specific Mice Whole-Body Mice 
N WT mKO WT KO 
1 1144.22 1381.40 1173.80 1067.00 
2 1322.50 1012.56 1124.75 1277.00 
3 1597.00 1546.42 1102.00 1485.00 
4 1150.00 1322.50 1091.75 1439.00 
5 970.00 1387.88 1077.89 668.00 
6 1559.00 477.00 1261.25 1167.00 
7 1578.00 523.25 1394.00 894.60 
8 962.00 855.23 794.00 1129.70 
9 1287.50 1466.50 1067.00 1197.60 
10 1189.44 1616.00 1150.00 1218.00 
11 1012.56 1635.00 1386.80 1422.80 
12 1201.00 804.80 1503.50 1386.80 
13 1509.42 922.50 1444.40 1433.60 
14 1394.00 876.00 1496.10 1175.50 
15 1192.50 970.00 1577.50 1235.00 
16 1301.50 1313.75 1397.60 1291.00 
17 1485.00 1503.50 1322.50 1221.40 
18  1201.00 1358.00 1042.25 
X 1285.626 1156.405 1262.380 1208.403 
SEM 50.830 85.428 47.654 48.436 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significant? 
Interaction 0.5361 ns No 
Mouse Model 0.8129 ns No 
Genotype 0.1347 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT vs. Muscle Specific:KO 129.2 1.5 > 0.05 ns 
Muscle Specific:WT vs. Whole Body:WT 23.25 0.2698 > 0.05 ns 
Muscle Specific:KO vs. Whole Body:KO -52 0.6123 > 0.05 ns 
Whole Body:WT vs. Whole Body:KO 53.98 0.6356 > 0.05 ns 
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Table 2B: Post-training final body mass measurement, comparison between Muscle-
Specific (MS) and W hole-Body (WB) Mice 
 Post-Training Final Body Mass (g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 31.52 29.02 42.40 27.10 22.83 20.09 33.40 22.76 
2 31.23 30.52 30.60 27.72 22.82 20.46 28.90 26.32 
3 34.03 30.35 33.40 25.61 28.70 23.30 31.50 25.79 
4 28.07 30.74 30.40 28.42 29.30 19.39 32.50 21.29 
5 36.13 30.07 30.40 28.92 28.10 19.28 29.60 28.80 
6 36.15 29.75 43.00 27.06 28.50 26.50 31.40 28.50 
7   38.40 26.82 31.70 25.80 28.20 30.00 
8   29.10 29.41 30.00 27.00 27.90 22.80 
9   38.40 30.10 30.6 26.30   
10   32.30 27.00     
X 32.855 30.075 34.840 27.816 28.061 23.124 30.425 25.783 
SEM 1.295 0.254 1.660 0.434 1.057 1.110 0.727 1.140 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1983 ns No 
Mouse Model <0.0001 **** Yes 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 2.78 1.511 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT -1.98 1.203 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 4.794 2.854 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T 2.259 1.373 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T 6.951 4.139 ≤ 0.01 ¶¶ 
Muscle Specific:KO UT vs. Muscle Specific:KO T 7.019 4.925 ≤ 0.005 *** 
Muscle Specific:KO UT vs. Whole Body:KO UT 4.416 2.922 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 2.034 1.346 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T 4.937 3.287 ≤0.05 * 
Whole Body:WT UT vs. Whole Body:KO UT -2.357 1.522 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T -2.658 1.716 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T 4.637 2.91 > 0.05 ns 
 
Unpaired T-test – MS WT UT versus MS WT T 
P value 0.0478 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test - MS WT UT versus WB WT UT 
P value 0.0132 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WB WT UT versus KO UT 
P value 0.0926 
P value summary ns 
Significantly different? (P<0.05) No 
 
Unpaired T-test – WB KO UT versus WB KO T 
P value 0.0041 
P value summary ** 
Significantly different? (P<0.05) Yes 
Unpaired T-test - MS KO UT versus WB KO UT 
P value 0.0401 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
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Table 2B: Post-training tibialis anterior (TA) mass, corrected for body mass, comparison 
between Muscle-Specific (MS) and Whole-Body (WB) Mice 
 
 Tibialis Anterior (TA) Skeletal Muscle Mass/Body Mass (mg/g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 2.00 1.51 2.57 1.93 2.09 1.65 2.37 1.72 
2 2.20 1.62 1.98 1.64 2.03 1.61 2.87 1.52 
3 2.20 1.69 1.91 1.82 2.11 1.62 1.69 1.83 
4 1.95 1.49 2.06 1.85 1.84 1.57 1.70 1.63 
5 1.86 1.83 1.91 1.62 1.95 1.40 1.55 1.59 
6 1.68 1.30 2.05 1.72 1.70 1.54 1.61 1.55 
7   2.01 1.78 1.69 1.54 1.56 1.80 
8   2.21 1.94   1.62 1.70 
X 1.982 1.573 2.088 1.788 1.916 1.561 1.871 1.668 
SEM 0.0822 0.0747 0.0768 0.0429 0.0665 0.0311 0.171 0.0403 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.6817 ns No 
Mouse Model 0.1068 ns No 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 0.4076 3.003 > 0.05 ns 
Muscle Specific:WT UT vs.Muscle Specific:KO UT -0.1059 0.8344 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 0.06336 0.4844 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.2138 1.684 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T 0.01088 0.0832 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T 0.2998 2.55 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT 0.2153 1.832 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 0.1188 1.011 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T 0.3551 2.826 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.04604 0.3784 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T -0.1058 0.8697 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T 0.2033 1.729 > 0.05 ns 
 
Unpaired T-test – MS WT UT versus MS WT T 
P value 0.0045 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WB WT UT versus WB WT T 
P value 0.0004 
P value summary *** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS KO UT versus MS KO T 
P value 0.0043 
P value summary ** 
Significantly different? (P<0.05) Yes 
192 
 
Table 2B: Post-training gastrocnemius mass, corrected for body mass, comparison between 
Muscle-Specific (MS) and Whole-Body (WB) Mice 
 
 Gastrocnemius Muscle Mass/Body Mass (mg/g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 7.42 6.32 8.13 6.24 6.58 6.94 6.50 6.20 
2 6.73 6.28 5.88 6.32 6.57 6.35 6.37 6.65 
3 5.89 5.56 6.18 6.52 6.90 6.22 5.50 6.31 
4 6.10 5.74 6.15 6.14 5.98 5.97 5.00 5.78 
5 5.90 5.81 6.16 6.36 5.90 6.05 5.70 6.03 
6 6.00 5.34 5.88 5.19 6.71 6.39 6.14 5.95 
7   6.25 6.45 5.48 6.39 5.76 6.42 
8   5.83 6.19   6.29 6.43 
X 6.340 5.842 6.308 6.176 6.303 6.330 5.908 6.221 
SEM 0.251 0.160 0.267 0.148 0.196 0.120 0.180 0.102 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1415 ns No 
Mouse Model 0.8459 ns No 
Genotype/Training 0.5897 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 0.5022 1.745 > 0.05 ns 
Muscle Specific:WT UT vs.Muscle Specific:KO UT 0.03814 0.1417 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 0.03465 0.1249 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.3361 1.248 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -0.4899 1.766 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T 0.1279 0.5133 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT 0.3969 1.592 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T -0.04472 0.1794 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -0.02235 0.0839 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.4004 1.552 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.1091 0.4227 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -0.3137 1.259 > 0.05 ns 
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Table 2B: Post-training quadriceps mass, corrected for body mass, comparison between 
Muscle-Specific (MS) and Whole-Body (WB) Mice 
 
 Quadriceps Muscle Mass/Body Mass (mg/g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 6.56 5.65 7.28 6.56 8.49 7.75 7.53 5.85 
2 6.51 5.95 6.96 6.50 7.58 7.48 6.29 6.65 
3 5.87 6.58 6.64 6.56 8.32 6.08 5.54 6.70 
4 6.15 6.08 6.52 6.45 6.54 7.51 5.44 6.56 
5 6.18 6.57 6.05 6.52 6.22 5.46 5.89 6.37 
6 6.15 6.22 6.05 6.60 7.16 6.65 7.91 6.38 
7   7.61 7.15 5.33 6.13 5.79 6.19 
8   5.93 6.73   6.73 6.95 
X 6.237 6.175 6.630 6.634 7.091 6.723 6.390 6.456 
SEM 0.105 0.148 0.218 0.0793 0.433 0.331 0.327 0.120 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0966 ns No 
Mouse Model 0.1771 ns No 
Genotype/Training 0.8766 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 0.06081 0.1542 > 0.05 ns 
Muscle Specific:WT UTvs.Muscle Specific:KO UT -0.3929 1.065 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.8553 2.251 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.4573 1.24 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -0.5487 1.444 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -0.003661 0.0107 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT 0.239 0.6997 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 0.1759 0.515 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T 0.3675 1.007 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.7014 1.984 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.2672 0.7559 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -0.06675 0.1955 > 0.05 ns 
 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.1708 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 2B: Post-training heart mass, corrected for body mass, comparison between Muscle-
Specific (MS) and Whole-Body (WB) Mice 
 
 Heart Mass/Body Mass (mg/g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 6.14 6.04 3.69 5.42 4.44 6.87 6.11 6.48 
2 5.71 6.26 4.29 5.69 6.00 6.56 6.07 6.33 
3 4.89 5.69 5.07 6.01 5.65 7.15 6.64 6.23 
4 3.99 5.13 4.76 5.51 5.82 7.04 5.56 6.99 
5 6.59 5.76 5.06 6.13 5.67 6.79 4.78 7.76 
6 4.94 5.66 5.14 5.64 5.46 9.62 4.56 7.09 
7   5.04 6.10 4.98 6.30 5.13 7.33 
8   5.11 6.00   4.32 6.59 
X 5.377 5.757 4.770 5.813 5.431 7.190 5.396 6.850 
SEM 0.388 0.157 0.184 0.0989 0.205 0.419 0.294 0.189 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0772 ns No 
Mouse Model <0.0001 **** Yes 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -0.3815 0.9603 > 0.05 ns 
Muscle Specific:WT UTvs.Muscle Specific:KO UT 0.6059 1.63 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.05545 0.1448 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.05429 0.1461 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -1.433 3.743 ≤ 0.05 * 
Muscle Specific:KO UT vs. Muscle Specific:KO T -1.042 3.028 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT -0.6252 1.817 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T -1.039 3.019 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -1.759 4.782 ≤ 0.005 *** 
Whole Body:WT UT vs. Whole Body:KO UT 0.03617 0.1016 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.34 0.9547 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -1.455 4.23 ≤ 0.01 ** 
 
Unpaired T-test – MS KO UT versus MS KO T 
P value 0.0002 
P value summary *** 
Significantly different? (P<0.05) Yes 
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Table 2B: Post-training epididymal fat mass, corrected for body mass, comparison between 
Muscle-Specific (MS) and Whole-Body (WB) Mice 
 
 Epididymal Fat Muscle Mass/Body Mass (mg/g) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 33.60 22.25 67.17 26.68 29.06 18.64 49.44 17.50 
2 43.06 24.78 59.87 27.04 35.80 21.60 40.08 14.09 
3 51.42 29.34 41.71 30.32 22.18 23.89 39.33 16.55 
4 38.65 39.98 53.59 24.04 29.74 21.75 52.07 17.03 
5 39.77 44.16 39.43 19.37 22.51 22.73 46.69 17.33 
6 54.89 28.43 58.87 27.07 33.29 22.14 23.70 20.86 
7   59.64 14.52 38.43 21.57 32.48 20.58 
8   56.22 22.32    17.18 
X 43.565 31.490 54.563 23.920 30.144 21.760 40.541 17.640 
SEM 3.307 3.545 3.352 1.792 2.358 0.606 3.780 0.773 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4031 ns No 
Mouse Model <0.0001 **** Yes 
Genotype/Training <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 12.07 2.989 > 0.05 ns 
Muscle Specific:WT UTvs.Muscle Specific:KO UT -11 2.911 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 13.42 3.447 ≤ 0.05 * 
Muscle Specific:WT T vs. Muscle Specific:KO T 7.569 2.003 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T 9.731 2.5 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T 30.64 8.76 ≤ 0.001 **** 
Muscle Specific:KO UT vs. Whole Body:KO UT 14.02 3.872 ≤ 0.01 ¶¶ 
Muscle Specific:KO T vs. Whole Body:KO T 6.282 1.796 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T 8.387 2.243 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT -10.4 2.78 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 4.12 1.138 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T 22.9 6.326 ≤0.001 **** 
 
Unpaired T-test – MS WT UT versus MS WT T 
P value 0.0320 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.0062 
P value summary ¶¶ 
Significantly different? (P<0.05) Yes 
 
 
Unpaired T-test – WB WT UT versus WB WT T 
P value 0.0049 
P value summary ** 
Significantly different? (P<0.05) Yes 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0417 
P value summary † 
Significantly different? (P<0.05) Yes 
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Table 2C: Post-training SS mitochondrial yield comparison between Muscle-Specific (MS) 
and Whole-Body (WB) Mice 
 SS Mitochondrial Yield (µg/mg) – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 0.47 0.95 0.58 0.8 0.46 0.76 0.51 0.6 
2 0.62 0.83 0.44 1.03 0.69 1 0.85 0.54 
3 0.71 0.89 0.83 0.9 0.59 1.01 0.69 0.59 
4 0.22 0.79 0.69 0.76 1.14 0.72 0.78 0.74 
5 0.56 0.87 0.036 0.85 0.73 0.8 0.43 0.58 
6 0.67 0.61 0.6 0.69 0.5 1.5 0.6 0.72 
7   0.59 0.64 0.61 1.15 0.76 0.73 
8   0.72  1.55 1.81 0.59 0.72 
9     0.52 1.82  0.72 
10     0.54   0.66 
11        0.91 
X 0.541 0.823 0.561 0.81 0.733 1.174 0.651 0.683 
SEM 0.0730 0.0481 0.0852 0.0498 0.110 0.144 0.0508 0.0314 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0358 * Yes 
Mouse Model 0.0141 * Yes 
Genotype/Training 0.0027 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -0.2809 1.763 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT -0.01550 0.104 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.3908 2.743 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T 0.01575 0.1026 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -0.3502 2.408 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -0.2496 1.748 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT -0.09303 0.6742 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 0.1256 0.9411 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -0.2402 1.895 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.2823 2.157 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.4915 3.963 ≤ 0.01 ** 
Whole Body:KO UT vs. Whole Body:KO T -0.03101 0.2418 > 0.05 ns 
 
Unpaired T-test – MS WT UT versus T 
P value 0.0089 
P value summary ** 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – WB WT UT versus WT T 
P value 0.0247 
P value summary * 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS KO UT versus T 
P value 0.0166 
P value summary * 
Significantly different? (P<0.05) Yes 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.2339 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 2C: Post-training IMF mitochondrial yield comparison between Muscle-Specific 
(MS) and Whole-Body (WB) Mice 
 IMF Mitochondrial Yield (µg/mg) – MS versus WB 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 1.11 1.047 0.98 1.1 0.7 1.17 0.67 1.35 
2 1.00 1.017 1.18 1.17 1.04 1.45 0.78 1.4 
3 1.22 1.06 1.22 1.35 0.94 1.21 1.26 1.1 
4 1.09 1.56 1.15 1.21 1.51 0.85 1.16 1.31 
5 1.08 1.58 1.06 1.61 0.5 1.24 0.97 1.35 
6 1.04 1.14 1.15 1.76 1.15 1.29 1.05 1.31 
7  1.38 0.12 1.54 1.42 1.3 1.25 1.41 
8   0.96 1.76 1.82 1.15 1.21 1.2 
9   1.23 1.44 0.73 2.11 1.25 1.37 
10   0.99  0.55 2.58 0.89  
11     1.78 2.18   
X 1.0903 1.255 1.004 1.438 1.104 1.503 1.049 1.311 
SEM 0.0308 0.0933 0.103 0.0828 0.143 0.162 0.0676 0.0336 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.2100 ns No 
Mouse Model 0.2508 ns No 
Genotype/Training 0.0008 *** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -0.1655 0.9203 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT 0.08605 0.5155 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.1042 0.6351 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.1820 1.117 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -0.3376 2.16 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -0.4335 2.919 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT -0.04359 0.3015 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 0.1274 0.836 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -0.3989 2.894 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.1467 1.038 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.2830 1.948 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -0.2625 1.768 > 0.05 ns 
 
Unpaired T-test – MS WT UT versus WT T 
P value 0.1455 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
Unpaired T-test – WB WT UT versus WT T 
P value 0.0796 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – MS KO UT versus KO T 
P value 0.0050 
P value summary ** 
Significantly different? (P<0.05) Yes 
Unpaired T-test – WB KO UT versus KO T 
P value 0.0038 
P value summary ** 
Significantly different? (P<0.05) Yes 
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Table 2C: Post-training respiratory control ratio (RCR) in SS mitochondria, comparison 
between Muscle-Specific (MS) and Whole-Body (WB) Mice 
 SS Mitochondria RCR – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 2.09 4.56 3.19 5.00 1.36 11.00 1.09 4.25 
2 0.70 3.62 2.52 4.22 1.05 7.50 9.13 2.32 
3 5.82 10.30 4.33 5.55 10.00 8.29 2.00 4.00 
4 3.56 37.00 7.35 5.64 8.70 13.00 0.14 11.2 
5 7.20 17.00 5.44 9.32 3.56 11.00 1.50 7.25 
6 3.15 4.71 4.90 4.39 1.00 2.60 4.57 5.29 
7 3.93  6.45 4.31 0.40 5.08  2.67 
8   2.75 19.00 0.50    
9     3.67    
X 3.779 12.865 4.616 7.179 3.360 8.353 3.072 5.283 
SEM 0.826 5.251 0.621 1.787 1.205 1.381 1.355 1.167 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.7667 ns No 
Mouse Model 0.1352 ns No 
Genotype/Training 0.0029 ** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -9.086 3.139 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT -0.8377 0.3111 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT 0.4186 0.1597 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T 5.686 2.024 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T 4.512 1.559 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -2.563 0.9851 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT 1.545 0.5497 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T 1.896 0.7041 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -4.993 1.904 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.2883 0.1052 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 3.070 1.104 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -2.211 0.7640 > 0.05 ns 
 
 
 
 
 
Unpaired T-test – MS WT UT versus WT T 
P value 0.0911 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – WB WT UT versus WT T 
P value 0.0164 
P value summary * 
Significantly different? (P<0.05) Yes 
Unpaired T-test – MS KO UT versus KO T 
P value 0.1971 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 2C: Post-training respiratory control ratio (RCR) in SS mitochondria, comparison 
between Muscle-Specific (MS) and Whole-Body (WB) Mice 
 IMF Mitochondria RCR – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 6.59 2.82 8.62 7.89 20.14 12.36 21.47 11.3 
2 5.43 18.47 5.22 7.97 15.9 12.33 3.82 9.72 
3 6.89 4.74 5.77 8.17 3.83 7.43 7.06 9.42 
4 5.86 19.06 12.36 1.80 4.50 13.04 11.22 15.64 
5 5.64 7.49 7.80 6.27 9.14 27.87 10.49 22.12 
6 5.89 8.04 6.66 4.97 11.37 25.04 11.98 12.73 
7   2.85 18.36 15.88 15.77  39.1 
8    41.50 9.66    
X 6.0500 10.103 7.0400 12.116 11.303 16.263 11.007 17.147 
SEM 0.232 2.847 1.134 4.521 2.025 2.808 2.436 4.016 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9879 ns No 
Mouse Model 0.0199 * Yes 
Genotype/Training 0.1217 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T -4.053 0.9000 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT -0.9900 0.2281 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -5.253 1.247 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -2.013 0.4778 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -6.160 1.419 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -5.076 1.257 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT -3.967 0.9140 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T -5.031 1.246 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T -4.960 1.229 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.2958 0.07023 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T -0.8843 0.2121 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T -6.140 1.415 > 0.05 ns 
 
 
 
Unpaired T-test – MS WT UT versus WT T 
P value 0.1863 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.0468 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
Unpaired T-test – WB WT UT versus WT T 
P value 0.1682 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – WB KO UT versus KO T 
P value 0.2367 
P value summary ns 
Significantly different? (P<0.05) No 
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Table 3: mRNA and protein fold comparison, average values and fold change 
mRNA and Protein Comparison – Muscle Specific Mice 
mRNA/protein WT KO Δ WT UT 
vs. mKO 
Δ WT UT 
vs. T 
Δ mKO 
UT vs. T UT T UT T 
p53 mRNA 3.9 2.3 n/a n/a n/a ↓ 41.0% n/a 
p53 protein 0.70 0.27 n/a n/a n/a ↓ 61.4% n/a 
p21 mRNA 5.6 3.5 4.1 5.4 ↓ 26.8% ↓ 37.5% ↑ 1.3-fold 
p21 protein 0.42 0.34 0.29 0.59 ↓ 31.0 % NS ↑ 2.0-fold 
Bax mRNA 8.3 6.7 5.1 3.4 ↓ 38.6 % ↓ 19.3% ↓ 33.3% 
Bax protein 0.25 0.38 0.59 0.34 ↑ 2.4-fold NS ↓ 42.4% 
Mdm2 mRNA 3.1 2.8 2.8 2.6 NS NS NS 
Mdm2 protein 0.34 0.56 0.35 0.74 NS ↑ 1.6-fold ↑ 2.1-fold 
Tfam mRNA 6.4 5.8 3.2 4.2 ↓ 50% NS ↑ 1.3-fold 
Tfam protein 0.57 0.69 0.41 0.86 ↓ 28.1% NS ↑ 2.1-fold 
PGC-1α mRNA 5.2 5.4 4.3 6.7 NS NS ↑ 1.6-fold 
PGC-1α protein 0.46 0.84 0.29 0.76 ↓ 37.0% ↑ 1.8-fold ↑ 2.6-fold 
p62 mRNA 5.7 5.6 4.5 4.9 ↓ 21.1% NS NS 
p62 protein 0.43 0.75 1.01 0.72 ↑ 2.3-fold ↑ 1.7-fold ↓ 28.7% 
LC3 mRNA 4.9 4.9 2.7 3.5 ↓ 44.9 % NS ↑ 1.3-fold 
LC3 protein 0.34 0.73 0.45 0.61 NS ↑ 2.1-fold ↑ 1.4-fold 
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Figure 2B: Pre-Training performance test, initial and final blood lactate comparison 
between Muscle-Specific (MS) and Whole-Body (WB) mice 
 
 
Pre-Training Stress Performance Test – Lactate Production (mM) – MS versus WB Mice 
 MS WT MS mKO WB WT WB KO 
N Pre-
Lactate 
Post-
Lactate 
Pre-
Lactate 
Post-
Lactate 
Pre-
Lactate 
Post-
Lactate 
Pre-
Lactate 
Post-
Lactate 
1 2.9 11.1 1.5 12.7 1.1 10.6 1.1 14.7 
2 1.1 11.5 2.0 13.4 1.4 9.6 2.3 9.1 
3 2.1 10.6 1.8 12.0 1.3 9.2 1.9 11.2 
4 2.2 10.5 2.0 10.9 2.2 8.5 2.4 15.3 
5 2.3 8.4 1.8 9.5 1.4 9.2 1.9 11.4 
6 2.3 8.8 1.6 18.6 1.7 10.8 2.3 10.6 
7 2.3 10.0 1.5 13.2 2.1 10.0 2.0 10.9 
8 2.6 11.8 1.8 9.3 2.6 8.7  11.5 
9 1.2 12.8 2.1 14.2 1.9 9.6  10.3 
10 2.5 13.5 2.3 12.2 1.6 11.9  14.4 
11 1.6 9.0 2.3 13.8 1.5 10.3  10.3 
12 1.3 8.7 2.6 13.3 2.2 8.8  11.0 
13 2.9 7.8 1.7 9.4  9.5  15.0 
14 2.4  1.5 9.7  10.3  10.6 
15 1.2  1.9 10.7  9.2  11.7 
16 2.1  2.1 9.7  10.3  12.0 
17 1.3  2.1 10.7  9.9  10.8 
18   1.6   8.8   
19      9.4   
20      10.8   
X 2.018 10.346 1.900 11.959 1.750 9.770 1.986 11.812 
SEM 0.148 0.490 0.0741 0.584 0.130 0.193 0.167 0.451 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0071 ** Yes 
Mouse Model/Genotype 0.0025 ** Yes 
Pre/Post Lactate <0.0001 **** Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS WT:Pre-Lactate vs. MS WT:Post-Lactate -8.329 16.56 ≤0.001 **** 
MS WT:Pre-Lactate vs. MS KO:Pre-Lactate 0.1176 0.2548 > 0.05 ns 
MS WT:Pre-Lactate vs. WB WT:Pre-Lactate 0.2676 0.5199 > 0.05 ns 
MS WT:Post-Lactate vs. MS KO:Post-Lactate -1.613 3.206 ≤ 0.05 † 
MS WT:Post-Lactate vs. WB WT:Post-Lactate 0.5762 1.184 > 0.05 ns 
MS KO:Pre-Lactate vs. MS KO:Post-Lactate -10.06 21.78 ≤0.001 **** 
MS KO:Pre-Lactate vs. WB KO:Pre-Lactate -0.08571 0.1409 > 0.05 ns 
MS KO:Post-Lactate vs. WB KO:Post-Lactate 0.1471 0.314 > 0.05 ns 
WB WT:Pre-Lactate vs. WB WT:Post-Lactate -8.02 16.09 ≤0.001 **** 
WB WT:Pre-Lactate vs. WB KO:Pre-Lactate -0.2357 0.363 > 0.05 ns 
WB WT:Post-Lactate vs. WB KO:Post-Lactate -2.042 4.533 ≤0.005 ††† 
WB KO:Pre-Lactate vs. WB KO:Post-Lactate -9.826 16.02 ≤0.001 **** 
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Figure 3A: Cage hanging grip strength test, time hanging   
Cage Hanging Grip Strength Test – Time (sec) – Whole Body Mice 
N WT KO 
1 105.17 278.02 
2 84.42 123.30 
3 171.70 129.30 
4 42.62 551.30 
5 254.38 143.67 
6 172.60 332.29 
7 179.80 156.71 
8 232.91 354.34 
9 114.77 280.00 
10 212.09 262.00 
11 272.90 85.99 
12 129.59 271.78 
13 164.75 334.33 
14 375.14 74.11 
X 179.489 241.224 
SEM 23.066 35.180 
 
Unpaired T-test – WT versus KO 
P value 0.1542 
P value summary ns 
Significantly different? (P<0.05) No 
 
Figure 3B: Cage hanging grip strength test, holding impulse   
Cage Hanging Grip Strength Test – Holding Impulse –Whole Body Mice 
N WT KO 
1 3018.379 7562.144 
2 2237.13 3723.66 
3 5030.81 4072.95 
4 1099.596 17035.17 
5 6944.574 4381.935 
6 4850.06 10799.43 
7 5124.3 5375.153 
8 6288.57 10204.99 
9 3638.209 7980 
10 5577.967 7755.2 
11 7422.88 2700.086 
12 3317.504 8153.4 
13 4332.925 9428.106 
14 9378.5 2067.669 
X 4875.815 7231.421 
SEM 586.216 1062.210 
 
Unpaired T-test – WT versus KO 
P value 0.0631 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
203 
 
Figure 4A: Balance Beam Test, time to cross  
 
 
Unpaired T-test – WT versus KO 
P value 0.0519 
P value summary † 
Significantly different? (P<0.05) Yes 
 
Figure 4B: Balance Beam Test, number of paw slips  
Balance Beam Test – Number of Paw Slips – Whole Body Mice 
N WT KO 
1 0 1 
2 2 4 
3 0 3 
4 0 2 
5 4 2 
6 2 5 
7 1 5 
8 9 2 
9 8 2 
10 4 9 
11 2 8 
12 1 1 
13 1 7 
14 3 4 
X 2.643 3.929 
SEM 0.753 0.691 
 
Unpaired T-test – WT versus KO 
P value 0.2196 
P value summary ns 
Significantly different? (P<0.05) No 
 
Balance Beam Test – Time to Cross (sec) – Whole Body Mice 
N WT KO 
1 6 5 
2 12 6 
3 4 9 
4 4 6 
5 8 27 
6 5 25 
7 4 14 
8 5 9 
9 5 5 
10 3 8 
11 3 5 
12 5 5 
13 7 8 
14 6 4 
X 5.500 9.714 
SEM 0.627 1.971 
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Figure 4C: Vertical pole test, time traversing down the pole 
Vertical Pole Test – Time (sec) – Whole Body Mice 
N WT KO 
1 4.077 4.157 
2 4.753 3.393 
3 3.403 4.137 
4 4.377 4.347 
5 3.630 5.013 
6 4.543 3.750 
7 3.840 3.987 
8 5.577 6.073 
9 3.710 4.033 
10 6.083 4.310 
11 6.760 4.583 
12 5.200 4.027 
13 4.087 2.947 
14 5.090 2.443 
X 4.652 4.086 
SEM 0.265 0.232 
 
Unpaired T-test – WT versus KO 
P value 0.1195 
P value summary ns 
Significantly different? (P<0.05) No 
 
Figure 4D: Cylinder escape test, time to escape cylinder 
Cylinder Escape Test – Time (sec) – Whole Body Mice 
N WT KO 
1 231.00 600.00 
2 537.75 600.00 
3 343.85 186.53 
4 588.04 98.62 
5 366.31 177.40 
6 345.82 600.00 
7 108.16 265.69 
8 600.00 217.87 
9 173.64 502.39 
10 244.34 466.83 
11 600.00 198.78 
12 281.10 403.9 
13 320.48 499.00 
14 319.83 162.96 
X 361.451 355.712 
SEM 43.021 49.788 
 
Unpaired T-test – WT versus KO 
P value 0.9312 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 5: Post-training DNA fragmentation, Muscle-Specific (MS) versus Whole-Body 
(WB) Mice 
 DNA Fragmentation – MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
 WT mKO WT KO 
N UT T UT T UT T UT T 
1 0.77 0.72 0.69 0.87 0.93 1.11 0.88 0.94 
2 0.72 0.84 0.83 0.76 1.71 0.88 1.13 0.93 
3 0.90 0.77 0.79 0.92 1.22 1.10 1.25 1.16 
4 0.77 0.83 0.81 1.06 1.13 1.28 1.20 1.25 
5 0.97 0.90 0.86 0.87 1.46 1.22 1.13 1.27 
6 1.51 0.84 1.37 0.94 1.28 1.07 1.46 0.15 
7 0.76 0.80 1.03 1.02 1.48    
8    0.94     
X 0.914 0.814 0.911 0.923 1.316 1.110 1.175 0.950 
SEM 0.105 0.0218 0.0856 0.0330 0.0972 0.0565 0.0771 0.171 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1921 ns No 
Mouse Model 0.0003 *** Yes 
Genotype/Training 0.1729 ns No 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
Muscle Specific:WT UT vs. Muscle Specific:WT T 0.1000 0.8194 > 0.05 ns 
Muscle Specific:WT UT vs. Muscle Specific:KO UT 0.002857 0.02341 > 0.05 ns 
Muscle Specific:WT UT vs. Whole Body:WT UT -0.4014 3.289 > 0.05 ns 
Muscle Specific:WT T vs. Muscle Specific:KO T -0.1082 0.9158 > 0.05 ns 
Muscle Specific:WT T vs. Whole Body:WT T -0.2957 2.328 > 0.05 ns 
Muscle Specific:KO UT vs. Muscle Specific:KO T -0.01107 0.09369 > 0.05 ns 
Muscle Specific:KO UT vs. Whole Body:KO UT -0.2636 2.075 > 0.05 ns 
Muscle Specific:KO T vs. Whole Body:KO T -0.0275 0.2230 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:WT T 0.2057 1.619 > 0.05 ns 
Whole Body:WT UT vs. Whole Body:KO UT 0.1407 1.108 > 0.05 ns 
Whole Body:WT T vs. Whole Body:KO T 0.1600 1.214 > 0.05 ns 
Whole Body:KO UT vs. Whole Body:KO T 0.2250 1.707 > 0.05 ns 
 
Unpaired T-test – MS KO UT versus WB KO UT 
P value 0.0434 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS WT T versus WB WT T 
P value 0.0003 
P value summary ¶¶¶ 
Significantly different? (P<0.05) Yes 
 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.0158 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
Unpaired T-test – WB WT UT versus WB WT T 
P value 0.1084 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – MS KO T versus WB KO T 
P value 0.8585 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 6A: Post-training AIF protein release from SS and IMF mitochondria under basal 
conditions 
 AIF Protein Release - Basal – SS & IMF Mitochondria – Muscle-Specific Mice 
 SS IMF 
 WT mKO WT mKO 
N UT T UT T UT T UT T 
1 2294.13 340.41 2919.26 12049.57 693.06 1564.26 826.01 2765.08 
2 2016.72 9556.91 11410.15 7472.45 495.58 3846.26 280.09 698.86 
3 1291.48 13763.81 345.53 520.36 251.97 354.305 340.24 337.48 
4 784.72 3254.91 319.46 496.65 451.01 729.8 426.68 137.97 
5 556.31 610.6 5800.08 291.49 459.58 367.94 162.26 426.44 
6 7734.15 446.82 353.6 949.41 283.23 351.16 50.9 300.85 
7 1074.89 2492.26 4672.5 1976.18 522.89 355.9 237.87 113.78 
8  1212.77 416.06 1178.53  294.26 202.7 332.09 
9  1678.79 923.28 629.28  719.79 230.11 961.48 
10  573.72 694.06 510.68  819.28 836.06 690.58 
11   1026.16 10476.57   868.06 1102.35 
12   1386.43 1372.08   892.81  
13   1057.96    939.21  
14   3592.03    599.34  
X 2250.343 3393.100 2494.04 3160.271 451.046 940.296 492.310 715.178 
SEM 944.250 1444.369 831.900 1231.770 56.396 345.100 85.674 226.692 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT:SS vs. WT UT:IMF 1904 1.316 > 0.05 ns 
WT UT:SS vs. WT T:SS -1049 0.7869 > 0.05 ns 
WT UT:SS vs. KO UT:SS -139.3 0.1112 > 0.05 ns 
WT UT:IMF vs. WT T:IMF -489.2 0.3669 > 0.05 ns 
WT UT:IMF vs. KO UT:IMF -41.26 0.03294 > 0.05 ns 
WT T:SS vs. WT T:IMF 2464 2.036 > 0.05 ns 
WT T:SS vs. KO T:SS 243.7 0.2104 > 0.05 ns 
WT T:IMF vs. KO T:IMF 202.3 0.1746 > 0.05 ns 
KO UT:SS vs. KO UT:IMF 2002 1.957 > 0.05 ns 
KO UT:SS vs. KO T:SS -666.3 0.6259 > 0.05 ns 
KO UT:IMF vs. KO T:IMF -245.7 0.2308 > 0.05 ns 
KO T:SS vs. KO T:IMF 2422 2.193 > 0.05 ns 
 
Unpaired T-test – IMF WT UT versus WT T 
P value 0.2614 
P value summary ns 
Significantly different? (P<0.05) No 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9826 ns No 
Genotype/Training 0.7779 ns No 
Mitochondrial Subfraction 0.0005 ### Yes 
Unpaired T-test – IMF KO UT versus T 
P value 0.2607 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 6B: Post-training AIF protein release from SS and IMF mitochondria under basal 
conditions 
 AIF Protein Release - Basal – SS & IMF Mitochondria – Whole-Body Mice 
 SS IMF 
 WT KO WT KO 
N UT T UT T UT T UT T 
1 663.82 2670.5 632.06 675.01 5741.9 501.28 5772.6 1960.7 
2 16699.1 788.01 526.31 1099.52 791.5 2701.52 2591.62 10169.21 
3 561.58 874.06 527.75 535.53 6295.62 10118.69 1675.84 808.84 
4 610.33 951.33 758.26 866.5 5981.9 650.26 827.03 3626.3 
5 510.33 641.43 4921.03 1486.03 4618.21 661.89 541.91 2328.4 
6 1471.69 709.77 1121.4 926.91 4663.08 780.84 6607.03 6676.62 
7 4572.26 666.06 537.74 147.21 388.23 9439.4 775.79 8036.15 
8 691.96 671.67 765.5 637.74 850.67 801.96 6063.18 6102.81 
9 590.77 4176.13 1229.15 1247.23 788.94 401.97 790.36 2182.45 
10 976.5 807.13 1004.82 2108.15 544.46 476.48 540.89 418.87 
11 3780.55 727.23  2785.05 245.97 428.16  1520.27 
12  551.36    671.06   
13  1058.31    2872.55   
X 2829.899 1176.384 1202.402 1137.716 2810.044 2346.620 2618.625 3984.602 
SEM 1450.087 291.828 420.872 227.956 780.908 943.402 797.131 979.268 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT:SS vs. WT UT:IMF 300.7 0.2561 > 0.05 ns 
WT UT:SS vs. WT T:SS 1662 1.473 > 0.05 ns 
WT UT:SS vs. KO UT:SS 1636 1.360 > 0.05 ns 
WT UT:IMF vs. WT T:IMF 190.7 0.1691 > 0.05 ns 
WT UT:IMF vs. KO UT:IMF -81.31 0.06759 > 0.05 ns 
WT T:SS vs. WT T:IMF -1170 1.084 > 0.05 ns 
WT T:SS vs. KO T:SS 38.67 0.03428 > 0.05 ns 
WT T:IMF vs. KO T:IMF -1638 1.452 > 0.05 ns 
KO UT:SS vs. KO UT:IMF -1416 1.150 > 0.05 ns 
KO UT:SS vs. KO T:SS 64.68 0.05376 > 0.05 ns 
KO UT:IMF vs. KO T:IMF -1366 1.135 > 0.05 ns 
KO T:SS vs. KO T:IMF -2847 2.425 > 0.05 ns 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3131 ns No 
Genotype/Training 0.5861 ns No 
Mitochondrial Subfraction 0.0306 * Yes 
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Figure 6C: Post-training AIF protein release from SS and IMF mitochondria treated with 
apoptotic stimulus (H2O2), presented as fold change 
 
 
AIF Protein Release – Treated/Control – SS & IMF Mitochondria – Muscle-Specific Mice 
 SS IMF 
 WT mKO WT mKO 
N UT T UT T UT T UT T 
1 6.04 2.76 6.16 1.43 16.95 10.63 11.10 4.61 
2 7.79 1.36 1.04 2.29 15.88 20.34 19.75 14.91 
3 10.75 1.20 2.88 8.30 11.95 19.88 8.27 22.45 
4 15.91 5.24 3.38 18.17 14.97 21.32 29.12 18.24 
5 2.67 8.10 6.85 7.40 14.91 7.31 25.87 23.96 
6 14.35 9.50 9.00 15.36 16.12 21.73 11.58 22.69 
7  14.10 15.59 1.91  24.72 14.80 22.96 
8   20.45 13.00  20.74 7.12 17.86 
9   18.97    22.05 10.64 
10   5.98    21.60  
11       18.31  
X 9.585 6.037 9.030 8.483 15.130 18.334 17.234 17.591 
SEM 2.063 1.812 2.181 2.291 0.708 2.131 2.182 2.184 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.5493 ns No 
Genotype/Training 0.9603 ns No 
Mitochondrial Subfraction <0.0001 #### Yes 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT:SS vs. WT UT:IMF -5.544 1.573 > 0.05 ns 
WT UT:SS vs. WT T:SS 3.546 1.044 > 0.05 ns 
WT UT:SS vs. KO UT:SS 0.5538 0.1757 > 0.05 ns 
WT UT:IMF vs. WT T:IMF -3.204 0.9717 > 0.05 ns 
WT UT:IMF vs. KO UT:IMF -2.103 0.6788 > 0.05 ns 
WT T:SS vs. WT T:IMF -12.29 3.891 ≤ 0.01 ** 
WT T:SS vs. KO T:SS -2.446 0.774 > 0.05 ns 
WT T:IMF vs. KO T:IMF 0.7412 0.2498 > 0.05 ns 
KO UT:SS vs. KO UT:IMF -8.201 3.074 > 0.05 ns 
KO UT:SS vs. KO T:SS 0.5466 0.1887 > 0.05 ns 
KO UT:IMF vs. KO T:IMF -0.3595 0.131 > 0.05 ns 
KO T:SS vs. KO T:IMF -9.107 3.07 > 0.05 ns 
 
 
 
 
Unpaired T-test – WT UT IMF vs WT T IMF 
P value 0.2344 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 6D: Post-training AIF protein release from SS and IMF mitochondria treated with 
apoptotic stimulus (H2O2), presented as fold change 
 AIF Protein Release – Treated/Control – SS & IMF Mitochondria – Whole-Body Mice 
 SS IMF 
 WT KO WT KO 
N UT T UT T UT T UT T 
1 9.73 4.23 10.56 12.75 1.78 4.01 2.13 8.47 
2 23.62 22.91 9.31 22.25 8.80 1.63 3.42 1.63 
3 28.80 17.62 4.47 6.28 1.05 10.51 7.56 3.06 
4 39.74 14.15 8.90 19.97 3.16 13.28 2.08 8.26 
5 13.18 21.18 24.49 29.89 2.54 1.17 1.10 2.33 
6 3.62 21.95 17.73 14.19 2.19 6.40 5.22 0.57 
7 5.28 7.90 19.69 10.20 18.49 1.30 2.81 1.96 
8 17.79 8.90 18.21 11.39 20.95 4.70 17.72 4.85 
9 12.57 2.09   6.36 15.00  30.01 
10 21.16 25.31   8.21 43.64  8.03 
11  24.44   15.60 6.06   
12  17.01       
X 17.549 15.641 14.170 15.865 8.103 9.791 5.255 6.917 
SEM 3.525 2.338 2.407 2.709 2.159 3.672 1.923 2.732 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT:SS vs. WT UT:IMF 9.447 2.453 > 0.05 ns 
WT UT:SS vs. WT T:SS 1.909 0.5059 > 0.05 ns 
WT UT:SS vs. KO UT:SS 3.379 0.8083 > 0.05 ns 
WT UT:IMF vs. WT T:IMF -1.689 0.4495 > 0.05 ns 
WT UT:IMF vs. KO UT:IMF 2.848 0.6953 > 0.05 ns 
WT T:SS vs. WT T:IMF 5.848 1.59 > 0.05 ns 
WT T:SS vs. KO T:SS 0.02642 0.0066 > 0.05 ns 
WT T:IMF vs. KO T:IMF 2.873 0.746 > 0.05 ns 
KO UT:SS vs. KO UT:IMF 8.915 2.023 > 0.05 ns 
KO UT:SS vs. KO T:SS -1.444 0.3276 > 0.05 ns 
KO UT:IMF vs. KO T:IMF -1.664 0.398 > 0.05 ns 
KO T:SS vs. KO T:IMF 8.695 2.08 > 0.05 ns 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9071 ns No 
Genotype/Training 0.6847 ns No 
Mitochondrial Subfraction 0.0001 ### Yes 
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Figure 7A: Post-training state 3 and 4 respiration in permeabilized fibers, WB Mice 
 
 
N 
KO UT KO T 
+P/M (CI) +ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) +P/M (CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 41.85 164.84 222.05 58.6 105.83 19.88 115.24 153.54 65 119.59 
2 11.91 78.81 93.63 57.13 96.56 20.51 171.81 230.18 46.65 68.41 
3 19.87 128.6 161.67 74.26 166.26      
4 29.57 134.46 181.73 59.87 117.99      
5           
X 25.80 126.68 164.77 62.47 121.66 20.20 143.52 191.86 55.83 94.00 
SEM 17.823 26.831 3.971 15.501 0.315 28.285 38.320 9.175 25.590 17.823 
 
 
 
 
 
 
 
 
 
 
N 
O2 Consumption  (pmol/s/mg tissue) - (Oroboros technology) – WB Mice 
WT UT WT T 
+P/M (CI) +ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 23.38 101.4 145.31 63.25 138.09 26.79 190.1 236.4 98.54 191.48 
2 6.25 57.35 68.2 77.32 138.95 17.18 139.48 170.87 60.67 107.11 
3 12.21 53.82 119.12 53.16 121.45 27.87 95.74 226.5 68.72 170.57 
4 15.6 85.7 116.32 76.62 134.1 21.02 103.58 137.22 76.07 119.36 
5 13.66 64.08 80.52 45.4 79.6 10.6 108.05 136.86 68.24 124.38 
X 14.22 72.47 105.89 63.15 122.4 20.69 127.39 181.57 74.45 142.58 
SEM 2.772 9.107 13.968 6.313 11.157 3.186 17.351 21.337 6.497 16.283 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0573 ns No 
Substrate < 0.0001 **** Yes 
Genotype/Training 0.0014 ** Yes 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT UT vs. +P/M:WT T -6.473 0.346 > 0.05 ns 
+P/M:WT UT vs. +P/M:KO UT -11.58 0.5835 > 0.05 ns 
+P/M:WT T vs. +P/M:KO T 0.496 0.02004 > 0.05 ns 
+P/M:KO UT vs. +P/M:KO T 5.603 0.2187 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T -54.92 2.935 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT -54.2 2.731 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T -16.13 0.6518 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T -16.85 0.6576 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T -75.68 4.044 ≤ 0.05 * 
+Succ:WT UT vs. +Succ:KO UT -58.88 2.967 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T -10.29 0.4157 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T -27.09 1.057 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T -11.3 0.604 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT 0.6853 0.03453 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T 18.63 0.7526 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 6.642 0.2592 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T -20.14 1.076 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.7781 0.03921 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T 48.58 1.963 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T 27.66 1.08 > 0.05 ns 
Unpaired T-test – + ADP WT UT versus WT T 
P value 0.0231 
P value summary * 
Significantly different? (P<0.05) Yes 
Unpaired T-test – + ADP WT UT versus KO UT 
P value 0.0233 
P value summary † 
Significantly different? (P<0.05) Yes 
Unpaired T-test – + P/M WT UT versus KO UT 
P value 0.1172 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – + Succ WT UT versus KO UT 
P value 0.0768 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 7B: Post-training fold change in state 3 and 4 respiration in permeabilized fibers, 
WB Mice 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT (T/UT) vs. +P/M:KO (T/UT) 0.6725 2.043 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) 0.6248 1.899 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.5502 1.672 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.2853 0.8669 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) 0.3919 1.191 > 0.05 ns 
 
 
 
 
 
 
 
 
 
 
 
 
N 
Fold Change O2 Consumption  (pmol/s/mg tissue - (Oroboros technology) – WB Mice 
WT T/UT KO T/UT 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 1.88 2.62 2.23 1.56 1.56 0.77 0.91 0.93 1.04 0.98 
2 1.21 1.92 1.61 0.96 0.87 0.8 1.36 1.4 0.75 0.56 
3 1.96 1.32 2.14 1.09 0.39      
4 1.48 1.43 1.3 1.2 0.97      
5 0.75 1.49 1.29 1.08 1.02      
X 1.456 1.756 1.714 1.178 0.962 0.785 1.135 1.165 0.895 0.770 
SEM 0.223 0.239 0.201 0.103 0.187 0.015 0.225 0.235 0.145 0.210 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9108 ns No 
Substrate 0.1439 ns No 
Genotype/Training 0.0021 †† Yes 
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Figure 7C: Post-training state 3 and 4 respiration in permeabilized fibers, corrected for 
mitochondrial content in WB Mice 
 
 
N 
KO UT KO T 
+P/M (CI) 
+ADP (CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 3.4 13.4 18.05 4.76 8.6 1 5.81 7.75 3.28 6.03 
2 0.58 4.55 4.55 2.78 4.69 1.06 8.88 11.9 2.41 3.54 
3 1.13 9.19 9.19 4.22 9.46      
4 3.33 20.46 20.46 6.74 13.28      
5    3.17 5.78      
X 2.11 11.9 13.0625 4.334 8.362 1.03 7.345 9.825 2.845 4.785 
SEM 0.733 3.378 3.731 0.698 1.510 0.030 1.535 2.075 0.435 1.245 
 
 
 
 
 
 
 
 
 
N 
O2 Consumption/COX Activity  (pmol/s/mg tissue/COX Activity) (Oroboros technology) – WB Mice 
WT UT WT T 
+P/M (CI) 
+ADP (CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) +ADP (CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 2.06 8.93 12.8 5.57 12.17 0.93 6.6 8.21 3.42 6.65 
2 0.49 4.45 5.29 6 10.79 0.75 6.12 7.5 2.66 4.7 
3 0.55 2.41 5.34 2.38 5.44 1.49 5.13 12.14 3.68 9.14 
4 0.93 5.11 6.94 4.57 8 0.7 3.44 4.56 2.53 3.96 
5 1.22 5.72 7.19 4.05 7.11 0.49 5.02 6.36   
X 1.05 5.324 7.512 4.514 8.702 0.872 5.262 7.754 3.0725 6.1125 
SEM 0.285 1.060 1.379 0.636 1.226 0.170 0.544 1.258 0.282 1.158 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.5030 ns No 
Substrate < 0.0001 **** Yes 
Genotype/Training 0.0073 ** Yes 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT UT vs. +P/M:WT T 0.1749 0.09733 > 0.05 ns 
+P/M:WT UT vs. +P/M:KO UT -1.061 0.5569 > 0.05 ns 
+P/M:WT T vs. +P/M:KO T -0.1582 0.06655 > 0.05 ns 
+P/M:KO UT vs. +P/M:KO T 1.078 0.4381 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T 0.06488 0.0361 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT -4.593 2.41 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T 2.571 1.045 > 0.05 ns 
+ADP:KO T vs. +Succ:WT T -0.4024 0.1693 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T -0.238 0.1324 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT -5.55 2.912 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T -2.073 0.872 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 3.239 1.316 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T 1.444 0.7574 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT 0.1821 0.1013 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T 0.2276 0.09251 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 1.489 0.6264 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T 2.588 1.358 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.339 0.1886 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T 1.328 0.5397 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T 3.577 1.505 > 0.05 ns 
Unpaired T-test – +P/M WT UT versus KO UT 
P value 0.1848 
P value summary ns 
Significantly different? (P<0.05) No 
Unpaired T-test – +Succ (CII) WT UT versus WT T 
P value 0.1007 
P value summary ns 
Significantly different? (P<0.05) No 
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Figure 7C: Post-training fold change state 3 and 4 respiration in permeabilized fibers, 
corrected for mitochondrial content in WB Mice 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT (T/UT) vs. +P/M:KO (T/UT) 0.3442 1.572 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) 0.2470 1.128 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.2796 1.277 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.06954 0.3176 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) 0.1637 0.7475 > 0.05 ns 
 
 
 
 
 
 
 
 
 
 
 
 
N 
Fold Change O2 Consumption  (pmol/s/mg tissue/COX Activity) corrected for COX- (Oroboros technology) – 
WB Mice 
WT T/UT KO T/UT 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 0.89 1.24 1.09 0.76 0.76 0.48 0.59 0.59 0.71 0.67 
2 0.72 1.15 1 0.59 0.54 0.5 0.9 0.91 0.52 0.39 
3 1.42 0.96 1.62 0.82 1.05      
4 0.67 0.65 0.61 0.56 0.46      
5 0.47 0.94 0.85 0.7 0.66      
X 0.834 0.988 1.034 0.686 0.694 0.490 0.745 0.750 0.615 0.530 
SEM 0.161 0.102 0.168 0.0494 0.103 0.01 0.155 0.160 0.095 0.140 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9145 ns No 
Substrate 0.2508 ns No 
Genotype/Training 0.0331 † Yes 
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Figure 8A: Post-training state 3 and 4 reactive oxygen species (ROS) emission rate from 
permeabilized fibers, WB Mice 
 
 
N 
KO UT KO T 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 0.52 0.015 0.0078 0.62 0.023 0.32 0.019 0.015 0.69 0.028 
2 0.61 0.018 0.055 0.15 0.036 0.25 0.011 0.013 0.19 0.023 
3 0.49 0.0086 0.0059 0.41 0.018      
4 0.3 0.0077 0.0055 0.32 0.016      
5           
X 0.48 0.0123 0.0186 0.375 0.0233 0.285 0.015 0.014 0.44 0.0255 
SEM 0.0652 0.00249 0.0122 0.0979 0.00450 0.035 0.004 0.001 0.25 0.0025 
 
 
 
 
 
 
 
N 
H2O2 Emission Rate  (pmol H2O2/pmol O2 consumed) (Oroboros technology) – WB Mice 
WT UT WT T 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 0.52 0.019 0.011 0.47 0.017 0.48 0.0091 0.0076 0.29 0.015 
2 0.57 0.02 0.017 0.2 0.012 0.28 0.0086 0.01 0.16 0.022 
3 0.36 0.035 0.017 0.3 0.049 0.93 0.061 0.013 0.25 0.02 
4 0.22 0.014 0.011 0.33 0.021 0.31 0.013 0.011 0.2 0.022 
5 0.35 0.012 0.011 0.21 0.03 0.45 0.019 0.013 0.38 0.016 
X 0.404 0.02 0.0134 0.302 0.0258 0.49 0.02214 0.01092 0.256 0.019 
SEM 0.0631 0.00404 0.00147 0.0489 0.00651 0.117 0.00989 0.00101 0.0380 0.00148 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.5680 ns No 
Substrate < 0.0001 **** Yes 
Genotype/Training 0.8224 ns No 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT UT vs. +P/M:WT T -0.0833 1.198 > 0.05 ns 
+P/M:WT UT vs. +P/M:KO UT -0.07751 1.051 > 0.05 ns 
+P/M:WT T vs. +P/M:KO T 0.2053 2.232 > 0.05 ns 
+P/M:KO UT vs. +P/M:KO T 0.1995 2.096 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T -0.002025 0.02913 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.007556 0.1025 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T 0.00708 0.07698 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T -0.002502 0.02628 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T 0.002804 0.04033 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT -0.004937 0.06695 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T -0.00332 0.0361 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 0.004421 0.04644 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T 0.04617 0.664 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT -0.07504 1.018 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T -0.1859 2.022 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T -0.06473 0.68 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T 0.006602 0.09496 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.002576 0.03493 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T -0.006496 0.07063 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T -0.00247 0.02594 > 0.05 ns 
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Figure 8B: Post-training fold change in state 3 and 4 reactive oxygen species (ROS) 
emission rate from permeabilized fibers, WB Mice 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT (T/UT) vs. +P/M:KO (T/UT) 0.6203 1.298 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) -0.09961 0.2084 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.03231 0.06759 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) -0.3250 0.68 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) -0.3615 0.7562 > 0.05 ns 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N 
H2O2 Emission Rate  Fold Change (pmol H2O2/pmol O2 consumed) (Oroboros technology) – WB Mice 
WT T/UT KO T/UT 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 1.18 0.45 0.56 0.95 0.58 0.66 1.54 0.82 1.83 1.22 
2 0.68 0.43 0.75 0.54 0.86 0.52 0.86 0.7 0.52 0.99 
3 2.3 3.05 0.94 0.82 0.78      
4 0.75 0.65 0.79 0.67 0.87      
5 1.12 0.93 0.92 1.25 0.63      
X 1.206 1.102 0.792 0.846 0.744 0.59 1.2 0.76 1.175 1.105 
SEM 0.291 0.495 0.0685 0.122 0.0594 0.0700 0.340 0.0600 0.655 0.115 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.6074 ns No 
Substrate 0.8499 ns No 
Genotype/Training 0.9015 ns No 
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Figure 8C: Post-training state 3 and 4 reactive oxygen species (ROS) emission rate from 
permeabilized fibers, corrected for mitochondrial content, in WB Mice 
 
 
N 
KO UT KO T 
+P/M (CI) +ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) +P/M (CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 6.45 0.19 0.096 7.64 0.28 6.26 0.38 0.3 2.77 0.26 
2 12.52 0.38 1.13 3.04 0.73 4.8 0.21 0.25 3.76 0.44 
3 8.66 0.15 0.1 7.26 0.32      
4 2.68 0.068 0.049 2.87 0.15      
5           
X 7.578 0.197 0.344 5.203 0.370 5.530 0.295 0.275 3.265 0.350 
SEM 2.0587 0.0661 0.262 1.300 0.125 0.730 0.0850 0.0250 0.495 0.0900 
 
 
 
 
 
 
 
 
 
 
N 
H2O2 Emission Rate (pmol H2O2/pmol O2 consumed/COX Activity) corrected for mitochondrial content (Oroboros 
technology) – WB Mice 
WT UT WT T 
+P/M (CI) +ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 5.9 0.22 0.12 5.31 0.2 13.69 0.26 0.22 8.22 0.43 
2 7.34 0.26 0.22 2.51 0.15 6.28 0.2 0.23 3.72 0.51 
3 8.06 0.77 0.39 6.7 1.1 17.32 1.14 0.24 1.62 0.38 
4 3.69 0.24 0.18 5.59 0.35 9.19 0.39 0.32 6.07 0.68 
5 3.92 0.13 0.13 2.37 0.34 9.76 0.4 0.27 8.15 0.35 
X 5.782 0.324 0.208 4.496 0.428 11.248 0.478 0.256 5.556 0.47 
SEM 0.880 0.114 0.0489 0.871 0.172 1.923 0.170 0.0181 1.284 0.0591 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0814 ns No 
Substrate < 0.0001 **** Yes 
Genotype/Training 0.0166 * Yes 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT UT vs. +P/M:WT T -5.466 -9.906 to -1.027 > 0.05 ns 
+P/M:WT UT vs. +P/M:KO UT -1.796 -6.505 to 2.913 > 0.05 ns 
+P/M:WT T vs. +P/M:KO T 5.714 -0.1592 to 11.59 > 0.05 ns 
+P/M:KO UT vs. +P/M:KO T 2.043 -4.036 to 8.123 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T -0.1529 -4.593 to 4.287 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.1283 -4.581 to 4.837 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T 0.1834 -5.690 to 6.057 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T -0.09783 -6.177 to 5.982 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T -0.04779 -4.488 to 4.392 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT -0.1352 -4.844 to 4.574 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T -0.01951 -5.893 to 5.854 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 0.06787 -6.012 to 6.147 > 0.05 ns 
+Succ:WT UT vs. +Succ:WT T -1.663 -6.103 to 2.777 > 0.05 ns 
+Succ:WT UT vs. +Succ:KO UT -0.7127 -5.422 to 3.996 > 0.05 ns 
+Succ:WT T vs. +Succ:KO T 2.891 -2.982 to 8.765 > 0.05 ns 
+Succ:KO UT vs. +Succ:KO T 1.941 -4.139 to 8.020 > 0.05 ns 
+ADP:WT UT vs. +ADP:WT T -0.04265 -4.483 to 4.397 > 0.05 ns 
+ADP:WT UT vs. +ADP:KO UT 0.05599 -4.653 to 4.765 > 0.05 ns 
+ADP:WT T vs. +ADP:KO T 0.1161 -5.757 to 5.989 > 0.05 ns 
+ADP:KO UT vs. +ADP:KO T 0.01745 -6.062 to 6.097 > 0.05 ns 
Unpaired T-test – P/M (CI) WT UT versus WT  T 
P value 0.0324 
P value summary * 
Significantly different? (P<0.05) Yes 
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Figure 8D: Post-training fold change in state 3 and 4 reactive oxygen species (ROS) 
emission rate from permeabilized fibers, corrected for mitochondrial content, in WB Mice 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
+P/M:WT (T/UT) vs. +P/M:KO (T/UT) 1.215 2.344 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) -0.02744 0.05294 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.4255 0.8208 > 0.05 ns 
+Succ:WT (T/UT) vs. +Succ:KO (T/UT) 0.7428 1.433 > 0.05 ns 
+ADP:WT (T/UT) vs. +ADP:KO (T/UT) 0.1471 0.2839 > 0.05 ns 
 
 
 
 
 
 
 
 
 
 
 
 
N 
H2O2 Emission Rate Fold Change (pmol H2O2/pmol O2 consumed/COX Activity) corrected for mitochondrial content 
(Oroboros technology) – WB Mice 
WT T/UT KO T/UT 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
+P/M 
(CI) 
+ADP 
(CI) 
+SUCC 
(CI&CII) 
+Succ 
(CII) 
+ADP 
(CII) 
1 2.37 0.81 1.05 1.83 1.01 0.83 1.94 0.88 0.53 0.7 
2 1.09 0.6 1.11 0.83 1.19 0.63 1.06 0.73 0.72 1.2 
3 3 3.51 1.15 1.03 0.88      
4 1.59 1.21 1.55 1.35 1.59      
5 1.69 1.23 1.29 1.81 0.82      
X 1.948 1.472 1.230 1.370 1.098 0.730 1.500 0.805 0.625 0.95 
SEM 0.333 0.523 0.0892 0.202 0.138 0.100 0.440 0.075 0.095 0.25 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.4730 ns No 
Substrate 0.5680 ns No 
Genotype/Training 0.0406 † Yes 
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Figure 9A: Post-training whole muscle Nrf2 protein 
 
 Whole Muscle Nrf2 Protein - Muscle 
Specific Mice 
 WT mKO 
N UT T UT T 
1 0.31 0.26 0.32 0.19 
2 0.38 0.25 0.34 0.22 
3 0.22 0.20 0.30 0.15 
4 0.34 0.22 0.32 0.24 
5 0.36 0.17   
X 0.324 0.220 0.321 0.199 
SEM 0.0276 0.016 0.007 0.020 
 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.1020 3.708 ≤ 0.05 * 
WT:UT vs. KO:UT 0.002000 0.06855 > 0.05 ns 
WT:UT vs. KO:T 0.1220 4.182 ≤ 0.01 ** 
WT:T vs. KO:UT -0.1000 3.428 ≤ 0.05 * 
WT:T vs. KO:T 0.0200 0.6855 > 0.05 ns 
KO:UT vs. KO:T 0.1200 3.902 ≤ 0.01 ** 
 
 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.6693 ns No 
Substrate 0.6022 ns No 
Genotype/Training < 0.0001 **** Yes 
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Figure 9B: Post-training whole muscle KEAP1 protein 
 
 Whole Muscle KEAP1 Protein - Muscle 
Specific Mice 
 WT KO 
N UT T UT T 
1 0.69 0.23 0.93 0.17 
2 1.01 0.16 0.71 0.56 
3 0.84 0.61 1.04 0.19 
4 1.11 0.24 0.90 0.70 
X 0.910 0.311 0.894 0.406 
SEM 0.094 0.101 0.070 0.132 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.5995 4.161 ≤ 0.01 ** 
WT:UT vs. KO:UT 0.01600 0.1110 > 0.05 ns 
WT:UT vs. KO:T 0.5046 3.502 ≤ 0.05 * 
WT:T vs. KO:UT -0.5835 4.050 ≤ 0.01 ** 
WT:T vs. KO:T -0.09495 0.6590 > 0.05 ns 
KO:UT vs. KO:T 0.4886 3.391 ≤ 0.05 * 
 
 
 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.5961 ns No 
Substrate 0.7052 ns No 
Genotype/Training 0.0002 *** Yes 
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Figure 10A: Post-training p53 mRNA transcript 
 p53 mRNA - Muscle Specific Mice 
 WT 
N UT T 
1 4.32 2.74 
2 3.99 3.47 
3 3.96 1.74 
4 3.81 3.62 
5 3.53 1.43 
6 3.85 1.25 
7  2.90 
8  3.67 
9  1.03 
10  1.43 
X 3.910 2.327 
SEM 0.106 0.334 
 
 
 
 
Figure 10B: Post-training whole muscle COX IV protein 
 Whole Muscle COX IV Protein - Muscle Specific Mice 
 WT KO 
N UT T UT T 
1 0.38 0.70 0.82 0.67 
2 0.24 0.69 0.95 0.58 
3 0.49 1.00 1.11 0.65 
4 0.54 1.12 1.21 0.84 
5 0.33 0.66 0.94 0.77 
6  0.68 1.34 0.74 
7   0.92 0.67 
X 0.398 0.807 1.041 0.702 
SEM 0.053 0.082 0.070 0.033 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.4123 4.387 ≤ 0.01 ** 
WT:UT vs. KO:UT -0.6454 7.101 ≤ 0.001 †††† 
WT:UT vs. KO:T -0.3069 3.376 ≤ 0.05 * 
WT:T vs. KO:UT -0.2331 2.699 > 0.05 ns 
WT:T vs. KO:T 0.1055 1.221 > 0.05 ns 
KO:UT vs. KO:T 0.3386 4.080 ≤ 0.01 ** 
 
Unpaired T-test – MS WT UT versus WT T 
P value 0.0032 
P value summary ** 
Significantly different? (P<0.05) Yes 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction < 0.0001 **** Yes 
Substrate 0.0003 *** Yes 
Genotype/Training 0.5626 ns No 
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Figure 10D: Whole muscle Bax protein, untrained Muscle-Specific (MS) and Whole-Body 
(WB) Mice 
 Whole Muscle Bax Protein– Untrained MS versus WB 
Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.31 0.59 0.61 0.17 
2 0.20 0.64 0.73 0.56 
3 0.38 0.65 0.83 0.24 
4 0.11 0.49 0.70 0.73 
5  0.64 0.91 0.36 
6  0.50 0.84  
X 0.250 0.585 0.770 0.412 
SEM 0.060 0.030 0.045 0.103 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO -0.3350 3.652 ≤ 0.05 † 
MS:WT vs. WB:WT -0.5200 5.669 ≤ 0.005 ¶¶¶ 
MS:WT vs. WB:KO -0.1620 1.700 > 0.05 ns 
MS:KO vs. WB:WT -0.1850 2.255 > 0.05 ns 
MS:KO vs. WB:KO 0.1730 2.011 > 0.05 ns 
WB:WT vs. WB:KO 0.3580 4.161 ≤ 0.01 †† 
 
 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction < 0.0001 **** Yes 
Substrate 0.0134 * Yes 
Genotype/Training 0.8570 ns No 
222 
 
Figure 10E: Whole muscle Bcl-2 protein, untrained Muscle-Specific (MS) and Whole-Body 
(WB) Mice 
 
 Whole Muscle Bcl-2 Protein– Untrained MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.59 0.22 0.31 0.24 
2 0.84 0.16 0.45 1.09 
3 0.86 0.52 0.61 0.54 
4 0.54 0.46 0.34 0.88 
5 0.70 0.41 0.56 0.32 
6  0.30  0.81 
7  0.48   
8  0.36   
X 0.705 0.363 0.496 0.587 
SEM 0.064 0.0457 0.0910 0.129 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO 0.3422 2.954 ≤ 0.05 † 
MS:WT vs. WB:WT 0.2508 1.952 > 0.05 ns 
MS:WT vs. WB:KO 0.05882 0.4781 > 0.05 ns 
MS:KO vs. WB:WT -0.09135 0.7886 > 0.05 ns 
MS:KO vs. WB:KO -0.2834 2.582 > 0.05 ns 
WB:WT vs. WB:KO -0.1920 1.561 > 0.05 ns 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0049 ** Yes 
Substrate 0.8493 ns No 
Genotype/Training 0.3847 ns No 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.0202 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
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Figure 10F: Whole muscle p21 protein, untrained Muscle-Specific (MS) and Whole-Body 
(WB) Mice 
 
 Whole Muscle p21 Protein– Untrained MS versus WB 
Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.35 0.28 1.56 0.45 
2 0.23 0.29 1.18 0.23 
3 0.56 0.34 0.54 0.43 
4 0.46 0.28 1.18 0.78 
5 0.42 0.30 0.68 0.57 
6 0.51 0.24 0.95 0.15 
7    0.14 
8    0.11 
X 0.420 0.288 1.0154 0.357 
SEM 0.049 0.013 0.152 0.0854 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO 0.1317 0.9866 > 0.05 ns 
MS:WT vs. WB:WT -0.5948 4.455 ≤ 0.01 ¶¶ 
MS:WT vs. WB:KO 0.06267 0.5017 > 0.05 ns 
MS:KO vs. WB:WT -0.7266 5.441 ≤ 0.005 *** 
MS:KO vs. WB:KO -0.06907 0.5530 > 0.05 ns 
WB:WT vs. WB:KO 0.6575 5.264 ≤ 0.005 ††† 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.0088 ** Yes 
Substrate 0.0015 ** Yes 
Genotype/Training 0.0003 *** Yes 
 Unpaired T-test – MS WT UT versus KO UT 
P value 0.0240 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 11A: State 3 respiration in IMF mitochondria, untrained Muscle-Specific (MS) and 
Whole-Body (WB) Mice 
 State 3 Respiration (natoms O2/mg protein/min) – IMF 
Mitochondria – Untrained MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 106.21 88.48 61.28 18.35 
2 122.63 87.14 78.42 79.49 
3 94.36 79.44 44.38 60.10 
4 110.43 86.33 46.17 104.98 
5 120.03 78.36 60.22 65.81 
6 71.54 46.20 79.56 104.27 
7 73.03  91.24  
8   91.94  
X 99.747 77.658 69.151 72.167 
SEM 7.912 6.520 6.661 13.220 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO 22.09 1.765 > 0.05 ns 
MS:WT vs. WB:WT 30.60 2.629 > 0.05 ns 
MS:WT vs. WB:KO 27.58 2.204 > 0.05 ns 
MS:KO vs. WB:WT 8.507 0.7004 > 0.05 ns 
MS:KO vs. WB:KO 5.492 0.4229 > 0.05 ns 
WB:WT vs. WB:KO -3.015 0.2483 > 0.05 ns 
 
 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.1634 ns No 
Substrate 0.0499 * Yes 
Genotype/Training 0.2854 ns No 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0549 
P value summary † 
Significantly different? (P<0.05) Yes 
Unpaired T-test – MS WT UT versus WB WT UT 
P value 0.0106 
P value summary ¶ 
Significantly different? (P<0.05) Yes 
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Figure 11B: State 3 reactive oxygen species (ROS) emission in IMF mitochondria, 
untrained Muscle-Specific (MS) and Whole-Body (WB) Mice 
 State 3 ROS (natoms O2/mg protein/min) – IMF Mitochondria – 
Untrained MS versus WB Mice 
 Muscle Specific Mice Whole Body Mice 
N WT mKO WT KO 
1 0.78 1.19 1.03 0.92 
2 0.60 1.05 1.20 1.04 
3 0.85 1.09 0.94 3.24 
4 0.66 1.38 0.77 1.11 
5 0.40 1.58 1.24 0.86 
6 1.38 1.35 0.93 1.08 
7 0.94 3.80 0.70 0.98 
8 0.35 1.15 0.65  
X 0.745 1.574 0.933 1.319 
SEM 0.116 0.324 0.0774 0.322 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO -0.8288 2.559 > 0.05 ns 
MS:WT vs. WB:WT -0.1875 0.5790 > 0.05 ns 
MS:WT vs. WB:KO -0.5736 1.711 > 0.05 ns 
MS:KO vs. WB:WT 0.6413 1.980 > 0.05 ns 
MS:KO vs. WB:KO 0.2552 0.7613 > 0.05 ns 
WB:WT vs. WB:KO -0.3861 1.152 > 0.05 ns 
 
 
 
 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.3506 ns No 
Substrate 0.8856 ns No 
Genotype/Training 0.0147 * Yes 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0304 
P value summary † 
Significantly different? (P<0.05) Yes 
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Figure 11C: Cytochrome c protein release from IMF mitochondria under basal conditions, 
untrained Muscle-Specific (MS) and Whole-Body (WB) Mice 
 Cytochrome C Protein Release – Basal - IMF 
Mitochondria 
 Muscle Specific Mice Whole Body Mice 
N WT UT KO UT WT UT KO T 
1 14777.075 11805.23 8882.55 4828.72 
2 10879.30 876.77 5446.012 5942.84 
3 5276.39 8269.96 8798.84 821.31 
4 10847.033 7693.74 10278.13 4366.74 
5 12690.50 15333.42 9556.74 7076.21 
6 16205.13 840.96 16467.20 4715.72 
7 13608.81 10962.15  
 8  10698.42  
9  2861.15   
10  790.69   
11  9118.45   
12  3422.40   
13  1381.96   
14 
 
11137.79  
 X 12040.605 6799.506 9904.910 4625.255 
SEM 1347.328 1327.0812 1477.323 862.741 
 
 
 
 
 
Post-Hoc Test 
Bonferroni Mean Diff. t-value P-value Summary 
MS:WT vs. MS:KO 5241 2.770 > 0.05 ns 
MS:WT vs. WB:WT 2136 0.9391 > 0.05 ns 
MS:WT vs. WB:KO 7415 3.261 ≤ 0.05 * 
MS:KO vs. WB:WT -3105 1.557 > 0.05 ns 
MS:KO vs. WB:KO 2174 1.090 > 0.05 ns 
WB:WT vs. WB:KO 5280 2.237 > 0.05 ns 
 
 
Two-Way ANOVA 
Source of Variation P value P value summary Significance 
Interaction 0.9899 ns No 
Substrate 0.1649 ns No 
Genotype/Training 0.0016 ** Yes 
Unpaired T-test – MS WT UT versus KO UT 
P value 0.0228 
P value summary † 
Significantly different? (P<0.05) Yes 
Unpaired T-test – WB WT UT versus KO UT 
P value 0.0115 
P value summary † 
Significantly different? (P<0.05) Yes 
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Fischerbrand Animal Ear-Punch 
and Tags tool (13-812-201) 
Appendix D: Laboratory Methods and Protocols 
Genotyping – p53 Whole Body mice and Muscle Specific Mice 
 
Reagents: 
1. Proteinase K (Pro K) from Tritirachium Album (Sigma-Aldrich, cat#: P6556-100 
mg). Store at -20°C 
2. Sterile Molecular Grade Water (Wisent Inc., cat#: 809-115-66). Store at room 
temperature. 
3. Lysis Buffer for DNA Extraction: Measure out 10 mM TRIS HCl (0.121g/100 mL) 
(Hydroxymethyl) Aminomethane (TRIS), Bioshop, cat#: 77-86-1, store at room 
temperature), 150 mM NaCl (0.8766g/100 mL) (Sodium Chloride, Bioshop, cat#: 7647-
14-5, stored at room temperature), and 20 mM EDTA (0.744g/100 mL) (Bioshop, cat#: 
6381-92-6, store at room temperature) and add the appropriate amount of ddH2O 
depending on measurements. Then pH to 8.0. Autoclave for 30 min and store at room 
temperature. 
4. Jumpstart REDTaq ReadyMix Reaction Mix for PCR (cat#: P0982-100RXN, Sigma 
Life Sciences, Store at -20°C).  
5. Mineral Oil (PE Express, material#: 01862302, cat#: 87200827, Store at room 
temperature). 
6. 1.5% Agarose (Bioshop, cat#: 9012-36-6). Store at room temperature. 
7. 50X TAE: Weigh out 242 g TRIS (Hydroxymethyl) Aminomethane (TRIS), Bioshop, 
cat#: 77-86-1, store at room temperature), add 500 mL ddH2O, add 57.1 mL Acetic Acid 
(Glacial, cat#64-19-7, stored at room temperature) into a beaker. Then prepare the 0.5M 
EDTA by adding 93.06 g of EDTA (Bioshop, cat#: 6381-92-6, store at room 
temperature) in 300 mL ddH2O, pH with NAOH to 8.0; volume up to 500 mL total. Then 
add 100 mL of the EDTA solution to the beaker with TRIS, ddH2O, and acetic acid. 
Autoclave and split the solution into sterile bottles. 
a. 1X TAE: Combine 80 mL of 50X TAE with 4 L of ddH2O. 
8. Ethidium Bromide (Sigma-Aldrich, cat#: E-8751). Store at 4°C. Make 10 mg/mL of 
ddH2O.  
Procedure: 
1. Prepare sterile 1.5 mL (MCT Graduated Natural Eppendorfs; cat# 05-
408-129; Fischer Brand) labeled eppendorf tubes on ice.  
2. Obtain a small ear clipping from each mouse using an ear-punch tool. 
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Mice should be held by pinching the skin along the spine and pulling back to prevent 
movement. Clippings should be placed in specified eppendorfs and placed on ice. 
3. Next prepare a fresh mixture of ProK by first measuring out approximately 1 mg of ProK 
and adding the associated ratio of 1000 µl of sterile ddH2O. If more ProK is added, add 
the correct ratio of water (i.e. 1.3 mg ProK to 1300 µl sterile ddH2O). 
4. Then make a 9:1 mixture of lysis buffer to the ProK solution made in step 3. This can be 
accomplished by adding 900 µl of lysis buffer and 100 µl of ProK solution to a new 
sterile 1.5 ml eppendorf. Vortex (Mini Vortex, cat#: 02215365, Fischer Scientific) this 
new ProK/Lysis buffer solution. 
5. Then add 20 µl of this ProK/Lysis buffer solution to each of the eppendorfs containing 
the ear clipping. Ensure that the ear clipping is submerged in solution. Then vortex to mix 
the solution with the ear clipping and tap the eppendorf on the bench to bring the ear 
clipping into the solution at the bottom of the eppendorf.  
6. Next, incubate the ear clipping and solution in the 55°C water bath (model 1122S, cat#: 
13271-138, VWR) for 30 min. Eppendorfs should be placed in floating foam pads. After 
the initial 15 min, take the ear clippings out of the water bath and vortex. Tap again to 
ensure the clipping is submerged in the fluid at the bottom of the eppendorf. Place back 
in the water bath for the remaining 15 min. Once completed, vortex one last time and 
place tubes on ice.  
7. Then add 180 µl of sterile ddH2O to each of the ear clipping containing eppendorfs and 
mix up and down with the pipette.  
8. Finally, place the tubes on the hot plate (VWR Block Heater, cat#: 12621-104) set to~95-
100°C for 5 min. Once completed, briefly tap the tubes to mix. 
9. Then store at -20°C or use immediately for PCR. 
 
PCR-Amplification Procedure: 
1. The mastermix solution must first be created. This solution contains the specific primers 
required for mouse breed/brand. This information can be found on the animal companies 
website. Three different mastermixes were required as there were three mouse 
breed/brand (p53 muscle specific mice (donated by Dr. Christopher Adams), Taconic p53 
whole body mice (Donehower et al., Nature, 1992), Jackson p53 whole body mice 
(B6.129S2-Trp53<tm1Tyj>/J)). Mastermix contains: *solutions are made either in 1.5 
mL sterile eppendorfs or sterile 15 mL polystyrene conical tubes (cat#: 352095, Falcon). 
a. Jumpstart Taq Polymerase *added first  
b. Sterile ddH2O *added second 
c. Forward and Reverse primers for specific mouse brand * add last 
i. Taconic p53 Mice:  
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1. p53 WT Reverse: ATGGGAGGCTGCCAGTCCTAACCC 
2. p53 WT Forward: GTGTTTCATTAGTTCCCCACCTTGAC 
3. p53 KO Reverse: TTTACGGAGCCCTGGCGCTCGATGT 
4. p53 KO Forward: GGGAATTCTGGGACAGCCAAGTCTGT 
ii. p53 Muscle Specific Mice *Cre Recombinase (~357 bp band) 
1. Cre Forward: TGCAACGAGTGATGAGGTTC 
2. Cre Reverse: ACGAACCTGGTCGAAATCAG 
iii. p53 Jackson Mice (Mutant band = 110 bp, HT = 110 & 321 bp, WT = 321 
bp) 
1. Common: TGGATGGTGGTATACTCAGAGC 
2. Mutant Forward: CAGCCTCTGTTCCACATACACT 
3. Wild Type Forward: AGGCTTAGAGGTGCAAGCTG 
2. Prior to using the primers, the primers had to be diluted to a 500 µmol concentration 
according to the equation X/1000/500*1000*1000 where x equals the nmol concentration 
on the primer ordered from customdna@sial.com, and the value of this equation is the 
amount of sterile ddH2O required to add in the primer bottle. Mix up and down 
repetitively for one minute.  
3. To get a 50µM stock, in a sterile 1.5 ml eppendorf, add 180 µl of sterile ddH2O and 20 µl 
of the 500 µM primer stock. 
 
** FULL MASTERMIX PLAN CAN BE OBSERVED BELOW** 
 
 
 
4. Next, label 0.5 mL Flat-Cap PCR Tubes (cat#: 87-C500-F, Ultident Scientific) 
microcentrifuge eppendorfs for each sample. If WT and KO primers exist such as for the 
               p53 Taconic Mice                         p53 Muscle Specific Mice                       p53 Jackson Mice 
50 
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Taconic mice, two sets of tubes are required (one with the WT primers and one with the 
KO primers). For the muscle specific and Jackson mice, all primers go into one tube. 
5. Then add the appropriate amount of mastermix to the 0.5 mL “mini” eppendorfs (30-48 
µl). 
6. Next add 20 µl of DNA from the ear clipping and solution eppendorf to the mastermix 
mini eppendorfs. Centrifuge the samples to ensure mixing using the eppendorf centrifuge 
54150 (Brinkmann Instruments, 5425-41150) machine.  
7. Add two drops of mineral oil to each tube to prevent evaporation of solution during PCR 
amplification cycling.  
8. Turn on the DNA Thermal Cycler (Perkin Elmer, model TC480) and place the mini 
eppendorfs inside the rack. Cycling times are different for each mouse breed/brand and 
must be set appropriately: 
a. p53 Taconic Mice: 
Initial Denaturing: 94° C for 2 min 
Amplification Cycles:  Denaturing Æ 95°C for 30 sec 
    Annealing Æ 60°C for 30 sec 
    Extension Æ 72°C for 45 sec 
Final Extension: 72°C for 5 min 
Hold at 4°C 
b. p53 Muscle Specific Mice:  
Initial Denaturing: 94° C for 3 min 
Amplification Cycles:  Denaturing Æ 94°C for 30 sec  
    Annealing Æ 56°C for 1 min 
       Extension Æ 72°C for 1 min 
Final Extension: 72°C for 2 min 
Hold at 4 °C 
c. p53 Jackson Mice:  
Initial Denaturing: 94° C for 2 min 
1st Amplification Cycle:  Denaturing Æ 94°C for 20 sec  
    Annealing Æ 65°C for 15 sec 
       Extension Æ 68°C for 10 sec 
2nd Amplification Cycle:  Denaturing Æ 94°C for 15 sec  
    Annealing Æ 60°C for 15 sec 
       Extension Æ 72°C for 10 sec 
Final Extension: 72°C for 2 min 
Hold at 10 °C 
 
9. Near the end of the PCR amplification, you can begin preparing the agarose gel required 
to visualize the genotype. The gel is prepared using the following recipe and ratio 
measured into an 500 mL Erlenmeyer flask: 
a. 1.5 g of 1.5% Agarose 
b. 3 mL of 50X TAE  
35 cycles 
35 cycles 
10 cycles 
28 cycles 
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c. 150 mL of sterile ddH2O 
d. 25 µl of Ethidium Bromide ** added last to solidify the gel. Add once the mixture 
has cooled. 
**these volumes are for a small gel. For one larger gel, double this amount. For two large 
gels, triple this amount. 
10. Microwave the mixture (Agarose powder, TAE, sterile ddH2O) for 2 min, adding 30 
second intervals until no more bubbles or opaque powder is visualize. Once sufficiently 
heated and mixed, leave on a stir plate (A. Thermo Scientific, model# S131125Q; B. 
Fischer Scientific, cat#: 11-000-49S; C. Fischer Scientific, cat# 11-600-49S) with a 
stirring rod to let it cool.  
11. In the meantime, set up the electrophoresis machine (BioRad PowerPac HC, serial# 
043BR59656) and apparatus (Electrophoresis Systems Large Horizontal System, FB-SB-
2025, Fischer Scientific). Make sure the black end is at the back – this is the direction of 
the current so that it moves down the gel). Once ready and the solution is warm to the 
touch, add the ethidium bromide. Seal in the chamber of the apparatus to prevent any 
leakage and allow time to solidify. Once the seal is solidified, pour in the remainder of 
the solution. Add in the well comb. The solution will turn opaque once solidified.  
12. Once solidified, pour 50x TAE around the gel so that it is submerged. Remove the well 
comb. 
13. When the samples in the PCR machine are finished their cycles, remove the samples. 
Using a glass pipette (50 µl Hamilton glass syringe, cat# 1482432), pipette 30 µl of the 
sample into the wells of the gel.  
14. Run the gel at 150-180 V until the sample has visually run approximately ¾ the length of 
the gel. Turn off the machine once at the appropriate distance. 
15. Remove the gel and place on an imager (Bio/CAN Scientific, model# 3-3035) to view the 
genotype of the samples. Record values.  
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Example of gels: 
 
p53 Muscle Specific Mice 
 
 
p53 Taconic Mice 
 
 
p53 Jackson Mice 
 
To visualize the molecular weights on the gel, use a 1 Kb DNA Ladder (Frogga Bio – BIO-
HELIX, Cat # DM010-R500). 
 
 
 
 
 
WT    WT   WT   WT   KO    WT   WT   WT  KO  WT 
 
HT           HT          HT         WT        HT          HT        WT          HT          HT          HT          KO         HT  
 
HT     HT   HT    WT  KO   HT    HT   HT    HT   WT   HT   HT    HT    KO   HT   WT   HT   HT    KO   HT 
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 Mitochondrial Isolations from Skeletal Muscle 
 
References:  Cogswell et al. Am J Physiol, 1993, 264: C388-C389; Krieger et al. J Appl Physiol, 
1980, 48: 23-28 
Reagents: 
1. Potassium Chloride (KCl) (Sigma-Aldrich, cat#: P3911-1kg, store at room 
temperature). 
2. Magnesium Sulfate Certified Anhydrous (MgSO4) (Fischer Scientific, cat#: M65-500, 
store at room temperature). 
3. Disodium Salt, Dihydrate (EDTA) (Bioshop, cat#: 6381-92-6, store at room 
temperature).  
4. Tris (Hydroxymethyl) Aminomethane (TRIS) (Bioshop, cat#: 77-86-1, store at room 
temperature). 
5. Adenosine 5’-Triphosphate Disodium Salt Hydrate (ATP) (Sigma-Aldrich, cat#: 
A7699-10G, store at -20°C) 
6. Ethylene glycol-bis (2-amino-ethylether)- N, N, N, N’- tetraacetic acid (EGTA) 
(Sigma-Aldrich, E4378-100C, store at room temperature). 
7. 3-(N-morpholino) propanesulfonic acid (MOPS) (Bioshop, cat# 1132-61-2, store at 
room temperature).  
8. Bovine Serum Albumin (BSA) (Sigma-Aldrich, cat#: A2153-50G, store at 4°C). 
9. Sucrose (C2H22O11) (Caledon Laboratories Inc., cat# 8270-1, store at room temperature). 
10. Potassium Phosphate (K2HPO4) (Fischer Scientific, cat#: P288-500, store at room 
temperature). 
11. Protease from Bacillus licheniformis (Nagarse) (Sigma-Aldrich, cat#: P-5380-1G, 
store at -20°C). 
 
Preparation:  
1. Prepare one glass scintillation vial per mouse analyzed and fill with buffer 1. 
Label. 
2. Label two 1.5 mL eppendorfs (MCT Graduated Natural Eppendorfs; cat# 05-
408-129; Fischer Brand) for SS and IMF subfractions per mouse.  
3. Prepare mitochondrial isolation buffers (only good for one week). Prepared in appropriate 
sized flasks. First measure out each powder into a labelled beaker. Add less volume of 
ddH2O than final volume listed. pH to 7.4 for all solutions. Then pour solution into 
graduated cylinder and volume up to the appropriate volume listed. Pour into the labelled 
flask and store at 4°C. 
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Buffer 1        
100 mM KCl       0.745 g 1.863 g 3.725 g 
5 mM MgSO4      0.06 g  0.15 g  0.30 g 
5 mM EDTA       0.186 g 0.465 g 0.93 g 
50 mM Tris base      0.604 g 1.51 g  3.02 g 
 
Buffer 1 + ATP 
100 mM KCl      0.745 g 1.863 g 3.725 g  
5 mM MgSO4      0.06 g  0.15 g  0.30 g 
5 mM EDTA      0.186 g 0.465 g 0.93 g 
50 mM Tris base     0.604 g 1.51 g  3.02 g 
1 mM ATP       0.055 g 0.138 g 0.275 g 
 
Buffer 2 
100 mM KCl      0.745 g 3.725 g 7.45 g 
5 mM MgSO4      0.06 g   0.300 g  0.600 g 
5 mM EGTA       0.19 g  0.95 g  1.900 g 
1 mM ATP      0.055 g 0.275 g 0.550 g 
50 mM Tris Base     0.604 g 3.02 g  6.040 g 
 
Resuspension Buffer 
100 mM KCl      0.075 g 0.15 g  0.45 g 
10 mM MOPS      0.021 g 0.042 g 0.063 g 
0.2% BSA       0.02 g  0.04 g  0.120 g 
 
VO2 Buffer 
250 mM sucrose      1.71 g  3.42 g  5.13 g 
50 mM KCl      0.074 g 0.148 g 0.222 g 
25 mM Tris Base     0.06 g  0.12 g  0.18 g 
10 mM K2HPO4      0.034 g 0.068 g 0.104 g 
 
Procedure: 
 
1. Obtain all hindlimb and forelimb muscle masses and place into the Buffer 1 scintillation 
vial at the time of extraction. Must be kept on ice. 
2. Next, place the tissue onto a curved watch glass dish on ice. Dab away extra Buffer 1 
solution. Trim away any fat and connective tissue. Then using tweezers and scissors, 
proceed mince the muscle with forceps and scissors until it resembles the consistency of 
jam and no large pieces remain.  
3. Prepare a 50 mL plastic centrifuge tube (Nalgene, Thermo Scientific, cat#: 3119-0050) 
with 2 mL of Buffer 1 + ATP. Zero the scale using this filled plastic tube. Then place the 
minced tissue into the vial using the tweezers, ensuring that it is placed within the liquid 
at the bottom. Then place on the scale (Mettler-Toledo Scale, Fischer Scientific, cat#: 
MS104TS) to record the final weight. Volume up with Buffer 1 + ATP (i.e. if weight of 
100 mL  250 mL  500 mL 
100 mL  500 mL  1000 mL 
10 mL  20 mL  60 mL 
20 mL  40 mL  60 mL 
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minced tissue is 895 mg Æ 0.895 g Æ 10 x mince tissue = 8.95 mL; 8.95 mL – 2 mL 
(previously added) = 6.95 mL Buffer 1+ATP to now add to volume up). 
4. Next, homogenize with the IKA T25 Digital Ultra-Turrax polytron machine (model# 
T25DS1) at 40% power output (9.8 Hz) for 10 seconds moving the tube around rapidly. 
Between samples, rinse the homogenizing tip with ddH2O.  
5. Then place the plastic centrifuge tube into the Beckman JA 25.50 rotor and spin in the 
ultracentrifuge (Beckman Coulter Avanti J-25 Centrifuge, Sys ID: 297812, CAN: 
605169-AA) at 800 g for 10 min. This step divides the IMF and SS mitochondrial 
subfractions. The supernate will contain the SS mitochondria and the pellet will contain 
the IMF mitochondria. 
* SS and IMF Isolations are performed simultaneously  
 
SS Mitochondrial Isolation: 
1. Filter the supernate through a double layer of cheesecloth gauze into a second set of 50 
ml plastic centrifuge tubes.  
2. Spin tubes at 9000 g for 10 min. Upon completion of the spin discard the supernate and 
gently resuspend the pellet in 3.5 ml of Buffer 1 + ATP with a p-1000. Since the 
mitochondria are easily damaged, it is important that the resuspension of the pellet is 
done carefully.  
3. Repeat the centifugation of the previous step (9000 g for 10 min) and discard the 
supernate.  
4. Resuspend the pellet in 100 μl of Resuspension medium (using the p-200 to dispense the 
100 μl; use the p-1000 to resuspend), being gentle so as to prevent damage to the SS 
mitochondria. Some extra time is needed during this final resuspension to ensure the SS 
pellet is completely resuspended (there should be no large chunks left).  
5. Keep the SS samples on ice while proceeding to islolate the IMF subfraction.  
 
IMF mitochondrial isolation: 
1. Gently resuspend the pellet (from step 5) in a 10-fold dilution of Buffer 1 + ATP using a 
teflon pestle (i.e. if the weight of the minced tissue is 0.895 g Æ 10 x mince = 8.95 mL to 
add). Pour in the 10-fold dilution and then use the P-1000 to spray the pellet gentle of the 
wall. Once off, use the pestle to lightly break apart the pellet. 
2. Using the Ultra-Turrax polytron set at 40% power output (9.8 Hz), homogenize and mix 
around the resuspended pellet for 10 sec. Rinse the shaft with ddH2O in between samples.  
3. Spin at 800 g for 10 min. Discard the resulting supernate.  
4. Resuspend the pellet in a 10-fold dilution of Buffer 2 (i.e. 8.95 mL). Use the p-1000 to 
lift the pellet of the wall and then use the teflon pestle to lightly break apart the pellet. 
5. Next, add the appropriate amount of nagarse which is 25x the minced weight. To make 
the nagarse solution, weigh out between 7 – 10 mg nagarse into a 1.5 ml eppendorf and 
then add the appropriate ratio of Buffer 2. For example, if 9.8 mg of nagarse is weighed 
out, add 980 μl of Buffer 2. Then add this solution to the plastic centrifuge tube. For 
example, if the amount of tissue you have is 895 mg Æ 0.895 g Æ 0.895 x 25 = 22.375 μl 
of the nagarse solution. The calculation for the appropriate volume is 0.025 ml/g of 
tissue. Mix gently back and forth 3-4 times and let it lie flat on ice for exactly 5 min. 
Every 1 min, gentle 3-4 times mix the tube back and forth. 
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6. After the 5 min, dilute the nagarse by adding 20 ml of Buffer 2. Mix back and forth 3-4 
times. 
7. Then, spin the diluted samples at 5000 g for 5 min. Discard the resulting supernate.  
8. Resuspend the pellet in a 10-fold dilution of Buffer 2 (i.e 8.95 mL). Use the P-1000 to lift 
the pellet off the wall and then gently resuspend with a teflon pestle until the pellet is 
broken down.  
9. Spin the samples at 800 g for 15 min.  
10. Upon the completion of the spin, the supernate is poured into a new set of 50 ml plastic 
tubes (on ice); the pellet is discarded.  
11. Spin the supernate at 9000 g for 10 min. The supernate is then discarded and the pellet is 
resuspended in 3.5 ml of Buffer 2. Use the p-1000 to lift the pellet off the wall and then 
mix up and down with the p-1000 to break apart the pellet. 
12. Spin samples at 9000 g for 10 min. Discard the supernate.  
13. Gently resuspend the pellet in 200 μl of Resuspension medium (use the p-200 to deliver 
the resuspension buffer and use the p-1000 to break down the pellet until no large pieces 
remain). 
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Mitochondrial Respiration 
 
Reference: Estabrook, R.W., Meth. Enzymol., 10: 41-47 (1967) 
The rate of mitochondrial respiration is an important consideration in the biochemical 
analysis of mitochondria.  There are three phases of interest in analyzing the respiratory ability of 
mitochondria.  Mitochondria produce ATP in the presence of oxygen.  The respiratory ability of 
the freshly isolated IMF and SS mitochondrial fractions and the homogenates can be illustrated 
by measuring the rate of oxygen consumption using a Clark oxygen electrode in the presence of 
a) the substrate alone (e.g. glutamate for state 4 or resting respiration); b) ADP, (state 3 or active 
respiration); and c) NADH+, which is used to measure the amount of damage that has occurred to 
the mitochondria, since the inner membrane is impermeable to NADH+. 
Reagents (prepare first): 
1. VO2 Buffer for muscle mitochondria (please see instructions to make this buffer in the 
mitochondrial isolation protocol). Leave in the 4°C fridge until ready to use. Take out 30 
min before use to allow it to reach room temperature. 
2. Glutamate: measure 123.34 mg of glutamate (L-glutamic acid potassium salt monohydrate, 
Sigma-Aldrich, cat#: G1501-100G, Store at room temperature)   into a 1.5 mL eppendorf 
(MCT Graduated Natural Eppendorfs; cat# 05-408-129; Fischer Brand). Add 1 mL of 
ddH2O. Vortex (Mini Vortex, cat#: 02215365, Fischer Scientific) to ensure adequate mixing. 
The final concentration will be a 11.1 mM solution. Discard after use.  
3. ADP: measure 11.29 mg of ADP (Adenosine 5’-diphosphate sodium salt, Sigma-Aldrich, 
cat#: A2754-500 mg, store at -20°C) into a 1.5 mL eppendorf. Add 1 mL of ddH2O. Vortex 
to ensure adequate mixing. The final concentration will be a 0.44 mM solution. Discard after 
use. 
4. NADH: measure 30 mg of NADH (β-nicotinamide adenine dinucleotide reduced disodium 
salt hydrate, Sigma-Aldrich, cat#: N8129-1G, store at -20°C)   into a 1.5 mL eppendorf. Add 
250 µl of ddH2O. Vortex to ensure adequate mixing. The final concentration will be a 2.8 
mM solution. Discard after use. 
 
 Procedure: 
1. Set the water bath to 25-30oC. Turn this on prior to opening the system. Take out the VO2 
buffer 30 min prior to using to allow to reach room temperature. 
2. Then turn on the computer. Go to START Æ Windows Virtual PC Æ Windows XP mode. 
Turn on the Strathkelvin 928 Oxygen Meter System (Strathkelvin Instruments, Model 782, 
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serial# 2214) and ensure that it is plugged into the computer. Go to USB Æ Attach 782 Æ 
Open 782 Oxygen System Æ Open Experiment. 
3. Then take off the parafilm cover on the Clark oxygen electrode (Strathkelvin Instruments, 
Mitocell-MT200, serial# 2158). Clean out the chamber with ddH2O and suction repeatedly 
(~3 times). Prepare the respiration glass 25 µl Hamilton glass syringe, mini stir bar, metal 
rod to remove the stir bar and plastic stopper. 
4. Into the electrode, add 250 µl of VO2 Buffer and then very slowly add 50 µl of the 
mitochondrial subfraction (add slow to not damage the mitochondria). Insert the stir bar and 
press the button on the electrode to turn on. Then insert the rubber stopper slowly making 
sure the volume that moves up the stopper is about half-way up canula in the centre of the 
stopper.  
5. Then calibrate: Set-up Experiment Æ Calibrate Æ Calibrate High Æ Continue 
a. Will take approximately 1 min to calibrate. Then click Accept Values Æ Calibration 
Complete Æ press START 
6. Let the electrode run for the first 2 minutes. This is the drift which analyzes basal 
mitochondrial respiration.  
7. After 2 minutes, you will then pick up 5 µl of the glutamate solution with the 25 µl Hamilton 
glass syringe and insert the syringe through the canula into the solution located at the base of 
the electrode. Make sure not to touch the stir bar as it could stall. Then press MARKER and 
type in glutamate to identify where is has been added. Then let it run with glutamate for 2 
min. This is STATE 4 RESPIRATION. 
8. After 2 minutes, you will then pick up 5 µl of the ADP solution with the 25 µl Hamilton 
glass syringe and insert the syringe through the canula into the solution located at the base of 
the electrode. Make sure not to touch the stir bar as it could stall. Then press MARKER and 
type in ADP to identify where is has been added. Then let it run with ADP for 2 min. This is 
STATE 3 RESPIRATION. 
9. After 2 minutes, you will then pick up 5 µl of the NADH solution with the 25 µl Hamilton 
glass syringe and insert the syringe through the canula into the solution located at the base of 
the electrode. Make sure not to touch the stir bar as it could stall. Then press MARKER and 
type in NADH to identify where is has been added. Then let it run with NADH for 2 min. 
This is a control check to assess the integrity of the mitochondria. If NADH decreases 
rapidly, it may mean that the mitochondria may have been damaged during the process of 
extraction. If the mitochondria are intact and function, the graph will run at a slight decline 
in this section. 
10. Once the 8-10 minute run is complete, press STOP and save the file (go to respiration and 
save under appropriate folder). 
11. Stop the electrode by pressing the button, this will turn off the stir bar. Take out the stopper 
and then remove the stir bar with the metal rod. Wipe both the stopper and stir bar dry. Then 
suction out the VO2 Buffer/Mitochondria out and rinse with ddH2O 3 times with suction.  
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12. At the end of the entire analysis, put away the stopper, stir bar, metal rod, and glass syringe. 
Turn off the electrode and the computer system. Fill up the electrode with ddH2O and then 
place parafilm  laboratory film (Bemis, PM-996) over the lid to cover.  
a. File Æ Exit from Program Æ USB Æ Release 
13. Repeat from step 4 for the next mitochondrial subfraction. This is completed for both 
SS and IMF curves. Below is an example of the curve you will likely observe: 
 
 
 
 
 
 
 
 
 
 
Analysis: 
1. On the computer that is used for respiration with the clark electrode, open the Windows XP 
mode. Instead of clicking experiment this time, click ANALYZE. This will then take you to 
your previous respiration folder (click on the specific graph to analyze).  
2. A window will open where you will need to adjust the “edit experiment values”. 
Temperature = 30°C; Oxygen Consumption at Saturation = 28.5; Water Volume = 300 (for 
both text sections). Press Okay and your graph will automatically adjust. 
3. Open the excel spreadsheet and input the appropriate values into the red boxes below. Each 
animal should have both their SS and IMF analyzed. To input the values you are required to 
move the two sectional lines on the graph on the computer within the drift, glutamate, ADP 
and NADH sections to find a section that is 1 min in length and representative of that 
section. Input the time for the first line and the second line and the total time length. Each of 
these lines will have an associated %saturation value that you will then input for the start 
(first line) and end (second line). 
a. The difference in saturation is calculated by: Start % saturation – Final % 
saturation 
b. % saturation/min is calculated by: Saturation difference/time of line analysis 
c. Corrected %saturation/min is calculated by: (%saturation/min of glutamate OR 
ADP OR NADH)/ (%saturation/min of drift) 
Glut            ADP               NADH Glut          ADP          NADH 
IMF Curve SS Curve 
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d. Protein is calculated by: (Protein concentration from Bradford/5)*50 
e. Respiration Glutamate is calculated by: (Corrected %saturation/min for 
glutamate*1112.5)/Protein 
f. Respiration ADP is calculated by: (Corrected %saturation/min for 
ADP*1112.5)/Protein 
g. RCR is calculated by: Respiration ADP/Respiration glutamate 
i. RCR values need to be above 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCR 
RCR 
The units for respiration is expressed in units of natoms. Thus State 3 or 4/mg protein x 
968 natoms O2 = x natoms O2/mg protein/min. 
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Mitochondrial Reactive Oxygen Species (ROS) Emission 
 
Background: Mitochondria are the primary source of reactive oxygen species (ROS) to the cell.  
It is estimated that about 2% of total cellular oxygen is converted ROS by the inappropriate 
reduction of molecular oxygen by intermediate members of the electron transport chain (ETC).  
ROS are damaging molecules that are capable of compromising the integrity of macromolecules 
within the mitochondria and may lead to overall organelle dysfunction.  In particular, mtDNA 
may be prone to attack by ROS because 1) mtDNA is located in close proximity to the ETC, 2) 
mtDNA lacks the protective sheath of histones compared to nuclear DNA and, 3) mitochondria 
have an insufficient repair system for mtDNA mutations.   ROS can exist in a variety of 
molecular permutations such as superoxide  (O2-), hydroxyl radical (OH-) and hydrogen peroxide 
(H2O2).    
DCF (2,7,-dichloro-fluorescein; Fig.1) is a reagent that is non-fluorescent until the acetate groups 
are removed by intracellular esterases and oxidation occurs within the mitochondria (Fig.1).  
DCF is oxidized by all of the different forms of ROS and this can be detected by monitoring the 
increase in fluorescence with a fluorometric plate reader.  The appropriate plate reader filter 
settings for fluorescein are the following: Excitation 485/20 and Emission 528/20 (Fig.2).    
 
  Fig.1-DCF molecule and oxidation of DCF resulting in fluorescence 
    
 
 
 
Fig.2-Absorption and Emission Spectra of oxidized dye               
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Reagents: 
1. DCF (2,7,-dichlorodihydrofluorescein diacetate – H2DCFDA) reagent MW=487.29 (Life 
Technologies, cat#: 1871963, store at -20°) * very light sensitive when added to liquid 
a. Stock solution is made by measuring 24 mg into a 1.5 mL eppendorf (MCT 
Graduated Natural Eppendorfs; cat# 05-408-129; Fischer Brand). Then add 1 mL 
of 100% anhydrous ethanol (ethyl alcohol anhydrous, Commercial Alcohols, lot#: 
022933). Wrap the eppendorf in aluminum foil and vortex (Mini Vortex, cat#: 
02215365, Fischer Scientific) until no chunks are visible in the solution. This is to 
be stored at -20°C for multiple uses. 
b. Working solution (used for experiment and must be made fresh) is made by 
adding 990 µl of 100% anhydrous ethanol to a 1.5 mL eppendorf and then adding 
10 µl of the H2DCFDA stock solution. The eppendorf is immediately covered in 
aluminum foil and vortexed. 
2. VO2 Buffer: Refer to the mitochondrial isolation protocol for making this buffer. It should 
be left out for 20-30 minutes to stabilize to room temperature.  
3. Glutamate: measure 51.4 mg of Glutamate (L-glutamic acid potassium salt monohydrate, 
Sigma-Aldrich, cat#: G1501-100G, Store at room temperature) into a 1.5 mL eppendorf. 
Add 1 mL of ddH2O. Vortex to ensure adequate mixing.  
4. ADP: measure 4.69 mg of ADP (Adenosine 5’-diphosphate sodium salt, Sigma-Aldrich, 
cat#: A2754-500 mg, store at -20°C) into a 1.5 mL eppendorf. Add 1 mL of ddH2O. Vortex 
to ensure adequate mixing.  
Procedure: 
1. Prior to setting up the plate, the KC4 plate reader (Program KC4 V3.1 Rev 15, License#: 
5YNM-66P96) set up to the Synergy HT (BioTek) Plate Reader, must be prepared. The 
following are the parameters that need to be changed in order to utilize the DCF and 
measure time-dependent ROS production from isolated mitochondria: 
a. Open WIZARD to access the Reading Parameters Settings 
b. Reading Type: Options “End Point, Kinetic, Spectrum” - choose Kinetic 
i. Click on larger box labeled Kinetic to set parameters- Run Time 0:30:00, 
Interval time – for minimal interval time, measure every 3 minutes, 
click on box labeled Individual Well Auto Scaling- The Auto scaling 
allows for monitoring each individual well during the experiment and 
scales it appropriately. For the scales – click Auto for both options. 
c. Synergy HT-I On: Options “Absorbance, Fluorescence, Luminescence” – choose 
Fluorescence 
d. Then adjust the following options: 
i. Filter Set = choose #1 and set the excitation to 485/20 
ii. Emission = 528/20 
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iii. Optics Position= The optics position should be set to the TOP (i.e. 
readings are taken from the top of the well) 
iv. Sensitivity = set at 50 (depending upon the amount and/or nature of the 
sample). 
e. Plate-Type-choose 96-well plate (8 x 12), choose which wells are to be read i.e. 
C1-D9 
f. Shaking-Intensity set at 1, Duration set at 15s and then click the box that is 
labeled before every reading (it shakes the samples for 15 s before every 
reading). 
g. Temperature Control- Click on the box indicating YES, also click on box labeled 
pre-heating, and put 37°C into the temperature box. Once the heating is reached, 
and your plate is loaded with the mitochondrial sample and VO2 buffer, press start 
as the heating lamp will require an additional 2 minutes to reach temperature. 
During this time, rapidly add the glutamate, ADP and DCF. 
 
Procedure: 
Below is a typical pipette plan for layout. All mitochondrial concentrations obtained through a 
Bradford Assay must be divided by 5 first and then placed into the pipette plan in the [mito] 
column. 
 
1. SS and IMF mitochondria are isolated as described in the mitochondrial isolation 
protocol.  Only fresh mitochondria may be used for this functional assessment. 
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2. Prepare a solid white 96-well plate (96-nontreated white microwell SI, Thermo Scientific, 
cat#: 236105). In the specified rows add the appropriate level of VO2 Buffer to each well. 
Then add the mitochondria (SS and IMF) according to the volume as seen in the pipette 
plan. Remember to include a control with only VO2 buffer and DCF reagent as in Well 
#1 *at this point, begin the count-down timer for 2 min for heating the KC4 reader lamp. 
3. Next add 10 µl of the glutamate solution rapidly to all wells (both State 4 and 3 ROS). Do 
not change tips in between adding glutamate to each well.  
4. Next add 10 µl of the ADP solution rapidly to only State 3 ROS wells. Do not change tips 
in between adding ADP to each well.  
5. As the final concentration of DCF is 50 µM and the total volume of the reaction mixture 
is 250 µl, 25 µl of DCF is used in the reaction mixture since this represents a 10-fold 
dilution.  Add the DCF rapidly to the reaction mixture. Once added, immediately place 
the plate into the KC4 reader and press READ. 
6. Once completed, go to REPORT to print. Under Availab Data/Select add KINETIC 
CURVES and M485/528. Then click add to move to selected data, then print. Documents 
can be visualized below: 
 
Kinetic Curve 
 
 
 
 
 
 
 
 
Analysis of ROS: 
1. ROS is analyzed by inputting the following values in the pipette plan below. The initial 
reading on the chart (time 0) and the final reading on the chart (time 28:49) are put into 
the initial and final sections of the table and the difference is calculated. Example of the 
M458/528 is below:  
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2. Then values are corrected for respiration in the following pre-existing excel spreadsheet. The 
final values in the highlighted section are what is analyzed in graphpad.  
 
 
STATE III ROS 
 
CON 132 SS 133 SS 163 SS 164 SS 132 IMF 133 IMF 163 IMF 164 IMF 
Initial Value 2472 2828 2936 2941 3086 3419 3298 3235 3265 
Final Value 2930 13040 8616 9152 8875 9320 7351 7872 7990 
Difference 458 10212 5680 6211 5789 5901 4053 4637 4725 
STATE IV ROS 
 
CON 132 SS 133 SS 163 SS 164 SS 132 IMF 133 IMF 163 IMF 164 IMF 
Initial Value 2583 3084 3046 3061 3166 3553 3459 3336 3380 
Final Value 2906 8228 8142 10861 12888 9276 8019 8011 8667 
Difference 323 5144 5096 7800 9722 5723 4560 4675 5287 
0 min time point 
30 min time point 
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Equations: 
x State 4 & 3 Control, IMF and SS are the difference values inputted from the above chart. 
x Corrected 4 SS = State 4 SS – State 4 Control 
x Corrected 3 SS = State 3 SS – State 3 Control 
x Corrected 4 IMF = State 4 IMF – State 4 Control 
x Corrected 3 IMF = State 3 IMF – State 3 Control 
x State 4 & 3 SS resp and State 4 & 3 IMF resp values are the respiration values from the 
mitochondrial respiration procedure once quantified.  
x SS Corrected 4/ug = corrected 4 SS/75 (*repeat for IMF) 
x Corrected 3/ug = corrected 3 SS/75 (* repeat for IMF) 
x SS State 4 ROS = Corrected SS 4/ug /  SS state 4 resp 
x SS State 3 ROS = Corrected SS 3/ug   /   SS state 3 resp 
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Western Blotting 
 
Reagents: 
1. Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop, ACR010.500, store at 
4°C). 
2. Under Tris Buffer: Measure out 1 M of Tris-HCL (Tris (Hydroxymethyl) 
aminomethane, Bioshop, cat#: 77-86-1, stored at room temperature) which is 60.5 g into 
400 mL of ddH2O. Then, with acid, pH to 8.8. Volume up with ddH2O to a total of 500 
mL. Store at 4°C. 
a. 5N HCl Acid: Combine 82 mL of HCl (Caledon, 6025-1-29) with 118 mL 
ddH2O. Pour the acid over the water. 
3. Over Tris Buffer: Measure out 1 M of Tris-HCL (Tris (Hydroxymethyl) aminomethane, 
Bioshop, cat#: 77-86-1) which is 12.1 g into 80 mL of ddH2O. Then pH to 6.8. Add 
Bromophenol Blue (Electrophoresis Purity Reagent, Bio-Rad, cat# 161-0404, stores at 
room temperature) after pH is done for colour. Volume up with ddH2O to a total of 100 
mL. Store at 4°C. 
4. Ammonium Persulfate (APS) Buffer: Add10% (w/v) APS (Siglma-Aldrich, cat# 
A3678-25G, stored at room temperature) in ddH20 (1g/10mL ratio). Store at 4°C. 
5. Sodium Dodecyl Sulfate (SDS) Buffer: Add 10% (w/v) SDS (Bioshop, cat#: 151-21-3, 
stored at room temperature) in ddH20 (1g/10mL ratio). Store at room temperature 
(solidifies at 4°C). 
6. TEMED (N,N,N’,N’-tetramethyl-ethylenediamine) (Sigma-Aldrich, T-9281-50ml, 
stored at 4°C). 
7. Electrophoresis Buffer: Add 25mM Tris (30.34g), 192mM Glycine (144g) (Bioshop, 
56-40-6, stored at room temperature), 0.1% SDS (10g) into a large nalgene bucket. Add 4 
L of ddH2O and stir. Using the pH meter, pH to 8.3. Add acid very slowly, the buffer 
takes time to adjust to the pH. Then pour into the large jug containing 6 L of ddH2O for a 
total volume of 10L. Store at room temperature, 
8. Blocking Solution: 5% Skim Milk Powder, 10% Skim Milk Powder, stored at 4°C. 
a. 5% (w/v) skim milk powder (pasteurized instant skim milk powder, Loblaws/No 
Frills, stored at room temperature) in wash buffer (more common) OR 
i. For example, for 400 mL of blocking solution, measure out 20 mg. 
Calculate this by 400 x 0.05 = 20 mg skim milk powder to add. 
b. 5% (w/v) Bovine Serum Albumin (Sigma-Aldrich, cat#: A2153-50G, stored at 
4°C) in wash buffer 
9. Transfer Buffer: Measure out 0.025M TRIS (12.14g), 0.15M Glycine (45.05g), 20% 
methanol (800 mL) (CH3OH, Caledon, cat#: 6700-1-42, stored at room temperature). 
Add 4 L of ddH20 and leave it on the stirring plate to mix. Store at 4°C. 
10. Wash Buffer: Measure out TRIS (12 g), NaCl (58.5g) (Sodium Chloride, Bioshop, cat#: 
7647-14-5, stored at room temperature), and 0.1% TWEEN 20 (10 mL) (Sigma-Aldrich, 
cat#: P1379-500ml, stored at room temperature) into a large nalgene bucket. Add 4 L of 
ddH2O and stir. Using the pH meter, pH to 7.5. Add acid very slowly, the buffer takes 
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time to adjust to the pH. Then pour into the large jug containing 6 L of ddH2O for a total 
volume of 10L. Store at room temperature 
11. Sample Dye: Make up 40% of sucrose (C2H22O11) (Caledon Laboratories Inc., cat# 
8270-1) in electrophoresis buffer (4g / 10 mL buffer). Add a spatula tip-full of 
Bromophenol Blue (Electrophoresis Purity Reagent, Bio-Rad, cat# 161-0404, stores at 
room temperature) to obtain the colour required. Store in 1 mL aliquots at -20°C. 
12. Beta-mercaptoethanol (Sigma-Aldrich, M6250, stored at room temperature) 
13. 2X Lysis Buffer: Measure out 100% glycerol (heated) (50 mL) (Caledon, 5650-14-40), 
SDS (11.5 g), and 1M TRIS (weigh out 12.1 g TRIS/ 100 mL ddH2O, pH to 6.8, then add 
31.25 mL of this solution) and add 400 mL of ddH2O. Then pH to 6.8. Volume up with 
ddH2O to a total of 500 mL. Store at 4°C. 
14. 6X SDS (not used frequently): Warm 100% glycerol in water bath at 65°C for 30 
minutes. Measure out SDS (1.2 g), Bromophenol Blue (0.06 g), 1M Tris (weigh out 12.1 
g TRIS/ 100 mL ddH2O, pH to 6.8, then add 3 mL of this stock solution to the SDS and 
Bromophenol Blue) and ddH20 (1 mL) in a beaker. Then stir at 4°C for 5 minutes. Add 
the glycerol (6 mL) to the beaker, stir and aliquot the mixture. Store at -20°C. Add 5% 
(v/v) ß-mercaptoethanol to the 6X SDS just prior to use 
15. Ponceau Stain (Red): Measure out 0.1% (w/v) Ponceau S (200 mg) (Sigma-Aldrich, 
cat#: P3504-10G, stored at room temperature), 0.5% (v/v) Acetic Acid (10 mL) (Glacial, 
cat#64-19-7, stored at room temperature) and 94% ddH20 (190 mL). Store at room 
temperature. 
16. Butanol (2-methyl-2-butanol, Sigma-Aldrich, cat#:152463-1L, stored at room 
temperature) 
17. Enhanced Chemiluminescence Fluid (ECL) (Santa Cruz, cat#:sc-2048, stored at room 
temperature) 
18. Protein Ladder (Precision Plus Protein Kaleidoscope, Bio-Rad, cat#: 161-0375, stored 
at -20°C) 
19. Nitrocellulose Membrane (0.45µm, Bio-Rad, cat#:10484060, stored at room 
temperature) 
20. 1 X TBS: Dilute 10X TBS in a 1:10 ratio. For example, add 100 mL 10X TBS: 900 mL 
ddH2O. 
a. 10X TBS: Measure out NaCl (80 g) (Sodium Chloride, Bioshop, cat#: 7647-14-5, 
stored at room temperature), KCl (2 g) (Sigma-Aldrich, cat#: P3911-1kg, stored at 
room temperature), TRIS (30 g) in 900 mL of ddH20. Then pH to 7.4. Volume up 
for a total of 1000 mL or 1 L. Store at -4°C, 
21. Stripping Buffer: Measure TRIS (7.6 g), SDS (20 g), β-mercaptoethanol (7 mL) in 700 
mL of ddH20. pH to 6.8. Volume up for a total of 1000 mL or 1 L. Store at room 
temperature.  
* All Western Blot experimental equipment is from Bio-Rad 
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Procedure: 
1. Prepare electrophoresis separating gels: 
a. Clean 1.5 mm spacer plates (Glass Plates, Bio-Rad, cat# 1653312) and short glass 
plates (Short Plates, Bio-Rad, cat# 1653308) thoroughly with soap followed by a 
rinse with 95% wash ethanol. Let them dry naturally.  
b. Then assemble glass plates by attaching together the spacer plate and short plate 
and fit them into the green holder. In the gel holding rack, place sponges along the 
bottom grooves and then clip the green holder.  
c. Next, check the seal by adding ddH20 until the top, then pour off and dry the 
plates using air suction.  
d. Then prepare to make the separating gel according to the percentage and volume 
requirements listed below. These volumes are listed per one gel, multiply volumes 
by however many gels are being made. 
 
 8% 10% 12% 15% 18% 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
ddH20 4.1 ml 3.5 ml 2.8 ml 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100µl 100µl 100µl 100µl 100µl 
APS 100µl 100µl 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 10µl 10µl 
Benefits of making different percentage gels allows for greater separation of bands at certain 
molecular weights. For example, an 8 or 10% gel will cutoff around the 37 kDa mark and 
upwards, thus providing large separation for higher molecular weight proteins. On the other hand 
the 12 and 15% gels will allow for a full analysis of all of the molecular weight markers with 
greater separation occurring at the lower molecular weights.  
e. To a 200 mL beaker, add the solution volumes of the gel in order, adding first 
acrylamide, ddH2O, Under Tris, SDS, and APS. Place on the stir plate with a stir 
bar and allow to mix.  When ready to pour into the plate, add TEMED and let stir 
for 10 sec.  
f. Slowly pour the solution into the space between the two plates while keeping 
plates tilted to prevent bubble formation. Pour just above the first green line of the 
green holder. 
g. Then add 1000 µl of butanol to coat top surface of gel solution and prevent 
evaporation. 
h. Allow 30-40 minutes for gel polymerization. Keep the beaker with the remaining 
solution to observe when solidified. 
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i. Remove the butanol by pouring it off and remove any remainder with a small 
piece of whatman paper.  
j. Next, prepare the stacking gel by adding the following solutions below in order to 
a 50 mL beaker. Place on a stir plate with a stir bar until ready to use.  
 
 Large Volume (4-5 gels) Small Volume (2-3 gels) 
Acrylamide 1000 µl 500 µl 
Over Tris 1.25 mL 625 µl 
ddH20 7.5 mL 3.75 mL 
SDS 100 µl 50 µl 
APS 100 µl 50 µl 
TEMED 15 µl 7.5 µl 
k. When ready to pour into the plate, add TEMED and let stir for 10 sec. Then 
slowly pour until it overflows the space between the glass plates. 
l. Add 10 well or 15 well comb (Bio-Rad, 1.5 mm wells) for the desired number of 
wells. 
m. Allow ~40 minutes for gel polymerization. 
n. Once solidified, wrap each gel in wet paper towel and cover with plastic wrap to 
prevent gel dehydration. Store at 4°C. Good for 2-3 days stored.  
 
2. Preparation of samples: 
a. Taking the concentration of the sample from the Bradford assay, place into the 
“protein for 5 ul” row in the pipette plan observed below. Adjust the total protein 
used. The more total protein, the greater the concentration and thus increased 
density of the bands.  
i. Protein ug/ul =  Protein for 5 ul / 5 
ii. Total protein = Protein Concentration (40) / Protein ug/ul 
iii. 2X lysis buffer = total protein 
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b. Prepare 1.5 mL eppendorfs (MCT Graduated Natural Eppendorfs; cat# 05-408-
129; Fischer Brand) labelled with the appropriate sample ID.  
c. Prepare the lysis buffer solution. Add a ratio of 475 µl 2x lysis buffer with 25 µl 
of beta mercaptoethanol. A larger ratio can be used of 950:50 µl if required. 
Vortex (Mini Vortex, cat#: 02215365, Fischer Scientific) to mix. 
d. Add the appropriate volume of lysis buffer solution to each labelled eppendorf. 
The volume of lysis buffer to sample is a 1:1 ratio. 
e. Next add the sample to the labelled eppendorfs. 
f. Lastly add 5 µl of sample dye to each tube.  
g. Briefly centrifuge each sample using the eppendorf centrifuge 54150 (Brinkmann 
Instruments, 5425-41150) machine to bring volume to the bottom of the 
eppendorf and to mix. 
h. Turn on the block heater to 95ºC and incubate each sample at 95 ºC for 5 minutes 
in the heating block to denature the proteins.  
i. Briefly spin again to return volume to the bottom of the eppendorf and store in the 
-20°C freezer until ready to use or use immediately.  
 
3. Assemble Mini-PROTEAN gel caster system: 
a. If one gel is only being run, a plastic rectangular pseudo 
plate (Buffer Dam, Bio-Rad) must be clamped on the 
other side of the gasket to still create the well. Place the correct way so that the 
ridges of the pseudo plate are facing towards the inside (or towards the gasket). If 
using two gels, fit appropriately so that the short place on either side is facing 
towards the inside of the gasket.   
b. Place the gasket apparatus with the gels into a plastic castor (2 gels = Mini-
Protean 3 Cell, Bio-Rad, cat#: 525BR-049940; 4 gels = Mini-Trans-Blot Cell, 
Bio-Rad, cat#: 153BR81099). The square castor is sufficient to hold two gels. 
However the rounded castor is sufficient to hold 4 gels. Two gaskets (one with 
pointed prong conductors and one with flat conductors) will be used, each able to 
hold two gels. 
c. Fill the castor with electrophoresis buffer by first filling in the well created 
between the plates, allowing the buffer to overflow and fill the rest of the castor. 
Fill to the top. ** very important that the well space between the plates is always 
filled to the top, otherwise the proteins may run down the gel on an angle.  
d. Slowly remove the comb using both hands (one on each side) by pulling the comb 
straight upwards.  
e. Rinse out each well with a small and gentle flush of electrophoresis buffer using a 
B-D (10 mL) syringe. Fix any wells that are deformed using the syringe. 
f. Place 13 µl of protein ladder into the first well. This allows you to visualize the 
molecular weights along the gel. 
g. Withdraw the entire volume of the sample using a 25 µl Hamilton syringe. Inject 
volume slowly into the bottom of the well, being careful of losing solution with 
bubbles that form. Then pick up 5-8 µl of the electrophoresis buffer and place 
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back into the empty eppendorf. Swirl around, then pick it up to obtain any leftover 
sample and place back into the same well.  
h. Once all the samples are loaded into the wells, refill the center well between the 
plates with more electrophoresis buffer so that it is overflowing.  
 
4. Gel electrophoresis  
a. Immediately after all samples are loaded place the lid on the gel chamber. 
b. Place positive (red) and negative (black) plugs into the power supply and turn on 
power supply. Ensure colour coding is correct. 
c. Set power supply to 120V. Gel will run for ~1.5- 2 hours depending on percent 
gel made. 
d. When the bromophenol blue sample dye has run off the bottom of the gel (or 
when gel has separated the desire amount) turn off the power supply to the 
electrophoresis machine. Remove plugs from power supply and remove lid. 
e. Prepare for electrotransfer of proteins from the gel to nitrocellulose membrane.  
 
 
5. Western Blotting Transfer 
a. Prior to shutting off the electrophoresis machine, prepare the following set-up 
i. Small rectangular glass dish with a test tube;  
ii. Paper towel with green wedge (Bio-Rad) and water bottle with a thin 
pipette tip attached; 
iii. Square dish containing Whatman paper (GE Healthcare-Life Sciences, 
cat#: 3030-917) sliced 8 ½ cm by 6 cm. You will need 6 pieces per gel, 
they must be placed in groups of 3 pieces; 
iv. Another square dish containing nitrocellulose membrane sliced 8 ½ cm by 
6 cm. You will need one membrane per gel; 
v. One plastic sandwhich Cassette per gel containing one thicker green 
sponge placed on the black side of the cassette and two thin black sponges 
placed on the clear side of the cassette; 
vi. Transfer buffer that has been refrigerated at 4°C; 
vii. Black and Red Transfer chamber with prongs, placed inside a 2-gel square 
castor. Place a stir bar at the bottom of the castor underneath the transfer 
chamber. Place the entire apparatus into a glass dish placed on a stir plate. 
b. Once set-up, shut off the electrophoresis machine and remove the electrophoresis 
glass plates from chamber. 
c. Lay the glass plate down on the paper towel and use the green wedge to lift 
between the plates, thus lifting away the short plate. With the wedge, cut away the 
stacking gel wells. 
d. Next, in the glass dish, place the cassette with the 
sponges so that the black side is facing down in the 
glass dish. Pour a small amount of transfer buffer 
over top and use the test tube (Corex 15 mL, cat#: 
8441) to roll out the thick green sponge with the 
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liquid. Then place a set of 3 Whatman paper onto the green sponge. Roll out to 
make flat. 
e. Then using the water bottle with the thin tip, gently slide under the gel and spray 
the water to lift the gel up off the 1.5 mm glass spacer plate. Go around all edges 
of the gel. Using the green wedge/spatula, lift under the ladder section of the gel 
and lift off the 1.5 mm spacer plate and lie flat along the Whatman paper on the 
cassette. The ladder on the gel MUST be on the right side. Roll out with the test 
tube gently to ensure the gel is flattened.  
f. Then, removing the protective blue sheets around the white nitrocellulose 
membrane, place the membrane directly over the gel. Roll out repeatedly with the 
test tube to ensure there are no bubbles trapped between the membrane and the 
gel. 
g. Then place another stack of 3 Whatman papers on top of the nitrocellulose 
membrane as a protective layer. Roll out with the test tube.  
h. Clamp together the cassette and place in the transfer chamber with the black side 
of the cassette facing the black side of the chamber.  
i. Place an ice pack in the chamber to prevent over-heating of the membrane/gel. 
Place ice around the base of the castor as well.  
j. Fill up the castor with transfer buffer until it reaches the top of the castor. 
k. Place lid on the chamber and connect the leads to the power supply.  
l. Turn on the power supply and run at 120V for 1 hour and 45 minutes.  
 
6. Removal of transfer membrane: 
a. After the 1 hour and 45 minutes, turn off the power supply and disconnect leads 
from the power supply, then remove the lid from the chamber. 
b. Remove each cassette from the chamber one at a time by pulling upwards. 
c. Open the cassette, remove the Whatman paper and gel and place the nitrocellulose 
membrane in a plastic dish so that it is upright, with the ladder now on the left 
side of the square plastic dish. 
d. Add Ponceau S stain on the membrane, enough so that is it submerged, and gently 
swirl.  
e. Drain off the remaining Ponceau S and save for reuse. Repeat for all blots 
simultaneously. 
f. Rinse the membrane with ddH20 and swirl to reduce the red background; rinse 
approximately 3-4 times. Lay the blot face up on top of plastic wrap and label 
with a sticker to keep track of the membranes. Then wrap with the plastic wrap 
and use a kim wipe to smooth out any creases. Either take a picture or scan the 
image (allows you to keep your ponceau for use as a loading control later on, if 
required). 
g. Next, prepare a faux gel plan of the proteins to be analyzed, their molecular 
weight and where to cut along the membrane. Refer to this prior to cutting the 
membrane. Once satisfied, use a scalpel and a ruler to precisely cut at the planned 
sections. Cut while the blot is still in the plastic wrap. Use a pen to label at the end 
(where no protein is) the ID of the gel as well as the protein being analyzed. 
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Using forceps, take the membrane strip and place in a square plastic dish. Repeat 
for all other proteins, placing similar proteins in similar plastic dishes.  
h. Then add enough wash buffer to submerge the blots. Swirl on a mixing plate 
(GFL (3017) Man-Tech Associates Inc Mixing Plate, Sarstedt, ref#: 62-151.006, 
lot#: 6092911) at room temperature until the remaining red Ponceau S has been 
removed. Remove the plastic wrap bits with forceps while stirring. 
i. Next, incubate the blots for 1 hour with 5% skim milk blocking solution while on 
rotation at room temperature. 
i. During this hour, prepare the primary antibodies. Depending on the 
primary volume, use either1.5 mL eppendords, 2 mL eppendorfs or 13 mL 
Rhohr tubes (Sarstedt, ref#: 62-515.006, lot# 6092911). Add first the 5 or 
10% skim milk blocking solution and then add the specific antibody 
(stored at either 4°C, -20°C or -80°C) ordered from the company.  
ii. Prepare the dish to place the blots in overnight. Using a large glass dish, 
set up a small plastic square dish upside down as a support. Then take a 
glass plate and wrap it in parafilm to prevent creases. Place four kimwipe 
balls (2 kimwipes wrapped together, sprayed with water, and rolled into a 
ball) into each corner of the -glass dish. Place plastic wrap overtop the 
glass dish to prevent evaporation.  
j. Once the blocking is complete, lift each blot and place it face up onto the parafilm 
dish. Spread each blot as far apart as possible to prevent accidental mixtures of 
primary antibody. Then place the glass dish into the 4ºC fridge. Vortex primary 
antibody and place 1000 µl of primary antibody over each specific blot to cover. 
Once all is added, cover the plastic wrap and close the fridge door.  
 
7. Immunodetection 
a. The next day, take the glass dish out of the 4ºC fridge and place on the bench. 
Remove the blots and place them into a square plastic dish. Wash the blots in 
wash buffer with gentle rotation for 5 minutes, repeat this wash 3 times. Pour out 
wash buffer and add new wash buffer in between each rinse. 
i. During these washes, wipe off the excess primary antibody from the 
parafilmed glass plate. Re-soak the kimwipe balls with ddH2O. 
ii. Prepare the secondary antibodies using rabbit, mouse or goat (stored at -
20°C) added to 5% blocking skim milk. Again, prepare this in a 1.5 mL, 
2.0 mL eppendorf or a 13 mL Rhohr tube.  
b. Once the 3 by 5 min washes are complete, lay the blots face up onto the parafilm 
plate. Incubate the blots for 1 hour in room temperature with 1000 µl of the 
appropriate secondary antibody diluted in blocking solution. Vortex before 
adding.  
c. Once the one hour is up, then lightly dab the blot to remove excess secondary 
onto a kimwipe, transfer to a plastic square dish, and then repeat the 3 by 5 min 
washes with wash buffer. Pour out wash buffer and add new wash buffer in 
between each rinse. 
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8. Enhanced Chemiluminescence Detection 
a. Mix ECL fluids “A” and “B” in a 1:1 ratio in a disposable Rohr tube. For each 
blot, 1000 µl of solution is required (i.e. 500 µl of A and 500 µl of B). The ECL 
in the brown bottle is extremely light sensitive – only add when immediately 
ready to use. When ready mix the two solutions vigourously. 
b. Place blots on plastic wrap face up and apply ECL solution for 5 minutes.  
c. Dab off excess ECL on a kimwipe and place blots face down on a fresh piece of 
plastic folder and seal tightly. 
d. Place the blot face down onto the imager and latch close the machine. 
e. Open the Carestream Molecular Imaging Software connected to the Carestream 
Imaging Apparatus (K4589-0020). Make sure the machine is turned on. Go to 
Capture In Vivo FX. Settings should be already pre-set at Matt Chemi. Settings 
will look like below: 
 
 
 
 
f. Click “Preview” to detect how long the first exposure must be. The preview will 
run for 10 sec. If distinct blots can be viewed through the preview, then expose 
for less time (around 2 min). If not blots can be visualized from the preview, 
expose for longer (around 10 min and up). Adjust the exposure time value and 
click “Expose”.  
g. Expose blot to film (time will vary depending on protein and antibody).  
h. Once the exposure if completed, play with the contrast and background using the 
blue and red lines respectively on the righthand Image Display panel. Move them 
along the scale to create the perfect image. 
i. Click “Auto” to go back to the initial exposure contrast. 
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i. Save the Carestream image. Then go to Export Data Æ Image Æ File type Æ 
JPEG. This is so that later analysis can be performed. 
j. Repeated exposures can then be made for the same blot. There is an approximate 
20 min ECL lifetime. 
k. Once completed, discard blot and shut down the program. Retrieve images off the 
program using a USB to then analyze with the Image J software.  
 
         9. Western Blot Analysis 
a. Open the image J software. Within the software click OPEN Æ select blot to 
analyze. 
b. Click the         button to highlight the blot. If multiple bands, highlight the specific 
band interested in analyzing.  
i. You can crop and adjust the rotation as well during this time to ensure 
only the bands interested in highlighting are highlighted. Click Image Æ 
Crop. Then click Image Æ Transform Æ Rotate Æ Input Angle (degrees) 
Æ negative number turns the image counter clockwise and a positive 
number turns the image clockwise. Start with a small number.  
c. Then click the number“1” to confirm the highlighted region and that the line is 
horizontal, then click the number“3” to analyze. A new window will open 
containing peaks for each specific band shown: 
 
d. Select the       function and then connect the base of the peak by drawing a line 
from one point to the next. Do this for all of the peaks. 
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e. Click on the   *     button. Then click on the inside of each of the peaks. The peaks 
will be highlighted and a new window will open containing the volume under 
each peak. These are the final quantified values of the contrast of each blot.  
f. Place these values into an excel spreadsheet.  Perform steps 2-5 for the control 
protein. Then divide the values of the protein of interest by the control proteins to 
obtain the final protein value which can then be grouped and graphed using the 
Graphpad Prism 6.0 software. 
            10. Stripping & Re-probing 
This process is required to analyze more than one protein at a similar molecular weight to 
another, without having to re-do the entire western blot process.  Another method is the 
Arturo stripping method, however that is only recommended for stripping the blot for the 
same protein, rather than a different one which is what this method is beneficial for. 
a. Once the original protein has been developed using the Carestream imager 
software, do not throw out the blot; instead, place the blot in a square plastic dish. 
Then wash the blot in wash buffer 3 times for 5 min intervals. 
b. After the final wash, remove the excess wash buffer and add 1 x TBS. Then seal 
the plastic container and leave in the fridge until ready to use.  
i. If stripping right after developing, ignore the 3 by 5 min washes and the 
1X TBS and proceed directly to step C. 
c. Empty the wash buffer or TBS that the blot is submerged in. Add in fresh wash 
buffer into the plastic dish and wash on the mixing plate for 15 min. Repeat this 
for a total of two times. 
d. Then turn on the rotating heating oven (NIO/CAN Scientific TEK STAR 
Hybridization Oven) and set it to 56°C. Prepare two long glass cylinder 
containers.  
e. Once the blots are washed, take the blot and lie it face up, flat along the inside of 
the glass container. The blot should be placed near the lid of the container, with 
the ladder facing towards the bottom of the cylinder. If multiple blots, place the 
blots across from each other and not directly beside. 
f. Then, add 4 mL of stripping buffer to the bottom of each container. The stripping 
buffer is light sensitive, only add when the blots are placed. Close the lid of the 
glass container. 
g. Place the glass containers into the rotating oven making sure that they are equally 
balanced. Then begin the rotation, close the door and time for 30 minutes.  
h. Once completed, remove the blots and place them back into the square dish and 
repeat the 2 times 15 minute washes with wash buffer on the mixing plate. 
i. Next, empty out the wash buffer and add the 5% skim milk blocking solution to 
the plastic dish. Leave on the mixing plate for 1 hour. 
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i. In the meantime, prepare similarly to how you prepare for step I and J in 
the Removal of transfer membrane section. 
i. Prepare primer antibodies and prepare glass dish for incubation. 
j. Continue with the method dictated in Step 7 (Immunodetection) and proceed 
onwards. 
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COX Enzyme Activity Assay 
 
The COX Enzyme activity assay is an indirect measure of mitochondrial content. This assay is 
based on observation of the decrease in absorbance of ferrocytochrome c measured at 550 nm, 
which is caused by its oxidation to ferricytochrome c by cytochrome c oxidase. This kit is 
suitable for the detection of mitochondrial outer membrane integrity/mitochondrial stress and for 
the detection of mitochondria in subcellular fractions. 
Reagents 
1. Muscle Enzyme Extraction Buffer: Measure out 20 mM Hepes (2.383 g/500 mL 
ddH2O) (Sigma-Aldrich, cat#H3375-500G) and pH to 7.4. Then in a separate beaker, 
measure out 2 mM EGTA (0.3804 g/500 mL) (Sigma-Aldrich, E4378-100C, store at 
room temperature), 1% Trition-X-100 (5 mL/500 mL), 50% glycerol (10 mL/500 mL) 
(Caledon, 5350-1-40), and 50 mM β-glycerophosphate (5.4 g/500 mL) into 400 mL of 
ddH2O and pH to 7.4. Then volume up to 500 mL total and store at 4°C.  
2. Cytochrome c from equine heart (Sigma-Aldrich, cat#: C2506-1G, store at -20°C) 
3. Sodium Dithionite (Sodium hydrosulfite, Sigma-Aldrich, cat#: 157953-5G, store at 
room temperature) 
4. 10 mM KPO4: Dilute 0.1 M KPO4 buffer prepared below with ddH2O in a 1:10 ratio 
(exp. 10 mL buffer + 90 mL ddH2O). Store at 4°C. 
5. 100 mM KPO4: Measure 0.1 M KH2PO4 (13.6 g/1000 mL ddH2O) (Potassium Phosphate 
Monobasic, Fischer Scientific, cat#: P285-500) and pH to about 5. Then prepare the 0.1 
M K2HPO4.3H2O (17.4 g/ 1000 mL ddH2O) (Potassium Phosphate, Fischer Scientific, 
P288B-500) and pH this solution to 8. Then mix these two solutions in equal proportions 
and pH to 7.0. Store at 4°C. 
Procedure: 
1. Prepare the appropriate set-up: 
a. Beige two-section dish; 
b. Metal tool with a small scoop at one end and a metal clamp for samples; 
c. Prepare a small liquid nitrogen tank containing the powdered samples in 
cryotubes (2 mL micro tube, Sarstedt, ref# 72.694.003, lot#: 3084701). 
d. Prepare two sets of 1.5 mL eppendorfs (MCT Graduated Natural Eppendorfs; cat# 
05-408-129; Fischer Brand) with the ID of the powdered samples. Label one tube 
with a 20 (for the 20-fold dilution) and label the other set of tubes with an 80 (for 
the 80-fold dilution). 
2. Add 50 µl of muscle enzyme extraction buffer to the 20-fold dilution labelled 1.5 mL 
eppendorfs. 
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3. Next, pour liquid nitrogen into the beige dish. Place the metal clamp and metal tool into 
the liquid nitrogen. Remove a powdered sample (in a crytotube) from the liquid nitrogen. 
Tap 3-4 times on the table and slightly twist the top open to let out extra gas from the 
cryotube. Then remove the lid and place the cryotube in the clamp in the liquid nitrogen. 
**The sample must always be stored in liquid nitrogen.  
4. Then, place the 20-fold dilution eppendorf with the 50 µl of muscle enzyme extraction 
buffer onto the scale and zero it. 
5. Next, using the metal tool, scoop out 5-7.5 mg of powdered tissue and place it in the 20-
fold eppendorf. Record the final measurement. 
6. Once correctly measured, remove the cryotube from the metal clamp and close the lid. 
Tap and open and close the lid multiple times until there is no more sound of gas 
escaping. 
7. Then volume up for the sample according to the following calculation. For example, if 
6.2 mg was measured Æ 6.2 x 19 – 50 =  67.8 µl of muscle enzyme extraction to volume 
up.  
8. Complete steps 2-7 for all samples. 
9. Next, place the samples on an aluminum eppendorf block on ice in a small plastic 
container. Ensure ice is surrounding the block. Place all samples inside the block, open 
the lids and place inside each one a mini stirring rod.  
10. Place the plastic container onto a mixing plate and turn on. Ensure that all of the stirring 
rods are moving in a circular motion. Start a timer for 15 min.  
11. While mixing, the cytochrome c test solution can be prepared.  
a. Turn on the large 30°C oven and allow to heat up. 
b. In a small glass scintillation vial, weigh out 20 mg of horse heart cytochrome c 
(stored normally at -20°C). 
c. Add 1 mL of 10 mM KPO4 buffer to the scintillation vial and swirl around with 
the cytochrome c to mix. This should be a dark red colour. 
d. In a 1.5 mL eppendorf, weight out between 7-10 mg of sodium dithionite. Add the 
equivalent of 10 mM KPO4 buffer. For example, if 8.3 mg was measured, then 
add 830 µl of 10 mM KPO4 buffer. Vortex vigorously to mix.  
e. Next, prepare three items: two pieces of aluminum foil (large enough to cover the 
scintillation vial), 8 mL of ddH2O, and 1 mL of 100 mM KPO4 buffer. 
f. Add 40 µl of the sodium dithionite solution to the cytochrome c solution and swirl 
to mix. There should be an immediate colour change to a light red/orange. As 
soon as this colour change occurs, quickly add the 8 mL of ddH2O and the 1 mL 
of 100 mM KPO4 buffer and cover in aluminum foil. 
g. Place in the 30°C oven for ~30 minutes.  
12. Once the eppendorfs with the 20-fold dilution are finished mixing, remove the stir bars 
with a magnet and rinse with ethanol to clean. Leave the eppendorfs in the aluminum 
block. 
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13. Sonicate with the Microson Ultrasonic Cell Disruptor machine (model MS-50) at 30% 
power three times for three rounds. One round consists of sonicating all the samples three 
times consecutively. Repeat this for an additional two rounds. Clean the probe with a 
kimwipe in between each sample. Move slowly during sonication. 
14. Once sonication is complete, in the 80-fold labelled eppendorfs, add 150 µl of the muscle 
extraction buffer.  
15. To these eppendorfs, then add 50 µl of the 20-fold solution. When picking up the 20-fold 
solution, pipette from the bottom rather than near the top where bubbles may be located. 
Leave the new 80-fold dilution samples on ice. The leftover 20-fold solution can be 
thrown out. 
16. In a clear 96 well-plate, quickly add 280 µl of the cytochrome c test solution to Row A 
for trial 1. Add into the wells depending on how many samples being analyzed. If 6 
samples, only add from A1-A6. Once added cover the plate immediately with aluminum 
foil, wrap up the test solution with aluminum foil, and place the 96-well plate into the 
oven for 10 min. 
17. In another 96-well plate, add the 80-fold samples into Row A. Add 30 µl of each sample 
into its own well. For example, if 6 samples, add from A1-A6 consecutively. Cover with 
a kim wipe until ready to use.  
18. Then prepare the KC4 plate reader while the test solution is heating up. Open Wizard to 
access the Reading Parameters Settings. 
a. Reading Type: Options “End Point, Kinetic, Spectrum” - choose Kinetic 
i. Click on larger box labeled Kinetic to set parameters- Run Time 0:01:00, 
Interval time – for minimal interval time, select minimum (under 
these conditions, it should measure the plate every 3 seconds), click on 
box labeled Allow Well Zoom- This allows to see the data in real time. 
Do not select individual well auto scaling (takes too long to occur). For the 
scales – click Auto for both options. 
b. Synergy HT-I On: Options “Absorbance, Fluorescence, Luminescence” – choose 
Absorbance and set the wavelength to 550 nm. 
c. Select Sweep for Read Mode 
d. Plate-Type-choose 96-well plate (8 x 12), choose which wells are to be read i.e. 
A1-A6 
i. 4 trials will be completed for the 6 samples. The plate will read therefore: 
A1-A6, C1-C6, E1-E6, G1-G6 
e. Shaking-Intensity set at 0, Duration set at 0s. Shaking is not necessary as it will 
delay the first reading. 
f. Select yes for temperature control and check pre-heating. Enter 30 for temperature 
control.  
19. Once the test solution is ready, remove it from the oven. With a multi-pipette, pick up 
250 µl of the test solution from the wells at the same time and quickly add it to the 
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samples in the other 96-well plate. Immediately, place the sample plate into KC4 reader 
and press start.  
20. During the reading time, add the test solution to the next set of wells on the clear 96-well 
plate– row C this time, filling one well for each of the number of required samples. Place 
the plate into the oven for 10 minutes. 
21. Once finished reading, save the first trial and remove the 96-well plate with the samples. 
To prevent analysis of the entire curve (all 21 points) which can increase variability 
between trials, only take the average of the first 8 points. On the chart table, press shift 
and then click of the graphs. Once all are highlighted, like the finger off the shift button 
and a chart will open. Click options and the adjust the final point number from 21 to 8. 
Then to print, go to Report Æ Add Well Zoom (for wells A1-A6Æ overlay wells) and 
Add the Kinetic Curve. Print and record the sample ID.  
22. Then in this same plate that was just read, add in the samples for the next trial – this time 
row C. 
23. Alter the settings for the KC4 reader this time, making sure that the wells being read are 
the C row between C1 to C4 for example. 
24. Then repeat steps 19-22 for trial 2 (row C). 
25. Repeat steps 19-23 for trial 3 (row E) 
26. Repeat steps 19-23 for trial 4 (row G) 
27. Below is an example of the graph and values. The graph should be starting around or 
above 2 on the y-axis.  
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To analyze the results, take the average Mean V value across all four trials. Exclude any values 
that are outliers from the average calculation. Do this for all of the samples. Then, divide the 
Mean V by 1000 and enter the Mean V values into the below calculation. Values to enter include 
the volume of the sample (30µl/1000=0.030), total well volume (30µl sample + 250µl test 
solution = 280 µl/1000=0.280), and the fold dilution (80): 
𝐶𝑂𝑋 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(𝑀𝑒𝑎𝑛 𝑉)(𝑇𝑜𝑡𝑎𝑙 𝑊𝑒𝑙𝑙 𝑉𝑜𝑙𝑢𝑚𝑒)(𝐹𝑜𝑙𝑑 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛)
(18.5)(𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒)
 
 
Therefore, an example calculation for a mean V of -284.2 would be: 
𝐶𝑂𝑋 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(0.284)(0.280)(80)
(18.5)(0.030)
= 11.462 µmol/min/g tissue OR U/g tissue 
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Muscle Extraction Procedure – Protein Extracts 
 
Reagents: 
1. Sakamoto Buffer: For a volume of 10 mL, add muscle extraction buffer (9.8 mL), 1 mM 
DTT (10 µl), 1 mM PMSF (100 µl), 1 mM Sodium Orthovanadate (50 µl), 2 µl/ml 
leupeptin (20 µl), 1 µl/ml pepstatin A (10 µl), and 1 µl/ml aprotinin (10 µl). Store at 4°C. 
2. Protease Inhibitor Buffer (Protease Inhibitor Cocktail Tablets, Roche, cat#: 
11697498001, store at 4°C): Measure out 1 tablet with 1000 µl ddH2O. Vortex until 
tablet is dissolved. Store at -20°C. 
3. Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich, cat#: P726-5ml, store at 4°C) 
4. Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich, cat#: P0044-5ml, store at 4°C) 
 
Procedure: 
1. Label two sets of 1.5 mL eppendorfs (MCT Graduated Natural Eppendorfs; cat# 05-408-
129; Fischer Brand) with the sample ID. The second set, label more extensively with the 
date, animal ID, animal conditions, and personal initials.  
2. Prepare the muscle extraction buffer in a 15 mL Falcon polystyrene conical tubes 
(Falcon, cat#: 352095). 
a. For however many samples you have, multiple this number by 200 µl and this is 
how much Sakamoto Buffer you will add to the Falcon tube. 
b. Then add 10 µl of the phosphate buffers and the protease buffers per 1 mL of 
Sakamoto buffer. 
i. For example, if you have 9 samples, 9x200 = 1800 µl OR 1.8 mL of 
Sakamoto Buffer. Then you would add 18 µl of the phosphate and 
protease buffers. 
c. Vortex to ensure adequate mixing.  
2. Add 50 µl of this muscle extraction buffer to the first ID labelled 1.5 mL eppendorfs. 
Place these tubes on ice in a Styrofoam cooler. 
3. Prepare the appropriate set-up: 
a. Beige two-section dish filled with liquid nitrogen; 
b. Metal tool with a small scoop at one end and a metal clamp for samples; placed 
inside the liquid nitrogen of the beige dish; 
c. Take a medium sized cooler and fill it up with liquid nitrogen. A small pee cup 
will be required; 
d. Small liquid nitrogen canister with the cryotubes to make protein extract samples 
from. 
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4. Remove one of the cryotubes and open and close to remove excess gas. Once opened, 
place it inside the beige dish into the liquid nitrogen using the clamp to hold it upright. 
5. Place the corresponding 1.5 mL eppendorf with the 50 µl Muscle extraction buffer on the 
scale. Zero the scale. 
6. Measure out 15-20 mg of the powdered sample. Record the value.  
7. Then volume up for the sample according to the following calculation. For example, if 
16.3 mg was measured Æ 16.3 x 10 – 50 = 113 µl of muscle extraction buffer to volume 
up.  
8. Complete steps 5-8 for other samples. 
9. Rotate all homogenates end over end using the Barnstead Thermolyne “LabQuake” 
Shaker (model 415110) in a 4°C fridge. 
10. Then place the 1.5 mL eppendorfs in an aluminum block on ice.  
11. Sonicate with the Microson Ultrasonic Cell Disruptor machine (model MS-50) machine 
at 30% power three times for three rounds. One round consists of sonicating all the 
samples three times consecutively. Repeat this for an additional two rounds. Clean the 
probe with a kimwipe in between each sample. Move slowly during sonication. 
12. Centrifuge samples using the eppendorf centrifuge 54150 (Brinkmann Instruments, 5425-
41150) machine at 14, 000 ref for 10 min at 4°C.  
13. Then extract the supernate from the 1.5 mL eppendorfs and place the supernate into the 
second set of extensively labelled eppendorf tubes. Dispose of the pellet. Repeat for all 
samples. 
14. Store protein extracts at -80°C until use for Bradford assay to determine protein 
concentration, OR until required to make protein samples for Western blotting.  
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Mitochondrial Protein Release Assay for Cytochrome C and AIF 
 
Reagents: 
1. Hydrogen Peroxide: Prepare a 15 mL Falcon polystyrene conical tubes (cat#: 352095, 
Falcon) tube with 10 mL of ddH2O. Add 10 µl of 30% H2O2 (Hydrogen Peroxide 
Solution (30%) w/w in H2O, contains stabilizer, Sigma-Aldrich, cat#: H1009-100ml, 
store at 4°C) to the falcon tube and vortex prior to using. Leave on ice until ready to use. 
2. Ferrous Sulfate: Measure 278 mg of FeSO4 (Ferrous Sulfate, BDH Chemicals, 
cat#ACS354, store at room temperature) into a 15 mL falcon tube. Add 10 mL of ddH2O 
to the falcon tube and vortex until completely mixed. Leave on ice until ready to use. 
3. Mitochondrial Isolation Resuspension Buffer (see recipe above) 
Procedure: 
1. Prepare mitochondrial SS and IMF subfractions. Refer to the mitochondrial isolation 
procedure. Prepare a Bradford on these subfractions and enter the concentrations into the 
pipette plan as observed below: 
 
 
 
 
Equations: 
x Protein ug/ul = Protein for 5 ul / 5 
x Total Protein = 150 / Protein ug/ul 
x Resuspension Buffer = Total – (Total Protein + H202 + FeSO4 + ddH20) 
x H202 (constant- 10), FeSO4 (constant -2), ddH20 (constant -12) 
 
2. Prepare two sets of 1.5 mL eppendorfs (MCT Graduated Natural Eppendorfs; cat# 05-
408-129; Fischer Brand) for each sample. The second set of tubes should be more 
distinctly labelled including the animals conditions, experimental information, date and 
personal initials.  
3. Next, prepare the hydrogen peroxide and ferrous sulfate and leave on ice.  
4. Then add the mitochondrial subfractions to all of the tubes first. Prepare the control tubes 
first. Add the ddH2O and then add the resuspension buffer last. Next prepare the treated 
tubes. Add the H2O2 first, then add the FeSO4, last add the resuspension buffer. Tap all 
the tubes to mix. 
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5. Incubate the eppendorfs in the water bath (model 1122S, cat#: 13271-138, VWR) for 90 
min at 30°C. Take out the eppendorfs and flick every 30 min to mix, place back in the 
water bath. 
6. Once completed, centrifuge in the eppendorf centrifuge 54150 (Brinkmann Instruments, 
5425-41150) machine at 9000 g for 5 min at 4°C.  
7. Carefully extract the supernate (without touching the pellet) and transfer to the second 
labelled tubes. Discard the pellet. The supernate will contain the final released products 
from the mitochondria. 
8. Better to prepare samples fresh and utilize immediately in a western blot or can store the 
samples at -80°C until ready for western blot analysis. 
Sample Preparation: 
1. To prepare samples, add 30 µl of the mitochondrial supernate, 10 µl of 2x Lysis Buffer, 
and 5 µl of sample dye. Add the lysis buffer first, then the mitochondrial supernate and 
lastly the sample dye. Tap to mix the solution together. 
2. Heat on the hot plate(VWR Block Heater, cat#: 12621-104) for 3-5 min.  
3. Utilize samples immediately, or store at -20 °C for later use.  
4. Run on a 15 % gel and follow the Western protocol. Probe for cytochrome c (15 kDa) 
and AIF (67 kDa). No control protein is required as analysis is performed by dividing the 
treated sample by the control sample for each mitochondrial subfraction. 
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Nuclear and Cytosolic Fractionation 
 
Reagents: 
1. D-PBS (Dulbecco’s Phosphate Buffered Saline 1X (DPBS), Wisent Inc, cat# 311-425-
CL, store at 4°C). 
2. Protease Inhibitor Buffer (Protease Inhibitor Cocktail Tablets, Roche, cat#: 
11697498001, store at 4°C): Measure out 1 tablet with 1000 µl ddH2O. Vortex (Mini 
Vortex, cat#: 02215365, Fischer Scientific) tablet is dissolved. Store at -20°C. 
3. Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich, cat#: P726-5ml, store at 4°C) 
4. Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich, cat#: P0044-5ml, store at 4°C) 
5. NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Thermo Scientific, cat#: 
78835) 
a. Cytoplasmic Extraction Reagent I (CER I), cat#: 78835A 
b. Cytoplasmic Extraction Reagent II (CER II), cat#: 78835B 
c. Nuclear Extraction Reagent (NER), cat#: 78835C 
Procedure: 
1. Prior to tissue extraction, prepare a 1.5 mL eppendorf (MCT Graduated Natural 
Eppendorfs; cat# 05-408-129; Fischer Brand) for the number of animal tissues to extract.  
a. Each eppendorf will require the addition of 500 µl of PBS, 5 µl of the protease 
inhibitor solution, and 5 µl of the phosphatase inhibitors 2 and 3. Leave 
eppendorfs on ice during tissue collection. 
b. If more than one tissue, prepare a stock solution in 15 mL Falcon polystyrene 
conical tubes (cat#: 352095, Falcon), following the above ratio of 500 µl PBS: 5 
µl of inhibitors for each sample (multiple values) and then aliquot to the number 
of 1.5 mL eppendorfs. 
2. Place the extracted tissue (one TA) into the prepared eppendorf. 
3. Next, prepare the reagent volume by adding the appropriate volume of CER I reagent 
which is equal to 400 µl x the number of samples. Prepare this in a 10 mL falcon tube. 
Then add the protease inhibitor and the phosphatase 2 & 3 inhibitors for a volume of 10 
µl for each 1 mL of CER I buffer. 
4. Next, place the tissue onto a curved watch glass dish on ice. Dab away extra solution. 
Trim away any fat and connective tissue. Then using tweezers and scissors, proceed 
mince the muscle with forceps and scissors until it resembles the consistency of jam and 
no large pieces remain.  
5. Once minced, place the tissue on the inside of the small glass test tube specific for the 
Fischer Scientific homogenizer machine (Eberbach Corporation). Place it near the top of 
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the inside. Next with a p-1000, add 400 µl of the CER I buffer solution into the test tube, 
washing down the minced tissue to the bottom of the test tube.  
6. Fit the mini pestle into the homogenizer. Then turning the machine on, place the pestle 
tightly into the test tube and move up and down until the tissue is broken down (10-30 
sec).  
7. Once the homogenization is complete, pour the tissue solution into a new labelled 1.5 mL 
eppendorf making sure to obtain the majority of the tissue chunks. Place on ice. Wipe 
down the test tube and the pestle and prepare for the next sample. 
8. Then add 20 µl of the CERII reagent to each eppendorf and vortex vigorously for 10-15 
sec. Shake 3 times to mix. Leave the tube on ice to sit for 1 min. Then vortex again for 15 
seconds vigorously and shake up and down once more to mix.  
9. Centrifuge at maximum speed (16 000 g) in the eppendorf centrifuge 54150 (Brinkmann 
Instruments, 5425-41150) in the 4°C fridge. If the tubes are still very murky after the spin 
and not clearly separated, centrifuge for another 5 minutes. 
10. Using a p-200, take up the supernate and place in a new 1.5 mL labelled eppendorf. This 
is the cytoplasm. Store on ice. 
11. The leftover pellet then needs to be washed. Slowly, with a p-1000, pour 1 mL of PBS 
into the eppendorf, being careful not to touch the pellet. Then centrifuge the sample in the 
centrifuge located in the 4 °C fridge for 30 sec. Then slowly pick up the supernate and 
discard it (be careful to not pick up the pellet). Repeat this wash step another two more 
times for a total of 3 washes. 
12. After the last wash, add between 150 – 200 µl of the NER reagent. The amount added 
depends on the size of the pellet. The larger the pellet, the more NER reagent you will 
add.  
13. Next place the eppendorfs on an aluminum block on ice. Sonicate each eppendorf using 
the Microson Ultrasonic Cell Disruptor machine (model MS-50) machine set to 30% 
power output. Sonicate 3 by 3 (sonicate in order). Wipe the tip with a kim wipe between 
the sonication of each sample.  
14. After sonication, place the samples on ice for 40 min. Every 10 min, vortex each sample 
vigorously for 15 sec. 
15. Then place the samples in the 4°C centrifuge for 10 min at maximum speed (16 000 g). 
Take up the supernate and transfer it to a new labelled 1.5 mL eppendorf. This is the 
nuclear fraction. The pellet is discarded.  
a. If after the centrifugation, there are two phases, take up the clear supernate. 
However, if there are three phases, take up the clear and murky sections, but not 
the bottom pellet. 
16. Once completed, store the cytoplasm and nuclear subfractions in the -80°C freezer. 
Utilize samples for the Bradford assay to determine protein concentration for later 
western blot analyses. 
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RNA Isolation 
 
**RNA isolation is a sterile procedure. Use sterile pipette tips, sterile eppendorfs and tubes, 
and continually wash hands and items being handled with ethanol to prevent any 
contamination of the sample. TriZol is a dangerous solution to work with, work with care.** 
 
Reagents: 
 
1. TriZol Reagent (Life Technologies, Ref#: 15596018, lot# 111701) 
2. 0.1 M NaOH (Sodium Hydroxide, Caledon, 7860-1) 
3. Chloroform (Caledon, 3000-1) 
4. Isopropanol (2-propanol, Caledon, 8600-1) 
5. 75% ethanol: Combine 100% anhydrous ethanol (ethyl alcohol anhydrous, Commercial 
Alcohols, lot#: 022933) to ddH2O, in a ratio of 75 mL: 25 mL respectively. 
 
Procedure: 
Day 1 
 
1. The homogenizer tip for the IKA T25 Digital Ultra-Turrax polytron machine (model# 
T25DS1) must be sterilized in 0.1M NaOH and rinsed in sterile water prior to use. Rinse 
homogenizer in sterile water between samples. 
2. On ice, prepare one 13 mL Rhorh (Sarstedt, ref#: 62-515.006, lot# 6092911) tube per 
sample. In each Rhorh tube, under the fumehood, carefully add 1 mL of TRIzol reagent.  
3. Prepare two sets of 1.5 mL sterile eppendorfs (MCT Graduated Natural Eppendorfs; cat# 
05-408-129; Fischer Brand) and label accordingly.  
4. Prepare the appropriate set-up: 
a. Beige two-section dish filled with liquid nitrogen; 
b. Metal tool with a small scoop at one end and a metal clamp for samples, placed in 
the beige dish in liquid nitrogen; 
c. Prepare a small liquid nitrogen tank containing the powdered samples in 
cryotubes (2 mL micro tube, Sarstedt, ref# 72.694.003, lot#: 3084701). 
5. Remove a powdered sample (in a crytotube) from the liquid nitrogen. Tap 3-4 times on 
the table and slightly twist the top open to let out extra gas from the cryotube. Then 
remove the lid and place the cryotube in the clamp in the liquid nitrogen. **The sample 
must always be stored in liquid nitrogen.  
6. Place the rhorh tube on the measuring scale and zero the scale. Then measure out 70-80 
mg of powdered tissue. Tap the rhorh tube to mix. Record the measured value.  
7. Remove the homogenizer tip from the NAOH solution and attach to the IKA T25 Digital 
Ultra-Turrax polytron homogenizer machine (model# T25DS1)set  at 40% power output 
(9.8 Hz). Homogenize each tube at 9000 g for 10 sec. During the 10 seconds vigorously 
move around the bottom of the rhorh tube. Do this for each tube 2-3 times if required. 
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There should be no visible chunks present at the bottom of the rhorh tube. Work through 
each sample once and then repeat if required.  
a. Have a cup of ddH2O to rinse the homogenizer tip between each sample. Use 
tweezers to remove any large pink chunks stuck within the homogenizer tip. Wipe 
with a kim wipe.  
b. The homogenizer tip must be taken apart and cleaned intensely, removing 
remaining clumps of pink solidified Trizol and sample solution. Do not re-add to 
NAOH to sterilize in between each 2-3 samples. 
8. Once completed, transfer homogenized solution to a sterile 1.5mL labelled eppendorf, 
and let stand for 5 min at room temperature. 
9. Add 200µl of chloroform and shake vigorously for 15 sec, let stand for 2-3 min at 
room temperature. Solution should turn a bubblegum pink once shaking is complete. 
10. Spin at maximum speed (16 000 g) for 15 min in the eppendorf centrifuge 54150 
(Brinkmann Instruments, 5425-41150) in the 4°C fridge. 
11. Following centrifugation, carefully transfer the clear aqueous phase to a new sterile 
1.5 mL eppendorf, making sure not to pick up any of the remaining pink solution. 
a. If the pink solution is picked up, place the remaining supernate picked up and 
centrifuge for 1 min to allow for separation. 
b. Discard of the remaining pink solution properly in the phenol waste bag. 
12. Add 500 µl of the isopropanol solution. Shake vigorously for 15 seconds until 
bubbles are visible. Place in the -20°C freezer over night to allow for RNA 
precipitation overnight so as to continue the experimentation the next day, OR place 
in the -80°C freezer for one hour and then continue. The -20°C option is preferred.  
 
Day 2 
 
1. Remove the RNA samples from the freezer and lit it sit at room temperature for 10 
min to allow for thawing.  
2. Next, spin the samples at maximum speed (16 000 g) for 10 min, in the centrifuge 
located in the 4°C fridge.  
3. Remove the supernate by pouring it into an empty beaker and discarding the contents.  
4. Add 700 µl of the 75% ethanol. During this addition process, slowly and carefully 
wash the white pellet at the bottom of the eppendorf, off of the wall so that it is 
floating in the tube.  
5. Spin the samples at maximum speed (16 000 g) for 10 min, in the centrifuge located 
in the 4°C fridge 
6. Discard the supernate by pouring it into the beaker. Use the p-20 to suck up any 
additional left at the bottom of the eppendorf, while carefully avoiding the pellet.  
7. Next, the pellet must air-dry for about 1 hour.  
8. Dissolve the pellet in 20 µl of sterile water. Pipette up and down to mix for 1 min. 
Repeat for all samples.  
9. Next, the RNA concentration is measured using the Nanodrop 2000 
Spectrophotometer (Thermo Scientific, Serial# M757) at an absorbance at 260 nm 
and 280 nm to determine RNA purity and concentration. 
a. Open the Nanodrop 2000 Program 
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b. Click Nucleic Acid option. Remove the kim wipe placed between the lid and 
base of the nanodrop machine. 
c. Change the Type to RNA and alter the concentration to read µg/µl 
d. With a sterile p-10, pick up 1 µl of sterile grade water and place it gently on 
the top of the nanodrop machine on the centre of the metal tip. Do not touch 
the surface. Close the lid of the nanodrop machine. 
e. Click Blank in the top left corner and write Blank into the sample ID space in 
the top right of the program. Then press measure. The value located under the 
Nucleic Acid Concentration column should be as close to 0 as possible. Take 
multiple readings of the same drop if required to obtain a concentration close 
to 0. If unattainable, open the nanodrop lid, lightly wipe off the drop of water 
with a kim wipe, and then redo steps d-e with another fresh drop of sterile 
water.  
f. Once a water drop concentration of 0 has been read, wipe away the water drop 
with a kim wipe. Then pipette 1 µl of the RNA sample from step 8. Place it on 
the centre of the metal tip of the nanodrop reader and close the lid. Type in the 
sample ID and click measure for a total of 3 trials. This will ensure a more 
accurate reading when obtaining the average of the 3 trials for the 
concentration of the RNA. 
i. To ensure the measurement is accurate, the 260/280 column ratio 
should have a value around 2, with an appropriate deviation of 0.03. If 
it is not around 2, it may mean the sample is contaminated (often less 
than 2 if you measure powdered tissue <50 mg). Therefore, repeated 
measures may sometimes be required (remove the current RNA drop, 
clean the tip and place a new drop). 
g. Repeat steps d-f for each sample, always place a fresh drop of sterile water on 
the nanodrop machine prior to adding the RNA. Need to zero before every 
RNA trial. 
h. To print the document with all of the RNA values, go to Reports Æ Print tab 
(landscape) Æ Print (top left). Below is an example of the RNA report. 
 
 
 
i. Once printed, shut down the program and place a kim wipe between the 
nanodrop base and lid for protection. 
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Reverse Transcription 
 
First-strand cDNA synthesis is performed following the manufacturer's recommendations that 
are outlined below. Performed on the same day as “Day 2” of RNA isolations. 
 
Reagents: 
 
1. Total RNA (isolated as described above) 
2. Oligo(dT)20 (Invitrogen, cat#: 18418020) 
3. 10 Mm dNTP (each dATP, dTTP, dCTP, dGTP is diluted in sterile DEPC treated water) 
4. Sterile DEPC treated ddH2O (Sterile Molecular Grade Water, Wisent Inc., cat#: 809-
115-66, Store at room temperature) 
5. RNAse OUT (Ribonucleotide Inhibitor [recombinant], Invitrogen, cat#: 10777-019)], 
store at -20°C) 
6. 0.1M Dithiothreitol (DTT) (Invitrogen, P/N Y00147, cat#: 1305696, store at -20°C) 
7. 5X First-strand Buffer (Invitrogen, P/N Y02321, cat# 1788535, store at -20°C) 
8. SuperScript III Reverse Transcriptase (Life Technologies, cat#: 18080-044, store at -
20°C) 
9. PerfeCTA SYBR Green Supermix ROX (Quanta Biosciences, P/N 84018, lot# 015507, 
store in aluminum foil at - 20°C). 
 
Procedure: 
 
1. Prepare the pipette plan below. Add in the RNA concentrations into the highlighted 
regions at the bottom and the rest of the reagent concentrations will adjust accordingly: 
 
 
 
 
274 
 
Equations: 
x RNA (1.5 ug) = 1.5 / RNA ug/ul  
x RNA (ul) = RNA (1.5 ug) 
x DEPC st. H20 = 20 – (oligo20 + 10 mM dNTP + RNA (ul) + 5x First Strand + 0.1m DTT 
+ RNAse OUT + SuperScript III RT) 
 
2. Next, prepare in a 1.5 mL sterile eppendorf mastermix 1 which contains an equal volume 
of oligo(dT)20 and the 10 mM dNTP. 1 µl of each is added to each sample. Prepare a 
volume +2 (room for error) into the eppendorf. Pipette up and down to mix. Leave on ice 
until ready to use.  
3. Label 0.5 mL Flat-Cap PCR “mini” eppendorf tubes (cat#: 87-C500-F, Ultident 
Scientific) according to the number of samples. Then follow the first section of the 
pipette plan above. First add the sterile water to each of the mini eppendorfs. Then add 
the RNA to the appropriate tubes. Lastly add 2 µl of the mastermix 1 solution to each 
tube. Pipette repeatedly to ensure adequate mixing. 
4. Employ the DNA Thermal Cycler (Perkin Elmer, model TC480)  to heat mixture to 65°C 
for 5 minutes.  Do not let the thermal cycler cool down and immediately once the 5 
minutes is done, leave the mini eppendorfs on ice for 1 min. Remove from ice and leave 
at room temperature while performing the next steps. 
5. In a second 1.5 mL sterile eppendorf, prepare mastermix 2. This contains 4 µl of the 5x 
first strand buffer and 1 µl of the 0.1 m DTT. Once again, prepare a volume +2 (room for 
error) in the eppendorf. Pipette up and down to mix. Leave on ice until ready to use.  
6. Then add 5 µl of mastermix 2 to each of the mini eppendorfs with the RNA. 
7. Once added, remove superscript III RT from the -20°C freezer. This solution is light 
sensitive and should not be left out for long. Only remove from the freezer immediately 
prior to using. Add 1 µl to each mini eppendorf.  
8. Next, remove RNAse OUT from the -20°C freezer. This solution is light sensitive and 
should not be left out for long. Only remove from the freezer immediately prior to using. 
Add 1 µl to each mini eppendorf. Pipette up and down to fully mix mini eppendorf. 
9. Using a thermal cycler, incubate at 50°C for 50 minutes, and then inactivate the reaction 
by heating at 72°C for 20 minutes. In the meantime, keep the original 1.5 mL RNA 
eppendorfs on ice.  
10. During the cycling process, prepare and label another set of sterile mini eppendorfs. 
These eppendorfs will be used to dilute the cDNA (currently in the thermal cycler) to a 
more manageable concentration to utilize for experimentation.  
11. Once the thermal cycler is completed, add 29 µl of sterile water to the newly labelled 
(empty) mini eppendorfs. Then add 1 µl of the cDNA. Mix up and down repeatedly to 
mix. This is a 1:30 ratio. As this volume is low and will be used up rapidly, make a large 
ratio; for example, prepare 4 µl cDNA: 116 µl sterile water.  
12. The diluted cDNA is now ready for use in PCR amplification. Both the diluted cDNA 
and the original amplified cDNA can be stored at -20°C until further use.  
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Oligonucleotide Primer Design 
 
Websites required: 
x Pubmed Nucleotide Search 
x Primer3 Primer Design Program Æ http://Frodo.wi.mit.edu/primer3 
x BLAST – http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
x IDT website – http://www.idtdna.com/calc/analyzer 
 
Process: 
1. Know the gene of interest. Search up the protein/gene ahead of time to determine relevant 
associated information. Determine if there are alternative names the genes is called in the 
same species or different species.  
a. Useful website is “Gene Card” under google. 
2. Go to the Pubmed.com cite; click on the nucleotide option in the drop down menu. Type in 
the gene and then the species. 
a. For example: p53 mus 
b. Mus= mus muscularis (mouse)  
c. Pick the option that best fits the gene description (i.e. in the above example, the 
best option that fits p53 mRNA in mouse). There may be many options available, 
therefore choose the best fit for specific experimental protocol. Investigate the 
different contenders by viewing the publications/sources available in the 
description of the option clicked.  
3. Once the best option has been chosen, click the “Fasta” hyperlink under the blue title 
(underlined) on the option page. This will give the entire sequence of the gene at interest.  
4. Copy and paste the sequence and into a word document and save it. 
5. Open the Primer3program. If the program is not bookmarked, it can be found at the 
weblink above. Click on “go to new version.” Copy the entire sequence from the word 
document and paste into the large text space at the bottom of the web page. Remove 
numbers from the copied sequence because the program will treat them as nucleotides. 
Then make the following changes to the options on the web page. 
a. Product Size Ranges: 100-150 (nucleotides) 
b. Number to Return: 10 
c. Primer Size: 18         Opt: 20        Max:22 
d. Primer TM: 58          Opt: 60        Max: 62 
e. Max TM Difference: 2 
f. Primer GC%:   Min: 40    Opt: 50      Max: 60 
g. Max Self Complementary: 6 
276 
 
h. Max 3’ Self Complementary: 2 
i. Max Poly-X: 3 
j. End Stability: 9 
k. Click on the “Pick Primers” button. 
6. Open the IDT website (oligo analyzer website). The webpage is listed above. After 
clicking pick primers, a list of primers at the bottom of the web page will be generated. 
This list will contain primary and secondary sequences. You will have to test both of the 
primary and secondary sequences for each primer to determine if the primer fits or fails 
with your conditions. To do this, follow the steps below: 
a. For copying the primary or secondary sequence (found at the bottom of the web 
page under additional oligos), make sure that the row doesn’t end in a G or C (if it 
does, do not highlight the G or C when copying). 
b. Copy the primary sequence for the first primer set and past it into the top text box 
on the EDT web page. Click analyze. 
c. Next click “Hairpin.” This determines if the primer folds back on itself. Scroll 
down the page and if the ΔG is >-9, then it passes this test. 
d. Next click “Self-Dimer.” This determined if the primer binds to itself. Scroll 
down the page and if the ΔG is >-9, then it passes this test 
7. Then go back to the additional oligo page and take the secondary sequence of the primer 
set (do not highlight G or C again when copying). Copy the secondary and place it into the 
secondary sequence box on the IDT web page. Click calculate and the value should be 
greater than -9.   
8. Click NCBI Blact first. Then to check specificity using BLAST (big blue button). Which 
will open a new tab with information mentioning if any other genes bind to the gene of 
interest.Go through the list. You only want to see your gene of interest in your species (i.e. 
mus. Muscularis).  
9. Return to the IDT webpage and repeat steps 10b-d for the secondary sequence. If the 
values are < -9, then it fails the test. Will then need to try the second primer set and if both 
the primary and secondary of the second set fail, then move onto the third set, so on and so 
forth until you obtain a primer set that passes all the tests. When you find the one that does, 
this will be the primer sequence to be ordered.  
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Polymerase Chain Reaction (qPCR) 
 
1. Primers must first be optimized prior to analyzing the cDNA with the primer of interest. 
Primers are either designed as indicated by the instructions above or are borrowed from 
previous studies in the laboratory (no expiration date on the primers). All primers can be 
orders from customdna@sial.com. 
a. Once Forward and Reverse primers for each mRNA are received, they must be 
diluted to 300 µmol. On the primer, there is a nmol concentration. Enter that into 
the shaded pipette plan below. 
Automatically the sterile H2O volume will 
adjust according to the equation 
(=X/1000/300*1000*1000) where X is 
the nmol concentration and that µl sterile 
H2O volume is how much is required to 
be added to the primer bottle. Constant 
pipetting up and down for 1 min is 
required for adequate mixing.  
b. Once diluted appropriately, prepare separate sterile 1.5 mL eppendorfs for the 
Forward and Reverse primers. To create a 20 µM stock, add 186.67 µl of sterile 
water to the eppendorf. Then add 13.3 µl of the 300 µM stock primer. As these 
are low volumes and are utilized quickly, you can make a larger volume by 
multiplying this ratio. For example, if multiplied by 4, add 746.68 µl of sterile 
water first and then add 53.2 µl of the appropriate stock primer. You should 
always have a forward and reverse tube (2 tubes) for each RNA. Leave on ice to 
thaw until ready to use. 
2. Next, prepare 5 mini sterile eppendorfs. Label 1:1, 1:2, 1:4, 1:8, and 1:16 ratios on the 5 
tubes respectively. As you want to find the appropriate primer concentrations to use for 
your conditions, you will need 2-3 representative samples for each condition for each 
primer. For example, if using the conditions Whole Body (WB) mouse WT UT, WB WT 
T, WB KO UT, WB KO T and Muscle Specific (MS) mouse WT UT, MS WT T, MS KO 
UT, MS KO T, that involves a total of 8 conditions and therefore 8 required samples. It is 
a better representation however if you obtain 2 samples for each condition, for a total of 
16 samples. 
a. In the 1:1 tube, you will add 4 µl from each condition (any samples you decide), 
obtaining a volume of 64 µl total of RNA (two samples from each condition). 
These samples are all being mixed into the same tube. Then you will add the 
corresponding 64 µl of sterile water to satisfy the 1:1 ratio. 
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3. Prepare the serial dilutions as follows. The total volume is the volume present in each 
tube after the dilutions are completed. 
 
 
 
 
 
 
 
4. Once the dilutions are completed, prepare the mastermixes for each table (3 tables) 
according to the plan below. You will prepare the volumes in the 14x column only. In 1.5 
mL sterile eppendorfs, first add the sterile ddH2O, next add the already prepared (step 1) 
20 µM forward and reverse primer solutions, and last add the SYBR Green Master Mix 
(extremely light sensitive – must be in 
a black sterile ice box with a lid at all 
times). Mix up and down to mix as the 
SYBR green is viscous and required 
multiple pipetting (10 times) to mix 
fully. When everything is added to the 
eppendorf, place in the black sterile 
lidded box as well until ready to use. 
Prepare all tables for each mRNA (two 
– as only two can fit in one table) 
ahead of time prior to loading the 
plate. There should then be a total of 6 
eppendorfs with the table optimization 
mixtures (3 per mRNA).  
5. Then organize the 96-well RNA plate 
(96-nontreated white microwell SI, Thermo Scientific, cat#: 236105) according to the 
plan below. Each plate can be used for two primer optimizations only. Samples must be 
duplicated to ensure accuracy. 
 
1:1                                   1:2                               1:4                               1:8                                1:16 
64 µl of sample 
(4 µl each sample) 
* 16 samples (2/condition) 
+ 
64 µl sterile water 
TOTAL VOLUME = 96 µl 
32 µl from 1:1  
+ 
32 µl sterile water 
TOTAL VOLUME = 32 µl 
 
 
32 µl from 1:2  
+ 
32 µl sterile water 
TOTAL VOLUME = 32 µl 
 
 
32 µl from 1:4  
+ 
32 µl sterile water 
TOTAL VOLUME = 32 µl 
 
 
32 µl from 1:8  
+ 
32 µl sterile water 
TOTAL VOLUME = 64 µl 
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6. Add first 2 µl of the serial dilution cDNA to the appropriate wells of the plate.  Check the 
bottom of the plate to ensure a small visible drop of the cDNA in each well (often wells 
can be skipped – must check prior to adding the mastermix). Then quickly add 23 µl the 
appropriate table 1, table 2 and table 3 mastermixes to the associated wells. Do not need 
to change pipette tips between each well – only change between each table mastermix.     
a. Total reaction volumes are always 25 μl 
b. Use negative wells to monitor contamination, using 2 µl sterile ddH₂O in place of 
cDNA. 
7. Once all is added, place an adhesive cover over the plate and smooth down. Cover then 
with aluminum foil to prevent excessive light exposure as the SYBR green is light 
sensitive. 
8. Remove the aluminum foil and spin the plate in the Sorval ST16R centrifuge (Thermo 
Scientific, cat#: 75004381) for 2 min at 4000 g to mix the cDNA with the mastermix and 
to bring solution to the bottom of the wells. Re-cover with the aluminum foil to minimize 
light exposure. 
a. If making multiple plates at once and one plate is currently reading in the Applied 
Biosystems StepONEPLUS Real-Time PCR System (serial#: 272002347), store the 
ready-made plate at 4°C for later use. One plate may be stored overnight if 
required and put through the reader early the next morning. 
9. Set-up the PCR machine.  
a. Allow time for the PCR machine to connect with the computer program – may 
take a couple minutes if just turned on. Place the plate into the machine by fitting 
it within the well template. 
b. Once on and connected, open the StepOne Software program. 
c. Use Guest Æ click OK 
d. Ignore calibration and continue 
e. Click Run/Quickstart option. 
i. Enter the experiment title and browse through documents for where the 
results will be saved 
ii. Quantitation, SYBR Green + Melt Curve, 2 hours, cDNA options. 
iii. On the next tab labelled “Run”, enter 25 μl to be read. 
iv. Then click Start at the bottom 
v. Ignore the calibration settings and continue 
vi. The machine lid will move upwards once it has start running – confirm 
this movement. 
vii. Next, set-up the plate reader to mimick the template of the plate with the 
template on the program. Go to Set-up Æ Plate Set-up 
1. Under Assign Targets, write gene name and Table #, for example 
PGC-1a Table 1. Add a new target to continue adding until you 
have all of the targets listed (should be 6 targets for the plate above 
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– for example: PGC-1a Plate 1, PGC-1a Plate 2, PGC-1a Plate 3, 
Tfam Plate 1, Tfam Plate 2, Tfam Plate 3). 
2. Next under Assign samples, in this case, adding the serial dilution 
ID. For example, 1:1, 1:2, 1:4, 1:8, and 1:16.  
3. Click the tab “Assign Target and Sample” and you will mimic the 
plate set-up. Highlight the appropriate wells in the example plate 
on the program and assign the targets. Then highlight the specific 
wells associated with the appropriate serial dilutions. Once 
everything is assigned, you do not need to save (automatically 
saves the layout). Wait for the 2 hour run to be completed. 
f. Save the file once completed. Save on the computer and then save on the USB to 
bring over to another computer (not hooked up to the machine) to then analyze the 
curves. 
i. Open the StepOne Software on the KC4 reader. Continue the program 
without the connection the PCR machine. 
ii. Click Analyze Experiment (top right corner). Open the file from the USB. 
iii. The file will open to the curve graph with the layout beside. If there is a 1 
or 2 in the layout wells, it means that the duplicates of the same serial 
dilution is not identical (some variation is present). Highlight each 
duplicate to see how different the curves are from each other. Want the 
curves to overlay perfectly. Make a note of the tables/samples that may 
not have a perfect overlap. 
iv. Then go to Plate Set-Up Æ Assign Targets & Samples Æ At the bottom, 
select dye and change from ROX to None (must turn ROX off to analyze 
the melt curve stage). 
v. Then go to Analysis Æ Melt Curve 
1. Multiple curves in the lines means that two separate products are 
melting and the primer only binds to one, OR the primer is binding 
to multiple sites OR it binds to itself if there is too much primer 
volume in the mastermix.  
2. Therefore, highlight each table, 1, 2 and 3, and see if there are 
bumps in the curves (do not highlight the negative). Record the 
best looking curves for each primer.  
a. Curves of different heights are normal because of the serial 
dilutions 
3. Then highlight the whole table by clicking the small white square 
in the top left corner of the plate. Click Export Data. Select 
Results, then save the appropriate folder, and export. This will 
export all the data in an excel spreadsheet.  
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4. In the Excel exported file, only look at the CT values. This is the 
cycle threshold values. These are the values that will be inputted 
into the Threshold cycle column in the excel spreadsheet below. 
Everything else will be pre-calculated. The mean is just the 
average of the two duplicates for each serial dilution; the 
log[cDNA] column =LOG[cDNA]; the graph is a combination of 
the log[cDNA] and mean. 
a. In terms of selection for the best table – require an R2 > 
0.99 and an m value of around – 3.32 (this is the more 
important requirement). Therefore, pick the graph with the 
best values and also take into account any variabilities that 
were seen in the melt curves. 
5. Save the file, take note of the appropriate table selection. Repeat 
for all primers including the control primers. 
 
 
 
 
 
 
 
 
 
 
 
 
10. Now that the primers have been optimized, prepare the pipette plans for analyzing the 
diluted cDNA samples. A maximum of 16 diluted cDNA samples can be analyzed per 
plate as each plate is required to also analyze two control primers. Example plates can be 
seen below. For PGC-1a for example, all three primers (PGC-1a, GAPDH and B2M) 
have all been optimized for table 1. On the other hand however, GAPDH and B2M are 
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optimized for Table 1 and Tfam is optimized for Table 3. Other controls can be used, 
GAPDH and B2M are just examples. 
 
 
11. Before loading the plate, prepare 1.5 mL sterile eppendorfs, one for each primer. Multiple 
the values by the number of rows being utilized for each primer. Prepare extra. For 
example, if 2.5 rows are being used, then prepare the mastermix for 3 rows, i.e. multiple 
the values by 3 (as shown below). Add the ddH2O first, then add the already prepared 
forward and reverse primers for the 
specified mRNA being analyzed. 
DO NOT ADD THE SYBR 
GREEN YET (add only 
immediately prior to use). Leave 
these samples on ice.  
12. In the 96 well mRNA plate, add the 
2 µl of the diluted cDNA as shown 
in the layout plate example above. 
Add in duplicates. Check the 
bottom to ensure that the diluted 
cDNA has been added to the 
appropriate wells.  
13. Once the diluted cDNA has been 
added to all of the appropriate wells add the SYBR green to the three mastermixes 
prepared (i.e. PGC-1a, GAPDH and B2M). Mix up and down to mix as the SYBR green 
is viscous and required multiple pipetting (10 times) to mix fully. When everything is 
added to the eppendorf, place in the black sterile lidded box as well until ready to use.  
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14. Add 23 µl of the PGC-1a to each of the wells listed on the pipette plan containing the 
diluted cDNA. Do not change tips when adding. Add quickly as the mastermix is now 
light sensitive with the SYBR green. Next add the GAPDH mastermix solution to the 
appropriate wells. Lastly add the B2M mastermix solution to the appropriate wells. Once 
all is added, place an adhesive cover over the plate and smooth down. Cover then with 
aluminum foil to prevent excessive light exposure as the SYBR green is light sensitive. 
15. Remove the aluminum foil and spin the plate in the Sorval ST16R centrifuge (Thermo 
Scientific, cat#: 75004381) for 2 min at 4000 g to mix the cDNA with the mastermix and 
to bring solution to the bottom of the wells. Re-cover with the aluminum foil to minimize 
light exposure. 
a. If making multiple plates at once and one plate is currently reading in the Applied 
Biosystems StepONEPLUS Real-Time PCR System (serial#: 272002347), store the 
ready-made plate at 4°C for later use. One plate may be stored overnight if 
required and put through the reader early the next morning. 
16. Then set-up the plate reader the exact same way as indicated in step 10 and onwards. Run 
the plate for two hours and save the file onto the computer and onto a USB. 
17. To analyze the plates, continue on from step 10f.  
a. The only alteration to the analysis process is that there is no need to make note of 
any differences in the curves and melt curves as they have already been adjusted 
for. Export data the same way. 
b. Then taking the values from the excel spreadsheet, place the CT values into the 
spreadsheet below. Enter the CT values from the exported excel spreadsheet into 
the highlighted column on the left (should be two values for each sample). The 
mean will be taken for these sampled and the STD will be calculated. From the 
sample exported file, you will also have the control values – enter those into the 
GAPDH and B2M column. The value you require is 2*-X which is then 
multiplied by 100 to create a whole number. This is the value that is then analyzed 
in Graphpad. 
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